CUMULATIVE SUPPLEMENT 11
NOVEMBER 2022

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

42nd EDITION

Department of Health and Human Services
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

2022

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

42nd EDITION

Cumulative Supplement 11
November 2022

CONTENTS

PAGE

Contents

1.0 INTRODUCTION v
1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT vi
1.2 CUMULATIVE SUPPLEMENT CONTENT vi
1.3 APPLICANT NAME CHANGES vii
1.4 LEVOTHYROXINE SODIUM viii
1.5 AVAILABILITY OF THE EDITION ix
1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST x
1.7 CUMULATIVE SUPPLEMENT LEGEND xii

DRUG PRODUCT LISTS
Prescription Drug Product List 1-1
OTC Drug Product List 2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List 3-1
Orphan Products Designations and Approvals List 4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution 5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM
A. Patent and Exclusivity Lists A-1
B. Patent and Exclusivity Terms B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

42nd EDITION

CUMULATIVE SUPPLEMENT 11
NOVEMBER 2022

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ATLANTIDE PHARMACEUTICALS AG (ATLANTIDE)	WOCKHARDT LTD (WOCKHARDT)
DAIICHI SANKYO INC (DAIICHI SANKYO)	COSETTE PHARMACEUTICALS INC (COSETTE)
DAIICHI SANKYO INC (DAIICHI SANKYO INC)	COSETTE PHARMACEUTICALS INC (COSETTE)
HERITAGE PHARMACEUTICALS INC (HERITAGE PHARMS INC)	HERITAGE PHARMACEUTICALS INC DBA AVET PHARMACEUTICALS INC (HERITAGE PHARMS)

LANNETT CO INC (LANNETT)	CHARTWELL MOLECULAR HOLDINGS LLC (CHARTWELL MOLECULAR)
LANNETT CO INC (LANNETT CO INC)	CHARTWELL MOLECULAR HOLDINGS LLC (CHARTWELL MOLECULAR)
MERCK AND CO INC (MERCK)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK AND CO INC (MERCK AND CO INC)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK RESEARCH LABORATORIES DIV MERCK CO INC (MERCK)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK SHARP AND DOHME CORP (MERCK SHARP DOHME)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC (MSD MERCK CO)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
SANDOZ INC (SANDOZ)	EPIC PHARMA INC (EPIC PHARMA)
TELIGENT OU (TELIGENT)	PAI HOLDINGS LLC DBA PHARMACEUTICALS ASSOCIATES INC (PAI HOLDINGS PHARM)
TELIGENT PHARMA INC (TELIGENT)	PAI HOLDINGS LLC DBA PHARMACEUTICALS ASSOCIATES INC (PAI HOLDINGS PHARM)
WYTELLS PHARMA PRIVATE LTD (WYTELLS PHARMA)	EUGIA PHARMA SPECIALITIES LTD (EUGIA PHARMA SPECLTS)

1.4 LEVOTHYROXINE SODIUM[1]

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to

[1] In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.[2]

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).

- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	–
AB4	LEVOTHYROXINE SODIUM[3]	MYLAN	0.3MG	A076187	–	RS

1.5 AVAILABILITY OF THE EDITION

[2] Please consult the Active Section of the Orange Book for information on other strengths.

[3] Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
https://www.fda.gov/about-fda/reports-manuals-forms/forms.

The current listing of the Orphan Product Designations and Approvals is available at https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2021	MAR 2022	JUN 2022	SEP 2022	DEC 2022
DRUG PRODUCTS	21133	21339	21640	21862	
LISTED SINGLE SOURCE	2701 (12.8%)	2716 (12.7%)	2748 (12.7%)	2709 (12.4%)	
MULTISOURCE	18432 (87.2%)	18623 (87.3%)	18892 (87.3%)	19153 (87.6%)	
THERAPEUTICALLY EQUIVALENT	18298 (86.6%)	18493 (86.7%)	18762 (86.7%)	19036 (87.1%)	
NOT THERAPEUTICALLY EQUIVALENT	134 (0.6%)	130 (0.6%)	130 (0.6%)	117 (0.5%)	
EXCEPTIONS[4]	54 (0.3%)	53 (0.2%)	53 (0.2%)	53 (0.2%)	
NEW MOLECULAR ENTITIES APPROVED	13	11	23	16	
NUMBER OF APPLICANTS	1190	1204	1219	1210	

[4] Amino acid containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN[5]	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

[5] The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET, FOR SUSPENSION;ORAL

TRIUMEQ PD

	+!	VIIV HLTHCARE	EQ 60MG BASE;EQ 5MG BASE;30MG	N215413	001	Mar 30, 2022	Mar NEWA

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

	@	AUROBINDO PHARMA	EQ 600MG BASE;300MG	A206151	001	Mar 28, 2017	Jun DISC
AB		LAURUS	EQ 600MG BASE;300MG	A216332	001	Jul 25, 2022	Jul NEWA

ABAMETAPIR

LOTION;TOPICAL

XEGLYZE

	+ @	HATCHTECH	0.74%	N206966	001	Jul 24, 2020	Jul CAHN

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB		GLENMARK PHARMS	500MG	A209227	002	May 19, 2022	May NEWA
AB		NOVUGEN	250MG	A215947	001	Jan 05, 2022	Aug CAHN
AB			500MG	A215947	002	Jan 05, 2022	Aug CAHN
AB		TEVA PHARMS USA	125MG	A212206	001	Jun 24, 2022	Jun NFTG

YONSA

AB	+!	SUN PHARM	125MG	N210308	001	May 22, 2018	Jun CFTG
	+!		125MG	N210308	001	May 22, 2018	Feb CAHN

ABROCITINIB

TABLET;ORAL

CIBINQO

	+	PFIZER	50MG	N213871	001	Jan 14, 2022	Jan NEWA
	+		100MG	N213871	002	Jan 14, 2022	Jan NEWA
	+!		200MG	N213871	003	Jan 14, 2022	Jan NEWA

ACALABRUTINIB MALEATE

TABLET;ORAL

CALQUENCE

	+!	ASTRAZENECA	EQ 100MG BASE	N216387	001	Aug 03, 2022	Aug NEWA

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL

ACEBUTOLOL HYDROCHLORIDE

AB	!	AMNEAL PHARM	EQ 200MG BASE	A075047	001	Dec 30, 1999	Jul CTEC
	!		EQ 200MG BASE	A075047	001	Dec 30, 1999	Apr CTEC
AB	!		EQ 400MG BASE	A075047	002	Dec 30, 1999	Jul CTEC
	!		EQ 400MG BASE	A075047	002	Dec 30, 1999	Apr CTEC
AB		ANI PHARMS	EQ 200MG BASE	A074007	001	Oct 18, 1995	Jul CMFD
AB			EQ 400MG BASE	A074007	002	Oct 18, 1995	Jul CMFD
	@	MYLAN	EQ 200MG BASE	A074288	001	Apr 24, 1995	Apr DISC
AB			EQ 200MG BASE	A074288	001	Apr 24, 1995	Apr CAHN
	@		EQ 400MG BASE	A074288	002	Apr 24, 1995	Apr DISC
AB			EQ 400MG BASE	A074288	002	Apr 24, 1995	Apr CAHN

ACETAMINOPHEN

SOLUTION;INTRAVENOUS

ACETAMINOPHEN

AP		ASPIRO	1GM/100ML (10MG/ML)	A216617	001	Jul 27, 2022	Jul NEWA
AP		HIKMA	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Aug CAHN
	+!		1GM/100ML (10MG/ML)	N206968	001	Jun 03, 2022	Jun CAHN
	+!	INNOPHARMA	1GM/100ML (10MG/ML)	N206968	001	Jun 03, 2022	Jun NEWA
AP	!	SANDOZ INC	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Feb CHRS
AP		ZYDUS PHARMS	1GM/100ML (10MG/ML)	A216467	001	Oct 25, 2022	Oct NEWA

OFIRMEV

	+ @	MALLINCKRODT HOSP	1GM/100ML (10MG/ML)	N022450	001	Nov 02, 2010	Feb DISC

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

ALLZITAL

	AA	!	LARKEN LABS INC	325MG;25MG	A203484	001	Dec 04, 2015	Apr CTEC

BUTALBITAL AND ACETAMINOPHEN

>D>	AA		AACE PHARMS	50MG;300MG	A214955	001	Aug 16, 2022	Nov CPOT
	AA			50MG;300MG	A214955	001	Aug 16, 2022	Aug NEWA
>A>	AA			300MG;50MG	A214955	001	Aug 16, 2022	Nov CPOT
	AA		HAVIX	300MG;50MG	A214088	001	Apr 07, 2022	Apr NEWA
	AA			325MG;25MG	A214088	002	Apr 07, 2022	Apr NEWA
	AA			325MG;50MG	A214088	003	Apr 07, 2022	Apr NEWA
	AA		RISE PHARMA	300MG;50MG	A214088	001	Apr 07, 2022	Sep CAHN
	AA			325MG;25MG	A214088	002	Apr 07, 2022	Sep CAHN
	AA			325MG;50MG	A214088	003	Apr 07, 2022	Sep CAHN
	AA		SENORES PHARMS	300MG;50MG	A214088	001	Apr 07, 2022	Jun CAHN
	AA			325MG;25MG	A214088	002	Apr 07, 2022	Jun CAHN
	AA			325MG;50MG	A214088	003	Apr 07, 2022	Jun CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

		@	HIKMA	300MG;50MG;40MG	A215135	001	Mar 25, 2022	Sep DISC
	AA			300MG;50MG;40MG	A215135	001	Mar 25, 2022	Mar NEWA
		@		325MG;50MG;40MG	A215135	002	Mar 25, 2022	Sep DISC
	AA			325MG;50MG;40MG	A215135	002	Mar 25, 2022	Mar NEWA
	AA		NOVAST LABS	300MG;50MG;40MG	A215047	001	Nov 17, 2021	Aug CAHN

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	AA		GRANULES	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Jul CMFD

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

	AB		HIKMA	300MG;50MG;40MG;30MG	A215138	002	Jan 26, 2022	Jan NEWA
	AB			325MG;50MG;40MG;30MG	A215138	001	Jan 26, 2022	Jan NEWA
	AB		LGM PHARMA	300MG;50MG;40MG;30MG	A076560	002	Jul 19, 2012	Jan CTEC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	AA		CHARTWELL	120MG/5ML;12MG/5ML	A089450	001	Oct 27, 1992	Apr CAHN
	AA		MIKART	120MG/5ML;12MG/5ML	A089450	001	Oct 27, 1992	Mar CAHN

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

		@	CHARTWELL	300MG;15MG	A089997	001	Dec 28, 1994	Feb CAHN
		@		300MG;30MG	A089998	001	Dec 28, 1994	Feb CAHN
		@		300MG;60MG	A089999	001	Dec 28, 1994	Feb CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	AA	!	CHARTWELL	325MG/15ML;7.5MG/15ML	A040482	001	Sep 25, 2003	Apr CAHN
	AA		EYWA	325MG/15ML;7.5MG/15ML	A211023	001	Mar 08, 2019	Sep CAHN
		!	MIKART	300MG/15ML;10MG/15ML	A040881	001	Feb 25, 2010	Apr CTEC
	AA	!		325MG/15ML;7.5MG/15ML	A040482	001	Sep 25, 2003	Mar CAHN
		@	TRIS PHARMA INC	300MG/15ML;10MG/15ML	A201295	002	Dec 30, 2021	Apr DISC
		@		325MG/15ML;7.5MG/15ML	A201295	001	Dec 30, 2021	Apr DISC

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D>		@	ANDA REPOSITORY	325MG;2.5MG	A040846	001	Jun 09, 2010	Nov CAHN
		@		325MG;2.5MG	A040846	001	Jun 09, 2010	May DISC
		!	ASCENT PHARMS INC	325MG;2.5MG	A211487	001	Nov 07, 2018	May CHRS
				325MG;2.5MG	A211487	001	Nov 07, 2018	May CTEC
	AA	!	CHARTWELL	300MG;5MG	A040658	001	Jan 19, 2006	Apr CAHN
	AA	!		300MG;7.5MG	A040658	002	Mar 24, 2006	Apr CAHN
	AA	!		300MG;10MG	A040658	003	Jun 23, 2004	Apr CAHN
		@		325MG;7.5MG	A040248	001	Apr 28, 2000	Feb CAHN
	AA			325MG;7.5MG	A040432	001	Jan 22, 2003	Apr CAHN
		@		325MG;10MG	A040248	002	Apr 28, 2000	Feb CAHN
>A>		@	MIKART	325MG;2.5MG	A040846	001	Jun 09, 2010	Nov CAHN
	AA			325MG;7.5MG	A040432	001	Jan 22, 2003	Mar CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

	SOLUTION;ORAL					
	OXYCODONE AND ACETAMINOPHEN					
	MIKART	300MG/5ML;10MG/5ML	A202142	001	Nov 27, 2018	Mar CAHN
	TABLET;ORAL					
	OXYCODONE 5/APAP 500					
	@ BRISTOL MYERS SQUIBB	500MG;5MG	A085911	001		Jun CRLD

ACETAZOLAMIDE

	CAPSULE, EXTENDED RELEASE;ORAL					
	ACETAZOLAMIDE					
AB !	CADILA	500MG	A205301	001	Jan 16, 2019	May CHRS
	@ INDICUS PHARMA	500MG	A090779	001	Jul 14, 2011	May DISC

ACETIC ACID, GLACIAL

	SOLUTION/DROPS;OTIC					
	ACETIC ACID					
	@ WOCKHARDT BIO AG	2%	A040166	001	Jul 26, 1996	Jun DISC
	VOSOL					
AT !	AKORN	2%	N012179	001		Jun CHRS

ACETYLCYSTEINE

	INJECTABLE;INTRAVENOUS					
	ACETYLCYSTEINE					
AP	ASPEN	6GM/30ML (200MG/ML)	A213693	001	Feb 03, 2022	Jan NEWA
	@ EXELA PHARMA	6GM/30ML (200MG/ML)	A204797	001	Apr 15, 2021	Feb DISC
AP	INDOCO	6GM/30ML (200MG/ML)	A215620	001	Feb 23, 2022	Feb NEWA

ACLIDINIUM BROMIDE

	POWDER, METERED;INHALATION					
	TUDORZA PRESSAIR					
+!	COVIS	0.4MG/INH	N202450	001	Jul 23, 2012	Apr CAHN

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

	POWDER, METERED;INHALATION					
	DUAKLIR PRESSAIR					
+!	COVIS	0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Apr CAHN

ACYCLOVIR

	OINTMENT;TOPICAL					
	ACYCLOVIR					
AB	CHARTWELL RX	5%	A212495	001	Apr 07, 2020	Sep CAHN
	@ PRINSTON INC	5%	A212202	001	Nov 15, 2021	Mar DISC
	SUSPENSION;ORAL					
	ACYCLOVIR					
	@ AUROBINDO PHARMA	200MG/5ML	A216331	001	Mar 31, 2022	Sep DISC
AB		200MG/5ML	A216331	001	Mar 31, 2022	Mar NEWA
AB	HETERO LABS LTD III	200MG/5ML	A215669	001	Jul 01, 2022	Jun NEWA
AB	RUBICON	200MG/5ML	A215724	001	Aug 18, 2022	Aug NEWA

ACYCLOVIR SODIUM

	INJECTABLE;INJECTION					
	ACYCLOVIR SODIUM					
AP	AM INJECTABLES	EQ 50MG BASE/ML	A207919	001	Jun 17, 2020	Apr CAHN
	@ CHARTWELL INJECTABLE	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Mar CAHN
	@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Mar CAHN
	@ DR REDDYS	EQ 50MG BASE/ML	A207919	001	Jun 17, 2020	Oct DISC
AP		EQ 50MG BASE/ML	A207919	001	Jun 17, 2020	Sep CAHN

ADAPALENE; BENZOYL PEROXIDE

	GEL;TOPICAL					
	ADAPALENE AND BENZOYL PEROXIDE					
AB	ACTAVIS LABS UT INC	0.3%;2.5%	A209641	001	Jun 22, 2022	Jun NEWA
AB	ALEOR DERMACEUTICALS	0.3%;2.5%	A214185	001	Aug 04, 2022	Jul NEWA
AB	PADAGIS ISRAEL	0.3%;2.5%	A212464	001	May 31, 2022	May NEWA
AB	ZYDUS PHARMS	0.3%;2.5%	A214553	001	Jun 03, 2022	May NEWA
AT		0.3%;2.5%	A214553	001	Jun 03, 2022	May NEWA

ALBENDAZOLE

		TABLET;ORAL					
		ALBENDAZOLE					
AB	!	DR REDDYS	200MG	A211034	001	Jan 26, 2021	Jun CHRS
		ALBENZA					
	+ @	IMPAX LABS INC	200MG	N020666	001	Jun 11, 1996	Jun DISC

ALBUTEROL SULFATE

		SOLUTION;INHALATION					
		ACCUNEB					
>D> AN	+!	MYLAN SPECIALITY LP	EQ 0.042% BASE	N020949	001	Apr 30, 2001	Nov DISC
>A>	+ @		EQ 0.042% BASE	N020949	001	Apr 30, 2001	Nov DISC
		ALBUTEROL SULFATE					
	@	BAUSCH	EQ 0.083% BASE	A075358	001	Mar 29, 2000	Jun CAHN
	@		EQ 0.5% BASE	A075050	001	Jun 18, 1998	Jun CAHN
>D> AN		NEPHRON	EQ 0.042% BASE	A076355	001	Jun 28, 2004	Nov CHRS
>A> AN	!		EQ 0.042% BASE	A076355	001	Jun 28, 2004	Nov CHRS
		SYRUP;ORAL					
		ALBUTEROL SULFATE					
AA		CHARTWELL RX	EQ 2MG BASE/5ML	A077788	001	Jun 26, 2007	May CMFD
		TABLET;ORAL					
		ALBUTEROL SULFATE					
AB		AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Sep CAHN
AB			EQ 4MG BASE	A210948	002	Mar 15, 2019	Sep CAHN
	@	CHARTWELL RX	EQ 4MG BASE	A072151	002	Dec 05, 1989	Feb CMS1
		TABLET, EXTENDED RELEASE;ORAL					
		VOSPIRE ER					
	@	STRIDES PHARMA	EQ 4MG BASE	A076130	002	Sep 26, 2002	Oct DISC

ALCOHOL

		SOLUTION;INTRA-ARTERIAL					
		ABLYSINOL					
	+	BPI LABS	99% (1ML)	N207987	001	Jun 21, 2018	Jul CAHN
	+!		99% (5ML)	N207987	002	Jun 21, 2018	Jul CAHN

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

		TABLET;ORAL					
		TEKTURNA HCT					
	+ @	NODEN PHARMA	EQ 300MG BASE;12.5MG	N022107	003	Jan 18, 2008	May DISC
	+ @		EQ 300MG BASE;25MG	N022107	004	Jan 18, 2008	May DISC

ALLOPURINOL

		INJECTABLE;INJECTION					
>D>		ALLOPURINOL					
>D> AP		GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A212363	001	Jan 26, 2022	Nov CTNA
AP			EQ 500MG BASE/VIAL	A212363	001	Jan 26, 2022	Jan NEWA
		TABLET;ORAL					
		ALLOPURINOL					
AB	!	ACCORD HLTHCARE	300MG	A203154	002	May 06, 2013	Apr CHRS
AB		HARMAN FINOCHEM	100MG	A214443	001	Mar 07, 2022	Feb NEWA
AB			300MG	A214443	002	Mar 07, 2022	Feb NEWA
		ZYLOPRIM					
	+	CASPER PHARMA LLC	200MG	N016084	003	Aug 04, 2022	Aug NEWA
AB	+		300MG	N016084	002		Apr CHRS

ALLOPURINOL SODIUM

		INJECTABLE;INJECTION					
>A>		ALLOPURINOL SODIUM					
>A> AP		GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A212363	001	Jan 26, 2022	Nov CTNA
		ALOPRIM					
AP	+!	MYLAN	EQ 500MG BASE/VIAL	N020298	001	May 17, 1996	Apr CAHN

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

		TABLET;ORAL					
		OSENI					
	+ @	TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426	004	Jan 25, 2013	Mar DISC
	+ @		EQ 12.5MG BASE;EQ 45MG BASE	N022426	006	Jan 25, 2013	Mar DISC

ALOSETRON HYDROCHLORIDE

		TABLET;ORAL					
		ALOSETRON HYDROCHLORIDE					
		@ PAR PHARM INC	EQ 0.5MG BASE	A206113	001	Feb 23, 2018	Apr DISC
		@	EQ 1MG BASE	A206113	002	Feb 23, 2018	Apr DISC

ALPELISIB

		TABLET;ORAL					
		VIJOICE					
	+	NOVARTIS	50MG	N215039	001	Apr 05, 2022	Apr NEWA
	+		125MG	N215039	002	Apr 05, 2022	Apr NEWA
	+!		200MG	N215039	003	Apr 05, 2022	Apr NEWA

ALPROSTADIL

		SUPPOSITORY;URETHRAL					
		MUSE					
	+ @	MYLAN SPECIALITY LP	0.125MG	N020700	001	Nov 19, 1996	Jul DISC

AMANTADINE HYDROCHLORIDE

		CAPSULE, EXTENDED RELEASE;ORAL					
		GOCOVRI					
	+	ADAMAS OPERATIONS	EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug CAHN
	+!		EQ 137MG BASE	N208944	002	Aug 24, 2017	Aug CAHN
		SYRUP;ORAL					
		AMANTADINE HYDROCHLORIDE					
	@	ANDA REPOSITORY	50MG/5ML	A076352	001	Sep 10, 2004	Sep CAHN
AA	!	CHARTWELL RX	50MG/5ML	A074028	001	Jun 28, 1993	Mar CAHN
>D>	@	WOCKHARDT BIO AG	50MG/5ML	A075060	001	Dec 24, 1998	Nov CAHN
>A>	@	XTTRIUM LABS INC	50MG/5ML	A075060	001	Dec 24, 1998	Nov CAHN
		TABLET;ORAL					
		AMANTADINE HYDROCHLORIDE					
AB		EDENBRIDGE PHARMS	100MG	A212407	001	May 27, 2022	May NEWA
	@	JUBILANT GENERICS	100MG	A210403	001	Feb 07, 2018	May DISC
		TABLET, EXTENDED RELEASE;ORAL					
		OSMOLEX ER					
	+	ADAMAS OPERATIONS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Aug CAHN
	+ @		EQ 161MG BASE	N209410	004	Apr 22, 2020	Aug CAHN
	+		EQ 193MG BASE	N209410	002	Feb 16, 2018	Aug CAHN
	+ @		EQ 258MG BASE	N209410	003	Feb 16, 2018	Aug CAHN

AMBRISENTAN

		TABLET;ORAL					
		AMBRISENTAN					
AB		APOTEX	5MG	A210701	001	May 19, 2022	May NEWA
AB			10MG	A210701	002	May 19, 2022	May NEWA
AB		AUROBINDO PHARMA	5MG	A216531	001	Jul 21, 2022	Jul NEWA
AB			10MG	A216531	002	Jul 21, 2022	Jul NEWA

AMCINONIDE

		CREAM;TOPICAL					
		AMCINONIDE					
AB	!	GENUS LIFESCIENCES	0.1%	A076065	001	May 15, 2003	Aug CAHN
		LOTION;TOPICAL					
		AMCINONIDE					
	!	ANDA REPOSITORY	0.1%	A076329	001	Nov 06, 2002	Sep CAHN
	!	GENUS LIFESCIENCES	0.1%	A076329	001	Nov 06, 2002	Aug CAHN
		OINTMENT;TOPICAL					
		AMCINONIDE					
AB	!	ANDA REPOSITORY	0.1%	A076096	001	Nov 19, 2002	Sep CAHN
AB	!	GENUS LIFESCIENCES	0.1%	A076096	001	Nov 19, 2002	Aug CAHN

AMIFOSTINE

		INJECTABLE;INJECTION					
		AMIFOSTINE					
	@	EUGIA PHARMA SPECLTS	500MG/VIAL	A204363	001	Jul 17, 2017	Mar CAHN

AMILORIDE HYDROCHLORIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE

	@	CHARTWELL RX	5MG	A204180	001	Aug 07, 2015	Aug CAHN
	@	USPHARMA WINDLAS	5MG	A204180	001	Aug 07, 2015	May DISC

AMINOCAPROIC ACID

SOLUTION;ORAL

AMINOCAPROIC ACID

AA		AGENIX	0.25GM/ML	A215510	001	Mar 23, 2022	Mar NEWA
AA		ANNORA PHARMA	0.25GM/ML	A216464	001	Nov 04, 2022	Oct NEWA
AA		AUROBINDO PHARMA	0.25GM/ML	A216804	001	Sep 26, 2022	Sep NEWA
AA		CARNEGIE	0.25GM/ML	A214140	001	Jan 26, 2021	Jun CAHN
AA		FLORIDA	0.25GM/ML	A215510	001	Mar 23, 2022	Oct CAHN

TABLET;ORAL

AMINOCAPROIC ACID

AB		CARNEGIE	500MG	A213928	001	Feb 12, 2021	Jun CAHN
AB			1GM	A213928	002	Feb 12, 2021	Jun CAHN
AB		OPTIMUS	500MG	A213944	001	Sep 14, 2022	Sep NEWA
AB			1GM	A213944	002	Sep 14, 2022	Sep NEWA

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE;ORAL

PASER

	!	EUROCEPT PHARMS	4GM/PACKET	A074346	001	Jun 30, 1994	Oct CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION

AMIODARONE HYDROCHLORIDE

	@	EUGIA PHARMA	50MG/ML	A204550	001	Oct 25, 2017	Jul DISC

TABLET;ORAL

AMIODARONE HYDROCHLORIDE

AB	!	TARO	200MG	A075424	001	Mar 30, 2001	Oct CHRS
	@	UPSHER SMITH LABS	200MG	A075315	001	Dec 23, 1998	Oct DISC
	@		400MG	A075315	002	Jun 30, 2000	Oct DISC

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

>A>	@	AIPING PHARM INC	10MG	A212654	002	Sep 29, 2021	Nov CAHN
>A>	@		25MG	A212654	001	Apr 07, 2020	Nov CAHN
>A>	@		50MG	A212654	003	Sep 29, 2021	Nov CAHN
>A>	@		75MG	A212654	004	Sep 29, 2021	Nov CAHN
>A>	@		100MG	A212654	005	Sep 29, 2021	Nov CAHN
>A>	@		150MG	A212654	006	Sep 29, 2021	Nov CAHN
AB		CENTAUR PHARMS PVT	10MG	A216243	001	Jun 06, 2022	May NEWA
AB			25MG	A216243	002	Jun 06, 2022	May NEWA
AB			50MG	A216243	003	Jun 06, 2022	May NEWA
AB			75MG	A216243	004	Jun 06, 2022	May NEWA
AB			100MG	A216243	005	Jun 06, 2022	May NEWA
AB			150MG	A216243	006	Jun 06, 2022	May NEWA
AB		LEADING	10MG	A216243	001	Jun 06, 2022	Sep CAHN
AB			25MG	A216243	002	Jun 06, 2022	Sep CAHN
AB			50MG	A216243	003	Jun 06, 2022	Sep CAHN
AB			75MG	A216243	004	Jun 06, 2022	Sep CAHN
AB			100MG	A216243	005	Jun 06, 2022	Sep CAHN
AB			150MG	A216243	006	Jun 06, 2022	Sep CAHN
>D>	@	UPSHER SMITH LABS	10MG	A212654	002	Sep 29, 2021	Nov CAHN
	@		10MG	A212654	002	Sep 29, 2021	May DISC
>D>	@		25MG	A212654	001	Apr 07, 2020	Nov CAHN
	@		25MG	A212654	001	Apr 07, 2020	May DISC
>D>	@		50MG	A212654	003	Sep 29, 2021	Nov CAHN
	@		50MG	A212654	003	Sep 29, 2021	May DISC
>D>	@		75MG	A212654	004	Sep 29, 2021	Nov CAHN
	@		75MG	A212654	004	Sep 29, 2021	May DISC
>D>	@		100MG	A212654	005	Sep 29, 2021	Nov CAHN
	@		100MG	A212654	005	Sep 29, 2021	May DISC
>D>	@		150MG	A212654	006	Sep 29, 2021	Nov CAHN
	@		150MG	A212654	006	Sep 29, 2021	May DISC
	@	VINTAGE PHARMS	10MG	A040218	001	Sep 11, 1997	Jun DISC
	@		25MG	A040218	002	Sep 11, 1997	Jun DISC
	@		50MG	A040218	003	Sep 11, 1997	Jun DISC

TABLET;ORAL
AMITRIPTYLINE HYDROCHLORIDE

	@	75MG	A040218	004	Sep 11, 1997	Jun DISC
	@	100MG	A040218	005	Sep 11, 1997	Jun DISC
	@	150MG	A040218	006	Sep 11, 1997	Jun DISC

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

AB	MICRO LABS	EQ 12.5MG BASE;5MG	A211925	001	Feb 02, 2022	Jan NEWA
AB		EQ 25MG BASE;10MG	A211925	002	Feb 02, 2022	Jan NEWA
AB	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986	Jan CTEC
AB !		EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986	Jan CTEC
@	UNITED RES LABS	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Apr CAHN
@		EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Apr CAHN

AMLODIPINE BESYLATE

SOLUTION;ORAL
NORLIQVA

+!	CMP DEV LLC	EQ 1MG BASE/ML	N214439	001	Feb 24, 2022	Feb NEWA

TABLET;ORAL
AMLODIPINE BESYLATE

@	CHARTWELL RX	EQ 2.5MG BASE	A076859	001	Sep 10, 2007	Jan CAHN
@		EQ 5MG BASE	A076859	002	Sep 10, 2007	Jan CAHN
@		EQ 10MG BASE	A076859	003	Sep 10, 2007	Jan CAHN
AB	TEVA	EQ 2.5MG BASE	A076846	001	Jun 28, 2007	Mar CMFD
AB		EQ 5MG BASE	A076846	002	Jun 28, 2007	Mar CMFD
AB		EQ 10MG BASE	A076846	003	Jun 28, 2007	Mar CMFD

NORVASC

AB +	VIATRIS	EQ 2.5MG BASE	N019787	001	Jul 31, 1992	Jan CAHN
AB +		EQ 5MG BASE	N019787	002	Jul 31, 1992	Jan CAHN
AB +!		EQ 10MG BASE	N019787	003	Jul 31, 1992	Jan CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
AMLODIPINE BESYLATE

+ @	SYNTHON PHARMS	EQ 2.5MG BASE	N022026	001	Sep 27, 2007	Oct CRLD
+ @		EQ 5MG BASE	N022026	002	Sep 27, 2007	Oct CRLD
+ @		EQ 10MG BASE	N022026	003	Sep 27, 2007	Oct CRLD

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	STRIDES PHARMA	EQ 5MG BASE;12.5MG;160MG	A201087	001	Jun 01, 2015	Jun CMFD
AB		EQ 5MG BASE;25MG;160MG	A201087	002	Jun 01, 2015	Jun CMFD
AB		EQ 10MG BASE;12.5MG;160MG	A201087	003	Jun 01, 2015	Jun CMFD
AB		EQ 10MG BASE;25MG;160MG	A201087	004	Jun 01, 2015	Jun CMFD
AB		EQ 10MG BASE;25MG;320MG	A201087	005	Jun 01, 2015	Jun CMFD

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL
AMLODIPINE AND OLMESARTAN MEDOXOMIL

@	TORRENT	EQ 5MG BASE;20MG	A202933	001	Nov 25, 2016	Aug DISC
@		EQ 5MG BASE;40MG	A202933	002	Nov 25, 2016	Aug DISC
@		EQ 10MG BASE;20MG	A202933	003	Nov 25, 2016	Aug DISC
@		EQ 10MG BASE;40MG	A202933	004	Nov 25, 2016	Aug DISC

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL
TELMISARTAN AND AMLODIPINE

@	TORRENT	EQ 5MG BASE;40MG	A202517	001	Jan 08, 2014	Mar DISC
@		EQ 5MG BASE;80MG	A202517	003	Jan 08, 2014	Mar DISC
@		EQ 10MG BASE;40MG	A202517	002	Jan 08, 2014	Mar DISC
@		EQ 10MG BASE;80MG	A202517	004	Jan 08, 2014	Mar DISC

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL
AMLODIPINE BESYLATE AND VALSARTAN

AB	HETERO LABS	EQ 5MG BASE;160MG	A205137	001	Sep 16, 2016	Aug CAHN
AB		EQ 5MG BASE;320MG	A205137	003	Sep 16, 2016	Aug CAHN
AB		EQ 10MG BASE;160MG	A205137	002	Sep 16, 2016	Aug CAHN
AB		EQ 10MG BASE;320MG	A205137	004	Sep 16, 2016	Aug CAHN
AB	STRIDES PHARMA	EQ 5MG BASE;160MG	A090011	001	Mar 28, 2013	Jun CMFD
AB		EQ 5MG BASE;320MG	A090011	003	Mar 28, 2013	Jun CMFD

TABLET;ORAL
AMLODIPINE BESYLATE AND VALSARTAN

AB		EQ 10MG BASE;160MG	A090011	002	Mar 28, 2013	Jun CMFD
AB		EQ 10MG BASE;320MG	A090011	004	Mar 28, 2013	Jun CMFD

AMMONIA N-13

INJECTABLE;INTRAVENOUS
AMMONIA N 13

AP	UNIV ALAHAMA BIRM	15mCi-150mCi/4ML (3.75-37.5mCi/ML)	A211698	001	Nov 03, 2022	Oct NEWA
AP		3.75-37.5mCi/ML	A211698	001	Nov 03, 2022	Oct NEWA

AMMONIUM LACTATE

CREAM;TOPICAL
LAC-HYDRIN

+ @	SUN PHARM INDS INC	EQ 12% BASE	N020508	001	Aug 29, 1996	Aug CRLD

AMOXICILLIN

CAPSULE;ORAL
AMOXICILLIN

AB	MICRO LABS	250MG	A207471	001	Jun 24, 2022	Jun NEWA
AB		500MG	A207471	002	Jun 24, 2022	Jun NEWA

AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET, TABLET;ORAL
VOQUEZNA TRIPLE PACK

+!	PHATHOM	500MG;500MG;EQ 20MG BASE	N215152	001	May 03, 2022	May NEWA
>D>	VOQUEZNA TRIPLE PAK					
>D> +!	PHATHOM	500MG;500MG;EQ 20MG BASE	N215152	001	May 03, 2022	Nov DISC
>A> + @		500MG;500MG;EQ 20MG BASE	N215152	001	May 03, 2022	Nov DISC
+!		500MG;500MG;EQ 20MG BASE	N215152	001	May 03, 2022	May CMS1

AMOXICILLIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET;ORAL
VOQUEZNA DUAL PACK

+!	PHATHOM	500MG;EQ 20MG BASE	N215153	001	May 03, 2022	May NEWA
>D>	VOQUEZNA DUAL PAK					
>D> +!	PHATHOM	500MG;EQ 20MG BASE	N215153	001	May 03, 2022	Nov DISC
>A> + @		500MG;EQ 20MG BASE	N215153	001	May 03, 2022	Nov DISC
+!		500MG;EQ 20MG BASE	N215153	001	May 03, 2022	May CMS1

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL
DETROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

@	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	May DISC
@		2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	May DISC
@		3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	May DISC
@		5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	May DISC
@		6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	May DISC
@		7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	May DISC

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

@	ANI PHARMS	2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jul DISC
@	TEVA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	A210876	001	Jan 31, 2022	Sep DISC
AB		3.125MG;3.125MG;3.125MG;3.125MG	A210876	001	Jan 31, 2022	Jan NEWA
@		6.25MG;6.25MG;6.25MG;6.25MG	A210876	002	Jan 31, 2022	Sep DISC
AB		6.25MG;6.25MG;6.25MG;6.25MG	A210876	002	Jan 31, 2022	Jan NEWA
@		9.375MG;9.375MG;9.375MG;9.375MG	A210876	003	Jan 31, 2022	Sep DISC
AB		9.375MG;9.375MG;9.375MG;9.375MG	A210876	003	Jan 31, 2022	Jan NEWA
@		12.5MG;12.5MG;12.5MG;12.5MG	A210876	004	Jan 31, 2022	Sep DISC
AB		12.5MG;12.5MG;12.5MG;12.5MG	A210876	004	Jan 31, 2022	Jan NEWA

TABLET;ORAL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

@	ACCORD HLTHCARE	1.25MG;1.25MG;1.25MG;1.25MG	A214347	001	Nov 22, 2021	Jul DISC
@		1.875MG;1.875MG;1.875MG;1.875MG	A214347	002	Nov 22, 2021	Jul DISC
@		2.5MG;2.5MG;2.5MG;2.5MG	A214347	003	Nov 22, 2021	Jul DISC
@		3.125MG;3.125MG;3.125MG;3.125MG	A214347	004	Nov 22, 2021	Jul DISC
@		3.75MG;3.75MG;3.75MG;3.75MG	A214347	005	Nov 22, 2021	Jul DISC
@		5MG;5MG;5MG;5MG	A214347	006	Nov 22, 2021	Jul DISC
@		7.5MG;7.5MG;7.5MG;7.5MG	A214347	007	Nov 22, 2021	Jul DISC
@	CEDIPROF INC	1.25MG;1.25MG;1.25MG;1.25MG	A210754	001	Jul 05, 2022	Oct DISC
AB		1.25MG;1.25MG;1.25MG;1.25MG	A210754	001	Jul 05, 2022	Jun NEWA
@		2.5MG;2.5MG;2.5MG;2.5MG	A210754	002	Jul 05, 2022	Oct DISC
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210754	002	Jul 05, 2022	Jun NEWA

TABLET;ORAL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

	@		3.75MG;3.75MG;3.75MG;3.75MG	A210754	003	Jul 05, 2022	Oct DISC
AB			3.75MG;3.75MG;3.75MG;3.75MG	A210754	003	Jul 05, 2022	Jun NEWA
	@		5MG;5MG;5MG;5MG	A210754	004	Jul 05, 2022	Oct DISC
AB			5MG;5MG;5MG;5MG	A210754	004	Jul 05, 2022	Jun NEWA
	@		7.5MG;7.5MG;7.5MG;7.5MG	A210754	005	Jul 05, 2022	Oct DISC
AB			7.5MG;7.5MG;7.5MG;7.5MG	A210754	005	Jul 05, 2022	Jun NEWA
	@	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A215565	001	Jul 08, 2022	Sep DISC
AB			1.25MG;1.25MG;1.25MG;1.25MG	A215565	001	Jul 08, 2022	Jul NEWA
	@		1.875MG;1.875MG;1.875MG;1.875MG	A215565	002	Jul 08, 2022	Sep DISC
AB			1.875MG;1.875MG;1.875MG;1.875MG	A215565	002	Jul 08, 2022	Jul NEWA
	@		2.5MG;2.5MG;2.5MG;2.5MG	A215565	003	Jul 08, 2022	Sep DISC
AB			2.5MG;2.5MG;2.5MG;2.5MG	A215565	003	Jul 08, 2022	Jul NEWA
	@		3.125MG;3.125MG;3.125MG;3.125MG	A215565	004	Jul 08, 2022	Sep DISC
AB			3.125MG;3.125MG;3.125MG;3.125MG	A215565	004	Jul 08, 2022	Jul NEWA
	@		3.75MG;3.75MG;3.75MG;3.75MG	A215565	005	Jul 08, 2022	Sep DISC
AB			3.75MG;3.75MG;3.75MG;3.75MG	A215565	005	Jul 08, 2022	Jul NEWA
	@		5MG;5MG;5MG;5MG	A215565	006	Jul 08, 2022	Sep DISC
AB			5MG;5MG;5MG;5MG	A215565	006	Jul 08, 2022	Jul NEWA
	@		7.5MG;7.5MG;7.5MG;7.5MG	A215565	007	Jul 08, 2022	Sep DISC
AB			7.5MG;7.5MG;7.5MG;7.5MG	A215565	007	Jul 08, 2022	Jul NEWA
AB		ZYDUS PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A207340	001	Oct 31, 2017	Mar CAHN
AB			1.875MG;1.875MG;1.875MG;1.875MG	A207340	002	Oct 31, 2017	Mar CAHN
AB			2.5MG;2.5MG;2.5MG;2.5MG	A207340	003	Oct 31, 2017	Mar CAHN
AB			3.125MG;3.125MG;3.125MG;3.125MG	A207340	004	Oct 31, 2017	Mar CAHN
AB			3.75MG;3.75MG;3.75MG;3.75MG	A207340	005	Oct 31, 2017	Mar CAHN
AB			5MG;5MG;5MG;5MG	A207340	006	Oct 31, 2017	Mar CAHN
AB			7.5MG;7.5MG;7.5MG;7.5MG	A207340	007	Oct 31, 2017	Mar CAHN

AMPHETAMINE SULFATE

TABLET;ORAL
AMPHETAMINE SULFATE

AA		RISE PHARMA	5MG	A212901	001	May 22, 2020	Sep CAHN
AA			10MG	A212901	002	May 22, 2020	Sep CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
EVEKEO ODT

	+ @	AZURITY	2.5MG	N209905	005	Apr 16, 2021	Apr CAHN
	+		5MG	N209905	001	Jan 30, 2019	Apr CAHN
	+		10MG	N209905	002	Jan 30, 2019	Apr CAHN
	+		15MG	N209905	003	Jan 30, 2019	Apr CAHN
	+!		20MG	N209905	004	Jan 30, 2019	Apr CAHN

AMPHOTERICIN B

INJECTABLE, LIPOSOMAL;INJECTION
AMPHOTERICIN B

>A> AB		EUGIA PHARMA	50MG/VIAL	A214010	001	Nov 17, 2022	Nov NEWA

AMPICILLIN SODIUM

INJECTABLE;INJECTION
AMPICILLIN SODIUM

	@	MYLAN LABS LTD	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Aug DISC
	@		EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Aug DISC

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL
ANAGRELIDE HYDROCHLORIDE

	@	RISING	EQ 0.5MG BASE	A077613	001	Jun 27, 2006	Oct CAHN
	@		EQ 1MG BASE	A077613	002	Jun 27, 2006	Oct CAHN

APOMORPHINE HYDROCHLORIDE

INJECTABLE;SUBCUTANEOUS
APOKYN

AP	+!	MDD US	30MG/3ML (10MG/ML)	N021264	002	Apr 20, 2004	Feb CFTG

APOMORPHINE HYDROCHLORIDE

AP		SAGE CHEMS	30MG/3ML (10MG/ML)	A212025	001	Feb 23, 2022	Feb NFTG

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

IOPIDINE

AT	+!	IMPRIMIS PHARMS USA	EQ 0.5% BASE	N020258	001	Jul 30, 1993	Jun CAHN
	+!		EQ 1% BASE	N019779	001	Dec 31, 1987	Jun CAHN

APREMILAST

TABLET;ORAL

APREMILAST

	@	AMNEAL	10MG	A211782	001	Jun 30, 2021	Jan DISC
	@		20MG	A211782	002	Jun 30, 2021	Jan DISC
	@		30MG	A211782	003	Jun 30, 2021	Jan DISC
AB		TEVA PHARMS USA INC	10MG	A211897	001	Aug 18, 2022	Aug NEWA
AB			20MG	A211897	002	Aug 18, 2022	Aug NEWA
AB			30MG	A211897	003	Aug 18, 2022	Aug NEWA

APREPITANT

EMULSION;INTRAVENOUS

APONVIE

	+!	HERON THERAPS INC	32MG/4.4ML (7.2MG/ML)	N216457	001	Sep 16, 2022	Sep NEWA

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION

ARFORMOTEROL TARTRATE

AN		ALEMBIC PHARMS LTD	EQ 0.015MG BASE/2ML	A214779	001	May 10, 2022	Apr NEWA
AN		LUPIN	EQ 0.015MG BASE/2ML	A213068	001	Feb 07, 2022	Jan NEWA
>A> AN		MANKIND PHARMA	EQ 0.015MG BASE/2ML	A216128	001	Nov 15, 2022	Nov NEWA
	@	RITEDOSE CORP	EQ 0.015MG BASE/2ML	A214736	001	Mar 02, 2022	Sep CAHN
AN		SLATE RUN PHARMA	EQ 0.015MG BASE/2ML	A213762	001	Jun 22, 2021	Sep CAHN
>A> AN		SLAYBACK PHARMA LLC	EQ 0.015MG BASE/2ML	A216815	001	Nov 25, 2022	Nov NEWA
AN		SUN PHARM	EQ 0.015MG BASE/2ML	A215385	001	May 26, 2022	May NEWA
AN		TAP	EQ 0.015MG BASE/2ML	A213762	001	Jun 22, 2021	Apr CAHN
	@	VISTAPHARM	EQ 0.015MG BASE/2ML	A214736	001	Mar 02, 2022	Aug DISC
AN			EQ 0.015MG BASE/2ML	A214736	001	Mar 02, 2022	Feb NEWA

BROVANA

>A> AN	+!	LUPIN	EQ 0.015MG BASE/2ML	N021912	001	Oct 06, 2006	Nov CAHN
>D> AN	+!	SUNOVION	EQ 0.015MG BASE/2ML	N021912	001	Oct 06, 2006	Nov CAHN

ARGATROBAN

INJECTABLE;INTRAVENOUS

ARGATROBAN IN SODIUM CHLORIDE

	+ @	CIPLA	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011	Apr CAHN

ARIPIPRAZOLE

SOLUTION;ORAL

ARIPIPRAZOLE

AA		GLASSHOUSE PHARMS	1MG/ML	A215595	001	Oct 25, 2022	Oct NEWA
AA		RUBICON	1MG/ML	A216351	001	Oct 27, 2022	Oct NEWA

TABLET;ORAL

ABILIFY

>D> AB	+!	OTSUKA	5MG	N021436	005	Nov 15, 2002	Nov CHRS
>A> AB	+		5MG	N021436	005	Nov 15, 2002	Nov CHRS

ARSENIC TRIOXIDE

INJECTABLE;INJECTION

ARSENIC TRIOXIDE

AP	!	FRESENIUS KABI USA	1MG/ML	A208231	001	Aug 31, 2018	Apr CHRS
AP		GLAND PHARMA LTD	1MG/ML	A215059	002	Apr 22, 2022	Apr NEWA

ARTESUNATE

POWDER;INTRAVENOUS

ARTESUNATE

	+!	AMIVAS	110MG/VIAL	N213036	001	May 26, 2020	Feb CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION;INTRAVENOUS

M.V.I. PEDIATRIC

	+ @	HOSPIRA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL ;5MG/VIAL;0.01MG/VIAL;0.14	N018920	001	Sep 21, 2000	Jan DISC

FOR SOLUTION;INTRAVENOUS
M.V.I. PEDIATRIC

			MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL				

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE;INTRAVENOUS
M.V.I. ADULT

	+ @	HOSPIRA	200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL	N021625	001	Jan 30, 2004	Jan DISC

M.V.I. ADULT (PHARMACY BULK PACKAGE)

	+ @	HOSPIRA	200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML	N021643	001	Feb 18, 2004	Jan DISC

ASENAPINE

SYSTEM;TRANSDERMAL
SECUADO

	+!	HISAMITSU	3.8MG/24HR	N212268	001	Oct 11, 2019	Mar CHRS
	+		7.6MG/24HR	N212268	003	Oct 11, 2019	Mar CHRS

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
BUTALBITAL, ASPIRIN AND CAFFEINE

	@	LGM PHARMA	500MG;50MG;40MG	A205230	001	Oct 18, 2021	Apr DISC
AA		NOSTRUM LABS INC	325MG;50MG;40MG	A078149	001	Jun 13, 2007	Apr CMFD

FIORINAL

	+ @	ALLERGAN	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Jun DISC
AA	+		325MG;50MG;40MG	N017534	005	Apr 16, 1986	Apr CHRS

LANORINAL

AA	!	LANNETT	325MG;50MG;40MG	A086996	002	Oct 11, 1985	Apr CHRS

TABLET;ORAL
BUTALBITAL, ASPIRIN AND CAFFEINE

	+ @	HIKMA INTL PHARMS	325MG;50MG;40MG	A086162	002	Feb 16, 1984	Mar CRLD

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

	@	MAYNE PHARMA INC	325MG;50MG;40MG;30MG	A203335	001	Oct 30, 2015	Jan DISC
AB	!	STEVENS J	325MG;50MG;40MG;30MG	A074951	001	Aug 31, 1998	May CHRS

FIORINAL W/CODEINE

	+ @	ALLERGAN	325MG;50MG;40MG;30MG	N019429	003	Oct 26, 1990	May DISC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL
ORPHENGESIC

		GALT PHARMS	385MG;30MG;25MG	A075141	001	May 29, 1998	Mar CMFD

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

	@	INGENUS PHARMS NJ	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Jul DISC

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL
AGGRENOX

	+ @	BOEHRINGER INGELHEIM	25MG;200MG	N020884	001	Nov 22, 1999	Oct DISC

ASPIRIN AND DIPYRIDAMOLE

AB	!	GLENMARK PHARMS SA	25MG;200MG	A210318	001	May 24, 2019	Oct CHRS

ASPIRIN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ASPIRIN

	!	LGM PHARMA	500MG;5MG	A205479	001	May 28, 2021	Jul CMFD

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

AB		HETERO LABS LTD III	EQ 150MG BASE	A212278	001	Feb 02, 2022	Jan NEWA
AB			EQ 200MG BASE	A212278	002	Feb 02, 2022	Jan NEWA
AB			EQ 300MG BASE	A212278	003	Feb 02, 2022	Jan NEWA

REYATAZ

	+ @	BRISTOL MYERS SQUIBB	EQ 150MG BASE	N021567	002	Jun 20, 2003	Apr DISC

ATENOLOL

TABLET;ORAL

ATENOLOL

>A>	@	CHARTWELL RX	25MG	A074265	001	Feb 28, 1994	Nov CAHN
>A>	@		50MG	A074265	002	Feb 28, 1994	Nov CAHN
>A>	@		100MG	A074265	003	Feb 28, 1994	Nov CAHN
>D>	@	INVATECH	25MG	A074265	001	Feb 28, 1994	Nov CAHN
>D>	@		50MG	A074265	002	Feb 28, 1994	Nov CAHN
>D>	@		100MG	A074265	003	Feb 28, 1994	Nov CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

>D>	@	MYLAN	10MG	A079021	001	Feb 18, 2021	Nov CAHN
>D>	@		18MG	A079021	002	Feb 18, 2021	Nov CAHN
>D>	@		25MG	A079021	003	Feb 18, 2021	Nov CAHN
>D>	@		40MG	A079021	004	Feb 18, 2021	Nov CAHN
>D>	@		60MG	A079021	005	Feb 18, 2021	Nov CAHN
>D>	@		80MG	A079021	006	Feb 18, 2021	Nov CAHN
>D>	@		100MG	A079021	007	Feb 18, 2021	Nov CAHN
>A>	@	STRIDES PHARMA	10MG	A079021	001	Feb 18, 2021	Nov CAHN
>A>	@		18MG	A079021	002	Feb 18, 2021	Nov CAHN
>A>	@		25MG	A079021	003	Feb 18, 2021	Nov CAHN
>A>	@		40MG	A079021	004	Feb 18, 2021	Nov CAHN
>A>	@		60MG	A079021	005	Feb 18, 2021	Nov CAHN
>A>	@		80MG	A079021	006	Feb 18, 2021	Nov CAHN
>A>	@		100MG	A079021	007	Feb 18, 2021	Nov CAHN

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		AGNITIO	EQ 10MG BASE	A214969	001	Sep 02, 2021	Sep CAHN
AB			EQ 20MG BASE	A214969	002	Sep 02, 2021	Sep CAHN
AB			EQ 40MG BASE	A214969	003	Sep 02, 2021	Sep CAHN
AB			EQ 80MG BASE	A214969	004	Sep 02, 2021	Sep CAHN
>A> AB		BIOCON PHARMA	EQ 10MG BASE	A216436	001	Nov 23, 2022	Nov NEWA
>A> AB			EQ 20MG BASE	A216436	002	Nov 23, 2022	Nov NEWA
>A> AB			EQ 40MG BASE	A216436	003	Nov 23, 2022	Nov NEWA
>A> AB			EQ 80MG BASE	A216436	004	Nov 23, 2022	Nov NEWA
AB		DR REDDYS	EQ 10MG BASE	A214659	001	Jul 14, 2021	Aug CMFD
AB			EQ 20MG BASE	A214659	002	Jul 14, 2021	Aug CMFD
AB			EQ 40MG BASE	A214659	003	Jul 14, 2021	Aug CMFD
AB			EQ 80MG BASE	A214659	004	Jul 14, 2021	Aug CMFD
AB		LEPU PHARM	EQ 10MG BASE	A216848	001	Nov 03, 2022	Oct NEWA
AB			EQ 20MG BASE	A216848	002	Nov 03, 2022	Oct NEWA
AB			EQ 40MG BASE	A216848	003	Nov 03, 2022	Oct NEWA
AB			EQ 80MG BASE	A216848	004	Nov 03, 2022	Oct NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LYPQOZET

		SCOV3	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Sep CTNA
			EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Sep CMFD
			EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Sep CTNA
			EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Sep CMFD
			EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Sep CTNA
			EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Sep CMFD
	!		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Sep CTNA

```
        TABLET;ORAL
          LYPQOZET
        !                        EQ 80MG BASE;10MG                  A206084  004  Apr 26, 2017   Sep CMFD

      ATOVAQUONE
        SUSPENSION;ORAL
          ATOVAQUONE
    AB      CHARTWELL RX         750MG/5ML                          A207833  001  Apr 28, 2017   Oct CAHN

      ATROPINE
        SOLUTION;INTRAMUSCULAR
          ATROPEN
        +!  MMT                  EQ 0.25MG SULFATE/0.3ML            N017106  004  Sep 17, 2004   May CAHN
        +!                       EQ 0.5MG SULFATE/0.7ML             N017106  003  Jun 19, 2003   May CAHN
        +!                       EQ 1MG SULFATE/0.7ML               N017106  002  Jun 19, 2003   May CAHN
        +!                       EQ 2MG SULFATE/0.7ML               N017106  001                  May CAHN

      ATROPINE SULFATE
        SOLUTION;INTRAVENOUS
          ATROPINE SULFATE
    AP  +!  ACCORD HLTHCARE      0.4MG/ML (0.4MG/ML)                N214652  001  Sep 29, 2020   May CFTG
    AP  +!                       1MG/ML (1MG/ML)                    N214652  002  Sep 29, 2020   May CFTG
    AP      AM REGENT            0.4MG/ML (0.4MG/ML)                A216120  001  May 26, 2022   May NFTG
    AP                           1MG/ML (1MG/ML)                    A216120  002  May 26, 2022   May NFTG
    AP      AMNEAL               0.5MG/5ML (0.1MG/ML)               A215342  001  Jan 26, 2022   Jan NEWA
    AP  +!  HOSPIRA              0.5MG/5ML (0.1MG/ML)               N021146  001  Jul 09, 2001   Jan CMFD
    AP      MEDEFIL INC          1MG/10ML (0.1MG/ML)                A214970  001  Nov 04, 2022   Oct NEWA
        SOLUTION/DROPS;OPHTHALMIC
          ATROPINE SULFATE
    AT      AMNEAL               1%                                 A214752  001  Jul 14, 2022   Jul NEWA
        +!  BAUSCH AND LOMB INC  1%                                 N213581  001  Mar 15, 2022   Jul CAHN
        +!  PARAGON BIOTECK       1%                                 N213581  001  Mar 15, 2022   Jul NEWA

      ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE
        TABLET;ORAL
          DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE
    AA      CHARTWELL RX         0.025MG;2.5MG                      A207128  001  Oct 21, 2020   Jun CAHN
          @ MAYNE PHARMA INC     0.025MG;2.5MG                      A210789  001  Jun 03, 2020   Jan DISC

      ATROPINE; PRALIDOXIME CHLORIDE
        INJECTABLE;INTRAMUSCULAR
          DUODOTE
        +!  MMT                  2.1MG/0.7ML;600MG/2ML              N021983  001  Sep 28, 2006   Jan CAHN

      AZACITIDINE
        POWDER;INTRAVENOUS, SUBCUTANEOUS
          AZACITIDINE
    AP      AMNEAL               100MG/VIAL                         A211549  001  Feb 03, 2022   Jan NEWA
>D> AP      MYLAN INSTITUTIONAL  100MG/VIAL                         A204949  001  Apr 28, 2016   Nov DISC
>A>       @                      100MG/VIAL                         A204949  001  Apr 28, 2016   Nov DISC
          VIDAZA
    AP  +!  BRISTOL-MYERS        100MG/VIAL                         N050794  001  May 19, 2004   Oct CAHN
        TABLET;ORAL
          ONUREG
>A>     +   BRISTOL              200MG                              N214120  001  Sep 01, 2020   Nov CAHN
>A>     +!                       300MG                              N214120  002  Sep 01, 2020   Nov CAHN
>D>     +   CELGENE CORP         200MG                              N214120  001  Sep 01, 2020   Nov CAHN
>D>     +!                       300MG                              N214120  002  Sep 01, 2020   Nov CAHN

      AZELASTINE HYDROCHLORIDE
        SOLUTION/DROPS;OPHTHALMIC
          AZELASTINE HYDROCHLORIDE
          @ AKORN                0.05%                              A203660  001  Nov 08, 2016   Aug DISC
        SPRAY, METERED;NASAL
          AZELASTINE HYDROCHLORIDE
          @ APOTEX INC           0.2055MG/SPRAY                     A201846  001  Aug 31, 2012   May DISC
          @ AUROBINDO PHARMA LTD 0.2055MG/SPRAY                     A212775  001  Nov 12, 2020   May DISC
          @ HIKMA                0.2055MG/SPRAY                     A207243  001  Sep 22, 2017   May DISC
```

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

AZILSARTAN MEDOXOMIL

		@ LUPIN LTD	EQ 40MG MEDOXOMIL	A214489	001	Jul 20, 2022	Aug DISC
	AB		EQ 40MG MEDOXOMIL	A214489	001	Jul 20, 2022	Jul NFTG
		@	EQ 80MG MEDOXOMIL	A214489	002	Jul 20, 2022	Aug DISC
	AB		EQ 80MG MEDOXOMIL	A214489	002	Jul 20, 2022	Jul NFTG

EDARBI

	+	AZURITY	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Aug CTEC
	AB +		EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Jul CFTG
	+		EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Mar CAHN
	+!		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Aug CTEC
	AB +!		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Jul CFTG
	+!		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Mar CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

	+	AZURITY	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Mar CAHN
	+!		EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Mar CAHN

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

>A>		@ CHARTWELL RX	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	Nov CAHN
>A>		@	EQ 200MG BASE/5ML	A065488	002	May 15, 2015	Nov CAHN
>D>		@ LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	Nov CAHN
>D>		@	EQ 200MG BASE/5ML	A065488	002	May 15, 2015	Nov CAHN
		@ TARO	EQ 200MG BASE/5ML	A211521	001	Dec 11, 2019	Sep DISC

SOLUTION/DROPS;OPHTHALMIC

AZASITE

	+!	THEA PHARMA	1%	N050810	001	Apr 27, 2007	Apr CAHN

TABLET;ORAL

AZITHROMYCIN

	AB	ACI	EQ 250MG BASE	A215772	001	Jul 15, 2022	Jul NEWA
	AB		EQ 500MG BASE	A215773	001	Jul 12, 2022	Jul NEWA
	AB	YUNG SHIN PHARM	EQ 250MG BASE	A211317	001	Jul 26, 2022	Jul NEWA

BACLOFEN

GRANULES;ORAL

LYVISPAH

	+	AMNEAL	5MG/PACKET	N215422	001	Nov 22, 2021	Feb CAHN
	+		10MG/PACKET	N215422	002	Nov 22, 2021	Feb CAHN
	+!		20MG/PACKET	N215422	003	Nov 22, 2021	Feb CAHN

INJECTABLE;INTRATHECAL

BACLOFEN

	AP	AMNEAL	0.05MG/ML	A091193	001	May 03, 2016	Jun CAHN
	AP		0.5MG/ML	A091193	002	May 03, 2016	Jun CAHN
	AP		2MG/ML	A091193	003	May 03, 2016	Jun CAHN

LIORESAL

	AP +!	AMNEAL	0.05MG/ML	N020075	003	Nov 07, 1996	Feb CAHN
	AP +!		0.5MG/ML	N020075	001	Jun 17, 1992	Feb CAHN
	AP +!		2MG/ML	N020075	002	Jun 17, 1992	Feb CAHN

SUSPENSION;ORAL

FLEQSUVY

	+!	AZURITY	25MG/5ML	N215602	001	Feb 04, 2022	Feb NEWA

TABLET;ORAL

BACLOFEN

	AB	MANKIND PHARMA	5MG	A215885	001	Jan 25, 2022	Jan NEWA
	AB		10MG	A215885	002	Jan 25, 2022	Jan NEWA
	AB		20MG	A215885	003	Jan 25, 2022	Jan NEWA

BARICITINIB

TABLET;ORAL

OLUMIANT

>D>	+!	ELI LILLY AND CO	2MG	N207924	001	May 31, 2018	Nov CHRS
>A>	+		2MG	N207924	001	May 31, 2018	Nov CHRS
>D>	+		4MG	N207924	003	May 10, 2022	Nov CHRS
>A>	+!		4MG	N207924	003	May 10, 2022	Nov CHRS
	+		4MG	N207924	003	May 10, 2022	May NEWA

BELINOSTAT

POWDER;INTRAVENOUS

BELEODAQ

	+!	ACROTECH BIOPHARMA	500MG/VIAL	N206256	001	Jul 03, 2014	Oct CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB	!	AUROBINDO PHARMA	40MG	A078212	003	May 22, 2008	Oct CHRS

LOTENSIN

	+ @	VALIDUS PHARMS	5MG	N019851	001	Jun 25, 1991	Jun DISC
AB	+		40MG	N019851	004	Jun 25, 1991	Oct CHRS

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		ANI PHARMS	5MG;6.25MG	A076342	001	Feb 11, 2004	Oct CMFD
AB			10MG;12.5MG	A076342	002	Feb 11, 2004	Oct CMFD
AB			20MG;12.5MG	A076342	003	Feb 11, 2004	Oct CMFD
AB			20MG;25MG	A076342	004	Feb 11, 2004	Oct CMFD
>D>		SANDOZ	5MG;6.25MG	A076631	001	Feb 11, 2004	Nov CTEC
>A> AB			5MG;6.25MG	A076631	001	Feb 11, 2004	Nov CTEC

BENDAMUSTINE HYDROCHLORIDE

POWDER;IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

>D> AP		ACCORD HLTHCARE	25MG/VIAL	A205574	001	May 19, 2016	Nov NFTG
>A> AP			25MG/VIAL	A205574	001	Dec 07, 2022	Nov NFTG
>D> AP			100MG/VIAL	A205574	002	May 19, 2016	Nov NFTG
>A> AP			100MG/VIAL	A205574	002	Dec 07, 2022	Nov NFTG
>A> AP		DR REDDYS	25MG/VIAL	A205376	001	Dec 07, 2022	Nov NFTG
>A> AP			100MG/VIAL	A205376	002	Dec 07, 2022	Nov NFTG

TREANDA

>D>	+!	CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Nov CFTG
>A> AP	+!		25MG/VIAL	N022249	002	May 01, 2009	Nov CFTG
>D>	+!		100MG/VIAL	N022249	001	Mar 20, 2008	Nov CFTG
>A> AP	+!		100MG/VIAL	N022249	001	Mar 20, 2008	Nov CFTG

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA		ACELLA	100MG	A091310	001	Jan 16, 2015	Jan CAHN
AA			200MG	A091310	002	Jan 16, 2015	Jan CAHN
AA		CHARTWELL RX	100MG	A210562	001	Nov 09, 2018	Oct CAHN
AA			150MG	A210562	002	Nov 09, 2018	Oct CAHN
AA			200MG	A210562	003	Nov 09, 2018	Oct CAHN
AA	!	THEPHARMANETWORK LLC	100MG	A040627	002	Mar 30, 2007	Jan CMS1
AA	!		150MG	A040627	003	Sep 24, 2014	Jan CMS1
AA	!		200MG	A040627	002	Jul 25, 2007	Mar CMS1

BENZOYL PEROXIDE

CREAM;TOPICAL

EPSOLAY

	+!	GALDERMA LABS LP	5%	N214510	001	Apr 22, 2022	Jun CAHN
	+!	SOL GEL TECHNOLOGIES	5%	N214510	001	Apr 22, 2022	Apr NEWA

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL

ERYTHROMYCIN AND BENZOYL PEROXIDE

	@	ENCUBE	5%;3%	A065112	001	Mar 29, 2004	Jul CAHN

BENZOYL PEROXIDE; TRETINOIN

CREAM;TOPICAL

TWYNEO

	+!	GALDERMA LABS LP	3%;0.1%	N214902	001	Jul 26, 2021	Mar CMFD
	+ @		3%;0.1%	N214902	001	Jul 26, 2021	Feb CAHN
	+ @	SOL-GEL TECHNOLOGIES	3%;0.1%	N214902	001	Jul 26, 2021	Jan DISC

BENZPHETAMINE HYDROCHLORIDE

	TABLET;ORAL						
	BENZPHETAMINE HYDROCHLORIDE						
	CHARTWELL	25MG	A090473	001	Sep 15, 2010	Apr	CAHN
AA		50MG	A090473	002	Sep 15, 2010	Apr	CAHN
	MIKART	25MG	A090473	001	Sep 15, 2010	Mar	CAHN
AA		50MG	A090473	002	Sep 15, 2010	Mar	CAHN

BENZTROPINE MESYLATE

	INJECTABLE;INJECTION						
	BENZTROPINE MESYLATE						
AP	! HIKMA FARMACEUTICA	1MG/ML	A090287	001	Aug 31, 2009	Mar	CHRS
	COGENTIN						
	+ @ AKORN	1MG/ML	N012015	001		Mar	DISC
	TABLET;ORAL						
	BENZTROPINE MESYLATE						
>A>	@ AIPING PHARM INC	0.5MG	A040103	001	Dec 12, 1996	Nov	CAHN
>A>	@	1MG	A040103	002	Dec 12, 1996	Nov	CAHN
>A>	@	2MG	A040103	003	Dec 12, 1996	Nov	CAHN
>D>	@ UPSHER SMITH LABS	0.5MG	A040103	001	Dec 12, 1996	Nov	CAHN
>D>	@	1MG	A040103	002	Dec 12, 1996	Nov	CAHN
>D>	@	2MG	A040103	003	Dec 12, 1996	Nov	CAHN

BETAINE

	FOR SOLUTION;ORAL						
	BETAINE						
AB	ETON	1GM/SCOOPFUL	A210508	001	Jan 28, 2022	Sep	CAHN
AB	LUKARE MEDICAL LLC	1GM/SCOOPFUL	A210508	001	Jan 28, 2022	Jan	NEWA

BETAMETHASONE DIPROPIONATE

	LOTION;TOPICAL						
	BETAMETHASONE DIPROPIONATE						
	@ AKORN	EQ 0.05% BASE	A209896	001	Feb 06, 2018	Sep	DISC
	LOTION, AUGMENTED;TOPICAL						
	BETAMETHASONE DIPROPIONATE						
AB	PAI HOLDINGS PHARM	EQ 0.05% BASE	A206389	001	Feb 13, 2018	Aug	CAHN
	OINTMENT;TOPICAL						
	BETAMETHASONE DIPROPIONATE						
AB	PADAGIS ISRAEL	EQ 0.05% BASE	A215847	001	Apr 12, 2022	Apr	NEWA
AB	TASMAN PHARMA	EQ 0.05% BASE	A215186	001	Feb 18, 2022	Feb	NEWA
	OINTMENT, AUGMENTED;TOPICAL						
	BETAMETHASONE DIPROPIONATE						
AB	PAI HOLDINGS PHARM	EQ 0.05% BASE	A206118	001	Nov 09, 2017	Aug	CAHN

BETAMETHASONE VALERATE

	AEROSOL, FOAM;TOPICAL						
	BETAMETHASONE VALERATE						
	@ NOVAST LABS	0.12%	A207144	001	May 24, 2017	Aug	CAHN

BETHANECHOL CHLORIDE

	TABLET;ORAL						
	BETHANECHOL CHLORIDE						
AA	AIPING LIFE SCI	5MG	A040728	002	Oct 26, 2007	Oct	CAHN
AA		10MG	A040728	003	Oct 26, 2007	Oct	CAHN
AA		25MG	A040728	004	Oct 26, 2007	Oct	CAHN
AA		50MG	A040728	001	Oct 26, 2007	Oct	CAHN

BEXAROTENE

	GEL;TOPICAL						
	BEXAROTENE						
AB	AMNEAL	1%	A215398	001	Apr 27, 2022	Apr	NFTG
	TARGRETIN						
AB	+! BAUSCH	1%	N021056	001	Jun 28, 2000	Apr	CFTG

BIMATOPROST

	SOLUTION/DROPS;OPHTHALMIC						
	BIMATOPROST						
AT	EUGIA PHARMA	0.03%	A205537	001	Oct 06, 2022	Sep	NEWA

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB		CADILA	5MG	A215680	001	Jul 25, 2022	Jul NEWA
AB			10MG	A215680	002	Jul 25, 2022	Jul NEWA
AB		UNITED RES LABS	5MG	A075474	001	Oct 25, 2002	Apr CAHN
AB			10MG	A075474	002	Oct 25, 2002	Apr CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB		CADILA	2.5MG;6.25MG	A215666	001	Nov 04, 2022	Oct NEWA
AB			5MG;6.25MG	A215666	002	Nov 04, 2022	Oct NEWA
AB			10MG;6.25MG	A215666	003	Nov 04, 2022	Oct NEWA
>A>	@	CHARTWELL RX	2.5MG;6.25MG	A075527	001	Sep 25, 2000	Nov CAHN
>A>	@		5MG;6.25MG	A075527	003	Sep 25, 2000	Nov CAHN
>A>	@		10MG;6.25MG	A075527	002	Sep 25, 2000	Nov CAHN
AB		GLENMARK PHARMS LTD	2.5MG;6.25MG	A215995	001	Jan 26, 2022	Jan NEWA
AB			5MG;6.25MG	A215995	002	Jan 26, 2022	Jan NEWA
AB			10MG;6.25MG	A215995	003	Jan 26, 2022	Jan NEWA
>D>	@	SANDOZ	2.5MG;6.25MG	A075527	001	Sep 25, 2000	Nov CAHN
>D>	@		5MG;6.25MG	A075527	003	Sep 25, 2000	Nov CAHN
>D>	@		10MG;6.25MG	A075527	002	Sep 25, 2000	Nov CAHN

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

BIVALIRUDIN

AP		MEITHEAL	250MG/VIAL	A091602	001	Jul 16, 2018	Apr CAHN

SOLUTION;INTRAVENOUS

BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

	+ @	BAXTER HLTHCARE CORP	250MG/50ML (5MG/ML)	N208374	001	Dec 21, 2017	Oct DISC
	+ @		500MG/100ML (5MG/ML)	N208374	002	Dec 21, 2017	Oct DISC

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

AP		ACCORD HLTHCARE	3.5MG/VIAL	A204405	001	Jul 26, 2022	Jul NEWA
AP		APOTEX	3.5MG/VIAL	A205533	001	May 02, 2022	Apr NFTG
AP		BAXTER HLTHCARE CORP	3.5MG/VIAL	A213823	001	May 02, 2022	Apr NFTG
AP		DR REDDYS	3.5MG/VIAL	A202963	001	Jul 26, 2022	Jul NEWA
AP		EUGIA PHARMA	3.5MG/VIAL	A212825	001	May 02, 2022	Apr NFTG
AP		FRESENIUS KABI USA	3.5MG/VIAL	A209659	001	May 02, 2022	Apr NFTG
AP		HOSPIRA	3.5MG/VIAL	A208460	001	Jul 26, 2022	Jul NEWA
AP		JIANGSU HANSOH PHARM	3.5MG/VIAL	A215011	001	Jul 26, 2022	Jul NEWA
AP		KINDOS	3.5MG/VIAL	A212958	001	Jul 26, 2022	Jul NEWA
AP		MEITHEAL	3.5MG/VIAL	A212958	001	Jul 26, 2022	Sep CAHN
AP		MSN	3.5MG/VIAL	A209622	001	Jul 26, 2022	Jul NEWA
>D> AP		MYLAN LABS LTD	3.5MG/VIAL	A205160	001	Oct 31, 2022	Nov DISC
>A>	@		3.5MG/VIAL	A205160	001	Oct 31, 2022	Nov DISC
AP			3.5MG/VIAL	A205160	001	Oct 31, 2022	Oct NEWA
AP		PHARMASCIENCE INC	3.5MG/VIAL	A208392	001	May 02, 2022	Apr NFTG
AP		QILU PHARM HAINAN	3.5MG/VIAL	A210824	001	May 02, 2022	Apr NFTG
AP		SANDOZ INC	3.5MG/VIAL	A203654	001	Jul 26, 2022	Jul NEWA
	@	TEVA PHARMS USA	3.5MG/VIAL	A205857	001	May 02, 2022	Oct DISC
AP			3.5MG/VIAL	A205857	001	May 02, 2022	Apr NFTG
AP		WAVERLEY PHARMA INC	3.5MG/VIAL	A211898	001	Oct 11, 2022	Sep NEWA
AP		ZYDUS PHARMS	3.5MG/VIAL	A210204	001	May 02, 2022	Apr NFTG

VELCADE

AP	+!	TAKEDA PHARMS USA	3.5MG/VIAL	N021602	001	May 13, 2003	Apr CFTG

POWDER;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

	+!	HOSPIRA	1MG/VIAL	N209191	001	May 02, 2022	May NEWA
	+!		2.5MG/VIAL	N209191	002	May 02, 2022	May NEWA

SOLUTION;INTRAVENOUS

BORTEZOMIB

	+!	ACCORD HLTHCARE	2.5MG/ML (2.5MG/ML)	N215441	001	Jul 26, 2022	Jul NEWA
	+!		3.5MG/1.4ML (2.5MG/ML)	N215441	002	Jul 26, 2022	Jul NEWA
	+ @	MAIA PHARMS INC	3.5MG/3.5ML (1MG/ML)	N215331	001	Jul 27, 2022	Oct DISC
	+!		3.5MG/3.5ML (1MG/ML)	N215331	001	Jul 27, 2022	Jul NEWA
	+!		3.5MG/1.4ML (2.5MG/ML)	N215331	002	Jul 27, 2022	Jul NEWA

BOSENTAN

TABLET;ORAL

BOSENTAN

@	CHARTWELL MOLECULAR	62.5MG	A210342	001	Jan 03, 2020	Mar CAHN
@		125MG	A210342	002	Jan 03, 2020	Mar CAHN

BREXPIPRAZOLE

TABLET;ORAL

BREXPIPRAZOLE

AB		SANDOZ INC	0.25MG	A213570	001	Sep 26, 2022	Sep NEWA
AB			0.5MG	A213570	002	Sep 26, 2022	Sep NEWA
AB			1MG	A213570	003	Sep 26, 2022	Sep NEWA
AB			2MG	A213570	004	Sep 26, 2022	Sep NEWA
AB			3MG	A213570	005	Sep 26, 2022	Sep NEWA
AB			4MG	A213570	006	Sep 26, 2022	Sep NEWA
AB		TEVA PHARMS USA INC	0.25MG	A213692	001	Aug 11, 2022	Aug NFTG
AB			0.5MG	A213692	002	Aug 11, 2022	Aug NFTG
AB			1MG	A213692	003	Aug 11, 2022	Aug NFTG
AB			2MG	A213692	004	Aug 11, 2022	Aug NFTG
AB			3MG	A213692	005	Aug 11, 2022	Aug NFTG
AB			4MG	A213692	006	Aug 11, 2022	Aug NFTG

REXULTI

AB	+	OTSUKA	0.25MG	N205422	001	Jul 10, 2015	Aug CFTG
AB	+		0.5MG	N205422	002	Jul 10, 2015	Aug CFTG
AB	+		1MG	N205422	003	Jul 10, 2015	Aug CFTG
AB	+!		2MG	N205422	004	Jul 10, 2015	Aug CFTG
AB	+		3MG	N205422	005	Jul 10, 2015	Aug CFTG
AB	+		4MG	N205422	006	Jul 10, 2015	Aug CFTG

BRIMONIDINE TARTRATE

GEL;TOPICAL

BRIMONIDINE TARTRATE

>D>		@	PADAGIS ISRAEL	EQ 0.33% BASE	A209158	001	Sep 23, 2021	Nov CMFD
>A>	AB			EQ 0.33% BASE	A209158	001	Sep 23, 2021	Nov CMFD
		@		EQ 0.33% BASE	A209158	001	Sep 23, 2021	Apr DISC

MIRVASO

>D>		+!	GALDERMA LABS LP	EQ 0.33% BASE	N204708	001	Aug 23, 2013	Nov CTEC
>A>	AB	+!		EQ 0.33% BASE	N204708	001	Aug 23, 2013	Nov CTEC
		+!		EQ 0.33% BASE	N204708	001	Aug 23, 2013	Apr CTEC

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

AT		APOTEX	0.15%	A078479	001	Jan 31, 2022	Jan NEWA

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

AB		AKORN	0.2%;EQ 0.5% BASE	A091086	001	Oct 31, 2022	Oct NEWA
AB		APOTEX INC	0.2%;EQ 0.5% BASE	A091442	001	Apr 20, 2022	Apr NEWA
AB		SANDOZ INC	0.2%;EQ 0.5% BASE	A091087	001	Apr 04, 2022	Mar NFTG
AB		WATSON LABS TEVA	0.2%;EQ 0.5% BASE	A201949	001	Oct 04, 2022	Sep NEWA

COMBIGAN

AB	+!	ALLERGAN	0.2%;EQ 0.5% BASE	N021398	001	Oct 30, 2007	Mar CFTG

BRINCIDOFOVIR

SUSPENSION;ORAL

TEMBEXA

+!	EMERGENT BIODEFENSE	10MG/ML	N214460	001	Jun 04, 2021	Sep CAHN

TABLET;ORAL

TEMBEXA

+!	EMERGENT BIODEFENSE	100MG	N214461	001	Jun 04, 2021	Sep CAHN

BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

BRINZOLAMIDE

AB		BAUSCH AND LOMB	1%	A204884	001	Aug 18, 2021	Mar CAHN

BRIVARACETAM

TABLET;ORAL

BRIVARACETAM

		@	SUNSHINE	10MG	A214748	001	Jun 09, 2022	Aug DISC
	AB			10MG	A214748	001	Jun 09, 2022	Jun NFTG
		@		25MG	A214748	002	Jun 09, 2022	Aug DISC
	AB			25MG	A214748	002	Jun 09, 2022	Jun NFTG
		@		50MG	A214748	003	Jun 09, 2022	Aug DISC
	AB			50MG	A214748	003	Jun 09, 2022	Jun NFTG
		@		75MG	A214748	004	Jun 09, 2022	Aug DISC
	AB			75MG	A214748	004	Jun 09, 2022	Jun NFTG
		@		100MG	A214748	005	Jun 09, 2022	Aug DISC
	AB			100MG	A214748	005	Jun 09, 2022	Jun NFTG
>D>	AB		ZYDUS PHARMS	10MG	A214501	001	Oct 03, 2022	Nov DISC
>A>		@		10MG	A214501	001	Oct 03, 2022	Nov DISC
	AB			10MG	A214501	001	Oct 03, 2022	Sep NEWA
>D>	AB			25MG	A214501	002	Oct 03, 2022	Nov DISC
>A>		@		25MG	A214501	002	Oct 03, 2022	Nov DISC
	AB			25MG	A214501	002	Oct 03, 2022	Sep NEWA
>D>	AB			50MG	A214501	003	Oct 03, 2022	Nov DISC
>A>		@		50MG	A214501	003	Oct 03, 2022	Nov DISC
	AB			50MG	A214501	003	Oct 03, 2022	Sep NEWA
>D>	AB			75MG	A214501	004	Oct 03, 2022	Nov DISC
>A>		@		75MG	A214501	004	Oct 03, 2022	Nov DISC
	AB			75MG	A214501	004	Oct 03, 2022	Sep NEWA
>D>	AB			100MG	A214501	005	Oct 03, 2022	Nov DISC
>A>		@		100MG	A214501	005	Oct 03, 2022	Nov DISC
	AB			100MG	A214501	005	Oct 03, 2022	Sep NEWA

BRIVIACT

>D>	AB	+	UCB INC	10MG	N205836	001	May 12, 2016	Nov CTEC
>A>		+		10MG	N205836	001	May 12, 2016	Nov CTEC
	AB	+		10MG	N205836	001	May 12, 2016	Sep CTEC
		+		10MG	N205836	001	May 12, 2016	Aug CTEC
	AB	+		10MG	N205836	001	May 12, 2016	Jun CFTG
>D>	AB	+		25MG	N205836	002	May 12, 2016	Nov CTEC
>A>		+		25MG	N205836	002	May 12, 2016	Nov CTEC
	AB	+		25MG	N205836	002	May 12, 2016	Sep CTEC
		+		25MG	N205836	002	May 12, 2016	Aug CTEC
	AB	+		25MG	N205836	002	May 12, 2016	Jun CFTG
>D>	AB	+		50MG	N205836	003	May 12, 2016	Nov CTEC
>A>		+		50MG	N205836	003	May 12, 2016	Nov CTEC
	AB	+		50MG	N205836	003	May 12, 2016	Sep CTEC
		+		50MG	N205836	003	May 12, 2016	Aug CTEC
	AB	+		50MG	N205836	003	May 12, 2016	Jun CFTG
>D>	AB	+		75MG	N205836	004	May 12, 2016	Nov CTEC
>A>		+		75MG	N205836	004	May 12, 2016	Nov CTEC
	AB	+		75MG	N205836	004	May 12, 2016	Sep CTEC
		+		75MG	N205836	004	May 12, 2016	Aug CTEC
	AB	+		75MG	N205836	004	May 12, 2016	Jun CFTG
>D>	AB	+!		100MG	N205836	005	May 12, 2016	Nov CTEC
>A>		+!		100MG	N205836	005	May 12, 2016	Nov CTEC
	AB	+!		100MG	N205836	005	May 12, 2016	Sep CTEC
		+!		100MG	N205836	005	May 12, 2016	Aug CTEC
	AB	+!		100MG	N205836	005	May 12, 2016	Jun CFTG

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM

		@	CHARTWELL RX	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Apr CAHN
	AT2		EUGIA PHARMA	EQ 0.09% ACID	A204813	001	Mar 18, 2022	Mar NEWA
		@	VISTAPHARM	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Feb CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

	AA		PHARM ASSOC	2MG/5ML;10MG/5ML;30MG/5ML	A202940	001	Jul 21, 2014	Oct CMFD
		@	RHODES PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	A202955	001	Nov 05, 2020	Jun DISC

BUDESONIDE

CAPSULE, DELAYED RELEASE;ORAL

		BUDESONIDE					
	@	NATCO	3MG	A206724	001	Nov 23, 2016	Jan CAHN
	@	SCIECURE PHARMA INC	3MG	A209041	001	Sep 28, 2017	Jul DISC
		ORTIKOS					
	+	SUN PHARM INDS INC	6MG	N211929	001	Jun 13, 2019	Jul CDFR
	+!		9MG	N211929	002	Jun 13, 2019	Jul CDFR

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED;INHALATION

		BREYNA					
AB		MYLAN	0.08MG/INH;0.0045MG/INH	A211699	001	Mar 15, 2022	Jul CTNA
AB			0.08MG/INH;0.0045MG/INH	A211699	001	Mar 15, 2022	Mar NFTG
AB			0.16MG/INH;0.0045MG/INH	A211699	002	Mar 15, 2022	Jul CTNA
AB			0.16MG/INH;0.0045MG/INH	A211699	002	Mar 15, 2022	Mar NFTG
		SYMBICORT					
AB	+!	ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929	001	Jul 21, 2006	Mar CFTG
AB	+!		0.16MG/INH;0.0045MG/INH	N021929	002	Jul 21, 2006	Mar CFTG

BUMETANIDE

INJECTABLE;INJECTION

		BUMETANIDE					
AP		ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Feb CMFD
AP		GLAND PHARMA LTD	0.25MG/ML	A216434	001	May 26, 2022	May NEWA
AP		MSN	0.25MG/ML	A215364	001	Aug 04, 2022	Jul NEWA

BUPIVACAINE

SOLUTION, EXTENDED RELEASE;INFILTRATION

		POSIMIR					
	+!	DURECT	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	May CMFD
	+!	INNOCOLL	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	May CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

		BUPIVACAINE HYDROCHLORIDE					
	@	CIVICA	0.5%	A211096	001	Feb 19, 2019	Apr CAHN
	@	NOVOCOL PHARM	0.5%	A211096	001	Feb 19, 2019	Mar CAHN
	@	STERISCIENCE	0.25%	A091503	001	Oct 18, 2011	Feb CAHN
	@		0.5%	A091503	002	Oct 18, 2011	Feb CAHN
		BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE					
	@	STERISCIENCE	0.25%	A091487	002	Oct 18, 2011	Feb CAHN
	@		0.5%	A091487	001	Oct 18, 2011	Feb CAHN
	@		0.75%	A091487	003	Oct 18, 2011	Feb CAHN
		SENSORCAINE					
AP	+	FRESENIUS KABI USA	0.25%	N018304	001		Oct CRLD
AP	+		0.5%	N018304	002		Oct CRLD
AP	+		0.75%	N018304	003		Oct CRLD

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

		SENSORCAINE					
AP	+	FRESENIUS KABI USA	0.5%;0.0091MG/ML	N018304	004	Sep 02, 1983	Oct CRLD
AP	+		0.75%;0.0091MG/ML	N018304	005	Sep 02, 1983	Oct CRLD

BUPIVACAINE; MELOXICAM

SOLUTION, EXTENDED RELEASE;PERIARTICULAR

		ZYNRELEF KIT					
	+ @	HERON THERAPS INC	60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML	N211988	001	May 12, 2021	Apr DISC
	+ @		300MG/10.5ML (29.25MG/ML);9MG/10.5ML	N211988	003	May 12, 2021	Apr DISC

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

		BUPRENORPHINE					
AB		ALVOGEN	5MCG/HR	A207490	001	May 17, 2022	May CAHN
AB			10MCG/HR	A207490	002	May 17, 2022	May CAHN
AB			15MCG/HR	A207490	003	May 17, 2022	May CAHN
AB			20MCG/HR	A207490	004	May 17, 2022	May CAHN
AB		ALVOGEN PINE BROOK	5MCG/HR	A207490	001	May 17, 2022	May NEWA

FILM, EXTENDED RELEASE;TRANSDERMAL
BUPRENORPHINE

AB		10MCG/HR	A207490	002	May 17, 2022	May NEWA
AB		15MCG/HR	A207490	003	May 17, 2022	May NEWA
AB		20MCG/HR	A207490	004	May 17, 2022	May NEWA

BUPRENORPHINE HYDROCHLORIDE

FILM;BUCCAL
BELBUCA

+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jan CTEC
+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jan CTEC
+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jan CTEC
+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jan CTEC
+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jan CTEC
+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jan CTEC
+!		EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jan CTEC

BUPRENORPHINE HYDROCHLORIDE

@	ALVOGEN	EQ 0.075MG BASE	A211594	001	Aug 03, 2021	Jan DISC
@		EQ 0.15MG BASE	A211594	002	Aug 03, 2021	Jan DISC
@		EQ 0.3MG BASE	A211594	003	Aug 03, 2021	Jan DISC
@		EQ 0.45MG BASE	A211594	004	Aug 03, 2021	Jan DISC
@		EQ 0.6MG BASE	A211594	005	Aug 03, 2021	Jan DISC
@		EQ 0.75MG BASE	A211594	006	Aug 03, 2021	Jan DISC
@		EQ 0.9MG BASE	A211594	007	Aug 03, 2021	Jan DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	AVEVA	EQ 8MG BASE;EQ 2MG BASE	A212756	001	Jun 02, 2022	May NEWA
AB		EQ 12MG BASE;EQ 3MG BASE	A212756	002	Jun 02, 2022	May NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

AB3	GRANULES	150MG	A215568	001	Feb 02, 2022	Oct CMFD
@		150MG	A215568	001	Feb 02, 2022	Jul DISC
AB3		150MG	A215568	001	Feb 02, 2022	Jan NEWA
AB3		300MG	A215568	002	Feb 02, 2022	Oct CMFD
@		300MG	A215568	002	Feb 02, 2022	Jul DISC
AB3		300MG	A215568	002	Feb 02, 2022	Jan NEWA
AB3	GRAVITI PHARMS	150MG	A211020	001	Jan 28, 2019	Sep CAHN
AB3		300MG	A211020	002	Jan 28, 2019	Sep CAHN
AB3	WOCKHARDT LTD	300MG	A202189	002	Jan 28, 2022	Feb NEWA

BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL
AUVELITY

+!	AXSOME	105MG;45MG	N215430	001	Aug 18, 2022	Aug NEWA

BUSPIRONE HYDROCHLORIDE

CAPSULE;ORAL
BUSPAR

+ @	BRISTOL MYERS SQUIBB	5MG	N021190	001	Dec 20, 2000	Sep CRLD
+ @		7.5MG	N021190	002	Dec 20, 2000	Sep CRLD
+ @		10MG	N021190	003	Dec 20, 2000	Sep CRLD
+ @		15MG	N021190	004	Dec 20, 2000	Sep CRLD

TABLET;ORAL
BUSPIRONE HYDROCHLORIDE

AB !	ACCORD HLTHCARE	15MG	A202557	004	Dec 30, 2014	Feb CHRS
@	MYLAN	7.5MG	A075467	002	Mar 28, 2001	Feb DISC
AB	TEVA	15MG	A075022	003	Feb 28, 2002	Feb CHRS

BUSULFAN

TABLET;ORAL
MYLERAN

+!	WOODWARD SPECL	2MG	N009386	001		Apr CAHN

CABAZITAXEL

SOLUTION;INTRAVENOUS

		CABAZITAXEL					
	+ @	ACCORD HLTHCARE	60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021	Jul DISC
AP			60MG/1.5ML (40MG/ML)	A207693	001	Oct 26, 2022	Oct NEWA
	@	BRECKENRIDGE	60MG/1.5ML (40MG/ML)	A207619	001	Jun 23, 2022	Jul DISC
AP			60MG/1.5ML (40MG/ML)	A207619	001	Jun 23, 2022	Jun NFTG
		JEVTANA KIT					
AP	+!	SANOFI AVENTIS US	60MG/1.5ML (40MG/ML)	N201023	001	Jun 17, 2010	Oct CTEC
	+!		60MG/1.5ML (40MG/ML)	N201023	001	Jun 17, 2010	Jul CTEC
AP	+!		60MG/1.5ML (40MG/ML)	N201023	001	Jun 17, 2010	Jun CFTG

CABERGOLINE

TABLET;ORAL

		CABERGOLINE					
AB		STRIDES PHARMA	0.5MG	A076310	001	Dec 29, 2005	Mar CMFD

CAFFEINE CITRATE

SOLUTION;ORAL

		CAFCIT					
	+ @	HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Jan DISC
		CAFFEINE CITRATE					
AA	!	EXELA PHARMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077304	001	Sep 21, 2006	Jan CHRS

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL

		MIGERGOT					
	+!	COSETTE	100MG;2MG	A086557	001	Oct 04, 1983	Jul CRLD

CALCIPOTRIENE

OINTMENT;TOPICAL

		CALCIPOTRIENE					
AB	!	GLENMARK PHARMS INC	0.005%	A090633	001	Mar 24, 2010	Sep CTEC
		DOVONEX					
AB	+	LEO PHARMA AS	0.005%	N020273	001	Dec 29, 1993	Sep CMFD

CALCITONIN SALMON

SPRAY, METERED;NASAL

		CALCITONIN-SALMON					
	!	APOTEX INC	200 IU/SPRAY	A076396	001	Nov 17, 2008	Jul CTEC
	@	PAR PHARM	200 IU/SPRAY	A076979	001	Jun 08, 2009	Jul DISC

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

		DEXTROSE 5% AND LACTATED RINGER'S					
	@	FRESENIUS KABI USA	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	A210332	001	Mar 28, 2022	Sep DISC
AP			20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	A210332	001	Mar 28, 2022	Mar NEWA
		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER					
	@	FRESENIUS KABI USA	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	A211428	001	Nov 09, 2021	Apr DISC

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION;IRRIGATION

		BALANCED SALT					
	@	AKORN	0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML	A075503	001	Sep 27, 2006	Aug DISC

CALCIUM GLUCONATE

SOLUTION;INTRAVENOUS

		CALCIUM GLUCONATE					
AP	+!	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N208418	001	Jun 15, 2017	Oct CFTG
AP		NIVAGEN PHARMS INC	1GM/10ML (100MG/ML)	A213071	001	Oct 14, 2022	Oct NFTG

CAPECITABINE

TABLET;ORAL

CAPECITABINE

	@	AMNEAL PHARMS	150MG	A204741	001	Feb 28, 2017	Sep DISC
	@		500MG	A204741	002	Feb 28, 2017	Sep DISC

CARBAMAZEPINE

SUSPENSION;ORAL

CARBAMAZEPINE

AB		NOVITIUM PHARMA	100MG/5ML	A214277	001	Oct 06, 2022	Sep NEWA

TABLET;ORAL

CARBAMAZEPINE

AB		UNICHEM	200MG	A213284	001	Aug 22, 2022	Aug NEWA
	@	VGYAAN	200MG	A214328	001	Aug 16, 2021	Feb DISC

TABLET, CHEWABLE;ORAL

CARBAMAZEPINE

AB		TARO PHARM INDS	100MG	A075687	001	Oct 24, 2000	Aug CHRS

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

>A> AB		RICONPHARMA LLC	100MG	A216404	001	Dec 02, 2022	Nov NEWA
>A> AB			200MG	A216404	002	Dec 02, 2022	Nov NEWA
>A> AB			400MG	A216404	003	Dec 02, 2022	Nov NEWA
AB		UMEDICA LABS PVT LTD	100MG	A216594	001	Aug 18, 2022	Aug NEWA
AB			200MG	A216594	002	Aug 18, 2022	Aug NEWA
AB			400MG	A216594	003	Aug 18, 2022	Aug NEWA
AB		ZHEJIANG JIUZHOU	100MG	A215591	001	Mar 31, 2022	Mar NEWA
AB			200MG	A215591	002	Mar 31, 2022	Mar NEWA
AB			400MG	A215591	003	Mar 31, 2022	Mar NEWA

CARBIDOPA

TABLET;ORAL

CARBIDOPA

	@	ANI PHARMS	25MG	A203261	001	Mar 10, 2014	Jun DISC

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB		RISING	12.5MG;200MG;50MG	A213212	001	Jan 25, 2022	Jan NEWA
AB			18.75MG;200MG;75MG	A213212	002	Jan 25, 2022	Jan NEWA
AB			25MG;200MG;100MG	A213212	003	Jan 25, 2022	Jan NEWA
AB			31.25MG;200MG;125MG	A213212	004	Jan 25, 2022	Jan NEWA
AB			37.5MG;200MG;150MG	A213212	005	Jan 25, 2022	Jan NEWA
AB			50MG;200MG;200MG	A213212	006	Jan 25, 2022	Jan NEWA

STALEVO 125

AB	+	ORION PHARMA	31.25MG;200MG;125MG	N021485	006	Aug 29, 2008	Jan CTEC

STALEVO 200

AB	+!	ORION PHARMA	50MG;200MG;200MG	N021485	004	Aug 02, 2007	Jan CTEC

STALEVO 50

AB	+!	ORION PHARMA	12.5MG;200MG;50MG	N021485	001	Jun 11, 2003	Jan CTEC

STALEVO 75

AB	+	ORION PHARMA	18.75MG;200MG;75MG	N021485	005	Aug 29, 2008	Jan CTEC

CARBIDOPA; LEVODOPA

TABLET;ORAL

CARBIDOPA AND LEVODOPA

>A> AB		AUROBINDO PHARMA LTD	10MG;100MG	A216537	001	Nov 28, 2022	Nov NEWA
>A> AB			25MG;100MG	A216537	002	Nov 28, 2022	Nov NEWA
>A> AB			25MG;250MG	A216537	003	Nov 28, 2022	Nov NEWA
AB		RUBICON	10MG;100MG	A216505	001	Sep 21, 2022	Sep NEWA
AB			25MG;100MG	A216505	002	Sep 21, 2022	Sep NEWA
AB			25MG;250MG	A216505	003	Sep 21, 2022	Sep NEWA

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

AP		TEYRO LABS	50MG/5ML (10MG/ML)	A077861	001	Jan 18, 2007	Apr CAHN
AP			150MG/15ML (10MG/ML)	A077861	002	Jan 18, 2007	Apr CAHN
AP			450MG/45ML (10MG/ML)	A077861	003	Jan 18, 2007	Apr CAHN
AP			600MG/60ML (10MG/ML)	A077861	004	Jan 18, 2007	Apr CAHN

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION

CARBOPROST TROMETHAMINE

	AP	AMNEAL	EQ 0.25MG BASE/ML	A215337	001	Jan 27, 2022	Jan NEWA
	AP	LONG GROVE PHARMS	EQ 0.25MG BASE/ML	A214499	001	Aug 09, 2022	Jul NEWA

CARGLUMIC ACID

TABLET, FOR SUSPENSION;ORAL

CARGLUMIC ACID

	AB	NAVINTA LLC	200MG	A213395	001	Jun 22, 2022	Jun NEWA

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL

CARIPRAZINE HYDROCHLORIDE

>D>	AB	SUN PHARM	EQ 1.5MG BASE	A213932	001	Sep 30, 2022	Nov DISC
>A>		@	EQ 1.5MG BASE	A213932	001	Sep 30, 2022	Nov DISC
	AB		EQ 1.5MG BASE	A213932	001	Sep 30, 2022	Sep NEWA
>D>	AB		EQ 3MG BASE	A213932	002	Sep 30, 2022	Nov DISC
>A>		@	EQ 3MG BASE	A213932	002	Sep 30, 2022	Nov DISC
	AB		EQ 3MG BASE	A213932	002	Sep 30, 2022	Sep NEWA
>D>	AB		EQ 4.5MG BASE	A213932	003	Sep 30, 2022	Nov DISC
>A>		@	EQ 4.5MG BASE	A213932	003	Sep 30, 2022	Nov DISC
	AB		EQ 4.5MG BASE	A213932	003	Sep 30, 2022	Sep NEWA
>D>	AB		EQ 6MG BASE	A213932	004	Sep 30, 2022	Nov DISC
>A>		@	EQ 6MG BASE	A213932	004	Sep 30, 2022	Nov DISC
	AB		EQ 6MG BASE	A213932	004	Sep 30, 2022	Sep NEWA
	AB	ZYDUS PHARMS	EQ 1.5MG BASE	A213984	001	Sep 09, 2022	Sep NFTG
	AB		EQ 3MG BASE	A213984	002	Sep 09, 2022	Sep NFTG
	AB		EQ 4.5MG BASE	A213984	003	Sep 09, 2022	Sep NFTG
	AB		EQ 6MG BASE	A213984	004	Sep 09, 2022	Sep NFTG

VRAYLAR

	AB	+! ALLERGAN	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Oct CHRS
	AB	+	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Sep CFTG
	AB	+	EQ 3MG BASE	N204370	002	Sep 17, 2015	Sep CFTG
	AB	+	EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Sep CFTG
	AB	+	EQ 6MG BASE	N204370	004	Sep 17, 2015	Oct CHRS
	AB	+!	EQ 6MG BASE	N204370	004	Sep 17, 2015	Sep CFTG

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

	AA	CHARTWELL RX	350MG	A040245	001	Sep 08, 1997	Sep CAHN
	AA	WANBANG BIOPHARMS	350MG	A081025	001	Apr 13, 1989	Jun CAHN

CARMUSTINE

IMPLANT;INTRACRANIAL

GLIADEL

	+!	AZURITY	7.7MG	N020637	001	Sep 23, 1996	Jun CAHN

INJECTABLE;INJECTION

CARMUSTINE

	AP	INGENUS PHARMS LLC	100MG/VIAL	A211011	001	Jun 21, 2022	Jun NEWA

POWDER;INTRAVENOUS

CARMUSTINE

	+!	ACCORD HLTHCARE	50MG/VIAL	N215000	001	May 16, 2022	May NEWA
	+!		300MG/VIAL	N215000	002	May 16, 2022	May NEWA

CASPOFUNGIN ACETATE

POWDER;INTRAVENOUS

CASPOFUNGIN ACETATE

	@	XELLIA PHARMS APS	50MG/VIAL	A205923	001	Jul 02, 2018	Oct DISC
	@		70MG/VIAL	A205923	002	Jul 02, 2018	Oct DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL

CEFADROXIL

>A>	@	CHARTWELL RX	EQ 500MG BASE	A065309	001	Sep 18, 2006	Nov CAHN
>D>	@	ORCHID HLTHCARE	EQ 500MG BASE	A065309	001	Sep 18, 2006	Nov CAHN
	@		EQ 500MG BASE	A065309	001	Sep 18, 2006	Mar DISC

FOR SUSPENSION;ORAL

CEFADROXIL

>A>	@	CHARTWELL RX	EQ 250MG BASE/5ML	A065307	002	Oct 16, 2006	Nov CAHN

```
          FOR SUSPENSION;ORAL
            CEFADROXIL
>A>         @                       EQ 500MG BASE/5ML                A065307  003  Oct 16, 2006   Nov CAHN
>D>         @ ORCHID HLTHCARE       EQ 250MG BASE/5ML                A065307  002  Oct 16, 2006   Nov CAHN
            @                       EQ 250MG BASE/5ML                A065307  002  Oct 16, 2006   Mar DISC
>D>         @                       EQ 500MG BASE/5ML                A065307  003  Oct 16, 2006   Nov CAHN
            @                       EQ 500MG BASE/5ML                A065307  003  Oct 16, 2006   Mar DISC
          TABLET;ORAL
            CEFADROXIL
>A>         @ CHARTWELL RX          EQ 1GM BASE                      A065301  001  Sep 18, 2006   Nov CAHN
>D>         @ ORCHID HLTHCARE       EQ 1GM BASE                      A065301  001  Sep 18, 2006   Nov CAHN
            @                       EQ 1GM BASE                      A065301  001  Sep 18, 2006   Mar DISC
    AB    !   TEVA PHARMS           EQ 1GM BASE                      A062774  001  Apr 08, 1987   Mar CTEC

        CEFAZOLIN SODIUM
          INJECTABLE;INJECTION
            CEFAZOLIN SODIUM
              QILU                  EQ 2GM BASE/VIAL                 A203661  002  Mar 11, 2022   Mar NEWA
          POWDER;INTRAVENOUS
            CEFAZOLIN SODIUM
          +!  HIKMA                 EQ 2GM BASE/VIAL                 N216109  001  Oct 07, 2022   Oct NEWA
          +!                        EQ 3GM BASE/VIAL                 N216109  002  Oct 07, 2022   Oct NEWA

        CEFDINIR
          FOR SUSPENSION;ORAL
            CEFDINIR
    AB    !   AUROBINDO PHARMA      250MG/5ML                        A065473  002  Dec 14, 2007   Oct CHRS
    AB        SANDOZ                250MG/5ML                        A065337  002  Apr 06, 2007   Oct CHRS

        CEFEPIME HYDROCHLORIDE
          INJECTABLE;INJECTION
            CEFEPIME HYDROCHLORIDE
    AP        ASTRAL                EQ 1GM BASE/VIAL                 A212721  001  Jul 21, 2020   Jan CMFD
    AP                              EQ 2GM BASE/VIAL                 A212721  002  Jul 21, 2020   Jan CMFD

        CEFIXIME
          CAPSULE;ORAL
            CEFIXIME
    AB        ALKEM LABS LTD        400MG                            A210574  001  Oct 09, 2018   Aug CTEC
                                    400MG                            A210574  001  Oct 09, 2018   Aug CHRS
            SUPRAX
    AB    +!  LUPIN LTD             400MG                            N203195  001  Jun 01, 2012   Aug CMFD

        CEFOTETAN DISODIUM
          INJECTABLE;INJECTION
            CEFOTAN IN PLASTIC CONTAINER
            @ PAI HOLDINGS PHARM    EQ 20MG BASE/ML                  N050694  002  Jul 30, 1993   Apr CAHN
            @                       EQ 40MG BASE/ML                  N050694  001  Jul 30, 1993   Apr CAHN
            CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER
          + @ B BRAUN               EQ 1GM BASE/VIAL                 N065430  001  Aug 09, 2007   Jul DISC
          + @                       EQ 2GM BASE/VIAL                 N065430  002  Aug 09, 2007   Jul DISC

        CEFPODOXIME PROXETIL
          TABLET;ORAL
            CEFPODOXIME PROXETIL
    AB        ALKEM LABS LTD        EQ 100MG BASE                    A210568  001  May 18, 2022   May NEWA
    AB                              EQ 200MG BASE                    A210568  002  May 18, 2022   May NEWA

        CEFPROZIL
          FOR SUSPENSION;ORAL
            CEFPROZIL
            @ CHARTWELL RX          125MG/5ML                        A065236  001  Dec 08, 2005   Mar CAHN
            @                       250MG/5ML                        A065236  002  Dec 08, 2005   Mar CAHN
            @ SANDOZ                125MG/5ML                        A065257  001  Dec 08, 2005   Oct DISC
            @                       250MG/5ML                        A065257  002  Dec 08, 2005   Oct DISC
```

CEFTAROLINE FOSAMIL

POWDER;INTRAVENOUS

CEFTAROLINE FOSAMIL

	@	APOTEX	400MG/VIAL	A208075	001	Sep 21, 2021	Mar DISC
	@		600MG/VIAL	A208075	002	Sep 21, 2021	Mar DISC

TEFLARO

	+!	ALLERGAN	400MG/VIAL	N200327	001	Oct 29, 2010	Mar CTEC
	+!		600MG/VIAL	N200327	002	Oct 29, 2010	Mar CTEC

CEFTAZIDIME

INJECTABLE;INJECTION

CEFTAZIDIME IN DEXTROSE CONTAINER

	+ @	B BRAUN	EQ 1GM BASE	N050823	001	Jun 13, 2011	Jul DISC
	+ @		EQ 2GM BASE	N050823	002	Jun 13, 2011	Jul DISC

CEFUROXIME SODIUM

INJECTABLE;INJECTION

ZINACEF

AP	+!	PAI HOLDINGS PHARM	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Feb CAHN
AP	+!		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Feb CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

ZINACEF

AB	+!	PAI HOLDINGS PHARM	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Feb CAHN

CELECOXIB

CAPSULE;ORAL

CELECOXIB

	@	UNICHEM	50MG	A213301	001	Jan 12, 2021	Feb DISC
	@		100MG	A213301	002	Jan 12, 2021	Feb DISC
	@		200MG	A213301	003	Jan 12, 2021	Feb DISC
	@		400MG	A213301	004	Jan 12, 2021	Feb DISC

SOLUTION;ORAL

ELYXYB

>D>	+!	BDSI	25MG/ML	N212157	001	May 05, 2020	Nov DISC
>A>	+ @		25MG/ML	N212157	001	May 05, 2020	Nov DISC

CEPHALEXIN

FOR SUSPENSION;ORAL

CEPHALEXIN

>A>	@	CHARTWELL RX	EQ 125MG BASE/5ML	A065326	001	Jul 10, 2006	Nov CAHN
>A>	@		EQ 250MG BASE/5ML	A065326	002	Jul 10, 2006	Nov CAHN
>D>	@	ORCHID HLTHCARE	EQ 125MG BASE/5ML	A065326	001	Jul 10, 2006	Nov CAHN
	@		EQ 125MG BASE/5ML	A065326	001	Jul 10, 2006	Mar DISC
>D>	@		EQ 250MG BASE/5ML	A065326	002	Jul 10, 2006	Nov CAHN
	@		EQ 250MG BASE/5ML	A065326	002	Jul 10, 2006	Mar DISC

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA		BAJAJ	5MG/5ML	A090191	001	Nov 12, 2009	Jun CAHN
	@	TORRENT	5MG/5ML	A078870	001	Apr 27, 2009	Jun DISC
AA			5MG/5ML	A078870	001	Apr 27, 2009	May CMFD

CETRORELIX

POWDER;SUBCUTANEOUS

CETROTIDE

AP	+!	EMD SERONO INC	EQ 0.25MG BASE/VIAL	N021197	001	Aug 11, 2000	Aug CFTG

CETRORELIX ACETATE

INJECTABLE;INJECTION

CETROTIDE

	@	EMD SERONO INC	EQ 3MG BASE/ML	N021197	002	Aug 11, 2000	Aug CAIN

POWDER;SUBCUTANEOUS

CETRORELIX ACETATE

AP		AKORN	EQ 0.25MG BASE/VIAL	A215737	001	Aug 12, 2022	Aug NFTG

CETROTIDE

AP	+!	EMD SERONO INC	EQ 0.25MG BASE/VIAL	N021197	001	Aug 11, 2000	Aug CAIN
	+ @		EQ 3MG BASE/VIAL	N021197	002	Aug 11, 2000	Aug CRLD
	@		EQ 3MG BASE/VIAL	N021197	002	Aug 11, 2000	Aug CPOT
	@		EQ 3MG BASE/ML	N021197	002	Aug 11, 2000	Aug CDFR

CHLORAMBUCIL

TABLET;ORAL

LEUKERAN

	+!	WOODWARD SPECL	2MG	N010669	002		Apr CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

AB	!	BARR	25MG	A084769	001		Aug CHRS
AB		CHARTWELL RX	5MG	A084678	001		Jul CMFD
AB			10MG	A084041	001		Jul CMFD
AB			25MG	A084679	002		Jul CMFD

LIBRIUM

AB	+	BAUSCH	25MG	A085475	001		Aug CHRS
AB	+!		25MG	A085475	001		Jul CAHN
AB	+	VALEANT PHARM INTL	5MG	A085461	001		Jan CRLD
AB	+		10MG	A085472	001		Jan CRLD

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

AB		CHARTWELL RX	5MG;2.5MG	A213530	001	Oct 20, 2020	Jun CAHN
AB		COREPHARMA	5MG;2.5MG	A215453	001	Jul 29, 2022	Jul NEWA
AB		MICRO LABS	5MG;2.5MG	A215835	001	Jul 19, 2022	Jul NEWA
	@	TEVA PHARMS USA	5MG;2.5MG	A211476	001	Nov 02, 2021	Jun DISC
AB		WESTMINSTER PHARMS	5MG;2.5MG	A215453	001	Jul 29, 2022	Sep CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

CHLORHEXIDINE GLUCONATE

	@	AKORN	0.12%	A074356	001	May 07, 1996	Jul DISC

PAROEX

	@	SUNSTAR AMERICAS	0.12%	A076434	001	Nov 29, 2005	Sep DISC

PERIOGARD

	@	COLGATE PALMOLIVE CO	0.12%	A073695	001	Jan 14, 1994	Apr DISC

TABLET;DENTAL

PERIOCHIP

+	@	DEXCEL PHARMA	2.5MG	N020774	001	May 15, 1998	Aug DISC

CHLOROPROCAINE HYDROCHLORIDE

GEL;OPHTHALMIC

IHEEZO

>A>	+!	HARROW EYE	3%	N216227	001	Sep 27, 2022	Nov CAHN
>D>	+!	SINTETICA SA	3%	N216227	001	Sep 27, 2022	Nov CAHN
	+!		3%	N216227	001	Sep 27, 2022	Sep NEWA

CHLOROQUINE PHOSPHATE

TABLET;ORAL

CHLOROQUINE PHOSPHATE

AA		IMPAX LABS	250MG	A080880	001		Oct CMFD
AA			500MG	A040516	001	Aug 29, 2003	Oct CMFD

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

TUZISTRA XR

	+!	TRIS PHARMA INC	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Jun CAHN

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE;ORAL

TUSSICAPS

	@	ECR PHARMA	EQ 4MG MALEATE;EQ 5MG BITARTRATE	A077273	002	Sep 24, 2007	Feb DISC
	@		EQ 8MG MALEATE;EQ 10MG BITARTRATE	A077273	001	Sep 24, 2007	Feb DISC

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

AP	+!	WEST-WARD PHARMS INT	25MG/ML	A083329	001		Sep CRLD

TABLET;ORAL
CHLORPROMAZINE HYDROCHLORIDE

		@	APPCO	10MG	A213590	001	Aug 31, 2020	Mar CAHN
		@		25MG	A213590	002	Aug 31, 2020	Mar CAHN
		@		50MG	A213590	003	Aug 31, 2020	Mar CAHN
		@		100MG	A213590	004	Aug 31, 2020	Mar CAHN
		@		200MG	A213590	005	Aug 31, 2020	Mar CAHN
>D>	AB		ENALTEC	10MG	A212630	001	Nov 29, 2021	Nov CAHN
>D>	AB			25MG	A212630	002	Nov 29, 2021	Nov CAHN
>D>	AB			50MG	A212630	003	Nov 29, 2021	Nov CAHN
>D>	AB			100MG	A212630	004	Nov 29, 2021	Nov CAHN
>D>	AB			200MG	A212630	005	Nov 29, 2021	Nov CAHN
	AB		MSN	25MG	A214827	001	Jan 27, 2022	Jan NEWA
	AB			50MG	A214827	002	Jan 27, 2022	Jan NEWA
	AB			100MG	A214827	003	Jan 27, 2022	Jan NEWA
	AB			200MG	A214827	004	Jan 27, 2022	Jan NEWA
>A>	AB		ZAMEER PHARMS	10MG	A212630	001	Nov 29, 2021	Nov CAHN
>A>	AB			25MG	A212630	002	Nov 29, 2021	Nov CAHN
>A>	AB			50MG	A212630	003	Nov 29, 2021	Nov CAHN
>A>	AB			100MG	A212630	004	Nov 29, 2021	Nov CAHN
>A>	AB			200MG	A212630	005	Nov 29, 2021	Nov CAHN

CHLORTHALIDONE

TABLET;ORAL
CHLORTHALIDONE

	AB		ALEMBIC PHARMS LTD	25MG	A216262	001	Aug 26, 2022	Aug NEWA
	AB			50MG	A216262	002	Aug 26, 2022	Aug NEWA
	AB		CHARTWELL RX	25MG	A211063	001	Feb 26, 2019	Jan CAHN
	AB			50MG	A211063	002	Feb 26, 2019	Jan CAHN
	AB		INVENTIA	25MG	A211320	001	Feb 09, 2022	Jan NEWA
	AB			50MG	A211320	002	Feb 09, 2022	Jan NEWA
	AB		MANKIND PHARMA	25MG	A215587	001	Aug 04, 2022	Jul NEWA
	AB			50MG	A215587	002	Aug 04, 2022	Jul NEWA
		@	SUNNY	25MG	A209068	001	Jan 25, 2022	May DISC
	AB			25MG	A209068	001	Jan 25, 2022	Jan NEWA
		@		50MG	A209068	002	Jan 25, 2022	May DISC
	AB			50MG	A209068	002	Jan 25, 2022	Jan NEWA
	AB		TAGI	25MG	A212878	001	Feb 24, 2022	Feb NEWA
	AB			50MG	A212875	001	Feb 24, 2022	Feb NEWA
	AB		UMEDICA LABS PVT LTD	25MG	A207222	001	May 24, 2018	Aug CTEC
	AB			50MG	A207222	002	May 24, 2018	Aug CTEC

CHLORZOXAZONE

TABLET;ORAL
CHLORZOXAZONE

	AB		COREPHARMA	375MG	A214941	001	Oct 20, 2022	Oct NEWA
	AA			500MG	A214941	002	Oct 20, 2022	Oct NEWA
	AB			750MG	A214941	003	Oct 20, 2022	Oct NEWA
	AB		RISING	375MG	A213126	001	Apr 05, 2022	Mar NEWA
	AB			500MG	A213126	002	Apr 05, 2022	Mar NEWA
	AB			750MG	A213126	003	Apr 05, 2022	Mar NEWA

CHOLESTYRAMINE

POWDER;ORAL
CHOLESTYRAMINE

		@	UPSHER SMITH LABS	EQ 4GM RESIN/PACKET	A214877	001	Jan 21, 2022	Mar DISC
	AB			EQ 4GM RESIN/PACKET	A214877	001	Jan 21, 2022	Jan NEWA
		@		EQ 4GM RESIN/SCOOPFUL	A214877	002	Jan 21, 2022	Mar DISC
	AB			EQ 4GM RESIN/SCOOPFUL	A214877	002	Jan 21, 2022	Jan NEWA

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL
FENOFIBRIC ACID

	AB		GRAVITI PHARMS	EQ 45MG FENOFIBRIC ACID	A211626	001	Jul 18, 2019	Sep CAHN
	AB			EQ 135MG FENOFIBRIC ACID	A211626	002	Jul 18, 2019	Sep CAHN

CICLOPIROX

GEL;TOPICAL
CICLOPIROX

		+ @	ALVOGEN	0.77%	N020519	001	Jul 21, 1997	Aug DISC
	AB	!	GLENMARK GENERICS	0.77%	A091595	001	Feb 29, 2012	Aug CHRS

```
          SHAMPOO;TOPICAL
            CICLOPIROX
    AT        PAI HOLDINGS PHARM     1%                              A209975  001  Apr 05, 2018   Mar CAHN
          SOLUTION;TOPICAL
            CICLOPIROX
    AT        CHARTWELL RX           8%                              A078046  001  Sep 18, 2007   Mar CAHN

        CILOSTAZOL
          TABLET;ORAL
            CILOSTAZOL
            @ HIKMA                  50MG                            A077024  001  May 17, 2005   Oct DISC
            @                        100MG                           A077024  002  May 17, 2005   Oct DISC

        CIMETIDINE
          TABLET;ORAL
            CIMETIDINE
            @ CHARTWELL RX           200MG                           A074100  001  Jan 31, 1995   Jan CAHN
            @                        300MG                           A074100  002  Jan 31, 1995   Jan CAHN
            @                        400MG                           A074100  003  Jan 31, 1995   Jan CAHN
            @                        800MG                           A074100  004  Jan 31, 1995   Jan CAHN

        CINACALCET HYDROCHLORIDE
          TABLET;ORAL
            CINACALCET HYDROCHLORIDE
            @ AMNEAL PHARMS          30MG                            A204364  001  Dec 02, 2021   Feb DISC
            @                        60MG                            A204364  002  Dec 02, 2021   Feb DISC
            @                        90MG                            A204364  003  Dec 02, 2021   Feb DISC

        CIPROFLOXACIN HYDROCHLORIDE
          TABLET;ORAL
            CIPROFLOXACIN HYDROCHLORIDE
            @ AIPING PHARM INC       EQ 250MG BASE                   A076593  002  Jun 09, 2004   Jan CAHN
            @                        EQ 500MG BASE                   A076593  003  Jun 09, 2004   Jan CAHN
            @                        EQ 750MG BASE                   A076593  004  Jun 09, 2004   Jan CAHN

        CIPROFLOXACIN; DEXAMETHASONE
          SUSPENSION/DROPS;OTIC
            CIPROFLOXACIN AND DEXAMETHASONE
    AB        SUN PHARM              0.3%;0.1%                       A210470  001  Aug 30, 2022   Aug NEWA

        CISATRACURIUM BESYLATE
          INJECTABLE;INJECTION
            CISATRACURIUM BESYLATE
    AP        HIKMA                  EQ 10MG BASE/ML                 A203078  001  Jun 28, 2022   Jun NEWA
    AP        PIRAMAL CRITICAL       EQ 2MG BASE/ML                  A215516  001  May 24, 2022   May NEWA
    AP                               EQ 10MG BASE/ML                 A215516  002  May 24, 2022   May NEWA
            @ PIRAMAL HLTHCARE UK    EQ 2MG BASE/ML                  A212432  001  Mar 11, 2022   Sep DISC
    AP                               EQ 2MG BASE/ML                  A212432  001  Mar 11, 2022   Mar NEWA
            @                        EQ 10MG BASE/ML                 A212432  002  Mar 11, 2022   Sep DISC
    AP                               EQ 10MG BASE/ML                 A212432  002  Mar 11, 2022   Mar NEWA
    AP        SAGENT PHARMS INC      EQ 2MG BASE/ML                  A201851  001  Nov 06, 2020   Mar CMFD

        CISPLATIN
          INJECTABLE;INJECTION
>A>         CISPLATIN
>A>       +!  HQ SPCLT PHARMA        50MG/VIAL                       N018057  002                Nov CTNA
>D>         PLATINOL
>D>       +!  HQ SPCLT PHARMA        50MG/VIAL                       N018057  002                Nov CTNA
          +!                         50MG/VIAL                       N018057  002                Oct CMFD

        CITALOPRAM HYDROBROMIDE
          CAPSULE;ORAL
            CITALOPRAM HYDROBROMIDE
          +!  ALMATICA               EQ 30MG BASE                    N215428  001  Jan 31, 2022   Jan NEWA
          SOLUTION;ORAL
            CITALOPRAM HYDROBROMIDE
>D> AA        CHARTWELL MOLECULAR    EQ 10MG BASE/5ML                A077629  001  Jun 15, 2006   Nov CMS1
>A> AA                               EQ 10MG BASE/5ML                A077629  001  Jun 14, 2006   Nov CMS1
```

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL

SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID

	!	HETERO LABS LTD V	12GM/PACKET;3.5GM/PACKET;10MG/PACKET	A212789	001	Jul 18, 2022	Jul NFTG

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION;ORAL

IDKIT:HP

>D>	+!	EXALENZ BIOSCIENCE	4GM;75MG	N021314	001	Dec 17, 2002	Nov CAHN
>A>	+!	MERIDIAN BIOSCIENCE	4GM;75MG	N021314	001	Dec 17, 2002	Nov CAHN

CLARITHROMYCIN

TABLET;ORAL

CLARITHROMYCIN

AB		ALEMBIC PHARMS LTD	250MG	A210459	001	Jan 31, 2022	Jan NEWA
AB			500MG	A210459	002	Jan 31, 2022	Jan NEWA

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

CLINDAMYCIN PHOSPHATE

AT		TARO PHARM INDS LTD	1%	A210004	001	Mar 11, 2020	Oct CMFD

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE

AB2		AMNEAL	EQ 1% BASE	A214668	001	Aug 05, 2022	Jul NEWA
AB1			EQ 1% BASE	A215219	001	Nov 03, 2022	Oct NEWA

LOTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AB		ENCUBE	EQ 1% BASE	A215607	001	Jan 18, 2022	Jan NEWA

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AT		PAI HOLDINGS PHARM	EQ 1% BASE	A206945	001	Dec 30, 2016	Mar CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB1		ACTAVIS MID ATLANTIC	1.2%;0.025%	A202564	001	Jun 12, 2015	Feb CTEC
AB2		SOLARIS PHARMA CORP	1.2%;0.025%	A212845	001	Feb 10, 2022	Feb NFTG

VELTIN

AB2	+!	ALMIRALL	1.2%;0.025%	N050803	001	Jul 16, 2010	Feb CFTG

ZIANA

AB1	+!	BAUSCH	1.2%;0.025%	N050802	001	Nov 07, 2006	Feb CTEC

CLOBAZAM

FILM;ORAL

SYMPAZAN

>D>	+	AQUESTIVE	5MG	N210833	001	Nov 01, 2018	Nov CAHN
>D>	+		10MG	N210833	002	Nov 01, 2018	Nov CAHN
>D>	+!		20MG	N210833	003	Nov 01, 2018	Nov CAHN
>A>	+	OTTER PHARMS	5MG	N210833	001	Nov 01, 2018	Nov CAHN
>A>	+		10MG	N210833	002	Nov 01, 2018	Nov CAHN
>A>	+!		20MG	N210833	003	Nov 01, 2018	Nov CAHN

SUSPENSION;ORAL

CLOBAZAM

AB		ACCORD HLTHCARE	2.5MG/ML	A216008	001	Sep 06, 2022	Aug NEWA
AB		AUROBINDO PHARMA LTD	2.5MG/ML	A214404	001	Mar 24, 2022	Mar NEWA
	@	HIKMA	2.5MG/ML	A209715	001	Oct 22, 2018	Sep DISC

TABLET;ORAL

CLOBAZAM

	@	HIKMA	10MG	A208785	001	Oct 22, 2018	Sep DISC
	@		20MG	A208785	002	Oct 22, 2018	Sep DISC
AB		MSN	10MG	A213404	001	May 11, 2021	Feb CMFD
AB			20MG	A213404	002	May 11, 2021	Feb CMFD

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB1		ALEOR DERMACEUTICALS	0.05%	A215838	001	Apr 21, 2022	Apr NEWA

```
        CREAM;TOPICAL
          CLOBETASOL PROPIONATE
          @ GLASSHOUSE PHARMS      0.05%                          A211207  001  Mar 26, 2021   Aug CAHN
          EMBELINE E
          @ AKORN                  0.05%                          A075325  001  Dec 24, 1998   Sep DISC
        GEL;TOPICAL
          CLOBETASOL PROPIONATE
    AB      PAI HOLDINGS PHARM     0.05%                          A208881  001  Mar 06, 2017   Mar CAHN
        LOTION;TOPICAL
          CLOBETASOL PROPIONATE
    AB      PAI HOLDINGS PHARM     0.05%                          A208667  001  Nov 29, 2016   Mar CAHN
        OINTMENT;TOPICAL
          CLOBETASOL PROPIONATE
    AB      PAI HOLDINGS PHARM     0.05%                          A208589  001  Jan 23, 2019   Mar CAHN
        SOLUTION;TOPICAL
          CLOBETASOL PROPIONATE
          @ ENCUBE                 0.05%                          A076977  001  Aug 05, 2005   Jul CAHN
          @ PRINSTON INC           0.05%                          A213139  001  Feb 08, 2021   Aug DISC
>A> AT      QUAGEN                 0.05%                          A211240  001  Feb 17, 2022   Nov CAHN
>D> AT      SOLARIS PHARMA CORP    0.05%                          A211240  001  Feb 17, 2022   Nov CAHN
    AT                             0.05%                          A211240  001  Feb 17, 2022   Feb NEWA
          @ TOLMAR                 0.05%                          A076977  001  Aug 05, 2005   Feb DISC
          @ WOCKHARDT BIO AG       0.05%                          A075205  001  Nov 13, 1998   Jun DISC

      CLOFARABINE
        SOLUTION;INTRAVENOUS
          CLOFARABINE
    AP      EUGIA PHARMA           20MG/20ML (1MG/ML)             A212457  001  Oct 03, 2022   Sep NEWA

      CLOMIPHENE CITRATE
        TABLET;ORAL
          CLOMIPHENE CITRATE
        !   COSETTE                50MG                           A075528  001  Aug 30, 1999   Jun CAHN

      CLONAZEPAM
        TABLET;ORAL
          CLONAZEPAM
    AB      RUBICON                0.5MG                          A075468  001  Oct 06, 2000   Sep CMFD
    AB                             1MG                            A075468  002  Oct 06, 2000   Sep CMFD
    AB                             2MG                            A075468  003  Oct 06, 2000   Sep CMFD

      CLONIDINE
        TABLET, EXTENDED RELEASE;ORAL
          NEXICLON XR
            ATHENA                 EQ 0.17MG BASE                 N022500  001  Dec 03, 2009   Feb CMFD
          @                        EQ 0.17MG BASE                 N022500  001  Dec 03, 2009   Jan CAHN
          @                        EQ 0.26MG BASE                 N022500  002  Dec 03, 2009   Jan CAHN

      CLONIDINE HYDROCHLORIDE
        TABLET;ORAL
          CLONIDINE HYDROCHLORIDE
    AB      AUROBINDO PHARMA LTD   0.1MG                          A070886  002  Aug 31, 1988   May CMFD
    AB                             0.2MG                          A070886  001  Aug 31, 1988   May CMFD
    AB                             0.3MG                          A070886  003  Aug 31, 1988   May CMFD
    AB      CHARTWELL MOLECULES    0.1MG                          A071785  002  Apr 05, 1988   Aug CMFD
    AB                             0.2MG                          A071785  003  Apr 05, 1988   Aug CMFD
    AB                             0.3MG                          A071785  001  Apr 05, 1988   Aug CMFD
    AB      URL LABS               0.1MG                          A070923  003  Sep 04, 1987   Apr CAHN
    AB                             0.2MG                          A070923  002  Sep 04, 1987   Apr CAHN
    AB                             0.3MG                          A070923  001  Sep 04, 1987   Apr CAHN
        TABLET, EXTENDED RELEASE;ORAL
          CLONIDINE HYDROCHLORIDE
          @ MAYNE PHARMA INC       0.1MG                          A210680  001  Apr 30, 2018   Feb DISC

      CLOPIDOGREL BISULFATE
        TABLET;ORAL
          CLOPIDOGREL BISULFATE
    AB      DR REDDYS              EQ 75MG BASE                   A076273  001  Jan 14, 2008   Apr CAHN
```

CLORAZEPATE DIPOTASSIUM

		CAPSULE;ORAL					
		TRANXENE					
	+ @	KEY THERAP	3.75MG	N017105	001		Aug CAHN
	+ @		7.5MG	N017105	002		Aug CAHN
	+ @		15MG	N017105	003		Aug CAHN
		TABLET;ORAL					
		CLORAZEPATE DIPOTASSIUM					
AB		AUROBINDO PHARMA	3.75MG	A071858	002	Jul 17, 1987	Sep CAHN
AB			7.5MG	A071858	003	Jul 17, 1987	Sep CAHN
AB	!		15MG	A071858	001	Jul 17, 1987	Sep CAHN
AB		COREPHARMA	3.75MG	A215566	001	Jun 14, 2022	Jun NEWA
AB			7.5MG	A215566	002	Jun 14, 2022	Jun NEWA
AB			15MG	A215566	003	Jun 14, 2022	Jun NEWA
AB		NOVITIUM PHARMA	3.75MG	A213730	001	Jun 16, 2022	Jun NEWA
AB			7.5MG	A213730	002	Jun 16, 2022	Jun NEWA
		TRANXENE					
	+ @	KEY THERAP	3.75MG	N017105	006		Aug CAHN
AB	+		7.5MG	N017105	007		Aug CAHN
	+ @		15MG	N017105	008		Aug CAHN
		TRANXENE SD					
	+ @	KEY THERAP	11.25MG	N017105	005		Aug CAHN
	+ @		22.5MG	N017105	004		Aug CAHN

COLCHICINE

		SOLUTION;ORAL					
		GLOPERBA					
	+!	SCILEX PHARMS	0.6MG/5ML	N210942	001	Jan 30, 2019	Jun CAHN
		TABLET;ORAL					
		COLCHICINE					
>D>	@	PAR PHARM INC	0.6MG	A203976	001	Aug 12, 2021	Nov CMFD
>A> AB			0.6MG	A203976	001	Aug 12, 2021	Nov CMFD
	@		0.6MG	A203976	001	Aug 12, 2021	Feb DISC
AB		STRIDES PHARMA	0.6MG	A209173	001	Mar 10, 2022	Mar NEWA

COLESEVELAM HYDROCHLORIDE

		TABLET;ORAL					
		COLESEVELAM HYDROCHLORIDE					
	@	LUPIN LTD	625MG	A201354	001	Dec 17, 2020	May DISC
AB		SPH	625MG	A213456	001	Jan 21, 2022	Jan NEWA

COLESTIPOL HYDROCHLORIDE

		TABLET;ORAL					
		COLESTID					
AB	+	PFIZER	1GM	N020222	001	Jul 19, 1994	Apr CHRS
		COLESTIPOL HYDROCHLORIDE					
AB	!	IMPAX LABS	1GM	A077510	001	Oct 24, 2006	Apr CHRS
AB		ZYDUS PHARMS	1GM	A215223	001	Mar 10, 2022	Feb NEWA

COPPER CU-64 DOTATATE

		SOLUTION;INTRAVENOUS					
		DETECTNET					
	+!	RADIOMEDIX	4mL (1mCi/ML)	N213227	001	Sep 03, 2020	Sep CAIN

CROMOLYN SODIUM

		SOLUTION;INHALATION					
		CROMOLYN SODIUM					
	@	BAUSCH	10MG/ML	A075585	001	Dec 21, 2000	Jun CAHN
AN		FERA PHARMS LLC	10MG/ML	A075437	001	Apr 21, 2000	Mar CMFD
AN		MICRO LABS	10MG/ML	A213658	001	Apr 29, 2022	Apr NEWA

CUPRIC CHLORIDE

		INJECTABLE;INJECTION					
		CUPRIC CHLORIDE					
AP		EXELA PHARMA	EQ 0.4MG COPPER/ML	A212071	001	Oct 31, 2022	Oct NFTG
		CUPRIC CHLORIDE IN PLASTIC CONTAINER					
AP	+!	HOSPIRA	EQ 0.4MG COPPER/ML	N018960	001	Jun 26, 1986	Oct CFTG

CUPRIC SULFATE

INJECTABLE;INJECTION

CUPRIC SULFATE

+ @	ABRAXIS PHARM	EQ 0.4MG COPPER/ML	N019350	001	May 05, 1987	Apr DISC

CYANOCOBALAMIN

INJECTABLE;INJECTION

CYANOCOBALAMIN

>A> AP	SAGENT PHARMS INC	1MG/ML	A215107	001	Nov 15, 2022	Nov NEWA
AP	SOLA PHARMS	1MG/ML	A215417	001	Apr 15, 2022	Sep CAHN
AP	WELDING	1MG/ML	A215417	001	Apr 15, 2022	Apr NEWA
AP	ZYDUS PHARMS	1MG/ML	A214655	001	Apr 15, 2022	Apr NEWA
	DODEX					
AP	ACCORD HLTHCARE	1MG/ML	A083022	001		May CTEC
		1MG/ML	A083022	001		Apr CMFD

CYCLOPHOSPHAMIDE

CAPSULE;ORAL

CYCLOPHOSPHAMIDE

>A> AB	ALEMBIC PHARMS LTD	25MG	A215892	001	Nov 10, 2022	Nov NEWA
>A> AB		50MG	A215892	002	Nov 10, 2022	Nov NEWA
@	ANI PHARMS	25MG	A207014	001	Mar 19, 2018	May DISC
@		50MG	A207014	002	Mar 19, 2018	Apr DISC
AB	ANIMA	25MG	A209872	001	May 07, 2018	Sep CAHN
AB		50MG	A209872	002	May 07, 2018	Sep CAHN

INJECTABLE;INJECTION

CYCLOPHOSPHAMIDE

AP	XELLIA PHARMS APS	500MG/VIAL	A211757	001	Oct 18, 2022	Oct NEWA
AP		1GM/VIAL	A211757	002	Oct 18, 2022	Oct NEWA
AP		2GM/VIAL	A211757	003	Oct 18, 2022	Oct NEWA

CYCLOSERINE

CAPSULE;ORAL

SEROMYCIN

>A> !	CEROVENE INC	250MG	A060593	001		Nov CAHN
>D> !	PURDUE	250MG	A060593	001		Nov CAHN

CYCLOSPORINE

CAPSULE;ORAL

CYCLOSPORINE

AB1	STRIDES PHARMA	25MG	A216046	001	Aug 02, 2022	Jul NEWA
AB1		50MG	A216046	002	Aug 02, 2022	Jul NEWA
AB1		100MG	A216046	003	Aug 02, 2022	Jul NEWA

EMULSION;OPHTHALMIC

CYCLOSPORINE

AB	MYLAN	0.05%	A205894	001	Feb 02, 2022	Jan NFTG

RESTASIS

AB +!	ALLERGAN	0.05%	N050790	001	Dec 23, 2002	Jan CFTG

SOLUTION;ORAL

CYCLOSPORINE

@	MAYNE PHARMA	100MG/ML	A065054	001	Dec 18, 2001	Feb DISC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	CHARTWELL MOLECULAR	2MG/5ML	A203191	001	Jul 13, 2017	Jun CAHN
@	TRIS PHARMA INC	2MG/5ML	A205431	001	Dec 21, 2021	Apr DISC

CYSTEAMINE BITARTRATE

GRANULE, DELAYED RELEASE;ORAL

PROCYSBI

+	HORIZON	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020	May CAHN
+!		EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020	May CAHN

CYSTEINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

CYSTEINE HYDROCHLORIDE

@	DR REDDYS LABS SA	500MG/10ML (50MG/ML)	A214082	001	Apr 08, 2022	Sep DISC
AP		500MG/10ML (50MG/ML)	A214082	001	Apr 08, 2022	Jun CAHN
AP	ETON	500MG/10ML (50MG/ML)	A214082	001	Apr 08, 2022	Apr NFTG

```
          SOLUTION;INTRAVENOUS
            ELCYS
          +!  EXELA PHARMA          500MG/10ML (50MG/ML)              N210660  001  Apr 16, 2019   Sep CTEC
    AP    +!                        500MG/10ML (50MG/ML)              N210660  001  Apr 16, 2019   Apr CFTG

        CYTARABINE
          INJECTABLE;INJECTION
            CYTARABINE
>D> AP        HONG KONG             20MG/ML                           A208485  001  Feb 28, 2022   Nov CAHN
    AP                              20MG/ML                           A208485  001  Feb 28, 2022   Feb NEWA
            @ MEITHEAL              20MG/ML                           A206189  001  Jun 26, 2020   Jun CAHN
>A> AP                              20MG/ML                           A208485  001  Feb 28, 2022   Nov CAHN

        DABIGATRAN ETEXILATE MESYLATE
          CAPSULE;ORAL
            DABIGATRAN ETEXILATE MESYLATE
    AB        ALKEM LABS LTD        EQ 150MG BASE                     A208040  002  Mar 11, 2020   Aug CMFD
            @                       EQ 150MG BASE                     A208040  002  Mar 11, 2020   Aug DISC

        DALFAMPRIDINE
          TABLET, EXTENDED RELEASE;ORAL
            DALFAMPRIDINE
            @ HIKMA                 10MG                              A206646  001  Oct 24, 2018   May DISC

        DALTEPARIN SODIUM
          INJECTABLE;SUBCUTANEOUS
            FRAGMIN
          +   PFIZER                10,000IU/4ML (2,500IU/ML)         N020287  012  Mar 15, 2022   Mar NEWA

        DANTROLENE SODIUM
          INJECTABLE;INJECTION
            DANTROLENE SODIUM
            @ EUGIA PHARMA SPECLTS  20MG/VIAL                         A205239  001  Feb 18, 2016   Mar CAHN

        DAPAGLIFLOZIN
          TABLET;ORAL
            DAPAGLIFLOZIN
            @ ZYDUS PHARMS          5MG                               A211582  001  Feb 22, 2022   Jul DISC
    AB                              5MG                               A211582  001  Feb 22, 2022   Feb NFTG
            @                       10MG                              A211582  002  Feb 22, 2022   Jul DISC
    AB                              10MG                              A211582  002  Feb 22, 2022   Feb NFTG
            FARXIGA
          +   ASTRAZENECA AB        5MG                               N202293  001  Jan 08, 2014   Jul CTEC
    AB    +                         5MG                               N202293  001  Jan 08, 2014   Feb CFTG
          +!                        10MG                              N202293  002  Jan 08, 2014   Jul CTEC
    AB    +!                        10MG                              N202293  002  Jan 08, 2014   Feb CFTG

        DAPSONE
          GEL;TOPICAL
            DAPSONE
    AB        COSETTE               5%                                A210178  001  Mar 31, 2022   Sep CAHN
    AB        MYLAN                 7.5%                              A213847  001  Feb 04, 2022   Jan NEWA
    AB        SEEGPHARM SA          5%                                A210178  001  Mar 31, 2022   Mar NEWA
    AB        TORRENT               7.5%                              A214722  001  Feb 10, 2022   Feb NEWA
          TABLET;ORAL
            DAPSONE
            @ ANDA REPOSITORY       25MG                              A204074  001  May 10, 2016   Sep CAHN
            @                       100MG                             A204074  002  May 10, 2016   Sep CAHN
>A> AB    +   EVEREST LIFE SCI      25MG                              A086841  001                  Nov CAHN
>A> AB    +!                        100MG                             A086842  001                  Nov CAHN
>D> AB    +   JACOBUS               25MG                              A086841  001                  Nov CAHN
>D> AB    +!                        100MG                             A086842  001                  Nov CAHN
            @ VIRTUS PHARMS         25MG                              A204074  001  May 10, 2016   Jan DISC
            @                       100MG                             A204074  002  May 10, 2016   Jan DISC

        DAPTOMYCIN
          POWDER;INTRAVENOUS
            CUBICIN RF
          + @ CUBIST PHARMS LLC     500MG/VIAL                        N021572  003  Jul 06, 2016   Sep DISC
            DAPTOMYCIN
    AP        HAINAN POLY PHARM     500MG/VIAL                        A215890  001  Aug 18, 2022   Aug NEWA
```

```
          POWDER;INTRAVENOUS
            DAPZURA RT
          + @ BAXTER HLTHCARE CORP   500MG/VIAL                N213645  001  Jan 25, 2022   Oct DISC
          +!                         500MG/VIAL                N213645  001  Jan 25, 2022   Jan NEWA

        DARIDOREXANT HYDROCHLORIDE
          TABLET;ORAL
            QUVIVIQ
          +   IDORSIA                EQ 25MG BASE              N214985  001  Apr 07, 2022   Apr NEWA
          +!                         EQ 50MG BASE              N214985  002  Apr 07, 2022   Apr NEWA

        DARUNAVIR
          TABLET;ORAL
            DARUNAVIR
    AB        LUPIN LTD              600MG                     A202073  001  Sep 29, 2022   Sep NEWA
    AB                               800MG                     A202073  002  Sep 29, 2022   Sep NFTG
            PREZISTA
    AB    +!  JANSSEN PRODS          800MG                     N021976  006  Nov 09, 2012   Sep CFTG

        DASATINIB
          TABLET;ORAL
            DASATINIB
            @ APOTEX                 80MG                      A203180  001  Nov 23, 2021   May DISC
            @                        140MG                     A203180  002  Nov 23, 2021   May DISC
            SPRYCEL
          +   BRISTOL MYERS SQUIBB   80MG                      N021986  005  Oct 28, 2010   May CTEC
          +                          140MG                     N021986  006  Oct 28, 2010   May CTEC

        DECITABINE
          INJECTABLE;INTRAVENOUS
            DACOGEN
          + @ OTSUKA                 50MG/VIAL                 N021790  001  May 02, 2006   Sep DISC
            DECITABINE
    AP    !   ACCORD HLTHCARE        50MG/VIAL                 A203475  001  Feb 27, 2017   Sep CHRS
    AP        JIANGSU HANSOH PHARM   50MG/VIAL                 A213472  001  Apr 15, 2022   Apr NEWA
    AP        NOVAST LABS            50MG/VIAL                 A210984  001  Sep 16, 2019   Aug CAHN

        DEFERASIROX
          GRANULE;ORAL
            DEFERASIROX
            @ AMNEAL                 90MG                      A214194  003  Aug 02, 2021   Mar DISC
            @                        180MG                     A214194  001  Feb 09, 2021   Jul DISC
            @                        360MG                     A214194  002  Feb 09, 2021   Jul DISC
    AB        ANNORA PHARMA          180MG                     A216229  001  Sep 22, 2022   Sep NEWA
    AB                               360MG                     A216229  002  Sep 22, 2022   Sep NEWA
    AB        CIPLA                  90MG                      A215026  001  Feb 23, 2022   Feb NEWA
    AB                               180MG                     A215026  002  Feb 23, 2022   Feb NEWA
    AB                               360MG                     A215026  003  Feb 23, 2022   Feb NEWA
    AB        MSN                    90MG                      A214650  003  Apr 20, 2022   Apr NEWA
    AB        TEVA PHARMS USA        90MG                      A214180  001  Nov 19, 2021   Aug CMFD
            @                        90MG                      A214180  001  Nov 19, 2021   Jun DISC
    AB                               180MG                     A214180  002  Nov 19, 2021   Aug CMFD
            @                        180MG                     A214180  002  Nov 19, 2021   Jun DISC
    AB                               360MG                     A214180  003  Nov 19, 2021   Aug CMFD
            @                        360MG                     A214180  003  Nov 19, 2021   Jun DISC
          TABLET;ORAL
            DEFERASIROX
            @ AMNEAL                 180MG                     A210727  003  Jun 15, 2020   Apr DISC
          TABLET, FOR SUSPENSION;ORAL
            DEFERASIROX
    AB        TEVA PHARMS USA        125MG                     A207124  001  Sep 23, 2022   Sep NEWA
    AB                               250MG                     A207124  002  Sep 23, 2022   Sep NEWA
    AB                               500MG                     A207124  003  Sep 23, 2022   Sep NEWA

        DEFERIPRONE
          TABLET;ORAL
            DEFERIPRONE
    AB        HIKMA                  1GM                       A213239  002  Feb 08, 2022   Jan NFTG
            FERRIPROX
>D> AB    +!  CHIESI                 500MG                     N021825  001  Oct 14, 2011   Nov CHRS
>A> AB    +                          500MG                     N021825  001  Oct 14, 2011   Nov CHRS
>D> AB    +                          1GM                       N021825  002  Jul 25, 2019   Nov CHRS
```

```
          TABLET;ORAL
            FERRIPROX
>A> AB    +!                        1GM                              N021825  002  Jul 25, 2019   Nov CHRS
    AB    +                         1GM                              N021825  002  Jul 25, 2019   Jan CFTG

        DESLORATADINE
          TABLET;ORAL
            DESLORATADINE
            @ PERRIGO               5MG                              A078361  001  Dec 22, 2011   Sep DISC
            @ SANDOZ                5MG                              A078364  001  Dec 03, 2010   Sep DISC

        DESMOPRESSIN ACETATE
          INJECTABLE;INJECTION
            DESMOPRESSIN ACETATE
    AP        DR REDDYS             0.004MG/ML                       A215961  001  Aug 19, 2022   Aug NEWA
>A> AP        GLAND PHARMA LTD      0.004MG/ML                       A216922  001  Nov 16, 2022   Nov NEWA
          SPRAY, METERED;NASAL
            DESMOPRESSIN ACETATE
    AB    !   BAUSCH                0.01MG/SPRAY                     A074830  001  Jan 25, 1999   Jun CAHN
            NOCTIVA
>A>       + @ ACERUS PHARMS         0.00083MG/SPRAY                  N201656  001  Mar 03, 2017   Nov CAHN
>A>       + @                       0.00166MG/SPRAY                  N201656  002  Mar 03, 2017   Nov CAHN
>D>       + @ SERENITY PHARMS LLC   0.00083MG/SPRAY                  N201656  001  Mar 03, 2017   Nov CAHN
>D>       + @                       0.00166MG/SPRAY                  N201656  002  Mar 03, 2017   Nov CAHN

        DESOGESTREL; ETHINYL ESTRADIOL
          TABLET;ORAL-28
            DESOGESTREL AND ETHINYL ESTRADIOL
            @ MAYNE PHARMA          0.15MG,N/A;0.02MG,0.01MG         A076916  001  Dec 29, 2008   Jan DISC
            @                       0.1MG,0.125MG,0.15MG;0.025MG,0.025 A077182  001  Jan 24, 2006   Jan DISC
                                    MG,0.025MG

        DESOXIMETASONE
          OINTMENT;TOPICAL
            DESOXIMETASONE
    AB        PAI HOLDINGS PHARM    0.25%                            A208101  001  Feb 25, 2016   Mar CAHN
    AB        THE J MOLNER          0.05%                            A209973  001  Oct 23, 2018   Oct CAHN

        DESVENLAFAXINE FUMARATE
          TABLET, EXTENDED RELEASE;ORAL
            DESVENLAFAXINE
          + @ SUN PHARM             EQ 50MG BASE                     N205583  001  Jan 28, 2014   Feb CAHN
          + @                       EQ 100MG BASE                    N205583  002  Jan 28, 2014   Feb CAHN

        DESVENLAFAXINE SUCCINATE
          TABLET, EXTENDED RELEASE;ORAL
            DESVENLAFAXINE SUCCINATE
    AB        LUPIN LTD             EQ 25MG BASE                     A204172  003  Apr 13, 2022   Apr NEWA
>A> AB        ZYDUS PHARMS          EQ 25MG BASE                     A204020  003  Nov 30, 2022   Nov NEWA

        DEUCRAVACITINIB
          TABLET;ORAL
            SOTYKTU
          +!  BRISTOL               6MG                              N214958  001  Sep 09, 2022   Sep NEWA

        DEXAMETHASONE
          SOLUTION;ORAL
            DEXAMETHASONE
          +!  HIKMA                 0.5MG/5ML                        A088248  001  Sep 01, 1983   Mar CRLD
          TABLET;ORAL
            DEXAMETHASONE
    AB        AMNEAL                2MG                              A216295  001  Sep 08, 2022   Sep NEWA
    BP    +   HIKMA                 0.5MG                            A084611  001                 Jan CRLD
    AB    +!                        2MG                              A087916  001  Aug 26, 1982   Sep CTEC
    AB        NOVITIUM PHARMA       1.5MG                            A215604  001  Aug 08, 2022   Jul NEWA
    AB                              4MG                              A215604  002  Aug 08, 2022   Jul NEWA
    AB                              6MG                              A215604  003  Aug 08, 2022   Jul NEWA
    AB        PRASCO                4MG                              A080399  002  Apr 20, 2022   Apr NEWA
```

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	+!	FRESENIUS KABI USA	EQ 4MG PHOSPHATE/ML	A084916	001		Feb CRLD

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OPHTHALMIC

MAXITROL

AT	+!	IMPRIMIS PHARMS USA	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		Jun CAHN

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

TOBRAMYCIN AND DEXAMETHASONE

AB		PADAGIS US	0.1%;0.3%	A212715	001	Feb 11, 2022	Feb NEWA

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

DEXCHLORPHENIRAMINE MALEATE

AA	+!	PAI HOLDINGS PHARM	2MG/5ML	A088251	001	Mar 23, 1984	Apr CAHN

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL

DEXILANT

AB	+	TAKEDA PHARMS USA	30MG	N022287	001	Jan 30, 2009	Jun CFTG

DEXLANSOPRAZOLE

AB		PAR PHARM INC	30MG	A202294	002	Jun 16, 2022	Jun NFTG
AB		TWI PHARMS	30MG	A202666	001	Sep 16, 2022	Sep NEWA
AB			60MG	A202666	002	Sep 16, 2022	Sep NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

IGALMI

	+!	BIOXCEL	EQ 0.12MG BASE	N215390	001	Apr 05, 2022	Apr NEWA
	+!		EQ 0.18MG BASE	N215390	002	Apr 05, 2022	Apr NEWA

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		MEITHEAL	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Apr CAHN
	@	PIRAMAL CRITICAL	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A214794	001	Sep 03, 2021	Feb DISC

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

	@	MAYNE PHARMA	5MG	A076137	001	Jan 18, 2002	Feb DISC
	@		10MG	A076137	002	Jan 18, 2002	Feb DISC
	@		15MG	A076137	003	Jan 18, 2002	Feb DISC

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

		ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011	Jan CTEC
			7.5MG	A090533	003	Oct 25, 2011	Jan CTEC
			15MG	A090533	005	Oct 25, 2011	Jan CTEC
			20MG	A090533	006	Oct 25, 2011	Jan CTEC
			30MG	A090533	007	Oct 25, 2011	Jan CTEC
AA		TRIS PHARMA INC	5MG	A206095	001	Aug 18, 2022	Aug NEWA
AA			10MG	A206095	002	Aug 18, 2022	Aug NEWA
	@	WINDER LABS LLC	2.5MG	A212160	001	Jun 07, 2021	Jan DISC
	@		5MG	A212160	002	Jun 07, 2021	Jan DISC
	@		7.5MG	A212160	003	Jun 07, 2021	Jan DISC
	@		10MG	A212160	004	Jun 07, 2021	Jan DISC
	@		15MG	A212160	005	Jun 07, 2021	Jan DISC
	@		20MG	A212160	006	Jun 07, 2021	Jan DISC
	@		30MG	A212160	007	Jun 07, 2021	Jan DISC

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%

AP		FRESENIUS KABI USA	5GM/100ML;75MG/100ML	A212346	001	Sep 10, 2020	Sep CMFD

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%

AP		FRESENIUS KABI USA	5GM/100ML;150MG/100ML	A212346	002	Sep 10, 2020	Sep CMFD

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

	INJECTABLE;INJECTION						
	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;450MG/100ML	A213523	005	Oct 11, 2022	Sep NEWA

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

	SOLUTION;ORAL, RECTAL						
	DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM						
AA	GUARDIAN DRUG	66%;10%	A214201	001	Jun 27, 2022	Jun NEWA

DIAZEPAM

	CONCENTRATE;ORAL						
	DIAZEPAM						
AA	CHARTWELL MOLECULAR	5MG/ML	A204433	001	Apr 14, 2014	Aug CMFD
	@	5MG/ML	A204433	001	Apr 14, 2014	Jun CAHN
	DIAZEPAM INTENSOL					
AA	! HIKMA	5MG/ML	A071415	001	Apr 03, 1987	Aug CTEC
	GEL;RECTAL					
	DIASTAT					
	+! BAUSCH	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997	May CHRS
	DIASTAT ACUDIAL					
	+! BAUSCH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005	May CHRS
	INJECTABLE;INJECTION					
	DIAZEPAM					
>A> AP	FRESENIUS KABI USA	10MG/2ML (5MG/ML)	A214745	001	Nov 10, 2022	Nov NEWA
	SOLUTION;ORAL					
	DIAZEPAM					
AA	CHARTWELL MOLECULAR	5MG/5ML	A206477	001	Jun 24, 2016	Jun CAHN
	TABLET;ORAL					
	VALIUM					
AB	+ WAYLIS THERAP	2MG	N013263	002		Mar CAHN
AB	+	5MG	N013263	004		Mar CAHN
AB	+!	10MG	N013263	006		Mar CAHN

DICLOFENAC

	CAPSULE;ORAL						
	ZORVOLEX						
	+ @ ZYLA	35MG	N204592	002	Oct 18, 2013	Jul DISC

DICLOFENAC POTASSIUM

	CAPSULE;ORAL						
	DICLOFENAC POTASSIUM						
AB	STRIDES PHARMA	25MG	A210078	001	Dec 03, 2019	Apr CMFD
	FOR SOLUTION;ORAL						
	DICLOFENAC POTASSIUM						
AB	ALKEM LABS LTD	50MG	A216635	001	Jul 20, 2022	Jul NEWA
AB	ANNORA PHARMA	50MG	A215375	001	Mar 04, 2022	Feb NEWA
	TABLET;ORAL						
	DICLOFENAC POTASSIUM						
AB	NOVAST LABS	50MG	A215585	001	Oct 08, 2021	Aug CAHN
AB	UMEDICA LABS PVT LTD	50MG	A215750	001	May 11, 2022	Apr NEWA

DICLOFENAC SODIUM

	GEL;TOPICAL						
	DICLOFENAC SODIUM						
AB	ALEOR DERMACEUTICALS	3%	A212351	001	Jul 27, 2022	Jul NEWA
	CIPLA	1%	A209903	001	Aug 03, 2018	Mar CTEC
	SOLUTION;TOPICAL						
	DICLOFENAC SODIUM						
>A> AB	ALEOR DERMACEUTICALS	2%	A212506	001	Nov 29, 2022	Nov NEWA
AB	AMNEAL	2%	A208198	001	Aug 18, 2022	Aug NEWA
AB	APOTEX	2%	A207714	001	May 06, 2022	Apr NFTG
AB	LUPIN PHARMS	2%	A208021	001	Sep 20, 2022	Sep NEWA
AB	TARO	2%	A208098	001	Sep 29, 2022	Sep NEWA
	PENNSAID						
AB	+! HORIZON	2%	N204623	001	Jan 16, 2014	Apr CFTG
	SOLUTION/DROPS;OPHTHALMIC						
	DICLOFENAC SODIUM						
	@ AKORN	0.1%	A077845	001	Apr 17, 2008	Aug DISC

TABLET, EXTENDED RELEASE;ORAL
DICLOFENAC SODIUM

AB		RICONPHARMA LLC	100MG	A216275	001	Sep 23, 2022	Sep NEWA

DICLOXACILLIN SODIUM

CAPSULE;ORAL
DICLOXACILLIN SODIUM

AB		AUROBINDO PHARMA	EQ 250MG BASE	A216845	001	Sep 23, 2022	Sep NEWA
AB			EQ 500MG BASE	A216845	002	Sep 23, 2022	Sep NEWA
AB		TEVA	EQ 250MG BASE	A062286	001	Jun 03, 1982	Oct CTEC
AB	!		EQ 500MG BASE	A062286	002	Jun 03, 1982	Sep CTEC

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL
DICYCLOMINE HYDROCHLORIDE

AB		AUROBINDO PHARMA USA	10MG	A040319	001	Sep 07, 1999	Oct CAHN

INJECTABLE;INJECTION
DICYCLOMINE HYDROCHLORIDE

	@	ATHENEX INC	10MG/ML	A212058	001	Apr 26, 2019	Oct CAHN
	@	GENE YORK PHARMS	10MG/ML	A212058	001	Apr 26, 2019	Feb DISC
	@	HIKMA	10MG/ML	A210788	001	Feb 11, 2019	Oct DISC
AP			10MG/ML	A210788	001	Feb 11, 2019	Oct CAHN

TABLET;ORAL
DICYCLOMINE HYDROCHLORIDE

>A> AB		COREPHARMA	20MG	A216760	001	Nov 28, 2022	Nov NEWA

DIFLORASONE DIACETATE

OINTMENT;TOPICAL
DIFLORASONE DIACETATE

AB		THE J MOLNER	0.05%	A210753	001	Jun 12, 2018	Oct CAHN

DIFLUPREDNATE

EMULSION;OPHTHALMIC
DIFLUPREDNATE

>A> AB		DR REDDYS	0.05%	A214894	001	Nov 16, 2022	Nov NEWA

DIGOXIN

ELIXIR;ORAL
DIGOXIN

AA		AMICI	0.05MG/ML	A215209	001	Mar 11, 2022	Mar NEWA

TABLET;ORAL
DIGOXIN

AB		AUROBINDO PHARMA LTD	0.0625MG	A214982	001	Feb 08, 2022	Jan NFTG
AB			0.125MG	A214982	002	Feb 08, 2022	Jan NEWA
AB			0.25MG	A214982	003	Feb 08, 2022	Jan NEWA
AB		NOVITIUM PHARMA	0.0625MG	A215307	003	Aug 25, 2022	Aug NEWA

LANOXIN

AB	+	CONCORDIA	0.0625MG	N020405	001	Sep 30, 1997	Jan CFTG

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION
D.H.E. 45

	+ @	BAUSCH	1MG/ML	N005929	001		Jul DISC

DIHYDROERGOTAMINE MESYLATE

AP	!	HIKMA PHARMS	1MG/ML	A206621	001	Sep 15, 2017	Jul CHRS

SPRAY, METERED;NASAL
DIHYDROERGOTAMINE MESYLATE

	@	AMNEAL	0.5MG/SPRAY	A214105	001	Jan 04, 2022	Jul DISC
AB		HIKMA	0.5MG/SPRAY	A211393	001	Feb 28, 2020	Aug CAHN

TRUDHESA

	+!	IMPEL PHARMS	0.725MG/SPRAY	N213436	001	Sep 02, 2021	May CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB2		AMTA	120MG	A216304	001	Aug 08, 2022	Jul NEWA
AB2			180MG	A216304	002	Aug 08, 2022	Jul NEWA
AB2			240MG	A216304	003	Aug 08, 2022	Jul NEWA
AB1		MAYNE PHARMA INTL	60MG	A215775	001	May 05, 2022	Apr NEWA
AB1			90MG	A215775	002	May 05, 2022	Apr NEWA
AB1			120MG	A215775	003	May 05, 2022	Apr NEWA

```
          CAPSULE, EXTENDED RELEASE;ORAL
            DILTIAZEM HYDROCHLORIDE
>D> AB3       SUN PHARM             120MG                          A090492  001  Oct 28, 2011   Nov DISC
>A>         @                       120MG                          A090492  001  Oct 28, 2011   Nov DISC
>D> AB3                             180MG                          A090492  002  Oct 28, 2011   Nov DISC
>A>         @                       180MG                          A090492  002  Oct 28, 2011   Nov DISC
>D> AB3                             240MG                          A090492  003  Oct 28, 2011   Nov DISC
>A>         @                       240MG                          A090492  003  Oct 28, 2011   Nov DISC
>D> AB3                             300MG                          A090492  004  Oct 28, 2011   Nov DISC
>A>         @                       300MG                          A090492  004  Oct 28, 2011   Nov DISC
          SOLUTION;INTRAVENOUS
            DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%
          + @ EXELA PHARMA          125MG/125ML (1MG/ML)           N215252  001  Oct 28, 2021   Feb DISC
          + @                       250MG/250ML (1MG/ML)           N215252  002  Oct 28, 2021   Feb DISC
          TABLET;ORAL
            DILTIAZEM HYDROCHLORIDE
    AB        SCIEGEN PHARMS INC    30MG                           A216521  001  Sep 23, 2022   Sep NEWA
    AB                              60MG                           A216521  002  Sep 23, 2022   Sep NEWA
    AB                              90MG                           A216521  003  Sep 23, 2022   Sep NEWA
    AB                              120MG                          A216521  004  Sep 23, 2022   Sep NEWA

        DIMETHYL FUMARATE
          CAPSULE, DELAYED RELEASE;ORAL
            DIMETHYL FUMARATE
            @ PHARMATHEN            120MG                          A210436  001  Mar 26, 2021   Apr DISC
            @                       240MG                          A210436  002  Mar 26, 2021   Apr DISC
    AB        PRINSTON INC          120MG                          A210414  001  Oct 18, 2022   Oct NEWA
    AB                              240MG                          A210414  002  Oct 18, 2022   Oct NEWA
            @ SAWAI USA             120MG                          A210285  001  Dec 21, 2021   Jun DISC
            @                       240MG                          A210285  002  Dec 21, 2021   Jun DISC
            @ SOLA PHARMS           120MG                          A210436  001  Mar 26, 2021   Jul CAHN
            @                       240MG                          A210436  002  Mar 26, 2021   Jul CAHN

        DIPYRIDAMOLE
          INJECTABLE;INJECTION
            DIPYRIDAMOLE
    AP    !   CHARTWELL INJECTABLE  5MG/ML                         A074939  001  Apr 13, 1998   Mar CAHN
          @ EUGIA PHARMA SPECLTS    5MG/ML                         A075769  001  Nov 27, 2002   Mar CAHN
          TABLET;ORAL
            DIPYRIDAMOLE
            @ ANDA REPOSITORY       25MG                           A040898  001  Apr 23, 2008   Sep CAHN
            @                       50MG                           A040898  002  Apr 23, 2008   Sep CAHN
            @                       75MG                           A040898  003  Apr 23, 2008   Sep CAHN

        DISOPYRAMIDE PHOSPHATE
          CAPSULE;ORAL
            DISOPYRAMIDE PHOSPHATE
    AB        MAYNE PHARMA          EQ 100MG BASE                  A070173  001  May 31, 1985   Feb CMFD
    AB                              EQ 150MG BASE                  A070173  002  May 31, 1985   Feb CMFD

        DIVALPROEX SODIUM
          CAPSULE, DELAYED REL PELLETS;ORAL
            DIVALPROEX SODIUM
            @ RISING                EQ 125MG VALPROIC ACID         A090407  001  Mar 28, 2011   Aug CAHN
          TABLET, EXTENDED RELEASE;ORAL
            DIVALPROEX SODIUM
    AB        UNICHEM               EQ 250MG VALPROIC ACID         A214643  001  Feb 25, 2022   Feb NEWA
    AB                              EQ 500MG VALPROIC ACID         A214643  002  Feb 25, 2022   Feb NEWA

        DOCETAXEL
          INJECTABLE;INJECTION
            DOCETAXEL
    AP        MEITHEAL              20MG/2ML (10MG/ML)             A209634  001  Aug 24, 2018   Apr CAHN
    AP                              80MG/8ML (10MG/ML)             A209634  002  Aug 24, 2018   Apr CAHN
    AP                              160MG/16ML (10MG/ML)           A209634  003  Aug 24, 2018   Apr CAHN
>A> AP        SUN PHARM             20MG/ML (20MG/ML)              N022534  003  Jan 08, 2019   Nov CDFR
>A> AP                              80MG/4ML (20MG/ML)             N022534  004  Jan 08, 2019   Nov CDFR
>A> AP                              160MG/8ML (20MG/ML)            N022534  005  Jan 08, 2019   Nov CDFR
          SOLUTION;INTRAVENOUS
            DOCETAXEL
>A>       +!  MERIDIAN LABS         20MG/2ML (10MG/ML)             N215813  001  Nov 22, 2022   Nov NEWA
>A>       +!                        80MG/8ML (10MG/ML)             N215813  002  Nov 22, 2022   Nov NEWA
```

```
          SOLUTION;INTRAVENOUS
            DOCETAXEL
>A>       +!                        160MG/16ML (10MG/ML)          N215813  003  Nov 22, 2022   Nov NEWA
>D> AP        SUN PHARM             20MG/ML (20MG/ML)             N022534  003  Jan 08, 2019   Nov CDFR
>D> AP                              80MG/4ML (20MG/ML)            N022534  004  Jan 08, 2019   Nov CDFR
>D> AP                              160MG/8ML (20MG/ML)           N022534  005  Jan 08, 2019   Nov CDFR

        DOFETILIDE
          CAPSULE;ORAL
            DOFETILIDE
            @ TEVA PHARMS USA       0.125MG                       A210018  001  Apr 15, 2022   Oct DISC
    AB                              0.125MG                       A210018  001  Apr 15, 2022   Apr NEWA
            @                       0.25MG                        A210018  002  Apr 15, 2022   Oct DISC
    AB                              0.25MG                        A210018  002  Apr 15, 2022   Apr NEWA
            @                       0.5MG                         A210018  003  Apr 15, 2022   Oct DISC
    AB                              0.5MG                         A210018  003  Apr 15, 2022   Apr NEWA
>A> AB        VGYAAN                0.125MG                       A215323  001  Apr 14, 2022   Nov CDFR
>A> AB                              0.25MG                        A215323  002  Apr 14, 2022   Nov CDFR
>A> AB                              0.5MG                         A215323  003  Apr 14, 2022   Nov CDFR
>D>       TABLET;ORAL
>D>         DOFETILIDE
>D> AB        NUVO PHARM            0.125MG                       A215323  001  Apr 14, 2022   Nov CDFR
    AB                              0.125MG                       A215323  001  Apr 14, 2022   Aug CAHN
>D> AB                              0.25MG                        A215323  002  Apr 14, 2022   Nov CDFR
    AB                              0.25MG                        A215323  002  Apr 14, 2022   Aug CAHN
>D> AB                              0.5MG                         A215323  003  Apr 14, 2022   Nov CDFR
    AB                              0.5MG                         A215323  003  Apr 14, 2022   Aug CAHN
    AB        VGYAAN                0.125MG                       A215323  001  Apr 14, 2022   Apr NEWA
    AB                              0.25MG                        A215323  002  Apr 14, 2022   Apr NEWA
    AB                              0.5MG                         A215323  003  Apr 14, 2022   Apr NEWA

        DONEPEZIL HYDROCHLORIDE
          SYSTEM;TRANSDERMAL
            ADLARITY
          +   CORIUM                5MG/DAY                       N212304  001  Mar 11, 2022   Mar NEWA
          +!                        10MG/DAY                      N212304  002  Mar 11, 2022   Mar NEWA
          TABLET;ORAL
            DONEPEZIL HYDROCHLORIDE
    AB        CHARTWELL RX          5MG                           A090425  001  May 31, 2011   Mar CAHN
    AB                              10MG                          A090425  002  May 31, 2011   Mar CAHN
            @ INDICUS PHARMA        23MG                          A203419  001  Apr 12, 2016   Sep DISC
    AB        RISING                5MG                           A202114  001  Jul 05, 2013   Sep CAHN
    AB                              10MG                          A202114  002  Jul 05, 2013   Sep CAHN
            @ SANDOZ                5MG                           A090290  001  May 31, 2011   Oct DISC
            @                       10MG                          A090290  002  May 31, 2011   Oct DISC

        DORZOLAMIDE HYDROCHLORIDE
          SOLUTION/DROPS;OPHTHALMIC
            DORZOLAMIDE HYDROCHLORIDE
    AT        GLAND PHARMA LTD      EQ 2% BASE                    A215660  001  Jan 27, 2022   Jan NEWA
    AT    !   MICRO LABS            EQ 2% BASE                    A204778  001  Nov 08, 2019   May CHRS
            TRUSOPT
          + @ MERCK                 EQ 2% BASE                    N020408  001  Dec 09, 1994   May DISC
          + @ MSD SUB MERCK         EQ 2% BASE                    N020408  001  Dec 09, 1994   Jun CAHN

        DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE
          SOLUTION/DROPS;OPHTHALMIC
            COSOPT
    AT    +!  THEA PHARMA           EQ 2% BASE;EQ 0.5% BASE       N020869  001  Apr 07, 1998   Apr CAHN
            COSOPT PF
    AT    +!  THEA PHARMA           EQ 2% BASE;EQ 0.5% BASE       N202667  001  Feb 01, 2012   Apr CAHN
            DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
    AT        GLAND PHARMA LTD      EQ 2% BASE;EQ 0.5% BASE       A215520  001  Sep 19, 2022   Sep NEWA
    AT        MICRO LABS            EQ 2% BASE;EQ 0.5% BASE       A215936  001  Jan 25, 2022   Jan NEWA

        DOXAPRAM HYDROCHLORIDE
          INJECTABLE;INJECTION
            DOXAPRAM HYDROCHLORIDE
    AP        CHARTWELL INJECTABLE  20MG/ML                       A076266  001  Jan 10, 2003   Mar CAHN
```

DOXAZOSIN MESYLATE

TABLET;ORAL

CARDURA

AB	+!	VIATRIS	EQ 1MG BASE	N019668	001	Nov 02, 1990	Jan CAHN
AB	+		EQ 2MG BASE	N019668	002	Nov 02, 1990	Jan CAHN
AB	+		EQ 4MG BASE	N019668	003	Nov 02, 1990	Jan CAHN
AB	+		EQ 8MG BASE	N019668	004	Nov 02, 1990	Jan CAHN

DOXAZOSIN MESYLATE

	@	CHARTWELL RX	EQ 1MG BASE	A075646	001	Oct 18, 2000	Jan CAHN
	@		EQ 2MG BASE	A075646	002	Oct 18, 2000	Jan CAHN
	@		EQ 4MG BASE	A075646	003	Oct 18, 2000	Jan CAHN
	@		EQ 8MG BASE	A075646	004	Oct 18, 2000	Jan CAHN
AB		METHOD	EQ 1MG BASE	A212727	001	Mar 15, 2022	Mar NEWA
AB			EQ 2MG BASE	A212727	002	Mar 15, 2022	Mar NEWA
AB			EQ 4MG BASE	A212727	003	Mar 15, 2022	Mar NEWA
AB			EQ 8MG BASE	A212727	004	Mar 15, 2022	Mar NEWA
AB		PHARMGEN	EQ 1MG BASE	A212727	001	Mar 15, 2022	Sep CAHN
AB			EQ 2MG BASE	A212727	002	Mar 15, 2022	Sep CAHN
AB			EQ 4MG BASE	A212727	003	Mar 15, 2022	Sep CAHN
AB			EQ 8MG BASE	A212727	004	Mar 15, 2022	Sep CAHN

TABLET, EXTENDED RELEASE;ORAL

CARDURA XL

	+	VIATRIS	EQ 4MG BASE	N021269	001	Feb 22, 2005	Jan CAHN
	+!		EQ 8MG BASE	N021269	002	Feb 22, 2005	Jan CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB		EDENBRIDGE PHARMS	EQ 150MG BASE	A213796	001	Apr 19, 2022	Apr NEWA
AB		EPIC PHARMA LLC	EQ 50MG BASE	A210675	004	Mar 03, 2022	Feb NEWA
AB			EQ 75MG BASE	A210675	005	Mar 03, 2022	Feb NEWA
AB		JUBILANT CADISTA	EQ 10MG BASE	A215483	001	Mar 14, 2022	Mar NEWA
AB			EQ 25MG BASE	A215483	002	Mar 14, 2022	Mar NEWA
AB			EQ 50MG BASE	A215483	003	Mar 14, 2022	Mar NEWA
AB			EQ 75MG BASE	A215483	004	Mar 14, 2022	Mar NEWA
AB			EQ 100MG BASE	A215483	005	Mar 14, 2022	Mar NEWA
AB		MANKIND PHARMA	EQ 10MG BASE	A215710	001	Feb 09, 2022	Jan NEWA
AB			EQ 25MG BASE	A215710	002	Feb 09, 2022	Jan NEWA
AB			EQ 50MG BASE	A215710	003	Feb 09, 2022	Jan NEWA
AB			EQ 75MG BASE	A215710	004	Feb 09, 2022	Jan NEWA
AB			EQ 100MG BASE	A215710	005	Feb 09, 2022	Jan NEWA
AB		MSN	EQ 10MG BASE	A215113	001	Jun 24, 2022	Jun NEWA
AB			EQ 25MG BASE	A215113	002	Jun 24, 2022	Jun NEWA
AB			EQ 50MG BASE	A215113	003	Jun 24, 2022	Jun NEWA
AB			EQ 75MG BASE	A215113	004	Jun 24, 2022	Jun NEWA
AB			EQ 100MG BASE	A215113	005	Jun 24, 2022	Jun NEWA
	@	PAR PHARM	EQ 10MG BASE	A071422	002	Nov 09, 1987	Oct DISC
	@		EQ 25MG BASE	A071422	003	Nov 09, 1987	Oct DISC
	@		EQ 50MG BASE	A071422	004	Nov 09, 1987	Oct DISC
	@		EQ 75MG BASE	A071422	005	Nov 09, 1987	Oct DISC
	@		EQ 100MG BASE	A071422	001	Nov 09, 1987	Oct DISC
AB	!		EQ 150MG BASE	A071422	006	Nov 09, 1987	Apr CTEC

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB		STRIDES PHARMA	EQ 3MG BASE	A202510	001	Jul 24, 2020	Jun CMFD
	@		EQ 3MG BASE	A202510	001	Jul 24, 2020	Jan CAHN
AB			EQ 6MG BASE	A202510	002	Jul 24, 2020	Jun CMFD
	@		EQ 6MG BASE	A202510	002	Jul 24, 2020	Jan CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

	@	AKORN	2MCG/ML (2MCG/ML)	A203929	002	Mar 28, 2016	Aug DISC
	@		4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Aug DISC
AP		EUGIA PHARMA	2MCG/ML (2MCG/ML)	A213717	001	Jan 24, 2022	Jan NEWA
AP			4MCG/2ML (2MCG/ML)	A213717	002	Jan 24, 2022	Jan NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL;INJECTION

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB		AYANA PHARMA LTD	20MG/10ML (2MG/ML)	A207228	001	Oct 12, 2021	Oct CTNA
AB			50MG/25ML (2MG/ML)	A207228	002	Oct 12, 2021	Oct CTNA
AB		CELERITY PHARMS	20MG/10ML (2MG/ML)	A212219	001	Oct 19, 2022	Oct NEWA
AB			50MG/25ML (2MG/ML)	A212219	002	Oct 19, 2022	Oct NEWA
AB		ZYDUS	20MG/10ML (2MG/ML)	A212299	001	Sep 10, 2020	Oct CTNA
AB			50MG/25ML (2MG/ML)	A212299	002	Sep 10, 2020	Oct CTNA

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

	@	IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011	Mar DISC
	@	STRIDES PHARMA	EQ 150MG BASE	A202778	001	Jun 08, 2012	Aug CAHN

MONODOX

AB	+	CHARTWELL RX	EQ 150MG BASE	N050641	004	Feb 17, 2022	Feb NEWA

TABLET;ORAL

DOXYCYCLINE

AB		STRIDES PHARMA	EQ 50MG BASE	A065070	001	Dec 15, 2000	Jul CMFD
AB			EQ 75MG BASE	A065070	003	Dec 30, 2002	Jul CMFD
AB			EQ 100MG BASE	A065070	002	Dec 15, 2000	Jul CMFD
AB			EQ 150MG BASE	A065070	004	Jul 14, 2005	Jul CMFD

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB		CADILA	EQ 50MG BASE	A207774	001	May 31, 2018	May CAHN
AB			EQ 100MG BASE	A207774	002	May 31, 2018	May CAHN
>D>	@	MYLAN	EQ 50MG BASE	A062337	001	Mar 29, 1982	Nov CAHN
>D>	@		EQ 100MG BASE	A062337	002	Mar 29, 1982	Nov CAHN
>A>	@	STRIDES PHARMA	EQ 50MG BASE	A062337	001	Mar 29, 1982	Nov CAHN
>A>	@		EQ 100MG BASE	A062337	002	Mar 29, 1982	Nov CAHN

CAPSULE, DELAYED RELEASE;ORAL

DORYX

>A>	+ @	MAYNE PHARMA	EQ 75MG BASE	N050582	002	Aug 13, 2001	Nov CAHN
>A>	+ @		EQ 100MG BASE	N050582	001	Jul 22, 1985	Nov CAHN
>D>	+ @	MAYNE PHARMA INTL	EQ 75MG BASE	N050582	002	Aug 13, 2001	Nov CAHN
>D>	+ @		EQ 100MG BASE	N050582	001	Jul 22, 1985	Nov CAHN

INJECTABLE;INJECTION

DOXYCYCLINE HYCLATE

>A> AP		PAR STERILE PRODUCTS	EQ 100MG BASE/VIAL	A216690	001	Dec 07, 2022	Nov NEWA

TABLET;ORAL

DOXYCYCLINE HYCLATE

AB		AMNEAL	EQ 100MG BASE	A216599	001	Oct 24, 2022	Oct NEWA
AB	!	CHARTWELL MOLECULAR	EQ 20MG BASE	A065277	001	Nov 10, 2005	Jun CAHN
	@	EMCURE PHARMS LTD	EQ 100MG BASE	A209969	001	Nov 09, 2018	Jan DISC
	@	PRAXGEN	EQ 100MG BASE	A212487	001	Mar 30, 2022	Aug DISC
AB			EQ 100MG BASE	A212487	001	Mar 30, 2022	Mar NEWA

TABLET, DELAYED RELEASE;ORAL

DORYX

>D> AB	+	MAYNE PHARMA	EQ 50MG BASE	N050795	006	Dec 19, 2014	Nov CAHN
>A> AB	+		EQ 50MG BASE	N050795	006	Dec 19, 2014	Nov CAHN
>D> AB	+		EQ 75MG BASE	N050795	001	May 06, 2005	Nov CAHN
>A> AB	+		EQ 75MG BASE	N050795	001	May 06, 2005	Nov CAHN
>D>	+		EQ 80MG BASE	N050795	004	Apr 11, 2013	Nov CAHN
>A>	+		EQ 80MG BASE	N050795	004	Apr 11, 2013	Nov CAHN
>D> AB	+		EQ 100MG BASE	N050795	002	May 06, 2005	Nov CAHN
>A> AB	+		EQ 100MG BASE	N050795	002	May 06, 2005	Nov CAHN
>D> AB	+		EQ 150MG BASE	N050795	003	Jun 20, 2008	Nov CAHN
>A> AB	+		EQ 150MG BASE	N050795	003	Jun 20, 2008	Nov CAHN
>D> AB	+!		EQ 200MG BASE	N050795	005	Apr 11, 2013	Nov CAHN
>A> AB	+!		EQ 200MG BASE	N050795	005	Apr 11, 2013	Nov CAHN

DORYX MPC

>D>	+ @	MAYNE PHARMA	EQ 60MG BASE	N050795	007	May 20, 2016	Nov CMFD
>A>	+		EQ 60MG BASE	N050795	007	May 20, 2016	Nov CMFD
>D>	+!		EQ 120MG BASE	N050795	008	May 20, 2016	Nov CAHN
>A>	+!		EQ 120MG BASE	N050795	008	May 20, 2016	Nov CAHN

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BONJESTA

	+!	DUCHESNAY	20MG;20MG	N209661	001	Nov 07, 2016	Sep CTEC
AB	+!		20MG;20MG	N209661	001	Nov 07, 2016	Feb CFTG

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

	@	ACTAVIS LABS FL INC	20MG;20MG	A212472	001	Mar 01, 2022	Sep DISC
AB			20MG;20MG	A212472	001	Mar 01, 2022	Feb NFTG

DRONABINOL

CAPSULE;ORAL

DRONABINOL

>D>	AB	LANNETT CO INC	2.5MG	A201463	001	May 18, 2018	Nov DISC
>A>	@		2.5MG	A201463	001	May 18, 2018	Nov DISC
>D>	AB		5MG	A201463	002	May 18, 2018	Nov DISC
>A>	@		5MG	A201463	002	May 18, 2018	Nov DISC
>D>	AB		10MG	A201463	003	May 18, 2018	Nov DISC
>A>	@		10MG	A201463	003	May 18, 2018	Nov DISC

SOLUTION;ORAL

SYNDROS

	+!	BENUVIA OPERATIONS	5MG/ML	N205525	001	Mar 23, 2017	Oct CAHN

DROSPIRENONE

TABLET, CHEWABLE;ORAL

DROSPIRENONE

	+!	EXELTIS USA INC	3.5MG	N216285	001	Jun 29, 2022	Jun NEWA

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

	@	SLATE RUN PHARMA	100MG	A215265	001	Nov 01, 2021	May DISC
	@		200MG	A215265	002	Nov 01, 2021	May DISC
	@		300MG	A215265	003	Nov 01, 2021	May DISC
AB		UPSHER SMITH LABS	100MG	A213661	001	Feb 18, 2021	Aug CAHN
AB			200MG	A213661	002	Feb 18, 2021	Aug CAHN
AB			300MG	A213661	003	Feb 18, 2021	Aug CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DRIZALMA SPRINKLE

>D>	+	SUN PHARM	EQ 20MG BASE	N212516	001	Jul 19, 2019	Nov DISC
>A>	+ @		EQ 20MG BASE	N212516	001	Jul 19, 2019	Nov DISC
	+		EQ 20MG BASE	N212516	001	Jul 19, 2019	Feb CAHN
	+		EQ 30MG BASE	N212516	002	Jul 19, 2019	Feb CAHN
	+		EQ 40MG BASE	N212516	003	Jul 19, 2019	Feb CAHN
	+!		EQ 60MG BASE	N212516	004	Jul 19, 2019	Feb CAHN

DUVELISIB

CAPSULE;ORAL

COPIKTRA

	+	SECURA	15MG	N211155	001	Sep 24, 2018	May CMFD
	+ @		15MG	N211155	001	Sep 24, 2018	Apr DISC
	+		25MG	N211155	002	Sep 24, 2018	May CMFD
	+ @		25MG	N211155	002	Sep 24, 2018	Apr DISC

ECONAZOLE NITRATE

CREAM;TOPICAL

SPECTAZOLE

	+ @	ALVOGEN	1%	N018751	001	Dec 23, 1982	Aug DISC

EDARAVONE

SUSPENSION;ORAL

RADICAVA ORS

	+!	MITSUBISHI TANABE	105MG/5ML	N215446	001	May 12, 2022	May NEWA

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

	@	AUROBINDO PHARMA	600MG	A205322	001	Aug 30, 2018	Apr DISC
AB	!	HETERO LABS LTD III	600MG	A078886	001	Apr 27, 2018	Sep CHRS

```
      TABLET;ORAL
        SUSTIVA
      + @ BRISTOL MYERS SQUIBB   600MG                          N021360  002  Feb 01, 2002   Sep DISC

    EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
      TABLET;ORAL
        EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE
AB        HETERO LABS LTD V      600MG;200MG;300MG              A203053  001  Jan 24, 2022   Jan NEWA

    EFINACONAZOLE
      SOLUTION;TOPICAL
        EFINACONAZOLE
        @ LUPIN LTD              10%                            A212169  001  Mar 02, 2022   May DISC
AB                               10%                            A212169  001  Mar 02, 2022   Feb NEWA
AB        NIVAGEN PHARMS INC     10%                            A211969  001  Jun 21, 2021   Aug CAHN

    EFLORNITHINE HYDROCHLORIDE
      CREAM;TOPICAL
        VANIQA
      + @ SKINMEDICA             13.9%                          N021145  001  Jul 27, 2000   Feb DISC

    ELBASVIR; GRAZOPREVIR
      TABLET;ORAL
        ZEPATIER
      +!  MSD SUB MERCK          50MG;100MG                     N208261  001  Jan 28, 2016   Jun CAHN

    ELETRIPTAN HYDROBROMIDE
      TABLET;ORAL
        ELETRIPTAN HYDROBROMIDE
AB        BEXIMCO PHARMS USA     EQ 20MG BASE                   A215467  001  Jul 13, 2022   Jul NEWA
AB                               EQ 40MG BASE                   A215467  002  Jul 13, 2022   Jul NEWA

    ELIGLUSTAT TARTRATE
      CAPSULE;ORAL
        ELIGLUSTAT TARTRATE
AB        AIZANT                 EQ 84MG BASE                   A212463  001  Sep 08, 2021   Feb CAHN
        @ DR REDDYS              EQ 84MG BASE                   A212449  001  Aug 17, 2022   Oct DISC
AB                               EQ 84MG BASE                   A212449  001  Aug 17, 2022   Aug NEWA
        @ TEVA PHARMS USA INC    EQ 84MG BASE                   A212474  001  Dec 27, 2021   Jun DISC

    EMPAGLIFLOZIN
      TABLET;ORAL
        EMPAGLIFLOZIN
AB        ZYDUS PHARMS           10MG                           A212138  001  Aug 03, 2022   Jul NFTG
AB                               25MG                           A212138  002  Aug 03, 2022   Jul NFTG
        JARDIANCE
AB    +   BOEHRINGER INGELHEIM   10MG                           N204629  001  Aug 01, 2014   Jul CFTG
AB    +!                         25MG                           N204629  002  Aug 01, 2014   Jul CFTG

    EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
      TABLET;ORAL
        EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE
AB        ZYDUS PHARMS           5MG;500MG                      A212198  001  Jul 07, 2022   Jul NFTG
AB                               5MG;1GM                        A212198  002  Jul 07, 2022   Jul NFTG
AB                               12.5MG;500MG                   A212198  003  Jul 07, 2022   Jul NFTG
AB                               12.5MG;1GM                     A212198  004  Jul 07, 2022   Jul NFTG
        SYNJARDY
AB    +   BOEHRINGER INGELHEIM   5MG;500MG                      N206111  001  Aug 26, 2015   Jul CFTG
AB    +                          5MG;1GM                        N206111  002  Aug 26, 2015   Jul CFTG
AB    +                          12.5MG;500MG                   N206111  003  Aug 26, 2015   Jul CFTG
AB    +!                         12.5MG;1GM                     N206111  004  Aug 26, 2015   Jul CFTG

    EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
      TABLET;ORAL
        DESCOVY
      +   GILEAD SCIENCES INC    120MG;EQ 15MG BASE             N208215  002  Jan 07, 2022   Jan NEWA
```

ENALAPRIL MALEATE

SOLUTION;ORAL

ENALAPRIL MALEATE

AB		ALKEM LABS LTD	1MG/ML	A213714	001	Mar 30, 2022	Mar NEWA
	@	AMNEAL	1MG/ML	A212894	001	Jun 29, 2022	Oct DISC
AB			1MG/ML	A212894	001	Jun 29, 2022	Jun NEWA
AB		ANNORA PHARMA	1MG/ML	A214467	001	Feb 24, 2022	Feb NEWA

TABLET;ORAL

ENALAPRIL MALEATE

	@	AIPING PHARM INC	2.5MG	A075178	002	Mar 23, 2001	Jun CAHN
	@		5MG	A075178	001	Mar 23, 2001	Jun CAHN
	@		10MG	A075178	003	Mar 23, 2001	Jun CAHN
	@		20MG	A075178	004	Mar 23, 2001	Jun CAHN
AB		PRINSTON INC	2.5MG	A213273	001	Jul 07, 2022	Jul NEWA
AB			5MG	A213273	002	Jul 07, 2022	Jul NEWA
AB			10MG	A213273	003	Jul 07, 2022	Jul NEWA
AB			20MG	A213273	004	Jul 07, 2022	Jul NEWA

ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

AP		ATHENEX INC	1.25MG/ML	A075634	001	Aug 22, 2000	Jan CHRS
AP		CHARTWELL INJECTABLE	1.25MG/ML	A075634	001	Aug 22, 2000	Mar CAHN
AP	!	HIKMA FARMACEUTICA	1.25MG/ML	A078687	001	Dec 23, 2008	Jan CHRS
AP		HOSPIRA	1.25MG/ML	A075458	001	Aug 22, 2000	Jan CHRS

ENASIDENIB MESYLATE

TABLET;ORAL

IDHIFA

	+	BRISTOL MYERS SQUIBB	EQ 50MG BASE	N209606	001	Aug 01, 2017	Oct CAHN
	+!		EQ 100MG BASE	N209606	002	Aug 01, 2017	Oct CAHN

ENOXAPARIN SODIUM

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

AB		NANJING KING-FRIEND	300MG/3ML (100MG/ML)	A214856	001	Jun 14, 2022	Jun NEWA

ENTACAPONE

TABLET;ORAL

ENTACAPONE

>D> AB		ATLANTIDE	200MG	A078941	001	Aug 16, 2012	Nov CAHN
>A> AB		WOCKHARDT BIO AG	200MG	A078941	001	Aug 16, 2012	Nov CAHN

ENTECAVIR

TABLET;ORAL

ENTECAVIR

	@	ACCORD HLTHCARE	0.5MG	A205824	001	Aug 25, 2017	Apr DISC
	@		1MG	A205824	002	Aug 25, 2017	Apr DISC
	@	YUNG SHIN PHARM	0.5MG	A208195	001	Nov 10, 2021	May DISC
	@		1MG	A208195	002	Nov 10, 2021	May DISC

ENZALUTAMIDE

CAPSULE;ORAL

ENZALUTAMIDE

	@	ACTAVIS LABS FL INC	40MG	A209614	001	May 14, 2021	Feb DISC
>D> AB		APOTEX	40MG	A209645	001	Apr 22, 2022	Nov DISC
>A>	@		40MG	A209645	001	Apr 22, 2022	Nov DISC
AB			40MG	A209645	001	Apr 22, 2022	Apr NEWA

XTANDI

>D> AB	+!	ASTELLAS	40MG	N203415	001	Aug 31, 2012	Nov CTEC
>A>	+!		40MG	N203415	001	Aug 31, 2012	Nov CTEC
AB	+!		40MG	N203415	001	Aug 31, 2012	Apr CTEC
	+!		40MG	N203415	001	Aug 31, 2012	Feb CTEC

EPHEDRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

REZIPRES

	+!	DR REDDYS LABS SA	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	Jun CAHN
	+ @		47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021	Jun CAHN
	+ @		47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021	Jun CAHN

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

EPHEDRINE SULFATE

AP		AGGREGA	50MG/ML (50MG/ML)	A215825	001	Apr 21, 2022	Apr NEWA
	+!	ENDO VENTURES	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	May NEWA
	+!		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Feb CMFD
AP		GLAND PHARMA LTD	50MG/ML (50MG/ML)	A216146	001	Feb 25, 2022	Feb NEWA
AP		MANKIND PHARMA	50MG/ML (50MG/ML)	A216129	001	Apr 14, 2022	Apr NEWA
AP		XIROMED	50MG/ML (50MG/ML)	A215825	001	Apr 21, 2022	Sep CAHN

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ELESTAT

	+ @	ALLERGAN	0.05%	N021565	001	Oct 16, 2003	Aug DISC

EPINASTINE HYDROCHLORIDE

	@	AKORN	0.05%	A204055	001	May 05, 2017	Aug DISC
AT	!	SOMERSET THERAPS LLC	0.05%	A090951	001	Oct 31, 2011	Aug CHRS

EPINEPHRINE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

ADRENALIN

AP	+!	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Oct CTEC

>A> EPINEPHRINE

>A> AP		AM REGENT	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568	001	Jul 06, 2018	Nov CDFR
	+!	BELCHER	10MG/10ML (1MG/ML)	N205029	002	Feb 04, 2022	Mar NEWA
	+!	BPI LABS	10MG/10ML (1MG/ML)	N205029	002	Feb 04, 2022	Oct CAHN

>D> SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

>D> EPINEPHRINE

>D> AP		AM REGENT	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568	001	Jul 06, 2018	Nov CDFR
AP			EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568	001	Jul 06, 2018	Oct CMFD

SOLUTION;INTRAVENOUS

EPINEPHRINE

	+!	INTL MEDICATION SYS	1MG/10ML (0.1MG/ML)	N211363	001	Aug 15, 2022	Aug NEWA

SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

	+!	BELCHER	1MG/ML (1MG/ML)	N205029	001	Jul 29, 2014	Mar CDFR
	+!	BPI LABS	1MG/ML (1MG/ML)	N205029	001	Jul 29, 2014	Oct CAHN

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIGNOSPAN FORTE

	+!	DEPROCO	EQ 0.02MG BASE/ML;2%	A088389	001	Jan 22, 1985	Feb CRLD

LIGNOSPAN STANDARD

	+!	DEPROCO	EQ 0.01MG BASE/ML;2%	A088390	001	Jan 22, 1985	Jan CRLD

EPLERENONE

TABLET;ORAL

EPLERENONE

AB		KARTHA	25MG	A214663	001	Mar 23, 2022	Mar NEWA
AB			50MG	A214663	002	Mar 23, 2022	Mar NEWA
AB		PIRAMAL HLTHCARE UK	25MG	A212765	001	Aug 10, 2020	Sep CMFD
AB			50MG	A212765	002	Aug 10, 2020	Sep CMFD

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

	@	AKORN	2MG/ML	A204589	001	Apr 18, 2017	Aug DISC
	@		75MG/100ML	A204589	002	Apr 18, 2017	Aug DISC
	@	BAXTER HLTHCARE CORP	2MG/ML	A208554	001	Nov 23, 2018	Sep DISC
AP		SHUANGCHENG	75MG/100ML	A213081	002	Apr 20, 2022	Apr NEWA

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

AB		EUGIA PHARMA	EQ 25MG BASE	A216342	001	Jun 22, 2022	Jun NEWA
AB			EQ 100MG BASE	A216342	002	Jun 22, 2022	Jun NEWA
AB			EQ 150MG BASE	A216342	003	Jun 22, 2022	Jun NEWA

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

INVANZ

AP	+!	MSD SUB MERCK	EQ 1GM BASE/VIAL	N021337	001	Nov 21, 2001	Jun CAHN

ERTUGLIFLOZIN

TABLET;ORAL

STEGLATRO

	+	MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017	Jun CAHN
	+!		15MG	N209803	002	Dec 19, 2017	Jun CAHN

ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

SEGLUROMET

	+	MSD SUB MERCK	2.5MG;500MG	N209806	001	Dec 19, 2017	Jun CAHN
	+		2.5MG;1GM	N209806	002	Dec 19, 2017	Jun CAHN
	+		7.5MG;500MG	N209806	003	Dec 19, 2017	Jun CAHN
	+!		7.5MG;1GM	N209806	004	Dec 19, 2017	Jun CAHN

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

STEGLUJAN

	+	MSD SUB MERCK	5MG;EQ 100MG BASE	N209805	001	Dec 19, 2017	Jun CAHN
	+!		15MG;EQ 100MG BASE	N209805	002	Dec 19, 2017	Jun CAHN

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYC

>D> AB	+!	MAYNE PHARMA	250MG	N050536	001		Nov CAHN
>A> AB	+!		250MG	N050536	001		Nov CAHN

SOLUTION;TOPICAL

ERYTHRA-DERM

AT		MICRO LABS	2%	A062687	001	Feb 05, 1988	Aug CAHN

ERYTHROMYCIN

	@	BAUSCH	2%	A064039	001	Jan 27, 1994	Jul CAHN

TABLET;ORAL

ERYTHROMYCIN

AB		ALKEM LABS LTD	250MG	A216066	001	Jul 13, 2022	Jul NEWA
AB			500MG	A216066	002	Jul 13, 2022	Jul NEWA

TABLET, COATED PARTICLES;ORAL

PCE

	+ @	AZURITY	333MG	N050611	001	Sep 09, 1986	May CAHN
	+ @		500MG	N050611	002	Aug 22, 1990	May CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

E.E.S.

AB	+	AZURITY	EQ 200MG BASE/5ML	N050207	001		May CAHN

ERYPED

AB	+	AZURITY	EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	May CAHN
AB	+!		EQ 400MG BASE/5ML	N050207	002		May CAHN

ERYTHROMYCIN ETHYLSUCCINATE

>A> AB		CADILA PHARMS LTD	EQ 200MG BASE/5ML	A216212	001	Nov 21, 2022	Nov NEWA
>A> AB			EQ 400MG BASE/5ML	A216212	002	Nov 21, 2022	Nov NEWA

TABLET, CHEWABLE;ORAL

E.E.S.

	@	AZURITY	EQ 200MG BASE	N050297	002		May CAHN

ERYPED

	@	AZURITY	EQ 200MG BASE	N050297	003	Jul 05, 1988	May CAHN

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION

ERYTHROMYCIN LACTOBIONATE

AP		NEXUS PHARMS	EQ 500MG BASE/VIAL	A215290	001	Feb 14, 2022	Feb NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

	AP	EUGIA PHARMA	10MG/ML	A216244	001	Mar 21, 2022	Mar NEWA
	AP		20MG/ML	A216244	002	Mar 21, 2022	Mar NEWA
>A>	AP	HQ SPCLT PHARMA	10MG/ML	A214172	001	Dec 02, 2022	Nov NEWA
>A>	AP		20MG/ML	A214172	002	Dec 02, 2022	Nov NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

>D>		@ AMTA	EQ 20MG BASE	A213859	001	Nov 18, 2020	Nov CAHN
>D>		@	EQ 40MG BASE	A213859	002	Nov 18, 2020	Nov CAHN
>A>		@ GUANGZHOU NOVAKEN	EQ 20MG BASE	A213859	001	Nov 18, 2020	Nov CAHN
>A>		@	EQ 40MG BASE	A213859	002	Nov 18, 2020	Nov CAHN

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

	AB	ACTAVIS LABS FL INC	EQ 20MG BASE;375MG	A204470	001	Aug 24, 2022	Aug NEWA
	AB		EQ 20MG BASE;500MG	A204470	002	Aug 24, 2022	Aug NEWA
	AB	AJANTA PHARMA LTD	EQ 20MG BASE;375MG	A213699	001	Oct 06, 2022	Sep NEWA
	AB		EQ 20MG BASE;500MG	A213699	002	Oct 06, 2022	Sep NEWA

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

	AP	HAINAN POLY	EQ 40MG BASE/VIAL	A215732	001	Feb 10, 2022	Feb NEWA
		@ MYLAN	EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	Apr CAHN
		@	EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	Apr CAHN
		@ MYLAN LABS LTD	EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	Apr DISC
		@ SUN PHARM	EQ 20MG BASE/VIAL	A200882	001	Mar 18, 2013	Feb CAHN
	AP		EQ 40MG BASE/VIAL	A200882	002	Mar 18, 2013	Feb CAHN

ESTRADIOL

GEL;TRANSDERMAL

DIVIGEL

	AB	+! VERTICAL PHARMS LLC	0.1%	N022038	001	Jun 04, 2007	Jul CFTG

ESTRADIOL

	AB	CHEMO RESEARCH SL	0.1%	A211783	001	Aug 10, 2022	Jul NFTG

SYSTEM;TRANSDERMAL

ESTRADIOL

	AB1	AMNEAL	0.025MG/24HR	A211293	001	Feb 04, 2019	Sep CTEC
	AB		0.025MG/24HR	A211293	001	Feb 04, 2019	Aug CTEC
	AB1		0.0375MG/24HR	A211293	002	Feb 04, 2019	Sep CTEC
	AB		0.0375MG/24HR	A211293	002	Feb 04, 2019	Aug CTEC
	AB1		0.05MG/24HR	A211293	003	Feb 04, 2019	Sep CTEC
	AB		0.05MG/24HR	A211293	003	Feb 04, 2019	Aug CTEC
	AB1		0.075MG/24HR	A211293	004	Feb 04, 2019	Sep CTEC
	AB		0.075MG/24HR	A211293	004	Feb 04, 2019	Aug CTEC
	AB1		0.1MG/24HR	A211293	005	Feb 04, 2019	Sep CTEC
	AB		0.1MG/24HR	A211293	005	Feb 04, 2019	Aug CTEC
>A>	AB1	ZYDUS NOVELTECH INC	0.025MG/24HR	A206241	001	Dec 01, 2022	Nov NEWA
>A>	AB1		0.0375MG/24HR	A206241	002	Dec 01, 2022	Nov NEWA
>A>	AB1		0.05MG/24HR	A206241	003	Dec 01, 2022	Nov NEWA
>A>	AB1		0.075MG/24HR	A206241	004	Dec 01, 2022	Nov NEWA
>A>	AB1		0.1MG/24HR	A206241	005	Dec 01, 2022	Nov NEWA

TABLET;ORAL

ESTRADIOL

		@ LANNETT CO INC	0.5MG	A040138	001	Jan 30, 1998	May CAHN
		@	1MG	A040138	002	Jan 30, 1998	May CAHN
		@	2MG	A040138	003	Jan 30, 1998	May CAHN
		@ MAYNE PHARMA	0.5MG	A040114	003	Mar 14, 1996	Feb DISC
		@	1MG	A040114	001	Mar 14, 1996	Feb DISC
		@	2MG	A040114	002	Mar 14, 1996	Feb DISC

ESTRADIOL; PROGESTERONE

CAPSULE;ORAL

BIJUVA

	+ @	THERAPEUTICSMD INC	0.5MG;100MG	N210132	002	Dec 28, 2021	Apr DISC
	+!		1MG;100MG	N210132	001	Oct 28, 2018	May CTEC
AB	+!		1MG;100MG	N210132	001	Oct 28, 2018	May CFTG

ESTRADIOL AND PROGESTERONE

	@	AMNEAL PHARMS	1MG;100MG	A214293	001	May 16, 2022	May DISC
AB			1MG;100MG	A214293	001	May 16, 2022	May NFTG

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

	@	CHARTWELL RX	1MG	A091165	001	Jul 14, 2011	Jan CAHN
	@		2MG	A091165	002	Jul 14, 2011	Jan CAHN
	@		3MG	A091165	003	Jul 14, 2011	Jan CAHN

ETHACRYNIC ACID

TABLET;ORAL

ETHACRYNIC ACID

	@	ALVOGEN	25MG	A205709	001	Jul 24, 2018	Aug DISC

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

ZOVIA 1/35E-28

	@	MAYNE PHARMA	0.035MG;1MG	A072721	001	Dec 30, 1991	Jan DISC

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL

HALOETTE

AB		MAYNE PHARMA	0.015MG/24HR;0.12MG/24HR	A211328	001	Aug 05, 2022	Jul NEWA

NUVARING

AB	+!	ORGANON USA ORGANON	0.015MG/24HR;0.12MG/24HR	N021187	001	Oct 03, 2001	Jul CAHN

VERARING

	@	DR REDDYS LABS SA	0.015MG/24HR;0.12MG/24HR	A207577	001	Dec 09, 2021	Jun DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

	@	MAYNE PHARMA	0.02MG,0.1MG;0.01MG,N/A	A200407	001	Oct 25, 2011	Aug DISC

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1		NAARI PTE LTD	0.02MG;0.1MG	A207065	001	Aug 17, 2020	Apr CTEC

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ETHINYL ESTRADIOL AND NORELGESTROMIN

AB		AMNEAL	0.035MG/24HR;0.15MG/24HR	A213950	001	Feb 25, 2021	Jul CTEC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL

FEMCON FE

	+ @	APIL	0.035MG;0.4MG	N021490	001	Nov 14, 2003	May CDFR

NEXESTA FE

AB		AUROBINDO PHARMA	0.035MG;0.4MG	A207535	001	Feb 02, 2017	May CDFR

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		AMNEAL PHARMS	0.035MG;0.4MG	A078892	001	Sep 26, 2011	May CDFR
AB		BARR	0.035MG;0.4MG	A078965	001	Aug 05, 2010	May CDFR
AB		LUPIN LTD	0.035MG;0.4MG	A091332	001	Mar 23, 2016	May CDFR
AB	!	MYLAN LABS LTD	0.035MG;0.4MG	A202086	001	Apr 01, 2015	May CDFR
AB		NAARI PTE LTD	0.035MG;0.4MG	A207066	001	Mar 29, 2017	May CDFR

TABLET;ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

	@	MAYNE PHARMA	0.035MG;0.5MG	A070686	001	Jan 29, 1987	Jan DISC

RHUZDAH

AB		AUROBINDO PHARMA	0.035MG;0.4MG	A207585	001	Oct 11, 2022	Sep NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		GLENMARK PHARMS LTD	0.02MG;1MG	A213418	001	Jul 27, 2022	Jul NEWA
	@	MAYNE PHARMA	0.02MG;1MG	A213901	001	Apr 28, 2022	Sep DISC
AB			0.02MG;1MG	A213901	001	Apr 28, 2022	Apr NEWA

TABLET;ORAL

FINZALA

AB		TEVA PHARMS USA INC	0.02MG;1MG	A210087	001	Apr 07, 2020	May CDFR

MIBELAS 24 FE

AB		LUPIN	0.02MG;1MG	A206287	001	May 24, 2016	May CDFR

MINASTRIN 24 FE

AB	+!	APIL	0.02MG;1MG	N203667	001	May 08, 2013	May CDFR

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

	@	AMNEAL PHARMS	0.02MG;1MG	A078267	001	Sep 01, 2009	Jun DISC
	@		0.02MG;1MG	A207514	001	Sep 11, 2017	May CDFR
AB	!	GLENMARK PHARMS LTD	0.02MG;1MG	A204847	001	Nov 17, 2017	Jun CHRS
AB			0.02MG;1MG	A210369	001	Dec 26, 2017	May CDFR
	@	MYLAN LABS LTD	0.02MG;1MG	A206120	001	Sep 12, 2017	May CDFR
AB		XIROMED	0.02MG;1MG	A209609	001	Jul 16, 2018	May CDFR

TABLET;ORAL-21

LOESTRIN 21 1.5/30

	+ @	TEVA BRANDED PHARM	0.03MG;1.5MG	N017875	001		Jun DISC

LOESTRIN 21 1/20

	+ @	TEVA BRANDED PHARM	0.02MG;1MG	N017876	001		Jul DISC

LOESTRIN FE 1.5/30

	+ @	TEVA BRANDED PHARM	0.03MG;1.5MG	N017355	001		Jun DISC

MICROGESTIN 1.5/30

	@	MAYNE PHARMA	0.03MG;1.5MG	A075548	002	Jul 30, 2003	Jan DISC

MICROGESTIN 1/20

	@	MAYNE PHARMA	0.02MG;1MG	A075647	002	Jul 30, 2003	Jan DISC

TABLET;ORAL-28

JUNEL FE 1.5/30

AB	!	BARR	0.03MG;1.5MG	A076064	001	Sep 18, 2003	Jun CHRS

LOESTRIN FE 1/20

	+ @	TEVA BRANDED PHARM	0.02MG;1MG	N017354	001		Jun DISC

MICROGESTIN FE 1.5/30

	@	MAYNE PHARMA	0.03MG;1.5MG	A075548	001	Feb 05, 2001	Jan DISC

MICROGESTIN FE 1/20

	@	MAYNE PHARMA	0.02MG;1MG	A075647	001	Feb 05, 2001	Jan DISC

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

	@	MAYNE PHARMA	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076629	001	Mar 18, 2010	Jan DISC
AB		MYLAN	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Feb CMFD
AB			0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Feb CAHN

TABLET, CHEWABLE;ORAL

FINZALA

AB		TEVA PHARMS USA INC	0.02MG;1MG	A210087	001	Apr 07, 2020	Jan CMFD

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

	@	AMNEAL PHARMS	0.02MG;1MG	A207514	001	Sep 11, 2017	Jan DISC

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

TRI-LO-LINYAH

AB		NOVAST LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A090541	001	Sep 02, 2022	Aug NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21

LO/OVRAL

	+ @	CADENCE HEALTH	0.03MG;0.3MG	N017612	001		Apr CRLD

TABLET;ORAL-28

CRYSELLE

AB	!	DURAMED PHARMS BARR	0.03MG;0.3MG	A075840	002	Nov 30, 2001	Apr CHRS

LO/OVRAL-28

	+ @	WYETH PHARMS	0.03MG;0.3MG	N017802	001		Apr CRLD

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

>D>	BX	PURACAP PHARM LLC	250MG	A210654	001	Mar 16, 2020	Nov CTEC
>A>	AB		250MG	A210654	001	Mar 16, 2020	Nov CTEC

ETONOGESTREL

IMPLANT;IMPLANTATION

IMPLANON

	@	ORGANON	68MG/IMPLANT	N021529	001	Jul 17, 2006	Jan CAHN

NEXPLANON

+!		ORGANON	68MG/IMPLANT	N021529	002	May 31, 2011	Jan CAHN

ETRAVIRINE

TABLET;ORAL

ETRAVIRINE

	AB	CARNEGIE	100MG	A215402	001	Apr 13, 2022	Apr NEWA
	AB		200MG	A215402	002	Apr 13, 2022	Apr NEWA

EXEMESTANE

TABLET;ORAL

EXEMESTANE

	AB	EUGIA PHARMA	25MG	A216454	001	May 20, 2022	May NEWA

EZETIMIBE

TABLET;ORAL

EZETIMIBE

	@	APOTEX	10MG	A208332	001	Jun 12, 2017	Apr DISC
	AB	HETERO LABS LTD III	10MG	A210859	001	Jul 26, 2022	Jul NEWA
	AB	ORIENT PHARMA	10MG	A215693	001	Sep 13, 2022	Sep NEWA

EZETIMIBE; ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSZET

+	@	ALTHERA PHARMS	10MG;EQ 5MG BASE	N213072	001	Mar 23, 2021	Sep DISC
+	@		10MG;EQ 10MG BASE	N213072	002	Mar 23, 2021	Sep DISC
+	@		10MG;EQ 20MG BASE	N213072	003	Mar 23, 2021	Sep DISC
+	@		10MG;EQ 40MG BASE	N213072	004	Mar 23, 2021	Sep DISC

FAMCICLOVIR

TABLET;ORAL

FAMCICLOVIR

	@	CIPLA	125MG	A078278	001	Mar 21, 2011	Mar DISC
	@		250MG	A078278	002	Mar 21, 2011	Mar DISC
	@		500MG	A078278	003	Mar 21, 2011	Mar DISC

FAMOTIDINE

FOR SUSPENSION;ORAL

FAMOTIDINE

	AB	AMNEALS PHARMS	40MG/5ML	A216427	001	Aug 04, 2022	Jul NEWA

INJECTABLE;INJECTION

FAMOTIDINE

>A>	AP	ZYDUS PHARMS	10MG/ML	A215828	001	Nov 22, 2022	Nov NEWA

FAMOTIDINE PRESERVATIVE FREE

	@	AKORN	10MG/ML	A076324	001	Nov 27, 2002	Feb CAHN

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

	@	AKORN	10MG/ML	A076322	001	Nov 27, 2002	Feb CAHN

TABLET;ORAL

FAMOTIDINE

>A>	AB	ALKEM LABS LTD	20MG	A215630	001	Jan 07, 2022	Nov CAHN
>A>	AB		40MG	A215630	002	Jan 07, 2022	Nov CAHN
	@	PERRIGO R AND D	20MG	A077352	002	Jul 27, 2005	Sep DISC
	@		40MG	A077352	001	Jul 27, 2005	Sep DISC
>D>	AB	VKT PHARMA	20MG	A215630	001	Jan 07, 2022	Nov CAHN
>D>	AB		40MG	A215630	002	Jan 07, 2022	Nov CAHN
	AB	ZYDUS PHARMS	20MG	A216441	001	Jun 03, 2022	May NEWA
	AB		40MG	A216441	002	Jun 03, 2022	May NEWA

FEBUXOSTAT

	TABLET;ORAL					
	FEBUXOSTAT					
AB	PRINSTON INC	40MG	A206266	001	Mar 28, 2022	Mar NEWA
AB		80MG	A206266	002	Mar 28, 2022	Mar NEWA

FENOFIBRATE

	CAPSULE;ORAL					
	ANTARA (MICRONIZED)					
	+ @ LUPIN	30MG	N021695	004	Oct 18, 2013	Jul DISC
	TABLET;ORAL					
	FENOFIBRATE					
AB	AUROBINDO PHARMA	54MG	A216798	001	Sep 27, 2022	Sep NEWA
AB		160MG	A216798	002	Sep 27, 2022	Sep NEWA
AB	GRAVITI PHARMS	54MG	A210606	001	Aug 17, 2018	Sep CAHN
AB		160MG	A210606	002	Aug 17, 2018	Sep CAHN

FENOFIBRIC ACID

	TABLET;ORAL					
	FIBRICOR					
	+ @ ATHENA	105MG	N022418	002	Aug 14, 2009	Oct DISC

FENOPROFEN CALCIUM

	CAPSULE;ORAL					
	FENOPROFEN CALCIUM					
AB	RISING	EQ 400MG BASE	A214475	001	Jul 18, 2022	Jul NFTG
	NALFON					
AB	+! XSPIRE PHARMA	EQ 400MG BASE	N017604	004	Jul 21, 2009	Jul CFTG
	TABLET;ORAL					
	FENOPROFEN CALCIUM					
	@ STRIDES PHARMA	EQ 600MG BASE	A072429	001	Aug 17, 1988	Jul CAHN

FENTANYL

	FILM, EXTENDED RELEASE;TRANSDERMAL					
	FENTANYL-100					
	@ AVEVA	100MCG/HR	A077449	004	Oct 20, 2008	Oct DISC
	FENTANYL-12					
	@ AVEVA	12.5MCG/HR	A077449	005	Sep 11, 2015	Oct DISC
	FENTANYL-25					
	@ AVEVA	25MCG/HR	A077449	001	Oct 20, 2008	Oct DISC
	FENTANYL-37					
	@ AVEVA	37.5MCG/HR	A077449	006	Dec 06, 2017	Oct DISC
	FENTANYL-50					
	@ AVEVA	50MCG/HR	A077449	002	Oct 20, 2008	Oct DISC
	FENTANYL-62					
	@ AVEVA	62.5MCG/HR	A077449	007	Dec 06, 2017	Oct DISC
	FENTANYL-75					
	@ AVEVA	75MCG/HR	A077449	003	Oct 20, 2008	Oct DISC
	FENTANYL-87					
	@ AVEVA	87.5MCG/HR	A077449	008	Dec 06, 2017	Oct DISC
	MYLAN TECHNOLOGIES	87.5MCG/HR	A076258	008	Dec 29, 2014	Oct CTEC
	SPRAY;SUBLINGUAL					
	SUBSYS					
	+ @ BTCP PHARMA	0.1MG	N202788	001	Jan 04, 2012	Aug DISC
	+ @	0.2MG	N202788	002	Jan 04, 2012	Aug DISC
	+ @	0.4MG	N202788	003	Jan 04, 2012	Aug DISC
	+ @	0.6MG	N202788	004	Jan 04, 2012	Aug DISC
	+ @	0.8MG	N202788	005	Jan 04, 2012	Aug DISC
	+ @	1.2MG	N202788	006	Aug 30, 2012	Aug DISC
	+ @	1.6MG	N202788	007	Aug 30, 2012	Aug DISC

FENTANYL CITRATE

	FILM;BUCCAL					
	ONSOLIS					
	@ ADALVO	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	Aug CAHN
	@	EQ 0.4MG BASE	N022266	002	Jul 16, 2009	Aug CAHN
	@	EQ 0.6MG BASE	N022266	003	Jul 16, 2009	Aug CAHN
	@	EQ 0.8MG BASE	N022266	004	Jul 16, 2009	Aug CAHN
	@	EQ 1.2MG BASE	N022266	005	Jul 16, 2009	Aug CAHN

SPRAY, METERED;NASAL
LAZANDA

	+ @	BTCP PHARMA	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Aug DISC
	+ @		EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Aug DISC

TABLET;BUCCAL, SUBLINGUAL
FENTANYL CITRATE

	@	MAYNE PHARMA	EQ 0.1MG BASE	A206329	001	Aug 22, 2022	Oct DISC
AB			EQ 0.1MG BASE	A206329	001	Aug 22, 2022	Aug NEWA
	@		EQ 0.2MG BASE	A206329	002	Aug 22, 2022	Oct DISC
AB			EQ 0.2MG BASE	A206329	002	Aug 22, 2022	Aug NEWA
	@		EQ 0.3MG BASE	A206329	003	Aug 22, 2022	Oct DISC
			EQ 0.3MG BASE	A206329	003	Aug 22, 2022	Aug NEWA
	@		EQ 0.4MG BASE	A206329	004	Aug 22, 2022	Oct DISC
AB			EQ 0.4MG BASE	A206329	004	Aug 22, 2022	Aug NEWA
	@		EQ 0.6MG BASE	A206329	005	Aug 22, 2022	Oct DISC
AB			EQ 0.6MG BASE	A206329	005	Aug 22, 2022	Aug NEWA
	@		EQ 0.8MG BASE	A206329	006	Aug 22, 2022	Oct DISC
AB			EQ 0.8MG BASE	A206329	006	Aug 22, 2022	Aug NEWA

FENTORA

	+	CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Oct CTEC
AB	+		EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Aug CTEC
	+		EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Oct CTEC
AB	+		EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Aug CTEC
	+!		EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Oct CTEC
AB	+!		EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Aug CTEC
	+		EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Oct CTEC
AB	+		EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Aug CTEC
	+		EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Oct CTEC
AB	+		EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Aug CTEC

FERRIC CARBOXYMALTOSE

SOLUTION;INTRAVENOUS
INJECTAFER

	+!	AM REGENT	100MG IRON/2ML (50MG IRON/ML)	N203565	004	Feb 04, 2022	Feb NEWA

FERRIC PYROPHOSPHATE CITRATE

FOR SOLUTION;INTRAVENOUS
TRIFERIC

	+ @	ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551	001	Apr 25, 2016	Oct DISC

SOLUTION;INTRAVENOUS
TRIFERIC

	+ @	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015	Oct DISC

TRIFERIC AVNU

	+ @	ROCKWELL MEDICAL INC	6.75MG IRON/4.5ML (1.5MG IRON/ML)	N212860	001	Mar 27, 2020	Oct DISC

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

AB		ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015	May CMFD
AB			8MG	A204827	002	Dec 10, 2015	May CMFD
AB		DR REDDYS	4MG	A204975	001	Aug 13, 2019	Jun CMFD
AB			8MG	A204975	002	Aug 13, 2019	Jun CMFD

FEXOFENADINE HYDROCHLORIDE

CAPSULE;ORAL
ALLEGRA

	@	CHATTEM SANOFI	60MG	N020625	001	Jul 25, 1996	Jan CAHN
	@		60MG	N020625	001	Jul 25, 1996	Jan CAHN

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL
FINGOLIMOD HYDROCHLORIDE

AB		ALKEM LABS LTD	EQ 0.5MG BASE	A208004	001	Dec 30, 2020	Sep CMFD
AB		APOTEX	EQ 0.5MG BASE	A207993	001	Dec 18, 2020	Oct CMFD
AB		DR REDDYS	EQ 0.5MG BASE	A208000	001	Mar 05, 2021	Aug CMFD
AB		GLENMARK PHARMS LTD	EQ 0.5MG BASE	A207985	001	Jun 18, 2020	Sep CMFD
AB		HETERO LABS LTD V	EQ 0.5MG BASE	A207933	001	May 18, 2020	Jul CMFD
AB		MYLAN	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Aug CMFD
	@		EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Feb DISC
AB			EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Feb CAHN
AB		PRINSTON INC	EQ 0.5MG BASE	A208003	001	Sep 07, 2022	Aug NEWA
AB		SUN PHARM	EQ 0.5MG BASE	A208014	001	Dec 04, 2019	Aug CMFD

```
        CAPSULE;ORAL
          FINGOLIMOD HYDROCHLORIDE
          @ TEVA PHARMS USA        EQ 0.25MG BASE                    A212152  001  Nov 12, 2021   Jun DISC
    AB      ZYDUS PHARMS           EQ 0.5MG BASE                     A207994  001  Oct 14, 2020   Oct CMFD
          GILENYA
        +   NOVARTIS               EQ 0.25MG BASE                    N022527  002  May 11, 2018   Jun CTEC

      FINGOLIMOD LAURYL SULFATE
        TABLET, ORALLY DISINTEGRATING;ORAL
          TASCENSO ODT
>D>     + @ HANDA                  EQ 0.25MG BASE                    N214962  001  Dec 23, 2021   Nov CMFD
>A>     +!                         EQ 0.25MG BASE                    N214962  001  Dec 23, 2021   Nov CMFD
        + @                        EQ 0.25MG BASE                    N214962  001  Dec 23, 2021   Sep DISC

      FLECAINIDE ACETATE
        TABLET;ORAL
          FLECAINIDE ACETATE
          @ CHARTWELL              50MG                              A079164  001  Jul 09, 2009   Feb CAHN
          @                        100MG                             A079164  002  Jul 09, 2009   Feb CAHN
          @                        150MG                             A079164  003  Jul 09, 2009   Feb CAHN
    AB      YICHANG HUMANWELL      50MG                              A215599  001  Sep 08, 2022   Aug NEWA
    AB                             100MG                             A215599  002  Sep 08, 2022   Aug NEWA
    AB                             150MG                             A215599  003  Sep 08, 2022   Aug NEWA

      FLORBETABEN F-18
        SOLUTION;INTRAVENOUS
          NEURACEQ
>D>     +!  LIFE MOLECULAR         30ML (1.4-135mCi/ML)              N204677  001  Mar 19, 2014   Nov CPOT
>A>     +!                         1.4-135mCi/ML                     N204677  001  Mar 19, 2014   Nov CPOT

      FLORTAUCIPIR F-18
        SOLUTION;INTRAVENOUS
          TAUVID
        +!  AVID RADIOPHARMS INC   50ML (8.1-100mCi/ML)              N212123  003  Jul 01, 2022   Sep NEWA
        +!                         100ML (8.1-100mCi/ML)             N212123  004  Jul 01, 2022   Sep NEWA

      FLUCONAZOLE
        TABLET;ORAL
          FLUCONAZOLE
    AB      THINQ PHARM-CRO PVT    50MG                              A076957  001  Sep 28, 2005   Jun CAHN
    AB                             100MG                             A076957  002  Sep 28, 2005   Jun CAHN
    AB                             150MG                             A076957  004  Feb 27, 2017   Jun CAHN
    AB                             200MG                             A076957  003  Sep 28, 2005   Jun CAHN

      FLUCYTOSINE
        CAPSULE;ORAL
          FLUCYTOSINE
    AB      STRIDES PHARMA         250MG                             A212632  001  Apr 17, 2020   Feb CMFD
    AB                             500MG                             A212632  002  Apr 17, 2020   Feb CMFD

      FLUDARABINE PHOSPHATE
        INJECTABLE;INJECTION
          FLUDARABINE PHOSPHATE
    AP      HIKMA                  50MG/VIAL                         A076349  001  Aug 28, 2003   Aug CAHN

      FLUDROCORTISONE ACETATE
        TABLET;ORAL
          FLUDROCORTISONE ACETATE
    AB      HIKMA                  0.1MG                             A216013  001  Oct 27, 2022   Oct NEWA
    AB      NOVITIUM PHARMA        0.1MG                             A215279  001  May 31, 2022   May NEWA

      FLUNISOLIDE
        SPRAY, METERED;NASAL
          FLUNISOLIDE
          @ APOTEX                 0.029MG/SPRAY                     A077436  001  Aug 09, 2007   May DISC
    AB  !   BAUSCH                 0.025MG/SPRAY                     A074805  001  Feb 20, 2002   Jun CAHN
    AB      RICONPHARMA LLC        0.025MG/SPRAY                     A207802  001  Jun 16, 2022   Jun NEWA
```

FLUOCINOLONE ACETONIDE

	CREAM;TOPICAL						
	FLUOCINOLONE ACETONIDE						
	@ MLV	0.025%	A088045	001	Dec 16, 1982	Sep	CAHN
	OIL;TOPICAL						
	FLUOCINOLONE ACETONIDE						
	@ AMNEAL	0.01%	A201759	001	Oct 17, 2011	Jul	DISC
	@	0.01%	A201764	001	Oct 17, 2011	Jul	DISC
	OIL/DROPS;OTIC						
	FLUOCINOLONE ACETONIDE						
	@ AMNEAL	0.01%	A091306	001	Oct 17, 2011	Jul	DISC
	SOLUTION;TOPICAL						
	FLUOCINOLONE ACETONIDE						
	@ PAI HOLDINGS PHARM	0.01%	A088312	001	Jan 27, 1984	Apr	CAHN

FLUOCINONIDE

	CREAM;TOPICAL						
	FLUOCINONIDE						
	@ ENCUBE	0.05%	A211410	001	Oct 16, 2018	Jul	CAHN
	LIDEX-E						
	+ @ ALVOGEN	0.05%	N016908	003		Aug	DISC

FLUOROMETHOLONE

	OINTMENT;OPHTHALMIC						
	FML						
	+ @ ALLERGAN	0.1%	N017760	001	Sep 04, 1985	Aug	DISC

FLUOROURACIL

	CREAM;TOPICAL						
	FLUOROPLEX						
	+ @ CHARTWELL RX	1%	N016988	001		Jul	CAHN
	INJECTABLE;INJECTION						
	FLUOROURACIL						
	@ EUGIA PHARMA SPECLTS	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Mar	CAHN
	@	1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Mar	CAHN
	@	2.5GM/50ML (50MG/ML)	A202669	001	Jul 17, 2012	Mar	CAHN
	@	5GM/100ML (50MG/ML)	A202669	002	Jul 17, 2012	Mar	CAHN

FLUOXETINE HYDROCHLORIDE

	CAPSULE;ORAL						
	FLUOXETINE HYDROCHLORIDE						
AB1	MICRO LABS	EQ 10MG BASE	A216232	001	Mar 29, 2022	Mar	NEWA
AB1		EQ 20MG BASE	A216232	002	Mar 29, 2022	Mar	NEWA
AB		EQ 40MG BASE	A216232	003	Mar 29, 2022	Mar	NEWA
	SOLUTION;ORAL						
	FLUOXETINE HYDROCHLORIDE						
>A> AA	APTAPHARMA INC	EQ 20MG BASE/5ML	A216953	001	Nov 15, 2022	Nov	NEWA
>A> AA	NOVITIUM PHARMA	EQ 20MG BASE/5ML	A216448	001	Nov 09, 2022	Nov	NEWA
	TABLET;ORAL						
	FLUOXETINE HYDROCHLORIDE						
AB	PIRAMAL HLTHCARE UK	EQ 10MG BASE	A211444	001	Sep 13, 2022	Sep	NEWA
AB		EQ 20MG BASE	A211444	002	Sep 13, 2022	Sep	NEWA

FLUPHENAZINE HYDROCHLORIDE

	TABLET;ORAL						
	FLUPHENAZINE HYDROCHLORIDE						
AB	APOTEX	1MG	A216649	001	Jul 15, 2022	Jul	NEWA
AB		2.5MG	A216649	002	Jul 15, 2022	Jul	NEWA
AB		5MG	A216649	003	Jul 15, 2022	Jul	NEWA
AB		10MG	A216649	004	Jul 15, 2022	Jul	NEWA
>D> AB	ENALTEC	1MG	A215141	001	Oct 20, 2021	Nov	CAHN
>D> AB		2.5MG	A215141	002	Oct 20, 2021	Nov	CAHN
>D> AB		5MG	A215141	003	Oct 20, 2021	Nov	CAHN
>D> AB		10MG	A215141	004	Oct 20, 2021	Nov	CAHN
AB	PRASCO	1MG	A089804	002	Aug 12, 1988	Jun	CMFD
@		1MG	A089804	002	Aug 12, 1988	Mar	CAHN
AB		2.5MG	A089804	003	Aug 12, 1988	Jun	CMFD
@		2.5MG	A089804	003	Aug 12, 1988	Mar	CAHN
AB		5MG	A089804	004	Aug 12, 1988	Jun	CMFD
@		5MG	A089804	004	Aug 12, 1988	Mar	CAHN
AB		10MG	A089804	001	Aug 12, 1988	Jun	CMFD

```
          TABLET;ORAL
            FLUPHENAZINE HYDROCHLORIDE
            @                        10MG                              A089804  001  Aug 12, 1988   Mar CAHN
>A> AB        SANDOZ INC             1MG                               A216891  001  Nov 15, 2022   Nov NEWA
>A> AB                               2.5MG                             A216891  002  Nov 15, 2022   Nov NEWA
>A> AB                               5MG                               A216891  003  Nov 15, 2022   Nov NEWA
>A> AB                               10MG                              A216891  004  Nov 15, 2022   Nov NEWA
    AB        TARO PHARM INDS LTD    1MG                               A215674  001  Apr 14, 2022   Apr NEWA
    AB                               2.5MG                             A215674  002  Apr 14, 2022   Apr NEWA
    AB                               5MG                               A215674  003  Apr 14, 2022   Apr NEWA
    AB                               10MG                              A215674  004  Apr 14, 2022   Apr NEWA
    AB        TWI PHARMS             2.5MG                             A215848  001  Apr 01, 2022   Mar NEWA
    AB                               5MG                               A215848  002  Apr 01, 2022   Mar NEWA
    AB                               10MG                              A215848  003  Apr 01, 2022   Mar NEWA
>A> AB        UPSHER SMITH LABS      1MG                               A213784  001  Oct 24, 2022   Nov CAHN
>A> AB                               2.5MG                             A213784  002  Oct 24, 2022   Nov CAHN
>A> AB                               5MG                               A213784  003  Oct 24, 2022   Nov CAHN
>A> AB                               10MG                              A213784  004  Oct 24, 2022   Nov CAHN
>A> AB        ZAMEER PHARMS          1MG                               A215141  001  Oct 20, 2021   Nov CAHN
>A> AB                               2.5MG                             A215141  002  Oct 20, 2021   Nov CAHN
>A> AB                               5MG                               A215141  003  Oct 20, 2021   Nov CAHN
>A> AB                               10MG                              A215141  004  Oct 20, 2021   Nov CAHN
>D> AB        ZENARA                 1MG                               A213784  001  Oct 24, 2022   Nov CAHN
    AB                               1MG                               A213784  001  Oct 24, 2022   Oct NEWA
>D> AB                               2.5MG                             A213784  002  Oct 24, 2022   Nov CAHN
    AB                               2.5MG                             A213784  002  Oct 24, 2022   Oct NEWA
>D> AB                               5MG                               A213784  003  Oct 24, 2022   Nov CAHN
    AB                               5MG                               A213784  003  Oct 24, 2022   Oct NEWA
>D> AB                               10MG                              A213784  004  Oct 24, 2022   Nov CAHN
    AB                               10MG                              A213784  004  Oct 24, 2022   Oct NEWA

      FLURANDRENOLIDE
          CREAM;TOPICAL
            CORDRAN SP
          + @ ALMIRALL               0.05%                             N012806  002                  Sep DISC
          +!                         0.05%                             N012806  002                  Feb CTEC
            FLURANDRENOLIDE
            @ CINTEX SVCS            0.05%                             A205342  001  Apr 13, 2016   Feb DISC
          LOTION;TOPICAL
            FLURANDRENOLIDE
            @ CINTEX SVCS            0.05%                             A205343  001  Dec 22, 2016   Feb DISC

      FLURAZEPAM HYDROCHLORIDE
          CAPSULE;ORAL
            FLURAZEPAM HYDROCHLORIDE
              RISING                 15MG                              A070345  002  Nov 27, 1985   Apr CAHN
          !                          30MG                              A070345  001  Nov 27, 1985   Apr CAHN

      FLUTAMIDE
          CAPSULE;ORAL
            FLUTAMIDE
            @ CHARTWELL RX           125MG                             A075818  001  Sep 18, 2001   Jan CAHN

      FLUTICASONE PROPIONATE
          LOTION;TOPICAL
            CUTIVATE
          + @ FOUGERA PHARMS         0.05%                             N021152  001  Mar 31, 2005   Mar DISC
    AB    +                          0.05%                             N021152  001  Mar 31, 2005   Mar CHRS
            FLUTICASONE PROPIONATE
    AB    !   GLENMARK GENERICS      0.05%                             A090759  001  May 02, 2011   Mar CHRS
          POWDER;INHALATION
            ARMONAIR DIGIHALER
          + @ TEVA PHARM             0.03MG/INH                        N208798  008  Apr 08, 2022   Apr NEWA

      FLUVOXAMINE MALEATE
          CAPSULE, EXTENDED RELEASE;ORAL
            FLUVOXAMINE MALEATE
    AB        BIONPHARMA INC         100MG                             A212182  002  Sep 16, 2020   Feb CMFD
          TABLET;ORAL
            FLUVOXAMINE MALEATE
            @ CHARTWELL RX           25MG                              A075900  001  Feb 23, 2006   Aug CAHN
            @                        50MG                              A075900  002  Feb 23, 2006   Aug CAHN
```

```
          TABLET;ORAL
            FLUVOXAMINE MALEATE
            @                       100MG                           A075900  003  Feb 23, 2006   Aug CAHN

        FORMOTEROL FUMARATE
          SOLUTION;INHALATION
            FORMOTEROL FUMARATE
>A> AN        AUCTA                 0.02MG/2ML                      A216486  001  Nov 25, 2022   Nov NEWA
    AN        LUPIN                 0.02MG/2ML                      A215053  001  Aug 22, 2022   Aug NEWA

        FOSAPREPITANT DIMEGLUMINE
          POWDER;INTRAVENOUS
            FOSAPREPITANT DIMEGLUMINE
>D> AP        APOTEX                EQ 150MG BASE/VIAL              A205020  001  Sep 05, 2019   Nov DISC
>A>         @                       EQ 150MG BASE/VIAL              A205020  001  Sep 05, 2019   Nov DISC
            @ ARTHUR GRP            EQ 150MG BASE/VIAL              A211624  001  Sep 05, 2019   Mar CAHN
            @                       EQ 150MG BASE/VIAL              A213199  001  Oct 04, 2021   Mar CAHN
            @ PRAXGEN               EQ 150MG BASE/VIAL              A211624  001  Sep 05, 2019   Feb DISC
            @                       EQ 150MG BASE/VIAL              A213199  001  Oct 04, 2021   Feb DISC
            @ SANDOZ INC            EQ 150MG BASE/VIAL              A203939  001  Dec 08, 2020   Oct DISC

        FOSDENOPTERIN HYDROBROMIDE
          POWDER;INTRAVENOUS
            NULIBRY
           +!  SENTYNL THERAPS INC  EQ 9.5MG BASE/VIAL              N214018  001  Feb 26, 2021   Mar CAHN

        FOSFOMYCIN TROMETHAMINE
          FOR SOLUTION;ORAL
            FOSFOMYCIN TROMETHAMINE
    AA        CIPLA                 EQ 3GM BASE/PACKET              A211881  001  Jan 26, 2022   Jan NEWA

        FROVATRIPTAN SUCCINATE
          TABLET;ORAL
            FROVATRIPTAN SUCCINATE
    AB        RENATA                EQ 2.5MG BASE                   A213891  001  Apr 06, 2022   May CAHN
    AB        ZENARA                EQ 2.5MG BASE                   A213891  001  Apr 06, 2022   Mar NEWA

        FULVESTRANT
          INJECTABLE;INTRAMUSCULAR
            FULVESTRANT
            @ APOTEX                50MG/ML                         A211730  001  Jun 11, 2021   Jan DISC
    AO        JIANGSU HANSOH PHARM  50MG/ML                         A214682  001  Feb 10, 2022   Feb NEWA
    AO        ZYDUS PHARMS          50MG/ML                         A215234  001  Jul 29, 2021   Feb CMFD
          SOLUTION;INTRAMUSCULAR
            FASLODEX
    AO     +!  ASTRAZENECA          50MG/ML                         N021344  001  Apr 25, 2002   Oct CDFR
           + @                      125MG/2.5ML (50MG/ML)           N021344  002  Apr 25, 2002   Oct DISC
           +                        125MG/2.5ML (50MG/ML)           N021344  002  Apr 25, 2002   Oct NEWA
    AO     +!                       250MG/5ML (50MG/ML)             N021344  001  Apr 25, 2002   Oct CPOT
            FULVESTRANT
    AO        ACCORD HLTHCARE       50MG/ML                         A211689  001  Nov 17, 2020   Oct CDFR
    AO                              250MG/5ML (50MG/ML)             A211689  001  Nov 17, 2020   Oct CPOT
    AO        AMNEAL                50MG/ML                         A210044  001  Mar 04, 2019   Oct CDFR
    AO                              250MG/5ML (50MG/ML)             A210044  001  Mar 04, 2019   Oct CPOT
            @ APOTEX                50MG/ML                         A211730  001  Jun 11, 2021   Oct CDFR
            @                       250MG/5ML (50MG/ML)             A211730  001  Jun 11, 2021   Oct CPOT
    AO        CHIA TAI TIANQING     50MG/ML                         A211422  001  Feb 07, 2020   Oct CDFR
    AO                              250MG/5ML (50MG/ML)             A211422  001  Feb 07, 2020   Oct CPOT
    AO        DR REDDYS             50MG/ML                         A209246  001  Aug 07, 2020   Oct CDFR
    AO                              250MG/5ML (50MG/ML)             A209246  001  Aug 07, 2020   Oct CPOT
    AO        EUGIA PHARMA          50MG/ML                         A208811  001  Jul 23, 2019   Oct CDFR
    AO                              250MG/5ML (50MG/ML)             A208811  001  Jul 23, 2019   Oct CPOT
    AO        GLENMARK PHARMS INC   50MG/ML                         A207754  001  Aug 22, 2019   Oct CDFR
    AO                              250MG/5ML (50MG/ML)             A207754  001  Aug 22, 2019   Oct CPOT
    AO        HBT LABS INC          50MG/ML                         A209714  001  Nov 21, 2019   Oct CDFR
    AO                              250MG/5ML (50MG/ML)             A209714  001  Nov 21, 2019   Oct CPOT
    AO        JIANGSU HANSOH PHARM  50MG/ML                         A214682  001  Feb 10, 2022   Oct CDFR
    AO                              250MG/5ML (50MG/ML)             A214682  001  Feb 10, 2022   Oct CPOT
    AO        SAGENT PHARMS INC     50MG/ML                         A205871  001  Aug 22, 2019   Oct CDFR
    AO                              250MG/5ML (50MG/ML)             A205871  001  Aug 22, 2019   Oct CPOT
    AO        SANDOZ INC            50MG/ML                         A205935  001  May 14, 2019   Oct CDFR
    AO                              250MG/5ML (50MG/ML)             A205935  001  May 14, 2019   Oct CPOT
```

```
        SOLUTION;INTRAMUSCULAR
          FULVESTRANT
AO          XIROMED                50MG/ML                          A213553  001  Aug 13, 2021   Oct CDFR
AO                                 250MG/5ML (50MG/ML)              A213553  001  Aug 13, 2021   Oct CPOT
AO          ZYDUS PHARMS           50MG/ML                          A215234  001  Jul 29, 2021   Oct CDFR
AO                                 250MG/5ML (50MG/ML)              A215234  001  Jul 29, 2021   Oct CPOT

      FUROSEMIDE
        INJECTABLE;INJECTION
          FUROSEMIDE
AP          HONG KONG              10MG/ML                          A212803  001  Jan 27, 2022   Jan NEWA
AP          MEITHEAL               10MG/ML                          A212803  001  Jan 27, 2022   Mar CAHN
        SOLUTION;ORAL
          FUROSEMIDE
        !   HIKMA                  10MG/ML                          A070434  001  Apr 22, 1987   May CTEC
          @ WOCKHARDT BIO AG       10MG/ML                          A070655  001  Oct 02, 1987   May DISC
        SOLUTION;SUBCUTANEOUS
          FUROSCIX
       +!   SCPHARMACEUTICALS      80MG/10ML (8MG/ML)               N209988  001  Oct 07, 2022   Oct NEWA
        TABLET;ORAL
          FUROSEMIDE
          @ EPIC PHARMA LLC        40MG                             N018750  002  Jul 30, 1984   Mar CAHN
AB          GRAVITI PHARMS         20MG                             A216629  001  Oct 17, 2022   Oct NEWA
AB                                 40MG                             A216629  002  Oct 17, 2022   Oct NEWA
AB                                 80MG                             A216629  003  Oct 17, 2022   Oct NEWA

      FUTIBATINIB
        TABLET;ORAL
          LYTGOBI
       +!   TAIHO ONCOLOGY         4MG                              N214801  001  Sep 30, 2022   Sep NEWA

      GABAPENTIN
        CAPSULE;ORAL
          GABAPENTIN
          @ CHARTWELL RX           100MG                            A091008  001  Oct 26, 2017   Jun CAHN
          @                        300MG                            A091008  002  Oct 26, 2017   Jun CAHN
          @                        400MG                            A091008  003  Oct 26, 2017   Jun CAHN
          NEURONTIN
AB     +    VIATRIS                100MG                            N020235  001  Dec 30, 1993   Feb CAHN
AB     +                           300MG                            N020235  002  Dec 30, 1993   Feb CAHN
AB     +!                          400MG                            N020235  003  Dec 30, 1993   Feb CAHN
        SOLUTION;ORAL
          GABAPENTIN
AA          BELCHER                250MG/5ML                        A091286  001  Mar 14, 2016   Jun CAHN
          @ PAI HOLDINGS PHARM     250MG/5ML                        A211330  001  Dec 03, 2019   Feb CAHN
          @ VISTAPHARM             250MG/5ML                        A211330  001  Dec 03, 2019   Feb CAHN
          NEURONTIN
AA     +!   VIATRIS                250MG/5ML                        N021129  001  Mar 02, 2000   Feb CAHN
        TABLET;ORAL
          NEURONTIN
AB     +    VIATRIS                600MG                            N020882  001  Oct 09, 1998   Feb CAHN
AB     +!                          800MG                            N020882  002  Oct 09, 1998   Feb CAHN

      GABAPENTIN ENACARBIL
        TABLET, EXTENDED RELEASE;ORAL
          HORIZANT
       +    AZURITY                300MG                            N022399  002  Dec 13, 2011   Mar CAHN
       +!                          600MG                            N022399  001  Apr 06, 2011   Mar CAHN

      GADOBUTROL
        SOLUTION;INTRAVENOUS
          GADAVIST
>D>    +!   BAYER HLTHCARE         1.20944GM/2ML (604.72MG/ML)      N201277  006  Dec 18, 2013   Nov CFTG
>A> AP +!                          1.20944GM/2ML (604.72MG/ML)      N201277  006  Dec 18, 2013   Nov CFTG
>D>    +!                          4.5354GM/7.5ML (604.72MG/ML)     N201277  001  Mar 14, 2011   Nov CFTG
>A> AP +!                          4.5354GM/7.5ML (604.72MG/ML)     N201277  001  Mar 14, 2011   Nov CFTG
>D>    +!                          6.0472GM/10ML (604.72MG/ML)      N201277  002  Mar 14, 2011   Nov CFTG
>A> AP +!                          6.0472GM/10ML (604.72MG/ML)      N201277  002  Mar 14, 2011   Nov CFTG
>D>    +!                          9.0708GM/15ML (604.72MG/ML)      N201277  003  Mar 14, 2011   Nov CFTG
>A> AP +!                          9.0708GM/15ML (604.72MG/ML)      N201277  003  Mar 14, 2011   Nov CFTG
```

```
          SOLUTION;INTRAVENOUS
>A>         GADOBUTROL
>A> AP        HENGRUI PHARMA        1.20944GM/2ML (604.72MG/ML)        A215061  001  Nov 17, 2022   Nov NFTG
>A> AP                              4.5354GM/7.5ML (604.72MG/ML)       A215061  002  Nov 17, 2022   Nov NFTG
>A> AP                              6.0472GM/10ML (604.72MG/ML)        A215061  003  Nov 17, 2022   Nov NFTG
>A> AP                              9.0708GM/15ML (604.72MG/ML)        A215061  004  Nov 17, 2022   Nov NFTG

        GADOPICLENOL
          SOLUTION;INTRAVENOUS
            ELUCIREM
          +!  GUERBET               1.4553GM/3ML (485.1MG/ML)          N216986  001  Sep 21, 2022   Sep NEWA
          +!                        3.63825GM/7.5ML (485.1MG/ML)       N216986  002  Sep 21, 2022   Sep NEWA
          +!                        4.851GM/10ML (485.1MG/ML)          N216986  003  Sep 21, 2022   Sep NEWA
          +!                        7.2765GM/15ML (485.1MG/ML)         N216986  004  Sep 21, 2022   Sep NEWA
          +!                        14.553GM/30ML (485.1MG/ML)         N216986  005  Sep 21, 2022   Sep NEWA
          +!                        24.255GM/50ML (485.1MG/ML)         N216986  006  Sep 21, 2022   Sep NEWA
          +!                        48.51GM/100ML (485.1MG/ML)         N216986  007  Sep 21, 2022   Sep NEWA

        GADOTERATE MEGLUMINE
          SOLUTION;INTRAVENOUS
            GADOTERATE MEGLUMINE
    AP        HENGRUI PHARMA        1.8845GM/5ML (376.9MG/ML)          A215304  001  Apr 11, 2022   Jun CAHN
    AP                              3.769GM/10ML (376.9MG/ML)          A215304  002  Apr 11, 2022   Jun CAHN
    AP                              5.6535GM/15ML (376.9MG/ML)         A215304  003  Apr 11, 2022   Jun CAHN
    AP                              7.538GM/20ML (376.9MG/ML)          A215304  004  Apr 11, 2022   Jun CAHN
    AP                              37.69GM/100ML (376.9MG/ML)         A215982  001  Apr 15, 2022   Jun CAHN
    AP        JIANGSU HENGRUI MED   1.8845GM/5ML (376.9MG/ML)          A215304  001  Apr 11, 2022   Apr NEWA
    AP                              3.769GM/10ML (376.9MG/ML)          A215304  002  Apr 11, 2022   Apr NEWA
    AP                              5.6535GM/15ML (376.9MG/ML)         A215304  003  Apr 11, 2022   Apr NEWA
    AP                              7.538GM/20ML (376.9MG/ML)          A215304  004  Apr 11, 2022   Apr NEWA
    AP                              37.69GM/100ML (376.9MG/ML)         A215982  001  Apr 15, 2022   Apr NEWA

        GALLIUM GA 68 DOTATOC
          SOLUTION;INTRAVENOUS
            GALLIUM GA 68 DOTATOC
          +!  UIHC PET IMAGING      0.5-4mCi/ML                        N210828  001  Aug 21, 2019   Sep CTNA

        GALLIUM GA-68 DOTATOC
          SOLUTION;INTRAVENOUS
            GALLIUM GA 68 DOTATOC
          +!  UIHC PET IMAGING      0.5-4mCi/ML                        N210828  001  Aug 21, 2019   Sep CAIN

        GALLIUM GA-68 GOZETOTIDE
          POWDER;INTRAVENOUS
            ILLUCCIX
          +!  TELIX                 N/A                                N214032  001  Dec 17, 2021   Mar CPOT
            LOCAMETZ
          +!  AAA USA NOVARTIS      N/A                                N215841  001  Mar 23, 2022   Mar NEWA
          SOLUTION;INTRAVENOUS
            GALLIUM GA 68 GOZETOTIDE
          +!  UNIV CA LOS ANGELES   0.5-5mCi/mL                        N212642  001  Dec 01, 2020   Jul CPOT
          +!                        30ML (0.5-5mCi/mL)                 N212642  001  Dec 01, 2020   Jun CTNA
          +!                        30ML (0.5-5mCi/mL)                 N212642  001  Dec 01, 2020   Jun CAIN
          +!  UNIV OF CA SAN FRAN   0.5-5mCi/mL                        N212643  001  Dec 01, 2020   Jul CPOT
          +!                        20ML (0.5-5mCi/mL)                 N212643  001  Dec 01, 2020   Jun CTNA
          +!                        20ML (0.5-5mCi/mL)                 N212643  001  Dec 01, 2020   Jun CAIN

        GANAXOLONE
          SUSPENSION;ORAL
            ZTALMY
          +!  MARINUS                50MG/ML                            N215904  001  Jun 01, 2022   Jun NEWA

        GANCICLOVIR SODIUM
          INJECTABLE;INJECTION
            GANCICLOVIR SODIUM
            @ STERISCIENCE          EQ 500MG BASE/VIAL                 A204560  001  Nov 17, 2017   Feb CAHN
```

GANIRELIX ACETATE

INJECTABLE;INJECTION

FYREMADEL

AP		SUN PHARM	250MCG/0.5ML	A204246	001	Nov 30, 2018	May CTNA

GANIRELIX ACETATE

AP		AMPHASTAR PHARMS INC	250MCG/0.5ML	A212613	001	Apr 07, 2022	Apr NEWA
>D> AP		HONG KONG	250MCG/0.5ML	A214996	001	Jun 06, 2022	Nov CAHN
AP			250MCG/0.5ML	A214996	001	Jun 06, 2022	May NEWA
>A> AP		MEITHEAL	250MCG/0.5ML	A214996	001	Jun 06, 2022	Nov CAHN

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

	@	RISING	0.5%	A206446	001	Jun 08, 2018	Jun CAHN
>D> AT		TORRENT	0.5%	A213542	001	Nov 03, 2021	Nov DISC
>A>	@		0.5%	A213542	001	Nov 03, 2021	Nov DISC

GEFITINIB

TABLET;ORAL

GEFITINIB

AB		APOTEX	250MG	A209532	001	Sep 23, 2022	Sep NFTG

IRESSA

AB	+!	ASTRAZENECA	250MG	N206995	001	Jul 13, 2015	Sep CFTG

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP		TEYRO LABS	EQ 200MG BASE/VIAL	A078759	001	Jul 25, 2011	Apr CAHN
AP			EQ 1GM BASE/VIAL	A078759	002	Jul 25, 2011	Apr CAHN

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

	@	CADILA	600MG	A204189	001	Aug 28, 2018	Oct DISC
	@	CHARTWELL RX	600MG	A074615	001	Sep 29, 1995	Feb CAHN

GEMIFLOXACIN MESYLATE

TABLET;ORAL

FACTIVE

	+ @	LG CHEM LTD	EQ 320MG BASE	N021158	001	Apr 04, 2003	Jan DISC

GEMIFLOXACIN MESYLATE

	@	ORBION PHARMS	EQ 320MG BASE	A090466	001	Jun 15, 2015	Jan DISC

GENTAMICIN SULFATE

SOLUTION/DROPS;OPHTHALMIC

GENTAMICIN SULFATE

	@	AKORN	EQ 0.3% BASE	A062635	001	Jan 08, 1987	Aug DISC

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

>A> AB		CHARTWELL MOLECULAR	1MG	A077295	001	Oct 06, 2005	Nov CAHN
>A> AB			2MG	A077295	002	Oct 06, 2005	Nov CAHN
>A> AB			4MG	A077295	003	Oct 06, 2005	Nov CAHN
>D> AB		INVAGEN PHARMS	1MG	A077295	001	Oct 06, 2005	Nov CAHN
>D> AB			2MG	A077295	002	Oct 06, 2005	Nov CAHN
>D> AB			4MG	A077295	003	Oct 06, 2005	Nov CAHN

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

AB	!	APOTEX	10MG	A075795	002	Jun 13, 2001	May CHRS
AB		AUROBINDO PHARMA USA	5MG	A074226	001	May 10, 1994	Feb CAHN
AB			10MG	A074226	002	May 10, 1994	Feb CAHN
	@	CHARTWELL RX	5MG	A074542	001	Jun 20, 1995	Sep CAHN
	@		10MG	A074542	002	Jun 20, 1995	Sep CAHN

GLUCOTROL

	+ @	PFIZER	5MG	N017783	001	May 08, 1984	May DISC
	+ @		10MG	N017783	002	May 08, 1984	May DISC

GLYBURIDE

TABLET;ORAL

GLYBURIDE

	@ CHARTWELL RX	1.25MG	A203581	001	Apr 14, 2016	Jul CAHN
	@	2.5MG	A203581	002	Apr 14, 2016	Jul CAHN
	@	5MG	A203581	003	Apr 14, 2016	Jul CAHN
	@ SUNNY	1.25MG	A203581	001	Apr 14, 2016	Mar DISC
	@	2.5MG	A203581	002	Apr 14, 2016	Mar DISC
	@	5MG	A203581	003	Apr 14, 2016	Mar DISC

GLYBURIDE (MICRONIZED)

	@ CHARTWELL RX	1.5MG	A075174	001	Jun 22, 1998	Feb CAHN
	@	3MG	A075174	002	Jun 22, 1998	Feb CAHN

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

AP	ALEMBIC PHARMS LTD	0.2MG/ML	A214635	001	Oct 26, 2022	Oct NEWA
AP	AMNEAL	0.2MG/ML	A215333	001	Oct 21, 2022	Oct NEWA
>A> AP	ASPEN	0.2MG/ML	A212871	001	Nov 29, 2022	Nov NEWA
	@ EUGIA PHARMA	0.2MG/ML	A210244	001	Nov 28, 2018	Jul DISC
	@ ZYDUS PHARMS	0.2MG/ML	A214213	001	Nov 09, 2021	May DISC

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

GLYCOPYRROLATE

+!	FRESENIUS KABI USA	0.6MG/3ML (0.2MG/ML)	N214919	001	Apr 21, 2022	Apr NEWA

SOLUTION;ORAL

GLYCOPYRROLATE

AA	ANNORA PHARMA	1MG/5ML	A213698	001	Jul 05, 2022	Jun NEWA
AA	SUVEN PHARMS	1MG/5ML	A212467	001	Jul 05, 2022	Jun NEWA

TABLET;ORAL

GLYCOPYRROLATE

	@ CHARTWELL RX	1MG	A040568	001	Dec 22, 2004	Jul CAHN
	@	2MG	A040568	002	Dec 22, 2004	Jul CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

	@ AKORN	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A079119	001	Sep 10, 2009	Jul DISC
AP	AMNEAL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262	001	Dec 31, 2007	May CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258	001	Jun 30, 2008	May CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258	002	Jun 30, 2008	May CAHN
	@ EUGIA PHARMA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204238	001	Jul 06, 2016	Jul DISC
	@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204238	002	Jul 06, 2016	Jul DISC

GRISEOFULVIN, MICROCRYSTALLINE

TABLET;ORAL

FULVICIN-U/F

>D> AB	CHARTWELL RX	250MG	A060569	002		Nov CTEC
>A>		250MG	A060569	002		Nov CTEC
>D> AB		500MG	A060569	001		Nov CTEC
>A>		500MG	A060569	001		Nov CTEC

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL

FULVICIN P/G

>D> AB	CHARTWELL RX	125MG	A061996	001		Nov CTEC
>A>		125MG	A061996	001		Nov CTEC
>D> AB		250MG	A061996	002		Nov CTEC
>A>		250MG	A061996	002		Nov CTEC

FULVICIN P/G 165

>D> AB	CHARTWELL RX	165MG	A061996	003	Apr 06, 1982	Nov CTEC
>A>		165MG	A061996	003	Apr 06, 1982	Nov CTEC

FULVICIN P/G 330

>D> AB	CHARTWELL RX	330MG	A061996	004	Apr 06, 1982	Nov CTEC
>A>		330MG	A061996	004	Apr 06, 1982	Nov CTEC

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

FLOWTUSS

@	CHARTWELL RX	200MG/5ML;2.5MG/5ML	N022424	001	May 14, 2015	Oct CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYCOFENIX

+ @	CHARTWELL RX	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015	Oct CAHN

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

AB	TWI PHARMS	EQ 1MG BASE	A216399	001	Jun 08, 2022	May NEWA
AB		EQ 2MG BASE	A216399	002	Jun 08, 2022	May NEWA

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

AB	YICHANG HUMANWELL	EQ 1MG BASE	A213428	001	Nov 25, 2020	May CMFD
AB		EQ 2MG BASE	A213428	002	Nov 25, 2020	May CMFD
AB		EQ 3MG BASE	A213428	003	Nov 25, 2020	May CMFD
AB		EQ 4MG BASE	A213428	004	Nov 25, 2020	May CMFD

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB	ACTAVIS GROUP	0.5MG	A200854	001	Jul 01, 2022	Jun NEWA
AB		1MG	A200854	002	Jul 01, 2022	Jun NEWA
AB		2MG	A200854	003	Jul 01, 2022	Jun NEWA
AB		5MG	A200854	004	Jul 01, 2022	Jun NEWA
AB		10MG	A200854	005	Jul 01, 2022	Jun NEWA
AB		20MG	A200854	006	Jul 01, 2022	Jun NEWA
>A> AB	MSN	0.5MG	A216004	001	Nov 18, 2022	Nov NEWA
>A> AB		1MG	A216004	002	Nov 18, 2022	Nov NEWA
>A> AB		2MG	A216004	003	Nov 18, 2022	Nov NEWA
>A> AB		5MG	A216004	004	Nov 18, 2022	Nov NEWA
>A> AB		10MG	A216004	005	Nov 18, 2022	Nov NEWA
>A> AB		20MG	A216004	006	Nov 18, 2022	Nov NEWA
AB	SANDOZ	0.5MG	A071209	002	Nov 17, 1986	Mar CMS1
AB		1MG	A071209	003	Nov 17, 1986	Mar CMS1
@		2MG	A071209	004	Nov 17, 1986	Mar CMS1

HALOPERIDOL LACTATE

INJECTABLE;INJECTION

HALOPERIDOL

@	AKORN	EQ 5MG BASE/ML	A204849	001	Sep 06, 2017	Aug DISC

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

+ @	HIKMA	1,000 UNITS/ML	N017007	001		Jul CAHN
+ @		2,500 UNITS/ML	N017007	007		Jul CAHN
+ @		5,000 UNITS/ML	N017007	002		Jul CAHN
+ @		5,000 UNITS/0.5ML	N017007	010		Jul CAHN
+ @		7,500 UNITS/ML	N017007	003		Jul CAHN
+ @		10,000 UNITS/ML	N017007	004		Jul CAHN
+ @		15,000 UNITS/ML	N017007	005		Jul CAHN
+ @		20,000 UNITS/ML	N017007	006		Jul CAHN

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

+!	B BRAUN	4,000 UNITS/100ML	N019952	001	Jul 20, 1992	Mar CTEC

HEPARIN SODIUM PRESERVATIVE FREE

AP	SHENZHEN TECHDOW	1,000 UNITS/ML	A202732	001	Jun 12, 2014	Jul CMFD

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDRALAZINE HYDROCHLORIDE

AP	AUSEIC PHARMS	20MG/ML	A203110	001	Jun 29, 2015	Sep CAHN
AP	BEOWULF ASSET	20MG/ML	A203110	001	Jun 29, 2015	Sep CAHN

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET;ORAL

BIDIL

AB	+!	AZURITY	37.5MG;20MG	N020727	001	Jun 23, 2005	Mar CFTG
	+!		37.5MG;20MG	N020727	001	Jun 23, 2005	Mar CAHN

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

AB		RICONPHARMA LLC	37.5MG;20MG	A215586	001	Apr 06, 2022	Mar NFTG

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

>D> AB		MYLAN	12.5MG	A075640	001	Jan 28, 2000	Nov DISC
>A>	@		12.5MG	A075640	001	Jan 28, 2000	Nov DISC

TABLET;ORAL

HYDROCHLOROTHIAZIDE

	@	CHARTWELL RX	25MG	A087565	001	Mar 09, 1982	Feb CAHN
	@		50MG	A084912	001		Feb CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

>D> AB		UNICHEM	12.5MG;150MG	A207018	001	Sep 19, 2017	Nov DISC
>A>	@		12.5MG;150MG	A207018	001	Sep 19, 2017	Nov DISC
>D> AB			12.5MG;300MG	A207018	002	Sep 19, 2017	Nov DISC
>A>	@		12.5MG;300MG	A207018	002	Sep 19, 2017	Nov DISC

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@	CHARTWELL RX	25MG;40MG	A071060	001	Aug 26, 1987	Feb CAHN
	@		25MG;80MG	A071061	001	Aug 26, 1987	Jan CAHN
	@	RISING	25MG;40MG	A070947	002	Mar 04, 1987	Jul CAHN
	@		25MG;80MG	A070947	001	Apr 01, 1987	Jul CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@	LUPIN	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	Jun CTNA
	@		12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	May DISC
AB			12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	May CTNA
	@		12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	Jun CTNA
	@		12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	May DISC
AB			12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	May CTNA
	@		25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	Jun CTNA
	@		25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	May DISC
AB			25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	May CTNA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

	@	MYLAN	25MG;37.5MG	A074701	001	Jun 07, 1996	Jun DISC

TABLET;ORAL

MAXZIDE

AB	+!	AUROBINDO PHARMA USA	50MG;75MG	N019129	001	Oct 22, 1984	Feb CAHN

MAXZIDE-25

AB	+	AUROBINDO PHARMA USA	25MG;37.5MG	N019129	003	May 13, 1988	Feb CAHN

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		RUBICON	25MG;37.5MG	A216211	001	Feb 23, 2022	Feb NEWA
AB			50MG;75MG	A216211	002	Feb 23, 2022	Feb NEWA

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE;ORAL

HYDROCODONE BITARTRATE

AB		ALVOGEN	20MG	A208269	001	Mar 01, 2021	May CAHN
AB			30MG	A208269	002	Mar 01, 2021	May CAHN
AB			40MG	A208269	003	Mar 01, 2021	May CAHN
AB			60MG	A208269	004	Mar 01, 2021	May CAHN
AB			80MG	A208269	005	Mar 01, 2021	May CAHN
AB			100MG	A208269	006	Mar 01, 2021	May CAHN
AB			120MG	A208269	007	Mar 01, 2021	May CAHN

HYDROCORTISONE

		CREAM;TOPICAL					
		HYDROCORTISONE					
		@ ENCUBE	2.5%	A203810	001	Jul 23, 2018	Jul CAHN
AT	+!	FOUGERA PHARMS INC	1%	A080693	003		Oct CRLD
		LOTION;TOPICAL					
		ALA-SCALP					
		DERM RX	2%	A083231	001		Jun CAHN

HYDROCORTISONE ACETATE

		CREAM;TOPICAL					
>D>		U-CORT					
>D>		TARO	1%	A089472	001	Jun 13, 1988	Nov DISC
>A>		@	1%	A089472	001	Jun 13, 1988	Nov DISC

HYDROCORTISONE BUTYRATE

		LOTION;TOPICAL					
		HYDROCORTISONE BUTYRATE					
AB		THE J MOLNER	0.1%	A209556	001	Nov 21, 2017	Oct CAHN

HYDROMORPHONE HYDROCHLORIDE

		INJECTABLE;INJECTION					
		HYDROMORPHONE HYDROCHLORIDE					
		HOSPIRA INC	0.5MG/0.5ML	N200403	004	Jun 13, 2022	Jun NEWA
		SOLUTION;ORAL					
		HYDROMORPHONE HYDROCHLORIDE					
		@ ANDA REPOSITORY	5MG/5ML	A207108	001	Apr 22, 2020	Sep CAHN
		TABLET;ORAL					
		HYDROMORPHONE HYDROCHLORIDE					
		@ ANDA REPOSITORY	2MG	A077471	002	Dec 09, 2009	Sep CAHN
		@	4MG	A077471	003	Dec 09, 2009	Sep CAHN
		@	8MG	A077471	001	Dec 09, 2009	Sep CAHN
		@ HIKMA	4MG	A074597	003	May 29, 2009	Aug DISC
		@	8MG	A074597	001	Jul 29, 1998	Aug DISC

HYDROXOCOBALAMIN

		INJECTABLE;INJECTION					
		CYANOKIT					
		@ BTG INTL	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Mar CAHN
	+!		5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Mar CAHN

HYDROXYCHLOROQUINE SULFATE

		TABLET;ORAL					
		HYDROXYCHLOROQUINE SULFATE					
AB		ACCORD HLTHCARE	100MG	A213342	002	Aug 18, 2021	Sep CTEC
AB			300MG	A213342	003	Aug 18, 2021	Sep CTEC
AB	!		400MG	A213342	004	Aug 18, 2021	Sep CTEC
	!		400MG	A213342	004	Aug 18, 2021	Jan CHRS
	!		400MG	A213342	004	Aug 18, 2021	Jan CHRS
AB		APPCO	100MG	A210441	002	Sep 19, 2022	Sep NEWA
AB			300MG	A210441	003	Sep 19, 2022	Sep NEWA
AB			400MG	A210441	004	Sep 19, 2022	Sep NEWA
AB		AUROBINDO PHARMA USA	200MG	A040274	001	May 29, 1998	May CAHN
	+	NOVITIUM PHARMA	200MG	N214581	001	Jan 14, 2022	Jan NEWA
	+!		300MG	N214581	002	Jan 14, 2022	Jan NEWA
AB		RISE PHARMA	200MG	A212902	001	May 14, 2020	Sep CAHN

HYDROXYUREA

		CAPSULE;ORAL					
		DROXIA					
	+	CHEPLAPHARM	200MG	N016295	002	Feb 25, 1998	Oct CAHN
	+		300MG	N016295	003	Feb 25, 1998	Oct CAHN
	+		400MG	N016295	004	Feb 25, 1998	Oct CAHN
		HYDREA					
AB	+!	CHEPLAPHARM	500MG	N016295	001		Oct CAHN

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDE

	@	AKORN	10MG/5ML	A040010	001	Oct 28, 1994	Aug DISC
	@	PAI HOLDINGS PHARM	10MG/5ML	A040391	001	Apr 10, 2002	Jan CAHN

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

AB		AIPING LIFE SCI	10MG	A040804	001	Jun 30, 2008	Oct CAHN
AB			25MG	A040804	002	Jun 30, 2008	Oct CAHN
AB			50MG	A040804	003	Jun 30, 2008	Oct CAHN
AB		AUROBINDO PHARMA LTD	10MG	A087871	002	Dec 20, 1982	May CMFD
AB			25MG	A087871	003	Dec 20, 1982	May CMFD
AB			50MG	A087871	001	Dec 20, 1982	May CMFD

IBRUTINIB

SUSPENSION;ORAL

IMBRUVICA

	+!	PHARMACYCLICS INC	70MG/ML	N217003	001	Aug 24, 2022	Aug NEWA

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

	@	AKORN	100MG/5ML	A205647	001	Nov 03, 2016	Sep DISC
AB		AUROBINDO PHARMA LTD	100MG/5ML	A209178	001	Feb 16, 2018	May CTEC
>D> AB		STRIDES PHARMA	100MG/5ML	A215311	001	May 27, 2022	Nov DISC
>A>	@		100MG/5ML	A215311	001	May 27, 2022	Nov DISC
AB			100MG/5ML	A215311	001	May 27, 2022	May NEWA

TABLET;ORAL

IBUPROFEN

	@	L PERRIGO CO	400MG	A077114	001	Jul 18, 2005	Sep DISC
	@		600MG	A077114	002	Jul 18, 2005	Sep DISC
	@		800MG	A077114	003	Jul 18, 2005	Sep DISC
	@	SUNSHINE	400MG	A204062	001	Sep 10, 2018	Mar CAHN
	@		600MG	A204062	002	Sep 10, 2018	Mar CAHN
	@		800MG	A204062	003	Sep 10, 2018	Mar CAHN
AB		YICHANG HUMANWELL	400MG	A215318	001	Mar 30, 2022	Mar NEWA
AB			600MG	A215318	002	Mar 30, 2022	Mar NEWA
AB			800MG	A215318	003	Mar 30, 2022	Mar NEWA

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS

FIRAZYR

AP	+!	TAKEDA PHARMS USA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N022150	001	Aug 25, 2011	Jul CAHN

ICATIBANT ACETATE

	@	GLENMARK PHARMS LTD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213222	001	May 21, 2021	Oct DISC

ICOSAPENT ETHYL

CAPSULE;ORAL

ICOSAPENT ETHYL

AB		TEVA PHARMS USA	500MG	A209525	001	Sep 11, 2020	Jul CMFD
>D>	@		1GM	A209525	002	Sep 11, 2020	Nov CMFD
>A> AB			1GM	A209525	002	Sep 11, 2020	Nov CMFD

VASCEPA

AB	+	AMARIN PHARMS	500MG	N202057	002	Feb 16, 2017	Oct CTEC

ILOPERIDONE

TABLET;ORAL

FANAPT

	+!	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Jul CTEC
AB	+!		1MG	N022192	001	May 06, 2009	Apr CTEC
	+		2MG	N022192	002	May 06, 2009	Jul CTEC
AB	+		2MG	N022192	002	May 06, 2009	Apr CTEC
	+		4MG	N022192	003	May 06, 2009	Jul CTEC
AB	+		4MG	N022192	003	May 06, 2009	Apr CTEC
	+		6MG	N022192	004	May 06, 2009	Jul CTEC
AB	+		6MG	N022192	004	May 06, 2009	Apr CTEC
	+		8MG	N022192	005	May 06, 2009	Jul CTEC
AB	+		8MG	N022192	005	May 06, 2009	Apr CTEC
	+		10MG	N022192	006	May 06, 2009	Jul CTEC
AB	+		10MG	N022192	006	May 06, 2009	Apr CTEC
	+		12MG	N022192	007	May 06, 2009	Jul CTEC

```
      TABLET;ORAL
        FANAPT
AB    +                        12MG                          N022192  007  May 06, 2009   Apr CTEC
        ILOPERIDONE
        @ LUPIN LTD            1MG                           A206890  001  May 05, 2022   Jul DISC
AB                             1MG                           A206890  001  May 05, 2022   Apr NEWA
        @                      2MG                           A206890  002  May 05, 2022   Jul DISC
AB                             2MG                           A206890  002  May 05, 2022   Apr NEWA
        @                      4MG                           A206890  003  May 05, 2022   Jul DISC
AB                             4MG                           A206890  003  May 05, 2022   Apr NEWA
        @                      6MG                           A206890  004  May 05, 2022   Jul DISC
AB                             6MG                           A206890  004  May 05, 2022   Apr NEWA
        @                      8MG                           A206890  005  May 05, 2022   Jul DISC
AB                             8MG                           A206890  005  May 05, 2022   Apr NEWA
        @                      10MG                          A206890  006  May 05, 2022   Jul DISC
AB                             10MG                          A206890  006  May 05, 2022   Apr NEWA
        @                      12MG                          A206890  007  May 05, 2022   Jul DISC
AB                             12MG                          A206890  007  May 05, 2022   Apr NEWA

    IMATINIB MESYLATE
      TABLET;ORAL
        IMATINIB MESYLATE
AB        QILU PHARM HAINAN    EQ 100MG BASE                 A212135  001  Jun 21, 2022   Jun NEWA
AB                             EQ 400MG BASE                 A212135  002  Jun 21, 2022   Jun NEWA

    INDAPAMIDE
      TABLET;ORAL
        INDAPAMIDE
        @ CHARTWELL RX         1.25MG                        A074594  001  May 23, 1996   Feb CAHN
        @                      2.5MG                         A074594  002  May 23, 1996   Feb CAHN

    INDIGOTINDISULFONATE SODIUM
      SOLUTION;INTRAVENOUS
        BLUDIGO
      +!  PROVEPHARM SAS       40MG/5ML (8MG/ML)             N216264  001  Jul 08, 2022   Jul NEWA

    IODIXANOL
      INJECTABLE;INJECTION
        IODIXANOL
AP        HENGRUI PHARMA       55%                           A214271  001  May 19, 2022   May NFTG
AP                             65.2%                         A214271  002  May 19, 2022   May NFTG
        VISIPAQUE 270
AP    +!  GE HEALTHCARE        55%                           N020351  001  Mar 22, 1996   May CFTG
        VISIPAQUE 320
AP    +!  GE HEALTHCARE        65.2%                         N020351  002  Mar 22, 1996   May CFTG

    IOFLUPANE I-123
      SOLUTION;INTRAVENOUS
        DATSCAN
AP    +!  GE HLTHCARE INC      5mCi/2.5ML (2mCi/ML)          N022454  001  Jan 14, 2011   Mar CFTG
        IOFLUPANE I-123
AP        CURIUM               5mCi/2.5ML (2mCi/ML)          A213792  001  Mar 30, 2022   Mar NFTG

    IPRATROPIUM BROMIDE
      SOLUTION;INHALATION
        IPRATROPIUM BROMIDE
        @ BAUSCH               0.02%                         A075835  001  Oct 15, 2001   Jun CAHN
      SPRAY, METERED;NASAL
        IPRATROPIUM BROMIDE
AB        AMNEAL               0.021MG/SPRAY                 A215104  001  Aug 16, 2022   Aug NEWA
AB                             0.042MG/SPRAY                 A215105  001  Aug 16, 2022   Aug NEWA
AB        BAUSCH               0.021MG/SPRAY                 A076025  001  Mar 31, 2003   Jun CAHN
AB                             0.042MG/SPRAY                 A076103  001  Mar 31, 2003   Jun CAHN

    IRBESARTAN
      TABLET;ORAL
        IRBESARTAN
>D> AB    UNICHEM              75MG                          A203020  001  Dec 07, 2015   Nov DISC
>A>     @                      75MG                          A203020  001  Dec 07, 2015   Nov DISC
>D> AB                         150MG                         A203020  002  Dec 07, 2015   Nov DISC
>A>     @                      150MG                         A203020  002  Dec 07, 2015   Nov DISC
>D> AB                         300MG                         A203020  003  Dec 07, 2015   Nov DISC
```

```
          TABLET;ORAL
            IRBESARTAN
>A>         @                        300MG                              A203020  003  Dec 07, 2015   Nov DISC

        IRINOTECAN HYDROCHLORIDE
          INJECTABLE;INJECTION
            IRINOTECAN HYDROCHLORIDE
    AP        EUGIA PHARMA           500MG/25ML (20MG/ML)               A213278  004  Apr 11, 2022   Apr NEWA

        ISONIAZID
          SYRUP;ORAL
            ISONIAZID
            @ CHARTWELL RX           50MG/5ML                           A081118  001  Jul 21, 1997   Mar CAHN
          TABLET;ORAL
            ISONIAZID
          + @ EPIC PHARMA LLC        100MG                              N008678  002                   Jul CAHN
          + @                        300MG                              N008678  003                   Jul CAHN
    AA        MIKART                 100MG                              A040090  001  Jun 26, 1997   Mar CAHN
    AA                               300MG                              A040090  002  Jun 26, 1997   Mar CAHN

        ISOPROTERENOL HYDROCHLORIDE
          INJECTABLE;INJECTION
            ISOPROTERENOL HYDROCHLORIDE
    AP        AM REGENT              0.2MG/ML                           A214775  001  Oct 19, 2022   Oct NEWA
    AP        MYLAN LABS LTD         0.2MG/ML                           A212573  001  Sep 06, 2022   Aug NEWA
    AP        STI PHARMA LLC         0.2MG/ML                           A215542  001  Sep 20, 2022   Sep NEWA

        ISOSORBIDE DINITRATE
          TABLET;ORAL
            ISOSORBIDE DINITRATE
    AB        RUBICON                5MG                                A215723  001  Jul 08, 2022   Jul NEWA
    AB                               10MG                               A215723  002  Jul 08, 2022   Jul NEWA
    AB                               20MG                               A215723  003  Jul 08, 2022   Jul NEWA
    AB                               30MG                               A215723  004  Jul 08, 2022   Jul NEWA
    AB                               40MG                               A215723  005  Jul 08, 2022   Jul NEWA

        ISOSORBIDE MONONITRATE
          TABLET, EXTENDED RELEASE;ORAL
            ISOSORBIDE MONONITRATE
    AB        AUROBINDO PHARMA       30MG                               A216557  001  Nov 07, 2022   Oct NEWA
    AB                               60MG                               A216557  002  Nov 07, 2022   Oct NEWA
    AB                               120MG                              A216557  003  Nov 07, 2022   Oct NEWA
    AB        SHANDONG               120MG                              A214115  001  Apr 29, 2022   Apr NEWA
    AB        ZYDUS PHARMS           30MG                               A075395  001  Mar 16, 2000   Mar CAHN
    AB                               60MG                               A075395  002  Mar 16, 2000   Mar CAHN
    AB                               120MG                              A075395  003  Mar 16, 2000   Mar CAHN

        ISOSULFAN BLUE
          INJECTABLE;INJECTION
            ISOSULFAN BLUE
            @ EUGIA PHARMA           1%                                 A206831  001  Feb 02, 2016   Jul DISC
            @ FRESENIUS KABI USA     1%                                 A211869  001  Sep 08, 2022   Oct DISC
    AP                               1%                                 A211869  001  Sep 08, 2022   Sep NEWA
    AP        MSN                    1%                                 A216090  001  Sep 16, 2022   Sep NEWA

        ITRACONAZOLE
          CAPSULE;ORAL
            ITRACONAZOLE
            @ JUBILANT GENERICS      100MG                              A203445  001  Feb 23, 2017   May DISC
            TOLSURA
>A>       +!  MAYNE PHARMA           65MG                               N208901  001  Dec 11, 2018   Nov CAHN
>D>       +!  MAYNE PHARMA INTL      65MG                               N208901  001  Dec 11, 2018   Nov CAHN

        IVABRADINE HYDROCHLORIDE
          TABLET;ORAL
            CORLANOR
    AB    +   AMGEN INC              EQ 5MG BASE                        N206143  001  Apr 15, 2015   Sep CTEC
          +                          EQ 5MG BASE                        N206143  001  Apr 15, 2015   Jan CTEC
    AB    +!                         EQ 7.5MG BASE                      N206143  002  Apr 15, 2015   Sep CTEC
          +!                         EQ 7.5MG BASE                      N206143  002  Apr 15, 2015   Jan CTEC
```

TABLET;ORAL
IVABRADINE HYDROCHLORIDE

AB		ANNORA PHARMA	EQ 5MG BASE	A213366	001	Oct 05, 2022	Sep NEWA
AB			EQ 7.5MG BASE	A213366	002	Oct 05, 2022	Sep NEWA
	@	CENTAUR PHARMS PVT	EQ 5MG BASE	A214051	001	Dec 30, 2021	Jan DISC
	@		EQ 7.5MG BASE	A214051	002	Dec 30, 2021	Jan DISC
	@	INGENUS PHARMS LLC	EQ 5MG BASE	A214051	001	Dec 30, 2021	Sep CAHN
	@		EQ 7.5MG BASE	A214051	002	Dec 30, 2021	Sep CAHN

IVACAFTOR; LUMACAFTOR

GRANULE;ORAL
ORKAMBI

	+	VERTEX PHARMS INC	94MG/PACKET;75MG/PACKET	N211358	003	Sep 02, 2022	Sep NEWA

IVERMECTIN

CREAM;TOPICAL
IVERMECTIN

AB		ZYDUS	1%	A215210	001	Aug 02, 2022	Jul NEWA

KETOCONAZOLE

GEL;TOPICAL
XOLEGEL

	+ @	ALMIRALL	2%	N021946	001	Jul 28, 2006	Sep DISC

KETOPROFEN

CAPSULE;ORAL
KETOPROFEN

	@	RISING	50MG	A074035	002	Dec 31, 1996	Oct CAHN
	@		75MG	A074035	003	Dec 31, 1996	Oct CAHN

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION
KETOROLAC TROMETHAMINE

AP		ALEMBIC PHARMS LTD	15MG/ML	A214456	001	Nov 02, 2022	Oct NEWA
AP			30MG/ML	A214456	002	Nov 02, 2022	Oct NEWA
>D>	@	ATLANTIDE	30MG/ML	A077943	001	Mar 27, 2007	Nov CAHN
	@	STERISCIENCE	15MG/ML	A078299	001	Jul 16, 2007	Feb CAHN
	@		15MG/ML	A201155	001	Aug 04, 2014	Feb CAHN
	@		30MG/ML	A078299	002	Jul 16, 2007	Feb CAHN
	@		30MG/ML	A201155	002	Aug 04, 2014	Feb CAHN
AP		SUN PHARM	15MG/ML	A078737	001	Oct 06, 2008	Sep CMFD
AP			30MG/ML	A078737	002	Oct 06, 2008	Sep CMFD
>A>	@	WOCKHARDT BIO AG	30MG/ML	A077943	001	Mar 27, 2007	Nov CAHN

SOLUTION/DROPS;OPHTHALMIC
KETOROLAC TROMETHAMINE

	@	AKORN	0.4%	A078399	001	Nov 05, 2009	Jun DISC

TABLET;ORAL
KETOROLAC TROMETHAMINE

AB		ATNAHS PHARMA US	10MG	A216407	001	Oct 21, 2022	Oct NEWA
AB		HAVIX	10MG	A215788	001	Mar 23, 2022	Mar NEWA
AB		HETERO LABS LTD III	10MG	A216651	001	Aug 25, 2022	Aug NEWA
AB		SENORES PHARMS	10MG	A215788	001	Mar 23, 2022	Mar CAHN
AB		ZYDUS	10MG	A217038	001	Oct 21, 2022	Oct NEWA

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION
OMIDRIA

AT	+!	RAYNER SURGICAL	EQ 0.3% BASE;EQ 1% BASE	N205388	001	May 30, 2014	Feb CAHN

KETOTIFEN FUMARATE

DRUG-ELUTING CONTACT LENS;OPHTHALMIC
ACUVUE THERAVISION WITH KETOTIFEN

	+!	JOHNSON JOHNSON VISN	EQ 19MCG BASE	N022388	001	Feb 25, 2022	Feb NEWA

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION
LABETALOL HYDROCHLORIDE

	@	STERISCIENCE	5MG/ML	A079134	001	Feb 03, 2010	Feb CAHN

SOLUTION;INTRAVENOUS
LABETALOL HYDROCHLORIDE

	+!	HIKMA	10MG/2ML (5MG/ML)	N213330	005	Mar 18, 2022	Aug NEWA

TABLET;ORAL
LABETALOL HYDROCHLORIDE

>D>	AB	UNICHEM	100MG	A212719	001	Aug 08, 2022	Nov DISC
>A>		@	100MG	A212719	001	Aug 08, 2022	Nov DISC
	AB		100MG	A212719	001	Aug 08, 2022	Jul NEWA
>D>	AB		200MG	A212719	002	Aug 08, 2022	Nov DISC
>A>		@	200MG	A212719	002	Aug 08, 2022	Nov DISC
	AB		200MG	A212719	002	Aug 08, 2022	Jul NEWA
>D>	AB		300MG	A212719	003	Aug 08, 2022	Nov DISC
>A>		@	300MG	A212719	003	Aug 08, 2022	Nov DISC
	AB		300MG	A212719	003	Aug 08, 2022	Jul NEWA

LACOSAMIDE

SOLUTION;INTRAVENOUS
LACOSAMIDE

	AP	ASPIRO	200MG/20ML (10MG/ML)	A216335	001	Sep 14, 2022	Sep NEWA
	AP	FRESENIUS KABI USA	200MG/20ML (10MG/ML)	A214677	001	May 03, 2022	Apr NEWA
	AP	GLAND PHARMA LTD	200MG/20ML (10MG/ML)	A215628	001	Sep 19, 2022	Sep NEWA
	AP	INDOCO	200MG/20ML (10MG/ML)	A214301	001	Apr 07, 2022	Apr NFTG
	AP	ZYDUS PHARMS	200MG/20ML (10MG/ML)	A209465	001	Jun 29, 2022	Jun NEWA
		VIMPAT					
	AP	+! UCB INC	200MG/20ML (10MG/ML)	N022254	001	Oct 28, 2008	Apr CFTG

SOLUTION;ORAL
LACOSAMIDE

	AA	ALKEM LABS LTD	10MG/ML	A214672	001	May 19, 2022	May NFTG
	AA	APOTEX	10MG/ML	A206355	001	Sep 26, 2022	Sep NEWA
	AA	HETERO LABS LTD III	10MG/ML	A209301	001	May 31, 2022	May NEWA
	AA	NOVITIUM PHARMA	10MG/ML	A216151	001	Aug 26, 2022	Aug NEWA
		VIMPAT					
	AA	+! UCB INC	10MG/ML	N022255	001	Apr 20, 2010	May CFTG

TABLET;ORAL
LACOSAMIDE

	AB	ACCORD HLTHCARE	50MG	A205011	001	Jul 12, 2022	Jul NEWA
	AB		100MG	A205011	002	Jul 12, 2022	Jul NEWA
	AB		150MG	A205011	003	Jul 12, 2022	Jul NEWA
	AB		200MG	A205011	004	Jul 12, 2022	Jul NEWA
	AB	ALEMBIC PHARMS LTD	50MG	A204974	001	Mar 17, 2022	Mar NFTG
	AB		100MG	A204974	002	Mar 17, 2022	Mar NFTG
	AB		150MG	A204974	003	Mar 17, 2022	Mar NFTG
	AB		200MG	A204974	004	Mar 17, 2022	Mar NFTG
	AB	ALKEM LABS LTD	50MG	A214695	001	Mar 31, 2022	Mar NEWA
	AB		100MG	A214695	002	Mar 31, 2022	Mar NEWA
	AB		150MG	A214695	003	Mar 31, 2022	Mar NEWA
	AB		200MG	A214695	004	Mar 31, 2022	Mar NEWA
	AB	AMNEAL PHARMS	50MG	A204857	001	Mar 17, 2022	Mar NFTG
	AB		100MG	A204857	002	Mar 17, 2022	Mar NFTG
	AB		150MG	A204857	003	Mar 17, 2022	Mar NFTG
	AB		200MG	A204857	004	Mar 17, 2022	Mar NFTG
	AB	APOTEX	50MG	A214567	001	Sep 23, 2022	Sep NEWA
	AB		100MG	A214567	002	Sep 23, 2022	Sep NEWA
	AB		150MG	A214567	003	Sep 23, 2022	Sep NEWA
	AB		200MG	A214567	004	Sep 23, 2022	Sep NEWA
	AB	GLENMARK PHARMS LTD	50MG	A205006	001	Mar 17, 2022	Mar NFTG
	AB		100MG	A205006	002	Mar 17, 2022	Mar NFTG
	AB		150MG	A205006	003	Mar 17, 2022	Mar NFTG
	AB		200MG	A205006	004	Mar 17, 2022	Mar NFTG
	AB	HETERO LABS LTD V	50MG	A204787	001	Mar 17, 2022	Mar NFTG
	AB		100MG	A204787	002	Mar 17, 2022	Mar NFTG
	AB		150MG	A204787	003	Mar 17, 2022	Mar NFTG
	AB		200MG	A204787	004	Mar 17, 2022	Mar NFTG
	AB	INDOCO	50MG	A208308	001	Mar 17, 2022	Mar NFTG
	AB		100MG	A208308	002	Mar 17, 2022	Mar NFTG
	AB		150MG	A208308	003	Mar 17, 2022	Mar NFTG
	AB		200MG	A208308	004	Mar 17, 2022	Mar NFTG
	AB	MSN LABS PVT LTD	50MG	A204921	001	Mar 17, 2022	Mar NFTG
	AB		100MG	A204921	002	Mar 17, 2022	Mar NFTG
	AB		150MG	A204921	003	Mar 17, 2022	Mar NFTG
	AB		200MG	A204921	004	Mar 17, 2022	Mar NFTG
	AB	SCIEGEN PHARMS INC	50MG	A205237	001	Mar 17, 2022	Mar NFTG
	AB		100MG	A205237	002	Mar 17, 2022	Mar NFTG
	AB		150MG	A205237	003	Mar 17, 2022	Mar NFTG
	AB		200MG	A205237	004	Mar 17, 2022	Mar NFTG
	AB	SUN PHARM	50MG	A205031	001	Mar 17, 2022	Mar NFTG

```
          TABLET;ORAL
            LACOSAMIDE
    AB                            100MG                           A205031  002  Mar 17, 2022   Mar NFTG
    AB                            150MG                           A205031  003  Mar 17, 2022   Mar NFTG
    AB                            200MG                           A205031  004  Mar 17, 2022   Mar NFTG
            VIMPAT
    AB   +   UCB INC              50MG                            N022253  001  Oct 28, 2008   Mar CFTG
    AB   +                        100MG                           N022253  002  Oct 28, 2008   Mar CFTG
    AB   +                        150MG                           N022253  003  Oct 28, 2008   Mar CFTG
    AB   +!                       200MG                           N022253  004  Oct 28, 2008   Mar CFTG

        LACTULOSE
          SOLUTION;ORAL
            LACTULOSE
            @ TORRENT             10GM/15ML                       A207786  001  Jun 11, 2018   Jun DISC
>D> AA        XTTRIUM LABS INC    10GM/15ML                       A075911  001  Feb 21, 2002   Nov DISC
>A>         @                     10GM/15ML                       A075911  001  Feb 21, 2002   Nov DISC
          SOLUTION;ORAL, RECTAL
            LACTULOSE
            @ TORRENT             10GM/15ML                       A203762  001  Mar 27, 2015   Jun DISC

        LAMIVUDINE
          TABLET;ORAL
            LAMIVUDINE
    AB        UPSHER SMITH LABS   150MG                           A206974  001  Nov 21, 2016   Sep CAHN
    AB                            300MG                           A206974  002  Nov 21, 2016   Sep CAHN

        LAMIVUDINE; ZIDOVUDINE
          TABLET;ORAL
            LAMIVUDINE AND ZIDOVUDINE
            @ CHARTWELL RX        150MG;300MG                     A079081  001  May 25, 2011   Mar CAHN

        LAMOTRIGINE
          TABLET, EXTENDED RELEASE;ORAL
            LAMOTRIGINE
>D> AB        ATLANTIDE           25MG                            A202498  001  Jan 04, 2013   Nov CAHN
>D> AB                            50MG                            A202498  002  Jan 04, 2013   Nov CAHN
>D> AB                            100MG                           A202498  003  Jan 04, 2013   Nov CAHN
>D> AB                            200MG                           A202498  004  Jan 04, 2013   Nov CAHN
>D> AB                            300MG                           A202498  005  Jan 04, 2013   Nov CAHN
            @ TORRENT             200MG                           A203370  004  Dec 23, 2013   Aug DISC
>A> AB        WOCKHARDT BIO AG    25MG                            A202498  001  Jan 04, 2013   Nov CAHN
>A> AB                            50MG                            A202498  002  Jan 04, 2013   Nov CAHN
>A> AB                            100MG                           A202498  003  Jan 04, 2013   Nov CAHN
>A> AB                            200MG                           A202498  004  Jan 04, 2013   Nov CAHN
>A> AB                            300MG                           A202498  005  Jan 04, 2013   Nov CAHN
          TABLET, FOR SUSPENSION;ORAL
            LAMICTAL CD
    AB   +   GLAXOSMITHKLINE LLC  2MG                             N020764  004  Sep 08, 2000   Jan CDFR
    AB   +                        5MG                             N020764  001  Aug 24, 1998   Jan CDFR
    AB   +!                       25MG                            N020764  002  Aug 24, 1998   Jan CDFR
            @                     100MG                           N020764  003  Aug 24, 1998   Jan CDFR
            LAMOTRIGINE
    AB        ALEMBIC PHARMS LTD  5MG                             A201168  001  Jun 12, 2014   Jan CDFR
    AB                            25MG                            A201168  002  Jun 12, 2014   Jan CDFR
    AB        AUROBINDO PHARMA    5MG                             A090401  002  Nov 04, 2009   Jan CDFR
    AB                            25MG                            A090401  003  Nov 04, 2009   Jan CDFR
    AB        DR REDDYS LABS LTD  5MG                             A076701  001  Jan 22, 2009   Jan CDFR
    AB                            25MG                            A076701  002  Jan 22, 2009   Jan CDFR
    AB        GLENMARK PHARMS LTD 5MG                             A079099  001  Feb 19, 2009   Jan CDFR
    AB                            25MG                            A079099  002  Feb 19, 2009   Jan CDFR
            @ JUBILANT GENERICS   5MG                             A200220  001  Feb 28, 2011   Jan CDFR
            @                     25MG                            A200220  002  Feb 28, 2011   Jan CDFR
            @ MYLAN               5MG                             A076630  001  Jan 22, 2009   Jan CDFR
            @                     25MG                            A076630  002  Jan 22, 2009   Jan CDFR
            @ SANDOZ              5MG                             A078409  002  Jan 22, 2009   Jan CDFR
            @                     25MG                            A078409  003  Jan 22, 2009   Jan CDFR
    AB        TARO                5MG                             A079204  001  Feb 04, 2009   Jan CDFR
    AB                            25MG                            A079204  002  Feb 04, 2009   Jan CDFR
            @ TEVA                5MG                             A076420  001  Jun 21, 2006   Jan CDFR
            @                     25MG                            A076420  002  Jun 21, 2006   Jan CDFR
    AB        WATSON LABS         2MG                             A076928  001  Jan 22, 2009   Jan CDFR
```

TABLET, FOR SUSPENSION;ORAL
LAMOTRIGINE

AB		5MG	A076928	002	Jan 22, 2009	Jan CDFR
AB		25MG	A076928	003	Jan 22, 2009	Jan CDFR
AB	ZYDUS PHARMS USA INC	5MG	A078009	002	Jan 22, 2009	Jan CDFR
AB		25MG	A078009	003	Jan 22, 2009	Jan CDFR

TABLET, ORALLY DISINTEGRATING;ORAL
LAMOTRIGINE

AB	AMRING PHARMS	25MG	A214124	001	Feb 03, 2022	Jan NEWA
AB		50MG	A214124	002	Feb 03, 2022	Jan NEWA
AB		100MG	A214124	003	Feb 03, 2022	Jan NEWA
AB		200MG	A214124	004	Feb 03, 2022	Jan NEWA
	@ IMPAX LABS INC	25MG	A200828	001	Jul 15, 2013	Jun DISC
	@	50MG	A200828	002	Jul 15, 2013	Jun DISC
	@	100MG	A200828	003	Jul 15, 2013	Jun DISC
	@	200MG	A200828	004	Jul 15, 2013	Jun DISC

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL
LANTHANUM CARBONATE

AB	BARR	EQ 500MG BASE	A090977	001	Jan 27, 2022	Jan NEWA
AB		EQ 750MG BASE	A090977	002	Jan 27, 2022	Jan NEWA
AB		EQ 1GM BASE	A090977	003	Jan 27, 2022	Jan NEWA
AB	INVAGEN PHARMS	EQ 500MG BASE	A206868	001	Jan 24, 2022	Jan NEWA
AB		EQ 750MG BASE	A206868	002	Jan 24, 2022	Jan NEWA
AB		EQ 1GM BASE	A206868	003	Jan 24, 2022	Jan NEWA

LEFLUNOMIDE

TABLET;ORAL
LEFLUNOMIDE

AB	AET PHARMA	10MG	A213497	001	May 10, 2021	Jan CMFD
AB		20MG	A213497	002	May 10, 2021	Jan CMFD
AB	WANBANG BIOPHARMS	10MG	A077087	001	Sep 13, 2005	Jun CAHN
AB		20MG	A077087	002	Sep 13, 2005	Jun CAHN

LENALIDOMIDE

CAPSULE;ORAL
LENALIDOMIDE

AB	APOTEX	5MG	A211022	001	Aug 30, 2022	Aug NEWA
AB		10MG	A211022	002	Aug 30, 2022	Aug NEWA
AB		15MG	A211022	003	Aug 30, 2022	Aug NEWA
AB		25MG	A211022	004	Aug 30, 2022	Aug NEWA
AB	CIPLA	5MG	A210435	001	Sep 06, 2022	Aug NEWA
AB		10MG	A210435	002	Sep 06, 2022	Aug NEWA
AB		15MG	A210435	003	Sep 06, 2022	Aug NEWA
AB		25MG	A210435	004	Sep 06, 2022	Aug NEWA
AB	DR REDDYS	5MG	A209348	003	Aug 30, 2022	Aug NEWA
AB		10MG	A209348	004	Aug 30, 2022	Aug NEWA
AB		15MG	A209348	005	Aug 30, 2022	Aug NEWA
AB		25MG	A209348	006	Aug 30, 2022	Aug NEWA
AB	LOTUS PHARM CO LTD	5MG	A210480	001	Aug 31, 2022	Aug NEWA
AB		10MG	A210480	002	Aug 31, 2022	Aug NEWA
AB		15MG	A210480	003	Aug 31, 2022	Aug NEWA
AB		25MG	A210480	004	Aug 31, 2022	Aug NEWA
AB	MYLAN	5MG	A213912	001	Aug 30, 2022	Aug NEWA
AB		5MG	A213912	001	Aug 30, 2022	Aug CAHN
AB		5MG	A213912	001	Aug 30, 2022	Aug NEWA
AB		10MG	A213912	002	Aug 30, 2022	Aug NEWA
AB		15MG	A213912	003	Aug 30, 2022	Aug NEWA
AB		25MG	A213912	004	Aug 30, 2022	Aug NEWA
AB	ZYDUS PHARMS	5MG	A210154	001	Sep 12, 2022	Sep NEWA
AB		10MG	A210154	002	Sep 12, 2022	Sep NEWA
AB		15MG	A210154	003	Sep 12, 2022	Sep NEWA
AB		25MG	A210154	004	Sep 12, 2022	Sep NEWA

LETROZOLE

TABLET;ORAL
LETROZOLE

	@ INDICUS PHARMA	2.5MG	A201804	001	Jun 03, 2011	Sep DISC

LEUPROLIDE ACETATE

FOR SUSPENSION;INTRAMUSCULAR

LUTRATE DEPOT KIT

	+!	GP-PHARM SA	22.5MG/VIAL	N205054	001	Aug 28, 2018	May CMFD
	+!	INVAGEN PHARMS	22.5MG/VIAL	N205054	001	Aug 28, 2018	Jun CAHN

INJECTABLE;INJECTION

LEUPROLIDE ACETATE

AP		AMNEAL	1MG/0.2ML	A215336	001	Oct 28, 2022	Oct NEWA
AP		EUGIA PHARMA	1MG/0.2ML	A212963	001	Jun 06, 2022	May NEWA

LEUPROLIDE MESYLATE

EMULSION;SUBCUTANEOUS

CAMCEVI KIT

	+!	ACCORD	EQ 42MG BASE	N211488	001	May 25, 2021	Jan CAHN

LEVALBUTEROL TARTRATE

AEROSOL, METERED;INHALATION

XOPENEX HFA

>A>	+!	LUPIN	EQ 0.045MG BASE/INH	N021730	001	Mar 11, 2005	Nov CAHN
>D>	+!	SUNOVION	EQ 0.045MG BASE/INH	N021730	001	Mar 11, 2005	Nov CAHN

LEVETIRACETAM

INJECTABLE;INTRAVENOUS

LEVETIRACETAM

	AP	AUSEIC PHARMS	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Sep CAHN
	AP	BEOWULF ASSET	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Sep CAHN
>A>	AP	MSN	500MG/5ML (100MG/ML)	A215980	001	Nov 15, 2022	Nov NEWA
	AP	PRINSTON INC	500MG/5ML (100MG/ML)	A209474	001	Mar 28, 2022	Mar NEWA

SOLUTION;ORAL

LEVETIRACETAM

	AA	AIPING PHARM INC	100MG/ML	A090079	001	Apr 11, 2012	Jun CAHN
	AA	BELCHER	100MG/ML	A090461	001	Sep 30, 2010	Jun CAHN
	AA	MSN	100MG/ML	A214757	001	Jul 15, 2022	Jul NEWA
		@ WOCKHARDT BIO AG	100MG/ML	A090028	001	Mar 03, 2010	Apr DISC

TABLET;ORAL

LEVETIRACETAM

	AB	ALKEM LABS LTD	250MG	A216375	001	May 27, 2022	May NEWA
	AB		500MG	A216375	002	May 27, 2022	May NEWA
	AB		750MG	A216375	003	May 27, 2022	May NEWA
	AB		1GM	A216375	004	May 27, 2022	May NEWA
	AB	MSN	250MG	A214815	001	Oct 07, 2022	Sep NEWA
	AB		500MG	A214815	002	Oct 07, 2022	Sep NEWA
	AB		750MG	A214815	003	Oct 07, 2022	Sep NEWA
	AB		1GM	A214815	004	Oct 07, 2022	Sep NEWA
	AB	SCIEGEN PHARMS INC	250MG	A215069	003	May 27, 2022	May NEWA
	AB		500MG	A215069	004	May 27, 2022	May NEWA
	AB		750MG	A215069	001	Jun 11, 2021	Jun CMFD
	@		750MG	A215069	001	Jun 11, 2021	Apr DISC
	AB		1GM	A215069	002	Jun 11, 2021	Jun CMFD
	@		1GM	A215069	002	Jun 11, 2021	Apr DISC
	@	SECAN PHARMS	500MG	A205102	004	Dec 16, 2015	Jan DISC
	@		1GM	A205102	003	Dec 16, 2015	Jan DISC
	AB	STALLION LABS	250MG	A079042	001	Jan 15, 2009	Mar CAHN
	AB		500MG	A079042	002	Jan 15, 2009	Mar CAHN
	AB		750MG	A079042	003	Jan 15, 2009	Mar CAHN
	AB		1GM	A079042	004	Jan 15, 2009	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

	AB	AIPING PHARM INC	500MG	A204754	001	Aug 26, 2016	Aug CAHN
	AB		750MG	A204754	002	Aug 26, 2016	Aug CAHN
	@	ANDA REPOSITORY	500MG	A091291	001	Sep 12, 2011	Sep CAHN
	@		750MG	A091291	002	Sep 12, 2011	Sep CAHN
>A>	AB	DEXCEL	500MG	A202167	001	Sep 04, 2015	Nov CAHN
>A>	AB		750MG	A202167	002	Sep 04, 2015	Nov CAHN
>D>	AB	FLORIDA	500MG	A202167	001	Sep 04, 2015	Nov CAHN
>D>	AB		750MG	A202167	002	Sep 04, 2015	Nov CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA		CHARTWELL MOLECULAR	2.5MG/5ML	A204599	001	May 15, 2017	Jun CAHN

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

AP	!	AKORN	EQ 500MG/20ML (EQ 25MG/ML)	A091644	001	Jun 20, 2011	Jul CHRS
AP	!		EQ 750MG/30ML (EQ 25MG/ML)	A091644	002	Jun 20, 2011	Jul CHRS
	@	EUGIA PHARMA	EQ 500MG/20ML (EQ 25MG/ML)	A202328	001	Jan 24, 2013	Jul DISC
	@		EQ 750MG/30ML (EQ 25MG/ML)	A202328	002	Jan 24, 2013	Jul DISC

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

	@	EUGIA PHARMA	EQ 250MG/50ML (EQ 5MG/ML)	A206919	001	Feb 10, 2016	Jul DISC
	@		EQ 500MG/100ML (EQ 5MG/ML)	A206919	002	Feb 10, 2016	Jul DISC
	@		EQ 750MG/150ML (EQ 5MG/ML)	A206919	003	Feb 10, 2016	Jul DISC

TABLET;ORAL

LEVOFLOXACIN

AB		CHARTWELL MOLECULAR	250MG	A076890	001	Mar 30, 2012	Mar CAHN
AB			500MG	A076890	002	Mar 30, 2012	Mar CAHN
AB			750MG	A076890	003	Mar 30, 2012	Mar CAHN

LEVOLEUCOVORIN

POWDER;INTRAVENOUS

KHAPZORY

	+!	ACROTECH BIOPHARMA	175MG/VIAL	N211226	001	Oct 19, 2018	Jul CAHN
	+!		300MG/VIAL	N211226	002	Oct 19, 2018	Jul CAHN

LEVOLEUCOVORIN CALCIUM

POWDER;INTRAVENOUS

FUSILEV

AP	+!	ACROTECH BIOPHARMA	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Oct CAHN

LEVOLEUCOVORIN CALCIUM

	@	HIKMA	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016	Jul DISC

SOLUTION;INTRAVENOUS

FUSILEV

	+ @	ACROTECH BIOPHARMA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 29, 2011	Oct CAHN
	+ @		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 29, 2011	Oct CAHN

LEVOLEUCOVORIN CALCIUM

>D> AP	!	GLAND PHARMA LTD	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210892	001	Sep 14, 2018	Nov CHRS
>A> AP			EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210892	001	Sep 14, 2018	Nov CHRS
>D> AP	!		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210892	002	Sep 14, 2018	Nov CTEC
>A>	!		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210892	002	Sep 14, 2018	Nov CTEC
>D> AP		MEITHEAL	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A211002	001	Aug 16, 2019	Nov CHRS
>A> AP	!		EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A211002	001	Aug 16, 2019	Nov CHRS
>D> AP			EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A211002	002	Aug 16, 2019	Nov DISC
>A>	@		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A211002	002	Aug 16, 2019	Nov DISC
	@	PRAXGEN	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A213797	001	Nov 02, 2021	Feb DISC

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

	@	L PERRIGO CO	0.75MG	A090740	001	Dec 30, 2010	May DISC

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

LEVOTHYROXINE SODIUM

	@	TEVA PHARMS USA INC	0.112MG	A211369	003	Apr 16, 2021	Jan DISC
>A> AB			0.2MG	A211369	004	Nov 09, 2022	Nov CPOT

TIROSINT

	+	INSTITUT BIOCHIMIQUE	0.0375MG	N021924	014	Jun 22, 2022	Jun NEWA
	+		0.044MG	N021924	015	Jun 22, 2022	Jun NEWA

```
          CAPSULE;ORAL
            TIROSINT
          +                        0.0625MG                        N021924  016  Jun 22, 2022   Jun NEWA
          +                        0.112MG                         N021924  008  Oct 02, 2009   Jan CTEC
>D>       +!                       0.200MG                         N021924  012  Apr 25, 2017   Nov CPOT
>A> AB    +!                       0.2MG                           N021924  012  Apr 25, 2017   Nov CPOT
          SOLUTION;INTRAVENOUS
            LEVOTHYROXINE SODIUM
          +!  HIKMA                100MCG/ML                       N214253  001  May 17, 2021   Aug CAHN
          SOLUTION;ORAL
            ERMEZA
          +!  MYLAN                150MCG/5ML                      N215809  001  Apr 29, 2022   Apr NEWA
            THYQUIDITY
          +!  AZURITY              100MCG/5ML                      N214047  001  Nov 30, 2020   Jul CAHN
```

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

```
          TABLET;ORAL
            LEVOLET
    AB1,      GENUS LIFESCIENCES   0.025MG                         N021137  001  Jun 06, 2003   Aug CTEC
    AB2,
    AB3,
    AB4
    AB1,                           0.025MG                         N021137  001  Jun 06, 2003   Jan CMFD
    AB3,
    AB4
    AB1,                           0.05MG                          N021137  002  Jun 06, 2003   Aug CTEC
    AB2,
    AB3,
    AB4
    AB1,                           0.05MG                          N021137  002  Jun 06, 2003   Jan CMFD
    AB3,
    AB4
    AB1,                           0.075MG                         N021137  003  Jun 06, 2003   Aug CTEC
    AB2,
    AB3,
    AB4
    AB1,                           0.075MG                         N021137  003  Jun 06, 2003   Jan CMFD
    AB3,
    AB4
    AB1,                           0.088MG                         N021137  004  Jun 06, 2003   Aug CTEC
    AB2,
    AB3,
    AB4
    AB1,                           0.088MG                         N021137  004  Jun 06, 2003   Jan CMFD
    AB3,
    AB4
    AB1,                           0.1MG                           N021137  005  Jun 06, 2003   Aug CTEC
    AB2,
    AB3,
    AB4
    AB1,                           0.1MG                           N021137  005  Jun 06, 2003   Jan CMFD
    AB3,
    AB4
    AB1,                           0.112MG                         N021137  006  Jun 06, 2003   Aug CTEC
    AB2,
    AB3,
    AB4
    AB1,                           0.112MG                         N021137  006  Jun 06, 2003   Jan CMFD
    AB3,
    AB4
    AB1,                           0.125MG                         N021137  007  Jun 06, 2003   Aug CTEC
    AB2,
    AB3,
    AB4
    AB1,                           0.125MG                         N021137  007  Jun 06, 2003   Jan CMFD
    AB3,
    AB4
    AB1,                           0.137MG                         N021137  008  Jun 06, 2003   Aug CTEC
    AB2,
    AB3,
    AB4
    AB1,                           0.137MG                         N021137  008  Jun 06, 2003   Jan CMFD
    AB3,
    AB4
    AB1,                           0.15MG                          N021137  009  Jun 06, 2003   Aug CTEC
    AB2,
    AB3,
    AB4
```

TABLET;ORAL

LEVOLET

	AB1, AB3, AB4	0.15MG	N021137	009	Jun 06, 2003	Jan CMFD
	AB1, AB2, AB3, AB4	0.175MG	N021137	010	Jun 06, 2003	Aug CTEC
	AB1, AB3, AB4	0.175MG	N021137	010	Jun 06, 2003	Jan CMFD
	AB1, AB2, AB3, AB4	0.2MG	N021137	011	Jun 06, 2003	Aug CTEC
	AB1, AB3, AB4	0.2MG	N021137	011	Jun 06, 2003	Jan CMFD
	AB1, AB2, AB3, AB4	0.3MG	N021137	012	Jun 06, 2003	Aug CTEC
	AB1, AB3, AB4	0.3MG	N021137	012	Jun 06, 2003	Jan CMFD

LEVOTHYROXINE SODIUM

>D>	AB2, AB3, AB4	ACCORD HLTHCARE	0.025MG	A212399	001	Oct 19, 2020	Nov CTEC
>A>	AB1, AB2, AB3, AB4		0.025MG	A212399	001	Oct 19, 2020	Nov CTEC
	AB2, AB3, AB4		0.025MG	A212399	001	Oct 19, 2020	Sep CTEC
>D>	AB2, AB3, AB4		0.05MG	A212399	002	Oct 19, 2020	Nov CTEC
>A>	AB1, AB2, AB3, AB4		0.05MG	A212399	002	Oct 19, 2020	Nov CTEC
	AB2, AB3, AB4		0.05MG	A212399	002	Oct 19, 2020	Sep CTEC
>D>	AB2, AB3, AB4		0.075MG	A212399	003	Oct 19, 2020	Nov CTEC
>A>	AB1, AB2, AB3, AB4		0.075MG	A212399	003	Oct 19, 2020	Nov CTEC
	AB2, AB3, AB4		0.075MG	A212399	003	Oct 19, 2020	Sep CTEC
>D>	AB2, AB3, AB4		0.088MG	A212399	004	Oct 19, 2020	Nov CTEC
>A>	AB1, AB2, AB3, AB4		0.088MG	A212399	004	Oct 19, 2020	Nov CTEC
	AB2, AB3, AB4		0.088MG	A212399	004	Oct 19, 2020	Sep CTEC
>D>	AB2, AB3, AB4		0.1MG	A212399	005	Oct 19, 2020	Nov CTEC
>A>	AB1, AB2, AB3, AB4		0.1MG	A212399	005	Oct 19, 2020	Nov CTEC
	AB2, AB3, AB4		0.1MG	A212399	005	Oct 19, 2020	Sep CTEC
>D>	AB2, AB3, AB4		0.112MG	A212399	006	Oct 19, 2020	Nov CTEC
>A>	AB1, AB2,		0.112MG	A212399	006	Oct 19, 2020	Nov CTEC

TABLET;ORAL
LEVOTHYROXINE SODIUM

	AB3,							
	AB4							
	AB2,		0.112MG		A212399	006	Oct 19, 2020	Sep CTEC
	AB3,							
	AB4							
>D>	AB2,		0.125MG		A212399	007	Oct 19, 2020	Nov CTEC
	AB3,							
	AB4							
>A>	AB1,		0.125MG		A212399	007	Oct 19, 2020	Nov CTEC
	AB2,							
	AB3,							
	AB4							
	AB2,		0.125MG		A212399	007	Oct 19, 2020	Sep CTEC
	AB3,							
	AB4							
>D>	AB2,		0.137MG		A212399	008	Oct 19, 2020	Nov CTEC
	AB3,							
	AB4							
>A>	AB1,		0.137MG		A212399	008	Oct 19, 2020	Nov CTEC
	AB2,							
	AB3,							
	AB4							
	AB2,		0.137MG		A212399	008	Oct 19, 2020	Sep CTEC
	AB3,							
	AB4							
>D>	AB2,		0.15MG		A212399	009	Oct 19, 2020	Nov CTEC
	AB3,							
	AB4							
>A>	AB1,		0.15MG		A212399	009	Oct 19, 2020	Nov CTEC
	AB2,							
	AB3,							
	AB4							
	AB2,		0.15MG		A212399	009	Oct 19, 2020	Sep CTEC
	AB3,							
	AB4							
>D>	AB2,		0.175MG		A212399	010	Oct 19, 2020	Nov CTEC
	AB3,							
	AB4							
>A>	AB1,		0.175MG		A212399	010	Oct 19, 2020	Nov CTEC
	AB2,							
	AB3,							
	AB4							
	AB2,		0.175MG		A212399	010	Oct 19, 2020	Sep CTEC
	AB3,							
	AB4							
>D>	AB2,		0.2MG		A212399	011	Oct 19, 2020	Nov CTEC
	AB3,							
	AB4							
>A>	AB1,		0.2MG		A212399	011	Oct 19, 2020	Nov CTEC
	AB2,							
	AB3,							
	AB4							
	AB2,		0.2MG		A212399	011	Oct 19, 2020	Sep CTEC
	AB3,							
	AB4							
>D>	AB2,		0.3MG		A212399	012	Oct 19, 2020	Nov CTEC
	AB3,							
	AB4							
>A>	AB1,		0.3MG		A212399	012	Oct 19, 2020	Nov CTEC
	AB2,							
	AB3,							
	AB4							
	AB2,		0.3MG		A212399	012	Oct 19, 2020	Sep CTEC
	AB3,							
	AB4							
	AB2	WATSON LABS TEVA	0.025MG		A207588	001	May 10, 2022	Sep CTEC
	AB1,		0.025MG		A207588	001	May 10, 2022	Apr NEWA
	AB2							
	AB2		0.05MG		A207588	002	May 10, 2022	Sep CTEC
	AB1,		0.05MG		A207588	002	May 10, 2022	Apr NEWA
	AB2							
	AB2		0.075MG		A207588	003	May 10, 2022	Sep CTEC
	AB1,		0.075MG		A207588	003	May 10, 2022	Apr NEWA
	AB2							
	AB2		0.088MG		A207588	004	May 10, 2022	Sep CTEC
	AB1,		0.088MG		A207588	004	May 10, 2022	Apr NEWA
	AB2							
	AB2		0.1MG		A207588	005	May 10, 2022	Sep CTEC
	AB1,		0.1MG		A207588	005	May 10, 2022	Apr NEWA

TABLET;ORAL

LEVOTHYROXINE SODIUM

AB2							
AB2		0.112MG	A207588	006	May 10, 2022	Sep CTEC	
AB1, AB2		0.112MG	A207588	006	May 10, 2022	Apr NEWA	
AB2		0.125MG	A207588	007	May 10, 2022	Sep CTEC	
AB1, AB2		0.125MG	A207588	007	May 10, 2022	Apr NEWA	
AB2		0.137MG	A207588	008	May 10, 2022	Sep CTEC	
AB1, AB2		0.137MG	A207588	008	May 10, 2022	Apr NEWA	
AB2		0.15MG	A207588	009	May 10, 2022	Sep CTEC	
AB1, AB2		0.15MG	A207588	009	May 10, 2022	Apr NEWA	
AB2		0.175MG	A207588	010	May 10, 2022	Sep CTEC	
AB1, AB2		0.175MG	A207588	010	May 10, 2022	Apr NEWA	
AB2		0.2MG	A207588	011	May 10, 2022	Sep CTEC	
AB1, AB2		0.2MG	A207588	011	May 10, 2022	Apr NEWA	
AB2		0.3MG	A207588	012	May 10, 2022	Sep CTEC	
AB1, AB2		0.3MG	A207588	012	May 10, 2022	Apr NEWA	
THYRO-TABS							
AB1, AB2, AB3, AB4	+ ALVOGEN	0.025MG	N021116	001	Oct 24, 2002	Apr CTEC	
AB1, AB2, AB3, AB4	+	0.05MG	N021116	002	Oct 24, 2002	Apr CTEC	
AB1, AB2, AB3, AB4	+	0.075MG	N021116	003	Oct 24, 2002	Apr CTEC	
AB1, AB2, AB3, AB4	+	0.088MG	N021116	010	Oct 24, 2002	Apr CTEC	
AB1, AB2, AB3, AB4	+	0.1MG	N021116	004	Oct 24, 2002	Apr CTEC	
AB1, AB2, AB3, AB4	+	0.112MG	N021116	011	Oct 24, 2002	Apr CTEC	
AB1, AB2, AB3, AB4	+	0.125MG	N021116	005	Oct 24, 2002	Apr CTEC	
AB1, AB2, AB3, AB4	+	0.137MG	N021116	012	Dec 07, 2004	Apr CTEC	
AB1, AB2, AB3, AB4	+	0.15MG	N021116	006	Oct 24, 2002	Apr CTEC	
AB1, AB2, AB3, AB4	+	0.175MG	N021116	007	Oct 24, 2002	Apr CTEC	
AB1, AB2, AB3, AB4	+	0.2MG	N021116	008	Oct 24, 2002	Apr CTEC	
AB1, AB2, AB3, AB4	+	0.3MG	N021116	009	Oct 24, 2002	Apr CTEC	

LIDOCAINE HYDROCHLORIDE

		GEL;OPHTHALMIC					
		AKTEN					
	+!	THEA PHARMA	3.5%	N022221	001	Oct 07, 2008	Apr CAHN
		INJECTABLE;INJECTION					
		LIDOCAINE HYDROCHLORIDE					
AP		AFAXYS	1%	A215132	001	Jun 09, 2022	Jun NEWA
>D> AP		SINTETICA SA	1%	A214267	001	Sep 19, 2022	Nov CAHN
AP			1%	A214267	001	Sep 19, 2022	Sep NEWA
>D> AP			2%	A214267	002	Sep 19, 2022	Nov CAHN
AP			2%	A214267	002	Sep 19, 2022	Sep NEWA
>D> AP			4%	A214269	001	May 05, 2022	Nov CAHN
AP			4%	A214269	001	May 05, 2022	Apr NEWA
>A> AP		SINTETICA US	1%	A214267	001	Sep 19, 2022	Nov CAHN
>A> AP			2%	A214267	002	Sep 19, 2022	Nov CAHN
>A> AP			4%	A214269	001	May 05, 2022	Nov CAHN
		LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE					
AP	!	HOSPIRA	4%	A088295	001	May 17, 1984	Apr CTEC
		INJECTABLE;SPINAL					
		LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%					
	+!	HOSPIRA	5%	A083914	001		Jul CRLD
		SOLUTION;TOPICAL					
		LIDOCAINE HYDROCHLORIDE					
AT		NOVITIUM PHARMA	4%	A216250	001	Mar 23, 2022	Mar NEWA

LIDOCAINE; PRILOCAINE

		CREAM;TOPICAL					
		EMLA					
	+ @	TEVA BRANDED PHARM	2.5%;2.5%	N019941	001	Dec 30, 1992	Jul DISC
		LIDOCAINE AND PRILOCAINE					
	@	ACRUX DDS PTY	2.5%;2.5%	A212482	001	Jul 27, 2021	Jan DISC
AB	!	AKORN	2.5%;2.5%	A076290	001	Sep 25, 2003	Jul CHRS
AB		ALEOR DERMACEUTICALS	2.5%;2.5%	A213923	001	Apr 08, 2022	Apr NEWA
>D>	@	PADAGIS US	2.5%;2.5%	A212482	001	Jul 27, 2021	Nov CMFD
>A> AB			2.5%;2.5%	A212482	001	Jul 27, 2021	Nov CMFD
	@		2.5%;2.5%	A212482	001	Jul 27, 2021	Jun CAHN

LIDOCAINE; TETRACAINE

		PATCH;TOPICAL					
		SYNERA					
	+ @	GALEN SPECIALTY	70MG;70MG	N021623	001	Jun 23, 2005	Sep DISC

LINCOMYCIN

		INJECTABLE;INJECTION					
>D>		LINCOMYCIN					
>D> AP		MICRO LABS	EQ 300MG BASE/ML	A215082	001	Nov 08, 2021	Nov CTNA

LINCOMYCIN HYDROCHLORIDE

		INJECTABLE;INJECTION					
>D>		LINCOMYCIN					
>D> AP		XGEN PHARMS	EQ 300MG BASE/ML	A201746	001	Jun 04, 2015	Nov CTNA
		LINCOMYCIN HYDROCHLORIDE					
	@	ATHENEX INC	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	Sep CAHN
AP		GLAND PHARMA LTD	EQ 300MG BASE/ML	A215657	001	Sep 26, 2022	Sep NEWA
>A> AP		MICRO LABS	EQ 300MG BASE/ML	A215082	001	Nov 08, 2021	Nov CTNA
>A> AP		XGEN PHARMS	EQ 300MG BASE/ML	A201746	001	Jun 04, 2015	Nov CTNA

LINDANE

		SHAMPOO;TOPICAL					
		LINDANE					
	@	WOCKHARDT BIO AG	1%	A088191	001	Sep 18, 1984	Jul DISC

LINEZOLID

		FOR SUSPENSION;ORAL					
		LINEZOLID					
AB		HETERO LABS	100MG/5ML	A211813	001	Oct 31, 2022	Oct NEWA
		SOLUTION;INTRAVENOUS					
		LINEZOLID					
AP		HIKMA	600MG/300ML (2MG/ML)	A206454	001	Aug 22, 2022	Aug NEWA
	@	HOSPIRA	600MG/300ML (2MG/ML)	A205442	001	Jul 07, 2015	May DISC

```
          TABLET;ORAL
            LINEZOLID
            @ AMNEAL PHARMS          600MG                              A204536  001  Dec 21, 2015   Jul DISC

        LISINOPRIL
          TABLET;ORAL
            LISINOPRIL
>D> AB        ATLANTIDE              2.5MG                              A078402  001  Apr 19, 2007   Nov CAHN
>D> AB                               5MG                                A078402  002  Apr 19, 2007   Nov CAHN
>D> AB                               10MG                               A078402  003  Apr 19, 2007   Nov CAHN
>D> AB                               20MG                               A078402  004  Apr 19, 2007   Nov CAHN
>D> AB                               30MG                               A078402  005  Apr 19, 2007   Nov CAHN
>D> AB                               40MG                               A078402  006  Apr 19, 2007   Nov CAHN
            @ GRAVITI PHARMS         2.5MG                              A075999  001  Jul 01, 2002   Apr CAHN
            @                        5MG                                A075999  002  Jul 01, 2002   Apr CAHN
            @                        10MG                               A075999  003  Jul 01, 2002   Apr CAHN
            @                        20MG                               A075999  004  Jul 01, 2002   Apr CAHN
            @                        30MG                               A075999  005  Jul 01, 2002   Apr CAHN
            @                        40MG                               A075999  006  Jul 01, 2002   Apr CAHN
            @ STRIDES PHARMA         2.5MG                              A076071  001  Jul 01, 2002   Jan CAHN
            @                        5MG                                A076071  002  Jul 01, 2002   Jan CAHN
            @                        10MG                               A076071  003  Jul 01, 2002   Jan CAHN
            @                        20MG                               A076071  004  Jul 01, 2002   Jan CAHN
            @                        30MG                               A076071  005  Jul 01, 2002   Jan CAHN
            @                        40MG                               A076071  006  Jul 01, 2002   Jan CAHN
>A> AB        WOCKHARDT BIO AG       2.5MG                              A078402  001  Apr 19, 2007   Nov CAHN
>A> AB                               5MG                                A078402  002  Apr 19, 2007   Nov CAHN
>A> AB                               10MG                               A078402  003  Apr 19, 2007   Nov CAHN
>A> AB                               20MG                               A078402  004  Apr 19, 2007   Nov CAHN
>A> AB                               30MG                               A078402  005  Apr 19, 2007   Nov CAHN
>A> AB                               40MG                               A078402  006  Apr 19, 2007   Nov CAHN

        LITHIUM CITRATE
          SYRUP;ORAL
            LITHIUM CITRATE
          + @ HIKMA                  EQ 300MG CARBONATE/5ML             N018421  001                  Apr DISC
          !   PAI HOLDINGS PHARM     EQ 300MG CARBONATE/5ML             A070755  001  May 21, 1986   Apr CAHN
          !   WOCKHARDT BIO AG       EQ 300MG CARBONATE/5ML             A070755  001  May 21, 1986   Apr CTEC
    AA    !                          EQ 300MG CARBONATE/5ML             A070755  001  May 21, 1986   Apr CHRS

        LOPERAMIDE HYDROCHLORIDE
          CAPSULE;ORAL
            LOPERAMIDE HYDROCHLORIDE
            @ CHARTWELL RX           2MG                                A072993  001  Aug 28, 1992   Mar CAHN

        LOPINAVIR; RITONAVIR
          TABLET;ORAL
            LOPINAVIR AND RITONAVIR
    AB        LAURUS                 100MG;25MG                         A213857  001  Mar 21, 2022   Mar NEWA
    AB                               200MG;50MG                         A213857  002  Mar 21, 2022   Mar NEWA

        LORAZEPAM
          CAPSULE, EXTENDED RELEASE;ORAL
            LOREEV XR
          +   ALMATICA               1.5MG                              N214826  004  Feb 16, 2022   Feb NEWA
          TABLET;ORAL
            LORAZEPAM
>D>         @ MYLAN                  0.5MG                              A071591  002  Oct 13, 1987   Nov CAHN
>D>         @                        1MG                                A071591  003  Oct 13, 1987   Nov CAHN
>D>         @                        2MG                                A071591  001  Oct 13, 1987   Nov CAHN
>A>         @ STRIDES PHARMA         0.5MG                              A071591  002  Oct 13, 1987   Nov CAHN
>A>         @                        1MG                                A071591  003  Oct 13, 1987   Nov CAHN
>A>         @                        2MG                                A071591  001  Oct 13, 1987   Nov CAHN

        LOSARTAN POTASSIUM
          TABLET;ORAL
            LOSARTAN POTASSIUM
            @ HIKMA                  25MG                               A077459  001  Oct 06, 2010   Jul DISC
            @                        50MG                               A077459  002  Oct 06, 2010   Oct DISC
            @                        100MG                              A077459  003  Oct 06, 2010   Oct DISC
```

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS;OPHTHALMIC

EYSUVIS

	+!	ALCON LABS INC	0.25%	N210933	001	Oct 26, 2020	Aug CAHN

INVELTYS

	+!	ALCON LABS INC	1%	N210565	001	Aug 22, 2018	Aug CAHN

LOVASTATIN

TABLET;ORAL

LOVASTATIN

AB		CHARTWELL RX	10MG	A075300	001	Dec 17, 2001	Aug CAHN
AB			20MG	A075300	002	Dec 17, 2001	Aug CAHN
AB			40MG	A075300	003	Dec 17, 2001	Aug CAHN

LUBIPROSTONE

CAPSULE;ORAL

LUBIPROSTONE

		@ AMNEAL	8MCG	A209450	001	Nov 30, 2021	May DISC
		@	24MCG	A209450	002	Nov 30, 2021	May DISC
		@ ANCHEN PHARMS	8MCG	A201442	001	Jun 27, 2022	Oct DISC
AB			8MCG	A201442	001	Jun 27, 2022	Jun NEWA
		@	24MCG	A201442	002	Jun 27, 2022	Oct DISC
AB			24MCG	A201442	002	Jun 27, 2022	Jun NEWA
AB		DR REDDYS	8MCG	A206994	001	Feb 08, 2022	Jan NEWA
AB			24MCG	A206994	002	Feb 08, 2022	Jan NEWA
>D>		@ TEVA PHARMS USA INC	8MCG	A209920	001	Jan 18, 2022	Nov CMFD
>A>	AB		8MCG	A209920	001	Jan 18, 2022	Nov CMFD
		@	8MCG	A209920	001	Jan 18, 2022	Aug DISC
AB			8MCG	A209920	001	Jan 18, 2022	Jan NEWA
>D>		@	24MCG	A209920	002	Jan 18, 2022	Nov CMFD
>A>	AB		24MCG	A209920	002	Jan 18, 2022	Nov CMFD
		@	24MCG	A209920	002	Jan 18, 2022	Aug DISC
AB			24MCG	A209920	002	Jan 18, 2022	Jan NEWA

LUMATEPERONE TOSYLATE

CAPSULE;ORAL

CAPLYTA

	+	INTRA-CELLULAR	EQ 10.5MG BASE	N209500	002	Apr 22, 2022	May NEWA
	+		EQ 21MG BASE	N209500	003	Apr 22, 2022	May NEWA

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AB		INVAGEN PHARMS	20MG	A208028	001	Jan 03, 2019	Aug CMFD
AB			40MG	A208028	002	Jan 03, 2019	Aug CMFD
AB			60MG	A208028	003	Jan 03, 2019	Aug CMFD
AB			80MG	A208028	004	Jan 03, 2019	Aug CMFD
AB			120MG	A208028	005	Jan 03, 2019	Aug CMFD
AB		MSN	20MG	A208037	001	Sep 09, 2022	Sep NEWA
AB			40MG	A208037	002	Sep 09, 2022	Sep NEWA
AB			60MG	A208037	003	Sep 09, 2022	Sep NEWA
AB			80MG	A208037	004	Sep 09, 2022	Sep NEWA
AB			120MG	A208037	005	Sep 09, 2022	Sep NEWA

LUTETIUM LU 177 DOTATATE

SOLUTION;INTRAVENOUS

LUTATHERA

	+!	AAA USA INC	10mCi/ML	N208700	001	Jan 26, 2018	Jun CAIN

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

SOLUTION;INTRAVENOUS

PLUVICTO

	+!	AAA USA NOVARTIS	27mCi/ML	N215833	001	Mar 23, 2022	Mar NEWA

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE

AT	!	PAR FORM	5%	A201511	001	Feb 12, 2013	Feb CHRS
>D>		SULFAMYLON					
>D>	+ @	MYLAN INSTITUTIONAL	5%	N019832	003	Jun 05, 1998	Nov DISC
>A>	+ @		5%	N019832	003	Jun 05, 1998	Nov DISC

```
        FOR SOLUTION;TOPICAL
          SULFAMYLON
        + @                        5%                                N019832  003  Jun 05, 1998   Feb DISC

      MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
        INJECTABLE;INJECTION
          PLASMA-LYTE A IN PLASTIC CONTAINER
    AP    +!  BAXTER HLTHCARE        30MG/100ML;37MG/100ML;368MG/100ML;  N017378  002  Nov 22, 1982   May CFTG
                                     526MG/100ML;502MG/100ML

      MAGNESIUM SULFATE
        INJECTABLE;INJECTION
          MAGNESIUM SULFATE IN PLASTIC CONTAINER
          @ MILLA PHARMS           2GM/50ML (40MG/ML)                A209642  001  Nov 08, 2021   Jul DISC
    AP                             2GM/50ML (40MG/ML)                A209642  001  Nov 08, 2021   Jun CAHN
>D>         @                      4GM/100ML (40MG/ML)               A209642  002  Nov 08, 2021   Nov CMFD
>A> AP                             4GM/100ML (40MG/ML)               A209642  002  Nov 08, 2021   Nov CMFD
            @                      4GM/100ML (40MG/ML)               A209642  002  Nov 08, 2021   Jul DISC
    AP                             4GM/100ML (40MG/ML)               A209642  002  Nov 08, 2021   Jun CAHN
>D>         @                      4GM/50ML (80MG/ML)                A209642  003  Nov 08, 2021   Nov CMFD
>A> AP                             4GM/50ML (80MG/ML)                A209642  003  Nov 08, 2021   Nov CMFD
            @                      4GM/50ML (80MG/ML)                A209642  003  Nov 08, 2021   Jul DISC
    AP                             4GM/50ML (80MG/ML)                A209642  003  Nov 08, 2021   Jun CAHN

      MANNITOL
        SOLUTION;IRRIGATION
          RESECTISOL IN PLASTIC CONTAINER
          @ B BRAUN                5GM/100ML                         N016772  002                 Oct DISC

      MARAVIROC
        TABLET;ORAL
          MARAVIROC
    AB      HETERO LABS LTD III    150MG                             A203347  001  Feb 07, 2022   Jan NFTG
    AB                             300MG                             A203347  002  Feb 07, 2022   Jan NFTG
          SELZENTRY
    AB    +   VIIV HLTHCARE        150MG                             N022128  001  Aug 06, 2007   Jan CFTG
    AB    +!                       300MG                             N022128  002  Aug 06, 2007   Jan CFTG

      MAVACAMTEN
        CAPSULE;ORAL
          CAMZYOS
        +   BRISTOL                2.5MG                             N214998  001  Apr 28, 2022   Sep CAHN
        +                          5MG                               N214998  002  Apr 28, 2022   Sep CAHN
        +                          10MG                              N214998  003  Apr 28, 2022   Sep CAHN
        +!                         15MG                              N214998  004  Apr 28, 2022   Sep CAHN
        +   MYOKARDIA              2.5MG                             N214998  001  Apr 28, 2022   Apr NEWA
        +                          5MG                               N214998  002  Apr 28, 2022   Apr NEWA
        +                          10MG                              N214998  003  Apr 28, 2022   Apr NEWA
        +!                         15MG                              N214998  004  Apr 28, 2022   Apr NEWA

      MECLIZINE HYDROCHLORIDE
        TABLET;ORAL
          MECLIZINE HYDROCHLORIDE
    AA      APNAR PHARMA LP        12.5MG                            A087128  002                 Apr CAHN
    AA                             25MG                              A087128  001                 Apr CAHN
    AA      INVAGEN PHARMS         12.5MG                            A200432  001  Feb 17, 2022   Feb NEWA
    AA                             25MG                              A200432  002  Feb 17, 2022   Feb NEWA
    AA                             50MG                              A200432  003  Feb 17, 2022   Feb NEWA
    AA      LUPIN LTD              12.5MG                            A203003  001  Aug 11, 2022   Aug NEWA
    AA                             25MG                              A203003  002  Aug 11, 2022   Aug NEWA
    AA                             50MG                              A203003  003  Aug 11, 2022   Aug NEWA
        TABLET, CHEWABLE;ORAL
          MECLIZINE HYDROCHLORIDE
    AA      INVAGEN PHARMS         25MG                              A200791  001  Feb 17, 2022   Feb NEWA

      MEDROXYPROGESTERONE ACETATE
        INJECTABLE;INJECTION
          MEDROXYPROGESTERONE ACETATE
    AB      EUGIA PHARMA           150MG/ML                          A212824  001  Aug 22, 2022   Aug NEWA
    AB                             150MG/ML                          A212844  001  Aug 31, 2022   Aug NEWA
          @ SUN PHARM              150MG/ML                          A210760  001  May 01, 2019   Jul DISC
          @                        150MG/ML                          A210761  001  Apr 24, 2019   Jul DISC
```

MELOXICAM

CAPSULE;ORAL

VIVLODEX

	+ @	ICEUTICA OPERATIONS	5MG	N207233	001	Oct 22, 2015	Mar	CAHN
	+ @		10MG	N207233	002	Oct 22, 2015	Mar	CAHN

SUSPENSION;ORAL

MELOXICAM

	+!	AVONDALE PHARMS	7.5MG/5ML	N021530	001	Jun 01, 2004	May	CTNA
	+!		7.5MG/5ML	N021530	001	Jun 01, 2004	May	CMFD

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

MELPHALAN HYDROCHLORIDE

AP		ARTHUR GRP	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Sep	CAHN
AP		NANJING	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Sep	CMFD
	@		EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Apr	CAHN

POWDER;INTRAVENOUS

EVOMELA

	+!	ACROTECH BIOPHARMA	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Oct	CAHN

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

		@	ANCHEN PHARMS	7MG	A205784	001	Jun 09, 2017	Oct DISC
		@		14MG	A205784	002	Jun 09, 2017	Oct DISC
		@		21MG	A205784	003	Jun 09, 2017	Oct DISC
		@		28MG	A205784	004	Jun 09, 2017	Oct DISC
>D>	AB		ANI PHARMS	7MG	A205365	001	Feb 28, 2020	Nov DISC
>A>		@		7MG	A205365	001	Feb 28, 2020	Nov DISC
		@		14MG	A205365	002	Feb 28, 2020	Apr DISC
		@		21MG	A205365	003	Feb 28, 2020	Oct DISC
	AB		XIAMEN LP PHARM CO	7MG	A213985	001	Oct 11, 2022	Sep NEWA
	AB			14MG	A213985	002	Oct 11, 2022	Sep NEWA
	AB			28MG	A213985	003	Oct 11, 2022	Sep NEWA

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

	AA	!	CHARTWELL MOLECULAR	2MG/ML	A204033	001	Oct 13, 2015	Oct CAHN

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

	AB		ALLIED	5MG	A209527	001	May 07, 2018	Feb CAHN
	AB			10MG	A209527	002	May 07, 2018	Feb CAHN
>D>	AB		ESKAYEF	5MG	A209527	001	May 07, 2018	Nov CAHN
	AB			5MG	A209527	001	May 07, 2018	Aug CAHN
>D>	AB			10MG	A209527	002	May 07, 2018	Nov CAHN
	AB			10MG	A209527	002	May 07, 2018	Aug CAHN
	AB		HETERO LABS LTD V	5MG	A204389	001	Sep 26, 2022	Sep NEWA
	AB			10MG	A204389	002	Sep 26, 2022	Sep NEWA
>A>	AB		RENATA	5MG	A209527	001	May 07, 2018	Nov CAHN
	AB			5MG	A209527	001	May 07, 2018	Jul CAHN
>A>	AB			10MG	A209527	002	May 07, 2018	Nov CAHN
	AB			10MG	A209527	002	May 07, 2018	Jul CAHN
		@	RISING	5MG	A079225	001	Jan 30, 2015	Jan CAHN
		@		10MG	A079225	002	Jan 30, 2015	Jan CAHN

MEPERIDINE HYDROCHLORIDE

TABLET;ORAL

MEPERIDINE HYDROCHLORIDE

		@	ANDA REPOSITORY	50MG	A040893	001	Jun 24, 2009	Sep CAHN
		@		75MG	A040893	002	Jun 24, 2009	Sep CAHN
		@		100MG	A040893	003	Jun 24, 2009	Sep CAHN
		@		150MG	A040893	004	Jun 24, 2009	Sep CAHN
		@	GENUS	50MG	A040893	001	Jun 24, 2009	Apr CAHN
		@		75MG	A040893	002	Jun 24, 2009	Apr CAHN
		@		100MG	A040893	003	Jun 24, 2009	Apr CAHN
		@		150MG	A040893	004	Jun 24, 2009	Apr CAHN
		@	MIKART	50MG	A040893	001	Jun 24, 2009	Mar CAHN
		@		75MG	A040893	002	Jun 24, 2009	Mar CAHN
		@		100MG	A040893	003	Jun 24, 2009	Mar CAHN
		@		150MG	A040893	004	Jun 24, 2009	Mar CAHN

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERGAN

	@	HIKMA	25MG/ML;25MG/ML	N011730	001		Jul CAHN

MEROPENEM

INJECTABLE;INJECTION

MEROPENEM

AP		BROOKS STERISCIENCE	500MG/VIAL	A216154	001	Aug 18, 2022	Sep CAHN
AP			1GM/VIAL	A216154	002	Aug 18, 2022	Sep CAHN
AP		STERISCIENCE	500MG/VIAL	A216154	001	Aug 18, 2022	Aug NEWA
AP			1GM/VIAL	A216154	002	Aug 18, 2022	Aug NEWA

MESALAMINE

CAPSULE, EXTENDED RELEASE;ORAL

MESALAMINE

AB		ALEMBIC PHARMS LTD	375MG	A216967	001	Oct 28, 2022	Oct NEWA
AB		SUN PHARM	500MG	A214585	001	May 11, 2022	Apr NFTG
>D> AB		TEVA PHARMS USA	375MG	A209970	001	May 06, 2022	Nov DISC
>A>	@		375MG	A209970	001	May 06, 2022	Nov DISC
AB			375MG	A209970	001	May 06, 2022	Apr NEWA

PENTASA

AB	+!	TAKEDA PHARMS USA	500MG	N020049	002	Jul 08, 2004	Apr CFTG

SUPPOSITORY;RECTAL

MESALAMINE

	@	AMNEAL	1GM	A210509	001	Jan 02, 2020	Sep DISC

TABLET, DELAYED RELEASE;ORAL

ASACOL HD

	+ @	APIL	800MG	N021830	001	May 29, 2008	May DISC

MESALAMINE

	!	ZYDUS PHARMS	800MG	A203286	001	Jul 21, 2017	May CTEC
AB	!		800MG	A203286	001	Jul 21, 2017	May CHRS

METAPROTERENOL SULFATE

SYRUP;ORAL

METAPROTERENOL SULFATE

	!	ANDA REPOSITORY	10MG/5ML	A073632	001	Jul 22, 1992	Sep CAHN

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL

METFORMIN HYDROCHLORIDE

AB	!	SAPTALIS PHARMS	500MG/5ML	A211309	001	Mar 03, 2020	Oct CHRS
AB		VISTAPHARM	500MG/5ML	A212677	001	Aug 19, 2022	Aug NEWA

RIOMET

	+ @	RANBAXY	500MG/5ML	N021591	001	Sep 11, 2003	Oct DISC

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

AB1		AMNEAL PHARMS NY	500MG	A078596	001	Jan 03, 2008	Feb CTEC
AB			750MG	A078596	002	Jan 03, 2008	Feb CTEC
	@	AMTA	500MG	A213394	001	Aug 03, 2021	Jan DISC
	@		1GM	A213394	002	Aug 03, 2021	Jan DISC
AB3		PRINSTON INC	500MG	A212681	001	Jun 09, 2022	Jun NEWA
AB3			1GM	A212681	002	Jun 09, 2022	Jun NEWA
AB2		SCIEGEN PHARMS INC	500MG	A214629	001	Feb 22, 2022	Feb NEWA
AB2			1GM	A214629	002	Feb 22, 2022	Feb NEWA

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOPLUS MET

	+ @	TAKEDA PHARMS USA	500MG;EQ 15MG BASE	N021842	001	Aug 29, 2005	May DISC

METHADONE HYDROCHLORIDE

TABLET;ORAL

METHADONE HYDROCHLORIDE

	@	NOSTRUM LABS INC	5MG	A210484	001	Aug 02, 2018	Feb DISC
	@		10MG	A210484	002	Aug 02, 2018	Feb DISC

METHAMPHETAMINE HYDROCHLORIDE

		TABLET;ORAL					
		DESOXYN					
AA	+!	KEY THERAP	5MG	N005378	002		Aug CAHN
		TABLET, EXTENDED RELEASE;ORAL					
		DESOXYN					
	@	KEY THERAP	5MG	N005378	004		Aug CAHN
	@		10MG	N005378	003		Aug CAHN
	@		15MG	N005378	005		Aug CAHN

METHAZOLAMIDE

		TABLET;ORAL					
		METHAZOLAMIDE					
AB		BAUSCH AND LOMB INC	25MG	A207438	001	Oct 05, 2018	Apr CAHN
AB			50MG	A207438	002	Oct 05, 2018	Apr CAHN

METHENAMINE HIPPURATE

		TABLET;ORAL					
		HIPREX					
AB	+	VALIDUS PHARMS	1GM	N017681	001		Apr CMFD

METHIMAZOLE

		TABLET;ORAL					
		METHIMAZOLE					
AB		AIPING LIFE SCI	5MG	A040547	001	Feb 18, 2005	Oct CAHN
AB			10MG	A040547	002	Feb 18, 2005	Oct CAHN
	@		20MG	A040547	004	Feb 18, 2005	Oct CAHN

METHOCARBAMOL

		SOLUTION;IM-IV					
		METHOCARBAMOL					
AP		BAXTER HLTHCARE CORP	1GM/10ML (100MG/ML)	A215065	001	Jul 14, 2022	Jul NEWA
AP		HAINAN POLY	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Aug CAHN
>D> AP		MYLAN INSTITUTIONAL	1GM/10ML (100MG/ML)	A204404	001	Dec 05, 2014	Nov DISC
>A>	@		1GM/10ML (100MG/ML)	A204404	001	Dec 05, 2014	Nov DISC
		TABLET;ORAL					
		METHOCARBAMOL					
AA		ACME LABS	500MG	A203550	001	Feb 08, 2017	Sep CAHN
AA			750MG	A203550	002	Feb 08, 2017	Sep CAHN
	@	CHARTWELL MOLECULAR	500MG	A084756	002	Mar 31, 2003	Aug CAHN
	@		750MG	A084756	001		Aug CAHN
AA		PRINSTON INC	500MG	A086988	002		Oct CMS1

METHOTREXATE

>A>		SOLUTION;ORAL					
>A>		JYLAMVO					
>A>	+!	THERAKIND	2MG/ML	N212479	001	Nov 29, 2022	Nov NEWA
		SOLUTION;SUBCUTANEOUS					
		REDITREX					
	+ @	CUMBERLAND PHARMS	7.5MG/0.3ML (7.5MG/0.3ML)	N210737	001	Nov 27, 2019	Sep DISC
	+ @		10MG/0.4ML (10MG/0.4ML)	N210737	002	Nov 27, 2019	Sep DISC
	+ @		12.5MG/0.5ML (12.5MG/0.5ML)	N210737	003	Nov 27, 2019	Sep DISC
	+ @		17.5MG/0.7ML (17.5MG/0.7ML)	N210737	005	Nov 27, 2019	Sep DISC
	+ @		22.5MG/ML (22.5MG/ML)	N210737	007	Nov 27, 2019	Sep DISC

METHOTREXATE SODIUM

		INJECTABLE;INJECTION					
		METHOTREXATE LPF					
	+ @	HOSPIRA	EQ 25MG BASE/ML	N011719	007	Mar 31, 1982	Jan CRLD
		METHOTREXATE PRESERVATIVE FREE					
	+ @	HOSPIRA	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719	014	Apr 13, 2005	Jan CRLD
	+ @		EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719	011	Apr 13, 2005	Jan CRLD
		METHOTREXATE SODIUM					
	+ @	HOSPIRA	EQ 2.5MG BASE/ML	N011719	004		Jan CRLD
	+ @		EQ 20MG BASE/VIAL	N011719	001		Jan CRLD
	+ @		EQ 25MG BASE/ML	N011719	005		Jan CRLD
	+ @		EQ 50MG BASE/VIAL	N011719	003		Jan CRLD
	+ @		EQ 100MG BASE/VIAL	N011719	006		Jan CRLD
		METHOTREXATE SODIUM PRESERVATIVE FREE					
	@	EUGIA PHARMA SPECLTS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Mar CAHN

		INJECTABLE;INJECTION					
		METHOTREXATE SODIUM PRESERVATIVE FREE					
		@	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Mar CAHN
		@	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Mar CAHN
		@	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012	Mar CAHN
AP		HIKMA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343	001	Sep 16, 1986	Jan CHRS
	+ @	HOSPIRA	EQ 1GM BASE/VIAL	N011719	009	Apr 07, 1988	Jan CRLD
		MEXATE-AQ					
	+ @	BRISTOL MYERS	EQ 25MG BASE/ML	A088760	001	Feb 14, 1985	Jan CRLD
	METHYLDOPA						
		TABLET;ORAL					
		METHYLDOPA					
	@	ACCORD HLTHCARE	250MG	A070084	001	Oct 15, 1985	Sep DISC
	@		500MG	A070085	001	Oct 15, 1985	Aug DISC
	METHYLPHENIDATE						
		FILM, EXTENDED RELEASE;TRANSDERMAL					
		DAYTRANA					
AB	+	NOVEN PHARMS INC	10MG/9HR (1.1MG/HR)	N021514	001	Apr 06, 2006	Mar CFTG
AB	+		15MG/9HR (1.6MG/HR)	N021514	002	Apr 06, 2006	Mar CFTG
AB	+		20MG/9HR (2.2MG/HR)	N021514	003	Apr 06, 2006	Mar CFTG
AB	+!		30MG/9HR (3.3MG/HR)	N021514	004	Apr 06, 2006	Mar CFTG
		METHYLPHENIDATE					
AB		MYLAN TECH VIATRIS	10MG/9HR (1.1MG/HR)	A206497	001	Mar 14, 2022	Mar NFTG
AB			15MG/9HR (1.6MG/HR)	A206497	002	Mar 14, 2022	Mar NFTG
AB			20MG/9HR (2.2MG/HR)	A206497	003	Mar 14, 2022	Mar NFTG
AB			30MG/9HR (3.3MG/HR)	A206497	004	Mar 14, 2022	Mar NFTG
	METHYLPHENIDATE HYDROCHLORIDE						
		CAPSULE, EXTENDED RELEASE;ORAL					
		ADHANSIA XR					
	+ @	PURDUE PHARMA LP	25MG	N212038	001	Feb 27, 2019	Jul DISC
	+ @		35MG	N212038	002	Feb 27, 2019	Jul DISC
	+ @		45MG	N212038	003	Feb 27, 2019	Jul DISC
	+ @		55MG	N212038	004	Feb 27, 2019	Jul DISC
	+ @		70MG	N212038	005	Feb 27, 2019	Jul DISC
	+ @		85MG	N212038	006	Feb 27, 2019	Jul DISC
		METADATE CD					
AB2	+	AYTU BIOPHARMA	10MG	N021259	003	May 27, 2003	May CAHN
AB2	+		20MG	N021259	001	Apr 03, 2001	May CAHN
AB2	+		30MG	N021259	002	Jun 19, 2003	May CAHN
AB2	+		40MG	N021259	004	Feb 19, 2006	May CAHN
AB2	+		50MG	N021259	005	Feb 19, 2006	May CAHN
AB2	+!		60MG	N021259	006	Feb 19, 2006	May CAHN
		TABLET, EXTENDED RELEASE;ORAL					
		METHYLPHENIDATE HYDROCHLORIDE					
AB		ACTAVIS LABS FL	72MG	A076655	002	Feb 28, 2022	Feb NEWA
AB	!	OSMOTICA	72MG	A205327	005	Jul 28, 2017	Feb CTEC
	@	RHODES PHARMS	18MG	A214111	001	May 31, 2022	Jun DISC
AB			18MG	A214111	001	May 31, 2022	May NEWA
	@		27MG	A214111	002	May 31, 2022	Jun DISC
AB			27MG	A214111	002	May 31, 2022	May NEWA
	@		36MG	A214111	003	May 31, 2022	Jun DISC
AB			36MG	A214111	003	May 31, 2022	May NEWA
	@		54MG	A214111	004	May 31, 2022	Jun DISC
AB			54MG	A214111	004	May 31, 2022	May NEWA
		RELEXXII					
	+	OSMOTICA PHARM US	18MG	N216117	001	Jun 23, 2022	Jun NEWA
	+		27MG	N216117	002	Jun 23, 2022	Jun NEWA
	+		36MG	N216117	003	Jun 23, 2022	Jun NEWA
	+		45MG	N216117	004	Jun 23, 2022	Jun NEWA
	+		54MG	N216117	005	Jun 23, 2022	Jun NEWA
	+		63MG	N216117	006	Jun 23, 2022	Jun NEWA
	+!		72MG	N216117	007	Jun 23, 2022	Jun NEWA

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

		@	AMNEAL	4MG	A207481	001	Sep 21, 2021	Mar DISC
		@		8MG	A207481	002	Sep 21, 2021	Mar DISC
		@		16MG	A207481	003	Sep 21, 2021	Mar DISC
		@		32MG	A207481	004	Sep 21, 2021	Mar DISC

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

DEPO-MEDROL

>D>	AB	+!	PFIZER	20MG/ML	N011757	002		Nov CTEC
>A>		+!		20MG/ML	N011757	002		Nov CTEC
	AB	+		40MG/ML	N011757	001		Jul CHRS
	AB	+		80MG/ML	N011757	004		Jul CHRS

METHYLPREDNISOLONE ACETATE

	AB	!	AMNEAL	40MG/ML	A210043	001	May 20, 2019	Jul CHRS
	AB	!		80MG/ML	A210043	002	May 20, 2019	Jul CHRS
		@	PAR STERILE PRODUCTS	40MG/ML	A214297	001	Jan 21, 2022	Jul DISC
	AB			40MG/ML	A214297	001	Jan 21, 2022	Jan NEWA
	AB			80MG/ML	A214297	002	Jan 21, 2022	Jan NEWA
>D>	AB		SAGENT PHARMS INC	20MG/ML	A201835	001	Jun 27, 2018	Nov DISC
>A>		@		20MG/ML	A201835	001	Jun 27, 2018	Nov DISC
>D>	AB			40MG/ML	A201835	002	Jun 27, 2018	Nov CHRS
>A>	AB	!		40MG/ML	A201835	002	Jun 27, 2018	Nov CHRS
	AB	!		80MG/ML	A201835	003	Jun 27, 2018	Sep CHRS

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

		@	EUGIA PHARMA	EQ 40MG BASE/VIAL	A207667	001	Dec 15, 2015	Jul DISC
		@		EQ 125MG BASE/VIAL	A207667	002	Dec 15, 2015	Jul DISC
		@		EQ 500MG BASE/VIAL	A207667	003	Dec 15, 2015	Jul DISC
		@		EQ 2GM BASE/VIAL	A207667	004	Dec 15, 2015	Jul DISC
	AP		HIKMA	EQ 40MG BASE/VIAL	A203125	001	Sep 26, 2022	Sep NEWA
	AP			EQ 125MG BASE/VIAL	A203125	002	Sep 26, 2022	Sep NEWA
	AP		TIANJIN KINGYORK	EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	Jan CMFD
	AP			EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	Jan CMFD
	AP			EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	Jan CMFD
	AP			EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	Jan CMFD
	AP			EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	Jan CMFD

METHYLTESTOSTERONE

CAPSULE;ORAL

METHYLTESTOSTERONE

	AB	!	IMPAX LABS INC	10MG	A204851	001	Sep 21, 2015	Feb CTEC
	AB		NOVITIUM PHARMA	10MG	A215270	001	Feb 18, 2022	Feb NEWA

METOCLOPRAMIDE HYDROCHLORIDE

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

		@	CHARTWELL RX	EQ 5MG BASE	A074478	001	Oct 05, 1995	Mar CAHN
		@		EQ 10MG BASE	A072215	001	Jan 30, 1990	Mar CAHN
		@		EQ 10MG BASE	A074478	002	Oct 05, 1995	Mar CAHN

METOLAZONE

TABLET;ORAL

METOLAZONE

	AB		AACE PHARMS	2.5MG	A216216	001	Oct 25, 2022	Oct NEWA
	AB			5MG	A216216	002	Oct 25, 2022	Oct NEWA
	AB			10MG	A216216	003	Oct 25, 2022	Oct NEWA
>D>	AB		ESKAYEF	2.5MG	A215616	001	Oct 24, 2022	Nov CAHN
	AB			2.5MG	A215616	001	Oct 24, 2022	Oct NEWA
>D>	AB			5MG	A215616	002	Oct 24, 2022	Nov CAHN
	AB			5MG	A215616	002	Oct 24, 2022	Oct NEWA
>D>	AB			10MG	A215616	003	Oct 24, 2022	Nov CAHN
	AB			10MG	A215616	003	Oct 24, 2022	Oct NEWA
>A>	AB		RENATA	2.5MG	A215616	001	Oct 24, 2022	Nov CAHN
>A>	AB			5MG	A215616	002	Oct 24, 2022	Nov CAHN
>A>	AB			10MG	A215616	003	Oct 24, 2022	Nov CAHN

TABLET;ORAL
ZAROXOLYN

>A>	+ @	I3 PHARMS	2.5MG	N017386	001		Nov CAHN
>A>	+ @		5MG	N017386	002		Nov CAHN
>A>	+ @		10MG	N017386	003		Nov CAHN
>D>	+ @	LANNETT CO INC	2.5MG	N017386	001		Nov CAHN
>D>	+ @		5MG	N017386	002		Nov CAHN
>D>	+ @		10MG	N017386	003		Nov CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
METOPROLOL SUCCINATE

AB		ACCORD HLTHCARE	EQ 25MG TARTRATE	A215637	001	Oct 18, 2022	Oct NEWA
AB			EQ 50MG TARTRATE	A215637	002	Oct 18, 2022	Oct NEWA
AB			EQ 100MG TARTRATE	A215637	003	Oct 18, 2022	Oct NEWA
AB			EQ 200MG TARTRATE	A215637	004	Oct 18, 2022	Oct NEWA
	@	PRINSTON INC	EQ 100MG TARTRATE	A210597	001	Jan 04, 2022	Aug DISC
	@		EQ 200MG TARTRATE	A210597	002	Jan 04, 2022	Aug DISC
AB		SUNSHINE	EQ 50MG TARTRATE	A214004	001	Sep 26, 2022	Sep NEWA
AB			EQ 100MG TARTRATE	A214004	002	Sep 26, 2022	Sep NEWA
AB			EQ 200MG TARTRATE	A214004	003	Sep 26, 2022	Sep NEWA
AB		YICHANG HUMANWELL	EQ 25MG TARTRATE	A213854	004	Aug 01, 2022	Jul NEWA

METOPROLOL TARTRATE

INJECTABLE;INJECTION
METOPROLOL TARTRATE

	@	STERISCIENCE	1MG/ML	A090317	001	Apr 19, 2010	Feb CAHN

TABLET;ORAL
METOPROLOL TARTRATE

	@	CHARTWELL RX	50MG	A073288	001	Mar 25, 1994	Mar CAHN
	@		100MG	A073289	001	Mar 25, 1994	Mar CAHN

METRONIDAZOLE

CREAM;TOPICAL
NORITATE

	+!	BAUSCH	1%	N020743	001	Sep 26, 1997	Jul CAHN

GEL;VAGINAL
METRONIDAZOLE

AB		GLENMARK PHARMS LTD	0.75%	A215794	001	Jan 27, 2022	Jan NEWA
>D> AB		TOLMAR	0.75%	A077264	001	Oct 31, 2006	Nov DISC
>A>	@		0.75%	A077264	001	Oct 31, 2006	Nov DISC

INJECTABLE;INJECTION
METRONIDAZOLE

	@	HIKMA	500MG/100ML	N018907	001	Mar 30, 1984	Jul CAHN

METRONIDAZOLE IN PLASTIC CONTAINER

	@	RISING	500MG/100ML	A205531	001	May 09, 2017	Jan CAHN

METYROSINE

CAPSULE;ORAL
DEMSER

AB	+!	BAUSCH	250MG	N017871	001		Oct CTEC

METYROSINE

AB		AMNEAL	250MG	A213734	001	Jul 24, 2020	Oct CTEC

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL
MEXILETINE HYDROCHLORIDE

>A> AB		ANNORA PHARMA	150MG	A216463	001	Nov 09, 2022	Nov NEWA
>A> AB			200MG	A216463	002	Nov 09, 2022	Nov NEWA
>A> AB			250MG	A216463	003	Nov 09, 2022	Nov NEWA
AB		AUCTA	150MG	A215315	001	Aug 26, 2022	Sep CAHN
AB			200MG	A215315	002	Aug 26, 2022	Sep CAHN
AB			250MG	A215315	003	Aug 26, 2022	Sep CAHN
AB		ZENARA	150MG	A215315	001	Aug 26, 2022	Aug NEWA
AB			200MG	A215315	002	Aug 26, 2022	Aug NEWA
AB			250MG	A215315	003	Aug 26, 2022	Aug NEWA

MICAFUNGIN SODIUM

INJECTABLE;INTRAVENOUS

MICAFUNGIN SODIUM

>A>	AP	MEITHEAL	EQ 50MG BASE/VIAL	A215381	001	Sep 28, 2022	Nov CAHN
>A>	AP		EQ 100MG BASE/VIAL	A215381	002	Sep 28, 2022	Nov CAHN
>D>	AP	NANJING KING-FRIEND	EQ 50MG BASE/VIAL	A215381	001	Sep 28, 2022	Nov CAHN
	AP		EQ 50MG BASE/VIAL	A215381	001	Sep 28, 2022	Sep NEWA
>D>	AP		EQ 100MG BASE/VIAL	A215381	002	Sep 28, 2022	Nov CAHN
	AP		EQ 100MG BASE/VIAL	A215381	002	Sep 28, 2022	Sep NEWA
	AP	ZYDUS PHARMS	EQ 50MG BASE/VIAL	A215241	001	Oct 24, 2022	Oct NEWA
	AP		EQ 100MG BASE/VIAL	A215241	002	Oct 24, 2022	Oct NEWA

MICONAZOLE NITRATE; WHITE PETROLATUM; ZINC OXIDE

OINTMENT;TOPICAL

VUSION

+!	MYLAN	0.25%;81.35%;15%	N021026	001	Feb 16, 2006	Jul CAIN

MIDAZOLAM

SOLUTION;INTRAVENOUS

MIDAZOLAM IN 0.8% SODIUM CHLORIDE

+!	EXELA PHARMA	50MG/50ML (1MG/ML)	N215868	001	Jul 20, 2022	Jul NEWA
+!		100MG/100ML (1MG/ML)	N215868	002	Jul 20, 2022	Jul NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

>D>	@ ATLANTIDE	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Nov CAHN
>D>	@	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Nov CAHN
>D>	@	EQ 5MG BASE/ML	A078141	002	May 30, 2008	Nov CAHN
>D>	@	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Nov CAHN
>A>	@ WOCKHARDT BIO AG	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Nov CAHN
>A>	@	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Nov CAHN
>A>	@	EQ 5MG BASE/ML	A078141	002	May 30, 2008	Nov CAHN
>A>	@	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Nov CAHN

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

@	STERISCIENCE	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	Jan CAHN
@		EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	Jan CAHN

MIDOZALAM HYDROCHLORIDE

@	STERISCIENCE	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Feb CAHN
@		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Feb CAHN

SOLUTION;INTRAMUSCULAR

MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)

+ @	RAFA LABS LTD	EQ 10MG BASE/0.7ML (EQ 10MG BASE/0.7ML)	N216359	001	Aug 08, 2022	Sep DISC
+!		EQ 10MG BASE/0.7ML (EQ 10MG BASE/0.7ML)	N216359	001	Aug 08, 2022	Aug NEWA

SEIZALAM

+!	MMT	EQ 50MG BASE/10ML (EQ 5MG BASE/ML)	N209566	001	Sep 14, 2018	May CAHN

SYRUP;ORAL

MIDAZOLAM HYDROCHLORIDE

@	AKORN	EQ 2MG BASE/ML	A075958	001	Sep 04, 2003	Aug DISC

MIGLITOL

TABLET;ORAL

MIGLITOL

AB	WESTMINSTER PHARMS	25MG	A203965	001	Feb 24, 2015	Aug CAHN
AB		50MG	A203965	002	Feb 24, 2015	Aug CAHN
AB		100MG	A203965	003	Feb 24, 2015	Aug CAHN

MIGLUSTAT

CAPSULE;ORAL

MIGLUSTAT

AB	BRECKENRIDGE	100MG	A209325	001	Feb 03, 2022	Jan NEWA

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM;TOPICAL

AMZEEQ

+!	JOURNEY	EQ 4% BASE	N212379	001	Oct 18, 2019	Jan CAHN

ZILXI

+!	JOURNEY	EQ 1.5% BASE	N213690	001	May 28, 2020	Jan CAHN

CAPSULE;ORAL
MINOCYCLINE HYDROCHLORIDE

AB		TORRENT	EQ 50MG BASE	A065062	001	Nov 30, 2000	Jun CAHN
AB			EQ 75MG BASE	A065062	002	Nov 30, 2000	Jun CAHN
AB			EQ 100MG BASE	A065062	003	Nov 30, 2000	Jun CAHN

INJECTABLE;INJECTION
MINOCIN

AP	+!	REMPEX	EQ 100MG BASE/VIAL	N050444	001		Jul CFTG

MINOCYCLINE HYDROCHLORIDE

AP		NEXUS PHARMS	EQ 100MG BASE/VIAL	A214934	001	Jul 22, 2022	Jul NFTG

TABLET;ORAL
MINOCYCLINE HYDROCHLORIDE

AB		BEXIMCO PHARMS USA	EQ 50MG BASE	A215466	001	May 27, 2022	May NEWA
AB			EQ 75MG BASE	A215466	002	May 27, 2022	May NEWA
AB			EQ 100MG BASE	A215466	003	May 27, 2022	May NEWA
AB		TORRENT	EQ 50MG BASE	A065156	001	Jan 06, 2004	Jun CAHN
AB			EQ 75MG BASE	A065156	002	Jan 06, 2004	Jun CAHN
AB			EQ 100MG BASE	A065156	003	Jan 06, 2004	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL
MINOCYCLINE HYDROCHLORIDE

AB		SIDMAK LABS INDIA	EQ 55MG BASE	A204394	002	Oct 07, 2022	Sep NEWA
AB			EQ 65MG BASE	A204394	003	Oct 07, 2022	Sep NEWA
AB			EQ 115MG BASE	A204394	006	Oct 07, 2022	Sep NEWA

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL
MIRABEGRON

AB		LUPIN LTD	25MG	A209485	001	Sep 28, 2022	Sep NEWA
AB			50MG	A209485	002	Sep 28, 2022	Sep NFTG
AB		ZYDUS PHARMS	25MG	A209488	001	Sep 29, 2022	Sep NEWA
AB			50MG	A209488	002	Sep 29, 2022	Sep NEWA

MYRBETRIQ

AB	+!	APGDI	25MG	N202611	001	Jun 28, 2012	Sep CTEC
AB	+!		50MG	N202611	002	Jun 28, 2012	Sep CFTG

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL
MIRTAZAPINE

AB		SQUARE PHARMS	15MG	A205798	001	Jun 01, 2017	Jan CAHN
AB			30MG	A205798	002	Jun 01, 2017	Jan CAHN
AB			45MG	A205798	003	Jun 01, 2017	Jan CAHN

MISOPROSTOL

TABLET;ORAL
CYTOTEC

AB	+	PFIZER	0.1MG	N019268	003	Sep 21, 1990	Mar CTEC
AB	+!		0.2MG	N019268	001	Dec 27, 1988	Mar CTEC

MISOPROSTOL

AB		ANI PHARMS	0.1MG	A076095	001	Jul 10, 2002	Mar CMFD
AB			0.2MG	A076095	002	Jul 10, 2002	Mar CMFD
AB		MICRO LABS	0.1MG	A216872	001	Oct 17, 2022	Oct NEWA
AB			0.2MG	A216872	002	Oct 17, 2022	Oct NEWA

MITAPIVAT SULFATE

TABLET;ORAL
PYRUKYND

	+	AGIOS PHARMS INC	EQ 5MG BASE	N216196	001	Feb 17, 2022	Feb NEWA
	+		EQ 20MG BASE	N216196	002	Feb 17, 2022	Feb NEWA
	+!		EQ 50MG BASE	N216196	003	Feb 17, 2022	Feb NEWA

MITOMYCIN

INJECTABLE;INJECTION
MITOMYCIN

>A> AP		GLAND PHARMA LTD	40MG/VIAL	A216648	001	Nov 22, 2022	Nov CMS1
AP		HONG KONG	5MG/VIAL	A214505	001	Sep 08, 2022	Sep NEWA
AP			20MG/VIAL	A214505	002	Sep 08, 2022	Sep NEWA
AP			40MG/VIAL	A214504	001	Sep 06, 2022	Aug NEWA
AP		MEITHEAL	5MG/VIAL	A214505	001	Sep 08, 2022	Oct CAHN
AP			20MG/VIAL	A214505	002	Sep 08, 2022	Oct CAHN
AP			40MG/VIAL	A214504	001	Sep 06, 2022	Oct CAHN

MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE

	SPRAY, METERED;NASAL						
	RYALTRIS						
	+! GLENMARK SPECIALTY	0.025MG/SPRAY;0.665MG/SPRAY	N211746	001	Jan 13, 2022	Jan NEWA

MONTELUKAST SODIUM

	GRANULE;ORAL					
	SINGULAIR					
AB	+! ORGANON	EQ 4MG BASE/PACKET	N021409	001	Jul 26, 2002	Mar CAHN
	TABLET;ORAL					
	MONTELUKAST SODIUM					
AB	GRAVITI PHARMS	EQ 10MG BASE	A209012	001	Apr 24, 2017	Sep CAHN
	@ L PERRIGO CO	EQ 10MG BASE	A206112	001	Apr 26, 2017	Sep DISC
	TABLET, CHEWABLE;ORAL					
	MONTELUKAST SODIUM					
AB	GRAVITI PHARMS	EQ 4MG BASE	A209011	001	Apr 18, 2017	Sep CAHN
AB		EQ 5MG BASE	A209011	002	Apr 18, 2017	Sep CAHN

MORPHINE SULFATE

	CAPSULE, EXTENDED RELEASE;ORAL					
	MORPHINE SULFATE					
	@ IMPAX LABS INC	20MG	A200411	001	Apr 12, 2016	Jul DISC
	@	30MG	A200411	002	Apr 12, 2016	Jul DISC
	@	40MG	A200411	007	Jul 25, 2018	Jul DISC
	@	50MG	A200411	003	Apr 12, 2016	Jul DISC
	@	60MG	A200411	004	Apr 12, 2016	Jul DISC
	@	80MG	A200411	005	Apr 12, 2016	Jul DISC
	@	100MG	A200411	006	Apr 12, 2016	Jul DISC
	@ NORTEC DEV ASSOC	20MG	A203158	001	Aug 04, 2021	Jan DISC
	@	30MG	A203158	002	Aug 04, 2021	Jan DISC
	@	50MG	A203158	003	Aug 04, 2021	Jan DISC
	@	60MG	A203158	004	Aug 04, 2021	Jan DISC
	@	80MG	A203158	005	Aug 04, 2021	Jan DISC
	@	100MG	A203158	006	Aug 04, 2021	Jan DISC
	UPSHER SMITH LABS	20MG	A202104	002	Jun 03, 2013	Jul CTEC
		30MG	A202104	003	Jun 03, 2013	Jul CTEC
		50MG	A202104	004	Jun 03, 2013	Jul CTEC
		60MG	A202104	005	Jun 03, 2013	Jul CTEC
		80MG	A202104	006	Jun 03, 2013	Jul CTEC
	!	100MG	A202104	007	Jun 03, 2013	Jul CTEC
	INJECTABLE;INJECTION					
	MORPHINE SULFATE					
	+! HOSPIRA INC	50MG/ML	N202515	006	Apr 29, 2021	May CMFD
	+ @	50MG/ML	N202515	006	Apr 29, 2021	Jan DISC
	INTL MEDICATION SYS	1MG/ML	A202861	001	Apr 29, 2021	Jan CMFD
	SOLUTION;ORAL					
	MORPHINE SULFATE					
	@ TRIS PHARMA INC	20MG/5ML	A203519	001	May 18, 2016	Aug DISC
	TABLET;ORAL					
	MORPHINE SULFATE					
	@ INGENUS PHARMS NJ	15MG	A215584	001	Feb 07, 2022	Sep CAHN
	@	30MG	A215584	002	Feb 07, 2022	Sep CAHN
	@ NOVAST LABS	15MG	A215584	001	Feb 07, 2022	Aug CAHN
	@	30MG	A215584	002	Feb 07, 2022	Aug CAHN
	@ RICONPHARMA LLC	15MG	A215584	001	Feb 07, 2022	Feb DISC
AB		15MG	A215584	001	Feb 07, 2022	Jan NEWA
	@	30MG	A215584	002	Feb 07, 2022	Feb DISC
AB		30MG	A215584	002	Feb 07, 2022	Jan NEWA

MOXIFLOXACIN HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC					
	MOXEZA					
AT2	+! IMPRIMIS PHARMS USA	EQ 0.5% BASE	N022428	001	Nov 19, 2010	Jun CAHN
	MOXIFLOXACIN HYDROCHLORIDE					
AT1	INDOCO	EQ 0.5% BASE	A202525	001	Mar 06, 2015	Apr CAHN

MUPIROCIN CALCIUM

CREAM;TOPICAL

MUPIROCIN

>A>	AB	AMNEAL	EQ 2% BASE	A214811	001	Nov 15, 2022	Nov NEWA
	AB	PADAGIS ISRAEL	EQ 2% BASE	A212465	001	Aug 03, 2022	Jul NEWA

MYCOPHENOLATE MOFETIL

FOR SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

	AB	TEVA PHARMS USA	200MG/ML	A211272	001	Jan 25, 2022	Jan NEWA

TABLET;ORAL

MYCOPHENOLATE MOFETIL

	AB	AMNEAL	500MG	A090606	001	Jul 16, 2010	Jun CMFD

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL

>D> MYCOPHENOLIC ACID

>D>	AB	BIOCON PHARMA	EQ 180MG BASE	A214630	001	Nov 29, 2021	Nov CTNA
>D>	AB		EQ 360MG BASE	A214630	002	Nov 29, 2021	Nov CTNA

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE;ORAL

>A> MYCOPHENOLIC SODIUM

>A>	AB	BIOCON PHARMA	EQ 180MG BASE	A214630	001	Nov 29, 2021	Nov CTNA
>A>	AB		EQ 360MG BASE	A214630	002	Nov 29, 2021	Nov CTNA

NADOLOL

TABLET;ORAL

NADOLOL

	AB	AUROBINDO PHARMA	20MG	A201893	003	Jun 07, 2022	Jun NEWA
>A>	AB	CHARTWELL RX	20MG	A209309	001	Oct 05, 2017	Nov CAHN
>A>	AB		40MG	A209309	002	Oct 05, 2017	Nov CAHN
>A>	AB		80MG	A209309	003	Oct 05, 2017	Nov CAHN
>D>	AB	LUPIN LTD	20MG	A209309	001	Oct 05, 2017	Nov CAHN
>D>	AB		40MG	A209309	002	Oct 05, 2017	Nov CAHN
>D>	AB		80MG	A209309	003	Oct 05, 2017	Nov CAHN

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

	@	STERISCIENCE	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Feb CAHN
	@		EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Feb CAHN

NALMEFENE HYDROCHLORIDE

INJECTABLE;INJECTION

REVEX

+	@	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020459	001	Apr 17, 1995	Jan CPOT
+	@		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	N020459	002	Apr 17, 1995	Jan CPOT

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

NALMEFENE HYDROCHLORIDE

!		PURDUE PHARMA LP	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	Jan NEWA

REVEX

+	@	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020459	001	Apr 17, 1995	Jan CDFR
+	@		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	N020459	002	Apr 17, 1995	Jan CDFR
+	@	HIKMA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020459	001	Apr 17, 1995	Jul CAHN
+	@		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	N020459	002	Apr 17, 1995	Jul CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE HYDROCHLORIDE

	AP	ACCORD HLTHCARE	0.4MG/ML	A216624	001	Oct 26, 2022	Oct NEWA
	AP		1MG/ML	A216624	002	Oct 26, 2022	Oct NEWA
	@	ANDA REPOSITORY	0.4MG/ML	A207846	001	Dec 17, 2018	Sep CAHN
	AP	BAXTER HLTHCARE CORP	0.4MG/ML	A214792	001	Nov 07, 2022	Oct NEWA
	AP	HIKMA	1MG/ML	A212300	001	Jun 10, 2022	Jun NEWA
	AP	MYLAN LABS LTD	1MG/ML	A213843	001	Jun 09, 2022	Jun NEWA
	AP	PAR STERILE PRODUCTS	1MG/ML	A215964	001	Jul 29, 2022	Jul NEWA

```
          SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
            NALOXONE HYDROCHLORIDE (AUTOINJECTOR)
          + @ KALEO INC             10MG/0.4ML (10MG/0.4ML)          N215457  001  Feb 28, 2022   May DISC
          +!                        10MG/0.4ML (10MG/0.4ML)          N215457  001  Feb 28, 2022   Feb NEWA
          SPRAY, METERED;NASAL
            NALOXONE HYDROCHLORIDE
    AB        PADAGIS ISRAEL        4MG/SPRAY                        A211951  001  Jun 21, 2022   Jun NEWA

        NANDROLONE DECANOATE
          INJECTABLE;INJECTION
            DECA-DURABOLIN
            @ WOODWARD SPECL        50MG/ML                          N013132  001  Jun 12, 1986   Apr CAHN
            @                       100MG/ML                         N013132  002  Jun 12, 1986   Apr CAHN
          + @                       200MG/ML                         N013132  003  Jun 12, 1986   Apr CAHN

        NAPROXEN
          SUSPENSION;ORAL
            NAPROXEN
    AB        HETERO LABS LTD III   25MG/ML                          A215776  001  Jun 07, 2022   May NEWA
          TABLET;ORAL
            NAPROXEN
            @ L PERRIGO CO          250MG                            A077339  001  Apr 27, 2005   Oct DISC
            @                       375MG                            A077339  002  Apr 27, 2005   Oct DISC
            @                       500MG                            A077339  003  Apr 27, 2005   Oct DISC

        NEBIVOLOL HYDROCHLORIDE
          TABLET;ORAL
            NEBIVOLOL HYDROCHLORIDE
            @ AJANTA PHARMA LTD     EQ 2.5MG BASE                    A213349  001  Mar 31, 2022   Sep DISC
    AB                              EQ 2.5MG BASE                    A213349  001  Mar 31, 2022   Mar NEWA
            @                       EQ 5MG BASE                      A213349  002  Mar 31, 2022   Sep DISC
    AB                              EQ 5MG BASE                      A213349  002  Mar 31, 2022   Mar NEWA
            @                       EQ 10MG BASE                     A213349  003  Mar 31, 2022   Sep DISC
    AB                              EQ 10MG BASE                     A213349  003  Mar 31, 2022   Mar NEWA
            @                       EQ 20MG BASE                     A213349  004  Mar 31, 2022   Sep DISC
    AB                              EQ 20MG BASE                     A213349  004  Mar 31, 2022   Mar NEWA
>A> AB        MANKIND PHARMA        EQ 2.5MG BASE                    A216172  001  Nov 14, 2022   Nov NEWA
>A> AB                              EQ 5MG BASE                      A216172  002  Nov 14, 2022   Nov NEWA
>A> AB                              EQ 10MG BASE                     A216172  003  Nov 14, 2022   Nov NEWA
>A> AB                              EQ 20MG BASE                     A216172  004  Nov 14, 2022   Nov NEWA
    AB        PRINSTON INC          EQ 2.5MG BASE                    A212682  001  Apr 07, 2022   Apr NEWA
    AB                              EQ 5MG BASE                      A212682  002  Apr 07, 2022   Apr NEWA
    AB                              EQ 10MG BASE                     A212682  003  Apr 07, 2022   Apr NEWA
    AB                              EQ 20MG BASE                     A212682  004  Apr 07, 2022   Apr NEWA
    AB        REYOUNG               EQ 2.5MG BASE                    A212917  001  Dec 17, 2021   May CAHN
    AB                              EQ 5MG BASE                      A212917  002  Dec 17, 2021   May CAHN
    AB                              EQ 10MG BASE                     A212917  003  Dec 17, 2021   May CAHN
    AB                              EQ 20MG BASE                     A212917  004  Dec 17, 2021   May CAHN
>D> AB        UNICHEM               EQ 2.5MG BASE                    A213830  001  Mar 15, 2022   Nov DISC
>A>         @                       EQ 2.5MG BASE                    A213830  001  Mar 15, 2022   Nov DISC
    AB                              EQ 2.5MG BASE                    A213830  001  Mar 15, 2022   Mar NEWA
>D> AB                              EQ 5MG BASE                      A213830  002  Mar 15, 2022   Nov DISC
>A>         @                       EQ 5MG BASE                      A213830  002  Mar 15, 2022   Nov DISC
    AB                              EQ 5MG BASE                      A213830  002  Mar 15, 2022   Mar NEWA
>D> AB                              EQ 10MG BASE                     A213830  003  Mar 15, 2022   Nov DISC
>A>         @                       EQ 10MG BASE                     A213830  003  Mar 15, 2022   Nov DISC
    AB                              EQ 10MG BASE                     A213830  003  Mar 15, 2022   Mar NEWA
>D> AB                              EQ 20MG BASE                     A213830  004  Mar 15, 2022   Nov DISC
>A>         @                       EQ 20MG BASE                     A213830  004  Mar 15, 2022   Nov DISC
    AB                              EQ 20MG BASE                     A213830  004  Mar 15, 2022   Mar NEWA

        NEBIVOLOL HYDROCHLORIDE; VALSARTAN
          TABLET;ORAL
            VYDUO
              PRINSTON INC          EQ 5MG BASE;80MG                 A210596  001  Sep 19, 2022   Sep NFTG

        NEDOCROMIL SODIUM
          SOLUTION/DROPS;OPHTHALMIC
            ALOCRIL
          +!  ALLERGAN              2%                               N021009  001  Dec 08, 1999   Jul CTEC
            NEDOCROMIL SODIUM
            @ AKORN                 2%                               A090638  001  Aug 22, 2012   Jul DISC
```

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

	@	CHARTWELL MOLECULAR	500MG	A204435	001	Jun 10, 2016	Aug CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

	@	AM REGENT	5MG/10ML (0.5MG/ML)	A209182	001	May 04, 2018	Apr DISC
	@		10MG/10ML (1MG/ML)	A209182	002	May 04, 2018	Apr DISC
AP		DR REDDYS	3MG/3ML (1MG/ML)	A216291	001	Jul 06, 2022	Jul CPOT
AP			3MG/ML (1MG/ML)	A216291	001	Jul 06, 2022	Jun NFTG
AP	+!	FRESENIUS KABI USA	3MG/3ML (1MG/ML)	N203629	003	Sep 18, 2018	Jun CFTG
AP		HIKMA	3MG/3ML (1MG/ML)	A216206	001	Jul 13, 2022	Jul NEWA
AP		NIVAGEN PHARMS INC	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Oct NEWA
AP			10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Oct NEWA

NEOSTIGMINE METHYSULFATE

>A> AP		AVET LIFESCIENCES	5MG/10ML (0.5MG/ML)	A208230	001	Nov 25, 2022	Nov NEWA
>A> AP			10MG/10ML (1MG/ML)	A208230	002	Nov 25, 2022	Nov NEWA

NEVIRAPINE

TABLET;ORAL

NEVIRAPINE

	@	PRINSTON INC	200MG	A078644	001	May 22, 2012	Sep DISC

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

	@	ALVOGEN	100MG	A204621	002	Nov 09, 2015	Sep DISC
>D> AB			400MG	A204621	001	Jul 10, 2015	Nov DISC
>A>	@		400MG	A204621	001	Jul 10, 2015	Nov DISC

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

	@	BEIJING	500MG	A214428	001	Nov 22, 2021	May DISC
	@		1GM	A214428	002	Nov 22, 2021	May DISC
AB		MACLEODS PHARMS LTD	500MG	A204934	001	Mar 03, 2022	Feb NEWA
AB			1GM	A204934	002	Mar 03, 2022	Feb NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

	+!	HIKMA INTL PHARMS	25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008	Apr CAHN

INJECTABLE;INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

	+!	HIKMA INTL PHARMS	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	Apr CAHN
	+!		40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	Apr CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

>A> AB2		ALEMBIC PHARMS LTD	30MG	A216896	001	Nov 18, 2022	Nov NEWA
>A> AB2			60MG	A216896	002	Nov 18, 2022	Nov NEWA
>A> AB2			90MG	A216896	003	Nov 18, 2022	Nov NEWA
AB2		ALKEM LABS LTD	30MG	A216067	001	Mar 29, 2022	Mar NEWA
AB2			60MG	A216067	002	Mar 29, 2022	Mar NEWA
AB2			90MG	A216067	003	Mar 29, 2022	Mar NEWA
>A> AB2		PHARMADAX INC	30MG	A216019	001	Nov 18, 2022	Nov NEWA
>A> AB2			60MG	A216019	002	Nov 18, 2022	Nov NEWA
	@	RISING	30MG	A090602	001	Sep 13, 2010	Oct CAHN
	@		30MG	A201071	001	Dec 03, 2010	Aug CAHN
	@		60MG	A090602	002	Sep 13, 2010	Oct CAHN
	@		60MG	A201071	002	Dec 03, 2010	Aug CAHN
	@		90MG	A090602	003	Sep 13, 2010	Oct CAHN
	@		90MG	A201071	003	Dec 03, 2010	Aug CAHN

NIMODIPINE

SOLUTION;ORAL

NYMALIZE

	+ @	AZURITY	3MG/ML	N203340	001	May 10, 2013	Mar CAHN
	+!		6MG/ML	N203340	002	Apr 08, 2020	Mar CAHN

NITISINONE

CAPSULE;ORAL

NITISINONE

AB	DIPHARMA	2MG	A212390	001	May 26, 2022	May NEWA
AB		5MG	A212390	002	May 26, 2022	May NEWA
AB		10MG	A212390	003	May 26, 2022	May NEWA
AB	MEDUNIK	2MG	A212390	001	May 26, 2022	Jun CAHN
AB		5MG	A212390	002	May 26, 2022	Jun CAHN
AB		10MG	A212390	003	May 26, 2022	Jun CAHN

NITRIC OXIDE

GAS;INHALATION

NOXIVENT

	LINDE GAS EQUIP	100PPM	A207141	001	Oct 02, 2018	Apr CAHN
AA		800PPM	A207141	002	Oct 02, 2018	Apr CAHN

NITROFURANTOIN

SUSPENSION;ORAL

NITROFURANTOIN

	@ AMNEAL PHARMS	25MG/5ML	A201679	001	May 11, 2011	Jul DISC

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

	@ ATHEM	25MG	A074336	001	Jan 25, 1995	Sep CAHN
	@	50MG	A074336	002	Jan 25, 1995	Sep CAHN
	@	100MG	A074336	003	Jan 25, 1995	Sep CAHN
	@ AUROBINDO PHARMA USA	100MG	A077025	001	Aug 18, 2004	Apr CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB	ALVOGEN	75MG;25MG	A215002	001	Jul 20, 2022	Jul NEWA
AB	INVENTIA	75MG;25MG	A211013	001	Feb 18, 2022	Feb NEWA

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

NITROGLYCERIN

AB2	ZYDUS PHARMS	0.1MG/HR	A089885	002	Oct 30, 2017	Aug CAHN
AB2		0.2MG/HR	A089884	001	Oct 30, 1998	Aug CAHN
AB2		0.4MG/HR	A089885	001	Oct 30, 1998	Aug CAHN
AB2		0.6MG/HR	A089886	001	Oct 30, 1998	Aug CAHN

TABLET;SUBLINGUAL

NITROGLYCERIN

AB	NATCO	0.3MG	A211604	001	Apr 30, 2019	Sep CAHN
AB		0.4MG	A211604	002	Apr 30, 2019	Sep CAHN
AB		0.6MG	A211604	003	Apr 30, 2019	Sep CAHN
	@ ZYDUS PHARMS	0.3MG	A210153	001	Mar 08, 2022	Aug DISC
AB		0.3MG	A210153	001	Mar 08, 2022	Feb NEWA
	@	0.4MG	A210153	002	Mar 08, 2022	Aug DISC
AB		0.4MG	A210153	002	Mar 08, 2022	Feb NEWA
	@	0.6MG	A210153	003	Mar 08, 2022	Aug DISC
AB		0.6MG	A210153	003	Mar 08, 2022	Feb NEWA

NITROSTAT

AB	+ VIATRIS	0.3MG	N021134	001	May 01, 2000	Jan CAHN
AB	+	0.4MG	N021134	002	May 01, 2000	Jan CAHN
AB	+!	0.6MG	N021134	003	May 01, 2000	Jan CAHN

NIZATIDINE

SOLUTION;ORAL

NIZATIDINE

	@ AMNEAL PHARMS	15MG/ML	A090576	001	Nov 18, 2009	Jun DISC

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

AP	ZYDUS PHARMS	EQ 1MG BASE/ML	A216341	001	Jul 19, 2022	Jul NEWA

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+!	INFORLIFE	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N215700	001	Sep 15, 2022	Sep NEWA

```
          SOLUTION;INTRAVENOUS
            NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
          +!                        EQ 8MG BASE/250ML (EQ 32MCG        N215700  002  Sep 15, 2022   Sep NEWA
                                    BASE/ML)
          +!                        EQ 16MG BASE/250ML (EQ 64MCG       N215700  003  Sep 15, 2022   Sep NEWA
                                    BASE/ML)
          +!  NEVAKAR INJECTABLES   EQ 4MG BASE/250 ML (EQ 16MCG       N214628  001  Oct 06, 2022   Oct NEWA
                                    BASE/ML)
          +!                        EQ 8MG BASE/250ML (EQ 32MCG        N214628  002  Oct 06, 2022   Oct NEWA
                                    BASE/ML)
          +!                        EQ 16MG BASE/250ML (EQ 64MCG       N214628  003  Oct 06, 2022   Oct NEWA
                                    BASE/ML)

        NORETHINDRONE
          TABLET;ORAL-28
            NORETHINDRONE
            @ AMNEAL PHARMS         0.35MG                             A202260  001  Aug 01, 2013   Sep DISC

        NORTRIPTYLINE HYDROCHLORIDE
          CAPSULE;ORAL
            NORTRIPTYLINE HYDROCHLORIDE
            @ AUROBINDO PHARMA LTD  EQ 10MG BASE                       A074835  001  Jun 30, 1997   Feb CAHN
            @                       EQ 25MG BASE                       A074835  002  Jun 30, 1997   Feb CAHN
            @                       EQ 50MG BASE                       A074835  003  Jun 30, 1997   Feb CAHN
            @                       EQ 75MG BASE                       A074835  004  Jun 30, 1997   Feb CAHN
          SOLUTION;ORAL
            NORTRIPTYLINE HYDROCHLORIDE
>D> AA    !   PHARM ASSOC           EQ 10MG BASE/5ML                   A075606  001  Aug 23, 2000   Nov CTEC
>A>       !                         EQ 10MG BASE/5ML                   A075606  001  Aug 23, 2000   Nov CTEC
    AA    !                         EQ 10MG BASE/5ML                   A075606  001  Aug 23, 2000   Oct CMS1
>D> AA        TARO                  EQ 10MG BASE/5ML                   A077965  001  Jun 20, 2006   Nov DISC
>A>         @                       EQ 10MG BASE/5ML                   A077965  001  Jun 20, 2006   Nov DISC

        NYSTATIN
          SUSPENSION;ORAL
            NILSTAT
          + @ GLENMARK PHARMS LTD   100,000 UNITS/ML                   N050299  001                  Apr CAHN
            NYSTATIN
            @ AKORN                 100,000 UNITS/ML                   A064042  001  Feb 28, 1994   Sep DISC
    AA        LEADING               100,000 UNITS/ML                   A214346  001  Mar 10, 2022   Aug CAHN
    AA        MEDLEY PHARMS         100,000 UNITS/ML                   A214346  001  Mar 10, 2022   Feb NEWA
    AA        VISTAPHARM            100,000 UNITS/ML                   A064142  002  Mar 07, 2011   May CMS1

        NYSTATIN; TRIAMCINOLONE ACETONIDE
          CREAM;TOPICAL
            NYSTATIN AND TRIAMCINOLONE ACETONIDE
    AT        MACLEODS PHARMS LTD   100,000 UNITS/GM;0.1%              A214181  001  Jul 13, 2022   Jul NEWA
          OINTMENT;TOPICAL
            NYSTATIN AND TRIAMCINOLONE ACETONIDE
    AT        ALEOR DERMACEUTICALS  100,000 UNITS/GM;0.1%              A214186  001  Mar 04, 2022   Feb NEWA
            @ CHARTWELL RX          100,000 UNITS/GM;0.1%              A207316  001  Nov 18, 2019   Sep CAHN

        OCTREOTIDE ACETATE
          CAPSULE, DELAYED RELEASE;ORAL
            MYCAPSSA
          +!  AMRYT                 EQ 20MG BASE                       N208232  001  Jun 26, 2020   Jan CAHN
          INJECTABLE;INJECTION
            OCTREOTIDE ACETATE
    AP        HERITAGE PHARMS       EQ 0.05MG BASE/ML                  A204669  001  Dec 27, 2018   Apr CMFD
    AP                              EQ 0.1MG BASE/ML                   A204669  002  Dec 27, 2018   Apr CMFD
    AP                              EQ 0.2MG BASE/ML                   A203765  001  Sep 07, 2018   Apr CMFD
    AP                              EQ 0.5MG BASE/ML                   A204669  003  Dec 27, 2018   Apr CMFD
    AP                              EQ 1MG BASE/ML                     A203765  002  Sep 07, 2018   Apr CMFD

        OFLOXACIN
          SOLUTION/DROPS;OPHTHALMIC
            OFLOXACIN
            @ AKORN                 0.3%                               A076615  001  May 14, 2004   Sep DISC
>A> AT        MANKIND PHARMA        0.3%                               A215886  001  Nov 23, 2022   Nov NEWA
          SOLUTION/DROPS;OTIC
            OFLOXACIN
            @ FDC LTD               0.3%                               A215038  001  Jan 19, 2022   Jun DISC
    AT                              0.3%                               A215038  001  Jan 19, 2022   Jan NEWA
```

SOLUTION/DROPS;OTIC
OFLOXACIN

AT	MANKIND PHARMA	0.3%	A216130	001	Jul 14, 2022	Jul NEWA

OLANZAPINE

TABLET;ORAL
OLANZAPINE

AB	CHARTWELL MOLECULAR	2.5MG	A203333	001	Mar 15, 2016	Mar CAHN
AB		5MG	A203333	002	Mar 15, 2016	Mar CAHN
AB		7.5MG	A203333	003	Mar 15, 2016	Mar CAHN
AB		10MG	A203333	004	Mar 15, 2016	Mar CAHN
AB		15MG	A203333	005	Mar 15, 2016	Mar CAHN
AB		20MG	A203333	006	Mar 15, 2016	Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

AB	CHARTWELL MOLECULAR	5MG	A203456	001	Mar 16, 2016	Mar CAHN
AB		10MG	A203456	002	Mar 16, 2016	Mar CAHN
AB		15MG	A203456	003	Mar 16, 2016	Mar CAHN
AB		20MG	A203456	004	Mar 16, 2016	Mar CAHN

OLMESARTAN MEDOXOMIL

TABLET;ORAL
OLMESARTAN MEDOXOMIL

>A> AB	PRINSTON INC	5MG	A206720	001	Dec 02, 2022	Nov NEWA
>A> AB		20MG	A206720	002	Dec 02, 2022	Nov NEWA
>A> AB		40MG	A206720	003	Dec 02, 2022	Nov NEWA
>D> AB	SANDOZ INC	5MG	A090237	001	Apr 13, 2020	Nov DISC
>A>	@	5MG	A090237	001	Apr 13, 2020	Nov DISC
>D> AB		20MG	A090237	002	Apr 13, 2020	Nov DISC
>A>	@	20MG	A090237	002	Apr 13, 2020	Nov DISC
>D> AB		40MG	A090237	003	Apr 13, 2020	Nov DISC
>A>	@	40MG	A090237	003	Apr 13, 2020	Nov DISC

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

AB	GLW	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091028	001	Apr 07, 2014	Jun CAHN

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

@	STRIDES PHARMA	10MG	A075876	001	May 29, 2003	Jan CAHN
@		20MG	A075876	002	May 29, 2003	Jan CAHN
@		40MG	A075876	003	Jan 21, 2009	Jan CAHN

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL
KONVOMEP

+!	AZURITY	2MG/ML;84MG/ML	N213593	001	Aug 30, 2022	Aug NEWA

OMIDENEPAG ISOPROPYL

SOLUTION;OPHTHALMIC
OMLONTI

+!	SANTEN	0.002%	N215092	001	Sep 22, 2022	Sep NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

AB	CHARTWELL MOLECULES	4MG	A077406	003	Dec 26, 2006	Apr CMFD
AB		8MG	A077406	004	Dec 26, 2006	Apr CMFD
		16MG	A077406	001	Dec 26, 2006	Apr CMFD
		24MG	A077406	002	Dec 26, 2006	Apr CMFD

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

@	EUGIA PHARMA	EQ 2MG BASE/ML	A202599	001	Dec 21, 2012	Jun DISC
@	STERISCIENCE	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008	Feb CAHN

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

@	EUGIA PHARMA	EQ 2MG BASE/ML	A202600	001	Dec 21, 2012	Jul DISC

```
      INJECTABLE;INJECTION
        ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE
        @ STERISCIENCE          EQ 2MG BASE/ML                    A078244  001  Apr 23, 2008   Feb CAHN
      TABLET;ORAL
        ONDANSETRON HYDROCHLORIDE
        @ AUROBINDO PHARMA      EQ 24MG BASE                      A078539  003  Jul 31, 2007   Feb DISC
        @ CASI PHARMS INC       EQ 24MG BASE                      A077517  003  Jun 25, 2007   Feb DISC
AB        CHARTWELL MOLECULES   EQ 4MG BASE                      A077303  001  Jun 25, 2007   May CMFD
AB                              EQ 8MG BASE                      A077303  002  Jun 25, 2007   May CMFD
AB    !                         EQ 24MG BASE                     A077303  004  Jun 25, 2007   May CMFD
        @ DR REDDYS LABS LTD    EQ 16MG BASE                     A076183  004  Dec 26, 2006   Mar DISC
        @                       EQ 24MG BASE                     A076183  001  Dec 26, 2006   Feb DISC
AB        GLENMARK GENERICS     EQ 8MG BASE                      A077535  002  Jun 25, 2007   May CHRS
AB    !                         EQ 8MG BASE                      A077535  002  Jun 25, 2007   Feb CHRS
        @                       EQ 24MG BASE                     A077535  003  Jun 25, 2007   Feb DISC
        @ TEVA                  EQ 4MG BASE                      A076252  001  Jun 25, 2007   Feb DISC
        @                       EQ 8MG BASE                      A076252  002  Jun 25, 2007   Feb DISC
        @                       EQ 24MG BASE                     A076252  003  Jun 25, 2007   Feb DISC
        ZOFRAN
      + @ NOVARTIS              EQ 4MG BASE                      N020103  001  Dec 31, 1992   Feb DISC
      + @                       EQ 8MG BASE                      N020103  002  Dec 31, 1992   Feb DISC
      + @                       EQ 24MG BASE                     N020103  003  Aug 27, 1999   Feb DISC

    ORPHENADRINE CITRATE
      TABLET, EXTENDED RELEASE;ORAL
        ORPHENADRINE CITRATE
AB        BAYSHORE PHARMS LLC   100MG                            A091158  001  Jul 27, 2012   Aug CAHN

    OSELTAMIVIR PHOSPHATE
      CAPSULE;ORAL
        OSELTAMIVIR PHOSPHATE
AB        ACCORD HLTHCARE       EQ 30MG BASE                     A214726  001  Jul 25, 2022   Jul NEWA
AB                              EQ 45MG BASE                     A214726  002  Jul 25, 2022   Jul NEWA
AB                              EQ 75MG BASE                     A214726  003  Jul 25, 2022   Jul NEWA
      FOR SUSPENSION;ORAL
        OSELTAMIVIR PHOSPHATE
AB        ALVOGEN               EQ 6MG BASE/ML                   A208823  001  Oct 31, 2017   May CAHN
        @ APTAPHARMA INC        EQ 6MG BASE/ML                   A212858  001  Aug 30, 2021   Mar DISC
AB        HETERO LABS LTD V     EQ 6MG BASE/ML                   A209590  001  Mar 28, 2022   Mar NEWA
        @ LEADING               EQ 6MG BASE/ML                   A214949  001  Feb 28, 2022   Sep DISC
AB                              EQ 6MG BASE/ML                   A214949  001  Feb 28, 2022   Feb NEWA
AB        MSN                   EQ 6MG BASE/ML                   A215313  001  May 02, 2022   Apr NEWA
AB        STRIDES PHARMA        EQ 6MG BASE/ML                   A211894  001  Jan 13, 2022   Oct CMFD
        @                       EQ 6MG BASE/ML                   A211894  001  Jan 13, 2022   Jul DISC
AB                              EQ 6MG BASE/ML                   A211894  001  Jan 13, 2022   Jan NEWA

    OTESECONAZOLE
      CAPSULE;ORAL
        VIVJOA
      +!  MYCOVIA PHARMS        150MG                            N215888  001  Apr 26, 2022   Apr NEWA

    OXACILLIN SODIUM
      INJECTABLE;INJECTION
        OXACILLIN SODIUM
        @ PIRAMAL CRITICAL      EQ 1GM BASE/VIAL                 A206681  001  Sep 11, 2017   Aug DISC
        @                       EQ 2GM BASE/VIAL                 A206681  002  Sep 11, 2017   Aug DISC
        @ STERISCIENCE          EQ 1GM BASE/VIAL                 A091486  001  Aug 25, 2014   Feb CAHN
AP                              EQ 2GM BASE/VIAL                 A091486  002  Aug 25, 2014   Oct CMFD
        @                       EQ 2GM BASE/VIAL                 A091486  002  Aug 25, 2014   Feb CAHN

    OXALIPLATIN
      INJECTABLE;INTRAVENOUS
        OXALIPLATIN
        @ CHARTWELL MOLECULAR   50MG/10ML (5MG/ML)               A208523  001  Feb 10, 2017   Mar CAHN
        @                       100MG/20ML (5MG/ML)              A208523  002  Feb 10, 2017   Mar CAHN

    OXAZEPAM
      CAPSULE;ORAL
        OXAZEPAM
AB        UNITED RES LABS       10MG                             A071026  002  Aug 10, 1987   Apr CAHN
AB                              15MG                             A071026  003  Aug 10, 1987   Apr CAHN
AB                              30MG                             A071026  001  Aug 10, 1987   Apr CAHN
```

```
          CAPSULE;ORAL
            SERAX
          + @ ALPHARMA US PHARMS     10MG                          N015539  002                Jan CRLD
          + @                        15MG                          N015539  004                Jan CRLD
          + @                        30MG                          N015539  006                Jan CRLD

        OXCARBAZEPINE
          SUSPENSION;ORAL
            OXCARBAZEPINE
>A> AB        AUCTA                  300MG/5ML                     A215332  001  Nov 30, 2022  Nov NEWA
    AB        BIONPHARMA INC         300MG/5ML                     A209652  001  Nov 04, 2022  Oct NEWA
    AB        RUBICON                300MG/5ML                     A215726  001  Aug 30, 2022  Aug NEWA

        OXYBUTYNIN CHLORIDE
          SYRUP;ORAL
            OXYBUTYNIN CHLORIDE
            @ CHARTWELL RX           5MG/5ML                       A075039  001  Jan 29, 1999  Mar CAHN
    AA    !   LANNETT CO INC         5MG/5ML                       A074520  001  Mar 29, 1996  Mar CHRS
            @ WOCKHARDT BIO AG       5MG/5ML                       A074868  001  Feb 12, 1997  Mar DISC
          TABLET;ORAL
            OXYBUTYNIN CHLORIDE
    AB        BEXIMCO PHARMS USA     5MG                           A213550  001  Jul 14, 2022  Jul NEWA
    AB        STRIDES PHARMA         5MG                           A208165  001  Dec 17, 2020  Jul CMFD

        OXYCODONE HYDROCHLORIDE
          SOLUTION;ORAL
            OXYCODONE HYDROCHLORIDE
            @ NOVEL LABS INC         100MG/5ML                     A204603  001  Apr 29, 2015  Feb DISC
            @ WOCKHARDT BIO AG       5MG/5ML                       A206456  001  Jun 16, 2015  Apr DISC
          TABLET;ORAL
            ROXYBOND
              PROTEGA PHARMS         5MG                           N209777  001  Apr 20, 2017  Mar CMFD
            @                        5MG                           N209777  001  Apr 20, 2017  Feb CAHN
                                     15MG                          N209777  002  Apr 20, 2017  Mar CMFD
            @                        15MG                          N209777  002  Apr 20, 2017  Feb CAHN
                                     30MG                          N209777  003  Apr 20, 2017  Mar CMFD
            @                        30MG                          N209777  003  Apr 20, 2017  Feb CAHN

        PACLITAXEL
          INJECTABLE;INJECTION
            PACLITAXEL
    AP        ALEMBIC PHARMS LTD     6MG/ML                        A216874  001  Oct 20, 2022  Oct NEWA
    AP        GLAND PHARMA LTD       6MG/ML                        A207326  001  Aug 23, 2016  Feb CTNA
          POWDER;INTRAVENOUS
            ABRAXANE
>D>       +!  ABRAXIS BIOSCIENCE     100MG/VIAL                    N021660  001  Jan 07, 2005  Nov CAHN
>A>       +!  BRISTOL-MYERS          100MG/VIAL                    N021660  001  Jan 07, 2005  Nov CAHN
            PACLITAXEL
          +!  HBT LABS INC           100MG/VIAL                    N211875  001  Jul 27, 2022  Jul NEWA

        PACRITINIB CITRATE
          CAPSULE;ORAL
            VONJO
          +!  CTI BIOPHARMA CORP     EQ 100MG BASE                 N208712  001  Feb 28, 2022  Feb NEWA

        PALIPERIDONE
          TABLET, EXTENDED RELEASE;ORAL
            PALIPERIDONE
    AB        AMNEAL PHARMS          1.5MG                         A204707  001  Sep 23, 2019  Sep CTEC
    AB                               3MG                           A204707  002  Sep 23, 2019  Sep CTEC
    AB                               6MG                           A204707  003  Sep 23, 2019  Sep CTEC
    AB                               9MG                           A204707  004  Sep 23, 2019  Sep CTEC
    AB        LUPIN LTD              1.5MG                         A208643  001  Jun 29, 2022  Jun NEWA
    AB                               3MG                           A208643  002  Jun 29, 2022  Jun NEWA
    AB                               6MG                           A208643  003  Jun 29, 2022  Jun NEWA
    AB                               9MG                           A208643  004  Jun 29, 2022  Jun NEWA
```

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

	!	EMCURE PHARMS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A202951	001	Jun 29, 2021	Jul CMFD
	@		EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A202951	001	Jun 29, 2021	Jan DISC
AP			EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202951	002	Jun 29, 2021	Jul CMFD
	@		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202951	002	Jun 29, 2021	Jan DISC

PANTOPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

PANTOPRAZOLE SODIUM

AP		ASPIRO	EQ 40MG BASE/VIAL	A213778	001	May 18, 2022	May NEWA
AP		BE PHARMS	EQ 40MG BASE/VIAL	A216171	001	May 18, 2022	May NEWA
AP		GLAND PHARMA LTD	EQ 40MG BASE/VIAL	A204400	001	May 18, 2022	May NEWA
>D> AP		KNACK	EQ 40MG BASE/VIAL	A214680	001	May 19, 2022	Nov DISC
>A>	@		EQ 40MG BASE/VIAL	A214680	001	May 19, 2022	Nov DISC
AP			EQ 40MG BASE/VIAL	A214680	001	May 19, 2022	May NEWA
>A> AP		MEITHEAL	EQ 40MG BASE/VIAL	A215860	001	Aug 29, 2022	Nov CAHN
>D> AP		NANJING KING-FRIEND	EQ 40MG BASE/VIAL	A215860	001	Aug 29, 2022	Nov CAHN
AP			EQ 40MG BASE/VIAL	A215860	001	Aug 29, 2022	Aug NEWA

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

>D> AB		ATLANTIDE	EQ 20MG BASE	A091231	001	Jan 19, 2011	Nov CAHN
>D> AB			EQ 40MG BASE	A091231	002	Jan 19, 2011	Nov CAHN
	@	L PERRIGO CO	EQ 20MG BASE	A203024	001	May 07, 2014	Sep DISC
AB		MANKIND PHARMA	EQ 40MG BASE	A215880	001	Jul 26, 2022	Jul NEWA
>A> AB		WOCKHARDT BIO AG	EQ 20MG BASE	A091231	001	Jan 19, 2011	Nov CAHN
>A> AB			EQ 40MG BASE	A091231	002	Jan 19, 2011	Nov CAHN

PARICALCITOL

SOLUTION;INTRAVENOUS

PARICALCITOL

	@	AKORN	0.005MG/ML (0.005MG/ML)	A207692	001	Oct 16, 2017	Aug DISC
	@		0.01MG/2ML (0.005MG/ML)	A207692	001	Oct 16, 2017	Aug CPOT
	@	RISING	0.002MG/ML (0.002MG/ML)	A203897	001	Nov 02, 2017	Mar DISC

PAROXETINE HYDROCHLORIDE

CAPSULE;ORAL

PAXIL

	+ @	APOTEX	EQ 10MG BASE	N020885	001	Oct 09, 1998	Feb CAHN
	+ @		EQ 20MG BASE	N020885	002	Oct 09, 1998	Feb CAHN
	+ @		EQ 30MG BASE	N020885	003	Oct 09, 1998	Feb CAHN
	+ @		EQ 40MG BASE	N020885	004	Oct 09, 1998	Feb CAHN

SUSPENSION;ORAL

PAXIL

AB	+!	APOTEX	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Feb CAHN

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

AB		CHARTWELL RX	EQ 10MG BASE	A076618	001	Aug 15, 2005	Mar CAHN
AB			EQ 20MG BASE	A076618	002	Aug 15, 2005	Mar CAHN
AB			EQ 30MG BASE	A076618	003	Aug 15, 2005	Mar CAHN
AB			EQ 40MG BASE	A076618	004	Aug 15, 2005	Mar CAHN

PAXIL

AB	+	APOTEX	EQ 10MG BASE	N020031	001	Dec 29, 1992	Feb CAHN
AB	+		EQ 20MG BASE	N020031	002	Dec 29, 1992	Feb CAHN
AB	+		EQ 30MG BASE	N020031	003	Dec 29, 1992	Feb CAHN
AB	+!		EQ 40MG BASE	N020031	005	Dec 29, 1992	Feb CAHN
	@		EQ 50MG BASE	N020031	004	Dec 29, 1992	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

	@	SINOTHERAPEUTICS INC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021	Jan DISC
	@		EQ 25MG BASE	A213612	002	Aug 11, 2021	Jan DISC
>D> AB			EQ 37.5MG BASE	A213612	003	May 26, 2022	Nov DISC
>A>	@		EQ 37.5MG BASE	A213612	003	May 26, 2022	Nov DISC
AB			EQ 37.5MG BASE	A213612	003	May 26, 2022	May NEWA

PAXIL CR

AB	+	APOTEX	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb CAHN
AB	+		EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb CAHN

```
        TABLET, EXTENDED RELEASE;ORAL
          PAXIL CR
    AB    +!                        EQ 37.5MG BASE                    N020936  003  Dec 06, 2000   Feb CAHN

      PAROXETINE MESYLATE
        TABLET;ORAL
          PEXEVA
        + @ SEBELA IRELAND LTD      EQ 40MG BASE                      N021299  004  Jul 03, 2003   Jun DISC

      PEGAPTANIB SODIUM
        INJECTABLE;INTRAVITREAL
          MACUGEN
        + @ BAUSCH AND LOMB INC     EQ 0.3MG ACID/0.09ML              N021756  001  Dec 17, 2004   Jun CAHN

      PEMETREXED
        SOLUTION;INTRAVENOUS
          PEMETREXED
        +!  ACTAVIS LLC             100MG/4ML (25MG/ML)               N208419  001  Aug 21, 2020   May CMFD
        +!                          500MG/20ML (25MG/ML)              N208419  002  Aug 21, 2020   May CMFD
        +!                          1GM/40ML (25MG/ML)                N208419  003  Aug 21, 2020   May CMFD

      PEMETREXED DISODIUM
        POWDER;INTRAVENOUS
          ALIMTA
    AP    +!  LILLY                 EQ 100MG BASE/VIAL                N021462  002  Sep 07, 2007   May CFTG
    AP    +!                        EQ 500MG BASE/VIAL                N021462  001  Feb 04, 2004   May CFTG
          PEMETREXED DISODIUM
    AP        ACCORD HLTHCARE       EQ 100MG BASE/VIAL                A203485  001  May 25, 2022   May NFTG
    AP                              EQ 500MG BASE/VIAL                A203485  002  May 25, 2022   May NFTG
    AP                              EQ 1GM BASE/VIAL                  A203485  003  May 25, 2022   May NEWA
    AP        AMNEAL                EQ 500MG BASE/VIAL                A210047  001  Aug 04, 2022   Jul NEWA
    AP        APOTEX                EQ 100MG BASE/VIAL                A203774  001  May 25, 2022   May NFTG
    AP                              EQ 500MG BASE/VIAL                A203774  002  May 25, 2022   May NFTG
    AP                              EQ 750MG BASE/VIAL                A209851  001  May 25, 2022   May NEWA
    AP                              EQ 1GM BASE/VIAL                  A209085  001  May 25, 2022   May NEWA
    AP        BAXTER HLTHCARE CORP  EQ 100MG BASE/VIAL                A214436  001  Aug 18, 2022   Aug NEWA
    AP                              EQ 500MG BASE/VIAL                A214436  002  Aug 18, 2022   Aug NEWA
>D> AP        BIOCON PHARMA         EQ 1GM BASE/VIAL                  A211090  001  May 25, 2022   Nov DISC
>A>         @                       EQ 1GM BASE/VIAL                  A211090  001  May 25, 2022   Nov DISC
    AP                              EQ 1GM BASE/VIAL                  A211090  001  May 25, 2022   May NEWA
    AP        DR REDDYS             EQ 100MG BASE/VIAL                A202596  001  May 25, 2022   May NFTG
    AP                              EQ 500MG BASE/VIAL                A202596  002  May 25, 2022   May NFTG
    AP                              EQ 1GM BASE/VIAL                  A202596  003  May 25, 2022   May NEWA
    AP        EUGIA PHARMA          EQ 100MG BASE/VIAL                A214632  001  May 25, 2022   May NFTG
    AP                              EQ 500MG BASE/VIAL                A214632  002  May 25, 2022   May NFTG
    AP                              EQ 1GM BASE/VIAL                  A214632  003  May 25, 2022   May NEWA
    AP        FRESENIUS KABI USA    EQ 100MG BASE/VIAL                A090384  001  May 25, 2022   May NFTG
    AP                              EQ 500MG BASE/VIAL                A090384  002  May 25, 2022   May NFTG
    AP    !                         EQ 750MG BASE/VIAL                A090384  003  May 25, 2022   May NEWA
    AP    !                         EQ 1GM BASE/VIAL                  A090384  004  May 25, 2022   May NEWA
>D> AP        HOSPIRA               EQ 100MG BASE/VIAL                A202111  001  May 25, 2022   Nov DISC
>A>         @                       EQ 100MG BASE/VIAL                A202111  001  May 25, 2022   Nov DISC
    AP                              EQ 100MG BASE/VIAL                A202111  001  May 25, 2022   Aug CAHN
    AP                              EQ 100MG BASE/VIAL                A202111  001  May 25, 2022   May NFTG
>D> AP                              EQ 500MG BASE/VIAL                A202111  002  May 25, 2022   Nov DISC
>A>         @                       EQ 500MG BASE/VIAL                A202111  002  May 25, 2022   Nov DISC
    AP                              EQ 500MG BASE/VIAL                A202111  002  May 25, 2022   Aug CAHN
    AP                              EQ 500MG BASE/VIAL                A202111  002  May 25, 2022   May NFTG
>D> AP                              EQ 1GM BASE/VIAL                  A202111  003  May 25, 2022   Nov DISC
>A>         @                       EQ 1GM BASE/VIAL                  A202111  003  May 25, 2022   Nov DISC
    AP                              EQ 1GM BASE/VIAL                  A202111  003  May 25, 2022   Aug CAHN
    AP                              EQ 1GM BASE/VIAL                  A202111  003  May 25, 2022   May NEWA
    AP        JIANGSU HANSOH PHARM  EQ 100MG BASE/VIAL                A208696  001  May 25, 2022   May NFTG
    AP                              EQ 500MG BASE/VIAL                A208696  002  May 25, 2022   May NFTG
    AP        NANG KUANG PHARM CO   EQ 100MG BASE/VIAL                A207352  001  May 25, 2022   May NFTG
    AP                              EQ 500MG BASE/VIAL                A207352  002  May 25, 2022   May NFTG
    AP        QILU PHARM HAINAN     EQ 100MG BASE/VIAL                A204890  001  May 25, 2022   May NFTG
    AP                              EQ 500MG BASE/VIAL                A204890  002  May 25, 2022   May NFTG
    AP        WAVERLEY PHARMA INC   EQ 100MG BASE/VIAL                A211899  001  May 25, 2022   May NFTG
    AP                              EQ 500MG BASE/VIAL                A211899  002  May 25, 2022   May NFTG
    AP        ZYDUS PHARMS          EQ 100MG BASE/VIAL                A214073  001  May 25, 2022   May NFTG
    AP                              EQ 500MG BASE/VIAL                A214073  002  May 25, 2022   May NFTG
    AP                              EQ 1GM BASE/VIAL                  A214073  003  May 25, 2022   May NEWA
```

SOLUTION;INTRAVENOUS
PEMETREXED DISODIUM

	+!	ACCORD HLTHCARE	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214408	001	Jul 19, 2022	Jul NEWA
	+!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214408	002	Jul 19, 2022	Jul NEWA
	+!		EQ 850MG BASE/34ML (EQ 25MG BASE/ML)	N214408	003	Jul 19, 2022	Jul NEWA
	+!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214408	004	Jul 19, 2022	Jul NEWA
	+!	HOSPIRA	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214218	001	Jun 22, 2022	Aug CTNA
	+!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214218	002	Jun 22, 2022	Aug CTNA
	+!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214218	003	Jun 22, 2022	Aug CTNA
	+!	HOSPIRA INC	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214218	001	Jun 22, 2022	Jun NEWA
	+!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214218	002	Jun 22, 2022	Jun NEWA
	+!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214218	003	Jun 22, 2022	Jun NEWA
	+!	SANDOZ INC	EQ 100MG BASE/4ML (EQ 25MG BASE/MG)	N214657	001	May 26, 2022	Aug CTNA
	+!		EQ 100MG BASE/4ML (EQ 25MG BASE/MG)	N214657	001	May 26, 2022	May NEWA
	+!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214657	002	May 26, 2022	Aug CTNA
	+!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214657	002	May 26, 2022	May NEWA
	+!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214657	003	May 26, 2022	Aug CTNA
	+!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214657	003	May 26, 2022	May NEWA

PEMETREXED DITROMETHAMINE

POWDER;INTRAVENOUS
PEMETREXED DITROMETHAMINE

	+!	HOSPIRA	EQ 100MG BASE/VIAL	N208746	001	Jun 10, 2022	Aug CAHN
	+!		EQ 100MG BASE/VIAL	N208746	001	Jun 10, 2022	Aug CTNA
	+!		EQ 100MG BASE/VIAL	N208746	001	Jun 10, 2022	Jun NEWA
	+!		EQ 500MG BASE/VIAL	N208746	002	Jun 10, 2022	Aug CAHN
	+!		EQ 500MG BASE/VIAL	N208746	002	Jun 10, 2022	Aug CTNA
	+!		EQ 500MG BASE/VIAL	N208746	002	Jun 10, 2022	Jun NEWA
	+ @		EQ 1GM BASE/VIAL	N208746	003	Jun 10, 2022	Sep DISC
	+!		EQ 1GM BASE/VIAL	N208746	003	Jun 10, 2022	Aug CAHN
	+!		EQ 1GM BASE/VIAL	N208746	003	Jun 10, 2022	Aug CTNA
	+!		EQ 1GM BASE/VIAL	N208746	003	Jun 10, 2022	Jun NEWA

PENCICLOVIR

CREAM;TOPICAL
DENAVIR

>D>	+!	MYLAN	1%	N020629	001	Sep 24, 1996	Nov CFTG
>A> AB	+!		1%	N020629	001	Sep 24, 1996	Nov CFTG
>A>		PENCICLOVIR					
>A> AB		TEVA PHARMS USA	1%	A212710	001	Nov 09, 2022	Nov NFTG

PENTAMIDINE ISETHIONATE

INJECTABLE;INJECTION
PENTAMIDINE ISETHIONATE

AP		XGEN PHARMS	300MG/VIAL	A206982	001	Mar 17, 2022	Mar NEWA

PENTOBARBITAL SODIUM

INJECTABLE;INJECTION
PENTOBARBITAL SODIUM

AP		HIKMA	50MG/ML	A203619	001	Nov 13, 2017	Aug CAHN

PERINDOPRIL ERBUMINE

TABLET;ORAL
PERINDOPRIL ERBUMINE

		AUROBINDO PHARMA	2MG	A079070	001	Nov 10, 2009	Sep CTEC
			4MG	A079070	002	Nov 10, 2009	Sep CTEC
>D> AB	!		8MG	A079070	003	Nov 10, 2009	Nov CTEC
>A>	!		8MG	A079070	003	Nov 10, 2009	Nov CTEC
	@	HIKMA	2MG	A090072	001	Nov 10, 2009	Sep DISC
	@		4MG	A090072	002	Nov 10, 2009	Sep DISC
>D> AB			8MG	A090072	003	Nov 10, 2009	Nov DISC
>A>	@		8MG	A090072	003	Nov 10, 2009	Nov DISC

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

AB		APPCO	2MG	A210163	001	May 18, 2022	May NEWA
AB			4MG	A210163	002	May 18, 2022	May NEWA
AB			8MG	A210163	003	May 18, 2022	May NEWA
AB			16MG	A210163	004	May 18, 2022	May NEWA
	@	MYLAN	2MG	A206691	001	Apr 14, 2017	Mar DISC
	@		4MG	A206691	002	Apr 14, 2017	Mar DISC
	@		8MG	A206691	003	Apr 14, 2017	Mar DISC
	@		16MG	A206691	004	Apr 14, 2017	Mar DISC

PEXIDARTINIB HYDROCHLORIDE

CAPSULE;ORAL

TURALIO

	+	DAIICHI SANKYO INC	EQ 125MG BASE	N211810	002	Oct 14, 2022	Oct NEWA

PHENDIMETRAZINE TARTRATE

TABLET;ORAL

PHENDIMETRAZINE TARTRATE

AA		CHARTWELL	35MG	A089452	001	Oct 30, 1991	Apr CAHN

>A> PHENOBARBITAL SODIUM

>A> POWDER;INTRAVENOUS

>A> SEZABY

>A>	+!	SPARC	100MG/VIAL	N215910	001	Nov 17, 2022	Nov NEWA

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENOXYBENZAMINE HYDROCHLORIDE

AB		NOVITIUM PHARMA	10MG	A215042	001	Jul 19, 2022	Jul NEWA

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

>D> AA		LANNETT CO INC	37.5MG	A201961	001	Jul 20, 2011	Nov DISC
>A>	@		37.5MG	A201961	001	Jul 20, 2011	Nov DISC
AA	+!	SANDOZ	30MG	A087190	001		Feb CRLD

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE

	@	LANNETT	37.5MG	A040555	001	Apr 15, 2005	Jul DISC

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

BIORPHEN

	+!	DR REDDYS LABS SA	0.5MG/5ML (0.1MG/ML)	N212909	001	Oct 21, 2019	Jun CAHN
	+ @		10MG/ML (10MG/ML)	N212909	002	Mar 11, 2021	Jun CAHN

PHENYLEPHRINE HYDROCHLORIDE

AP1		ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020	Feb CMFD
AP1			50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020	Feb CMFD
AP1			100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020	Feb CMFD
AP1		MANKIND PHARMA	10MG/ML (10MG/ML)	A217069	001	Aug 30, 2022	Aug NEWA
AP1			50MG/5ML (10MG/ML)	A217069	002	Aug 30, 2022	Aug NEWA
AP1			100MG/10ML (10MG/ML)	A217069	003	Aug 30, 2022	Aug NEWA
	@	PAR STERILE PRODUCTS	10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018	Jan DISC

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT		MANKIND PHARMA	2.5%	A216859	001	Sep 29, 2022	Sep NEWA

PHENYTOIN

SUSPENSION;ORAL

DILANTIN-125

AB	+!	VIATRIS	125MG/5ML	N008762	001		Feb CAHN

DILANTIN-30

	@	VIATRIS	30MG/5ML	N008762	002		Feb CAHN

PHENYTOIN

AB		PAI HOLDINGS PHARM	125MG/5ML	A040420	001	Apr 19, 2002	Apr CAHN
AB		VISTAPHARM	125MG/5ML	A040342	002	Aug 18, 2005	May CMS1

PHENYTOIN SODIUM

CAPSULE;ORAL

DILANTIN

	+!	VIATRIS	30MG EXTENDED	A084349	001		Feb CAHN
AB	+!		100MG EXTENDED	A084349	002		Feb CAHN

EXTENDED PHENYTOIN SODIUM

AB		UNICHEM	100MG EXTENDED	A213834	001	Oct 13, 2022	Oct NEWA

PHYTONADIONE

INJECTABLE;INJECTION

PHYTONADIONE

	@	CIPLA	1MG/0.5ML	A212424	001	Apr 22, 2022	Jul DISC
AB2	!		1MG/0.5ML	A212424	001	Apr 22, 2022	Apr NFTG
	!		1MG/0.5ML	A214596	001	Apr 22, 2022	Jul CTEC
AB2	!		1MG/0.5ML	A214596	001	Apr 22, 2022	Jul CHRS
AB2			1MG/0.5ML	A214596	001	Apr 22, 2022	Apr NFTG
	@		10MG/ML	A212424	002	Apr 22, 2022	Jul DISC
AB2	!		10MG/ML	A212424	002	Apr 22, 2022	Apr NFTG
	!		10MG/ML	A214596	002	Apr 22, 2022	Jul CTEC
AB2	!		10MG/ML	A214596	002	Apr 22, 2022	Jul CHRS
AB2			10MG/ML	A214596	002	Apr 22, 2022	Apr NFTG
AB1		DR REDDYS	10MG/ML	A207719	001	May 22, 2019	Apr CTEC

VITAMIN K1

AB1	+!	HOSPIRA	10MG/ML	A087955	001	Jul 25, 1983	Apr CTEC

PILOCARPINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC

ISOPTO CARPINE

AT	+!	NOVARTIS	1%	N200890	001	Jun 22, 2010	May CHRS
AT	+!		2%	N200890	002	Jun 22, 2010	May CHRS

PINDOLOL

TABLET;ORAL

PINDOLOL

AB		AUROBINDO PHARMA USA	5MG	A074019	001	Sep 03, 1992	Oct CAHN
AB	!		10MG	A074019	002	Sep 03, 1992	Oct CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP		STERISCIENCE	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	May CMFD
	@		EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Feb CAHN
AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	May CMFD
	@		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Feb CAHN
AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	May CMFD
	@		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	Feb CAHN

PIRFENIDONE

CAPSULE;ORAL

PIRFENIDONE

AB		ACCORD HLTHCARE	267MG	A212731	001	Jan 20, 2022	Jan NEWA
AB		AMNEAL	267MG	A212569	001	Jan 03, 2022	May CMFD
	@		267MG	A212569	001	Jan 03, 2022	Jan DISC
AB		LAURUS	267MG	A212724	001	Jul 19, 2022	Jul NEWA
AB		SANDOZ INC	267MG	A212600	001	Jun 13, 2022	Jun NEWA
AB		SCIEGEN PHARMS INC	267MG	A212077	001	Aug 01, 2022	Jul NEWA

TABLET;ORAL

ESBRIET

AB	+	GENENTECH INC	267MG	N208780	001	Jan 11, 2017	Jan CFTG
AB	+!		801MG	N208780	003	Jan 11, 2017	Jan CFTG

PIRFENIDONE

AB		ACCORD HLTHCARE	267MG	A212730	001	Jan 25, 2022	Jan NFTG
AB			801MG	A212730	002	Jan 25, 2022	Jan NFTG
AB		AIZANT	267MG	A212747	001	Jul 21, 2022	Jul NEWA
AB			534MG	A212747	002	Jul 21, 2022	Jul NEWA
AB			801MG	A212747	003	Jul 21, 2022	Jul NEWA
AB		ALEMBIC PHARMS LTD	267MG	A212708	001	May 20, 2022	May NEWA

```
          TABLET;ORAL
            PIRFENIDONE
    AB                            801MG                            A212708  002  May 20, 2022   May NEWA
    AB        AMNEAL              267MG                            A212570  001  Mar 25, 2022   Mar NEWA
    AB                            801MG                            A212570  002  Mar 25, 2022   Mar NEWA
    AB        HETERO LABS LTD V   267MG                            A212674  001  Sep 21, 2022   Sep NEWA
    AB                            801MG                            A212674  002  Sep 21, 2022   Sep NEWA
    AB        LAURUS              267MG                            A212722  001  Jul 19, 2022   Jul NEWA
    AB                            534MG                            A212722  002  Jul 19, 2022   Jul CTEC
                                  534MG                            A212722  002  Jul 19, 2022   Jul NEWA
    AB                            801MG                            A212722  003  Jul 19, 2022   Jul NEWA
    AB        MICRO LABS          267MG                            A212680  001  May 18, 2022   May NEWA
    AB                            801MG                            A212680  002  May 18, 2022   May NEWA
    AB        MSN                 267MG                            A212772  001  May 24, 2022   May NEWA
    AB                            801MG                            A212772  002  May 24, 2022   May NEWA
    AB        SANDOZ INC          267MG                            A212560  001  Apr 28, 2022   Apr NEWA
    AB                            801MG                            A212560  002  Apr 28, 2022   Apr NEWA
    AB        SCIEGEN PHARMS INC  267MG                            A212078  001  Aug 01, 2022   Jul NEWA
    AB                            801MG                            A212078  002  Aug 01, 2022   Jul NEWA
    AB        TEVA PHARMS USA     267MG                            A212759  001  Jan 25, 2022   Jan NFTG
    AB                            801MG                            A212759  002  Jan 25, 2022   Jan NFTG

        POLIDOCANOL
          SOLUTION;INTRAVENOUS
            VARITHENA
          + @ PROVENSIS           77.5MG/7.75ML (10MG/ML)          N205098  002  Dec 21, 2017   Sep DISC

        POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
          FOR SOLUTION;ORAL
            LAX-LYTE WITH FLAVOR PACKS
            @ L PERRIGO CO        420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 A079232  001  Feb 25, 2010   Oct DISC
                                  .2GM/BOT
            PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE
            @ NOVEL LABS INC      420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 A090019  001  May 27, 2009   Feb DISC
                                  .2GM/BOT

        POLYMYXIN B SULFATE
          INJECTABLE;INJECTION
            POLYMYXIN B SULFATE
>D>         @ GLAND               EQ 500,000 UNITS BASE/VIAL       A207322  001  Apr 14, 2016   Nov CMFD
>A> AP                            EQ 500,000 UNITS BASE/VIAL       A207322  001  Apr 14, 2016   Nov CMFD

        POMALIDOMIDE
          CAPSULE;ORAL
            POMALIDOMIDE
            @ MYLAN               1MG                              A210275  001  Jan 26, 2022   Feb CAHN
            @                     1MG                              A210275  001  Jan 26, 2022   Feb DISC
    AB                            1MG                              A210275  001  Jan 26, 2022   Jan NEWA
            @                     2MG                              A210275  002  Jan 26, 2022   Feb CAHN
            @                     2MG                              A210275  002  Jan 26, 2022   Feb DISC
    AB                            2MG                              A210275  002  Jan 26, 2022   Jan NEWA
            @                     3MG                              A210275  003  Jan 26, 2022   Feb CAHN
            @                     3MG                              A210275  003  Jan 26, 2022   Feb DISC
    AB                            3MG                              A210275  003  Jan 26, 2022   Jan NEWA
            @                     4MG                              A210275  004  Jan 26, 2022   Feb CAHN
            @                     4MG                              A210275  004  Jan 26, 2022   Feb DISC
    AB                            4MG                              A210275  004  Jan 26, 2022   Jan NEWA
>D> AB        TEVA PHARMS USA     1MG                              A209956  001  May 04, 2022   Nov DISC
>A>         @                     1MG                              A209956  001  May 04, 2022   Nov DISC
    AB                            1MG                              A209956  001  May 04, 2022   Apr NEWA
>D> AB                            2MG                              A209956  002  May 04, 2022   Nov DISC
>A>         @                     2MG                              A209956  002  May 04, 2022   Nov DISC
    AB                            2MG                              A209956  002  May 04, 2022   Apr NEWA
>D> AB                            3MG                              A209956  003  May 04, 2022   Nov DISC
>A>         @                     3MG                              A209956  003  May 04, 2022   Nov DISC
    AB                            3MG                              A209956  003  May 04, 2022   Apr NEWA
>D> AB                            4MG                              A209956  004  May 04, 2022   Nov DISC
>A>         @                     4MG                              A209956  004  May 04, 2022   Nov DISC
    AB                            4MG                              A209956  004  May 04, 2022   Apr NEWA
            POMALYST
>D> AB    +   CELGENE             1MG                              N204026  001  Feb 08, 2013   Nov CTEC
>A>       +                       1MG                              N204026  001  Feb 08, 2013   Nov CTEC
    AB    +                       1MG                              N204026  001  Feb 08, 2013   Apr CTEC
```

```
          CAPSULE;ORAL
            POMALYST
          +                          1MG                              N204026  001  Feb 08, 2013   Feb CTEC
     AB   +                          1MG                              N204026  001  Feb 08, 2013   Jan CTEC
>D>  AB   +                          2MG                              N204026  002  Feb 08, 2013   Nov CTEC
>A>       +                          2MG                              N204026  002  Feb 08, 2013   Nov CTEC
     AB   +                          2MG                              N204026  002  Feb 08, 2013   Apr CTEC
          +                          2MG                              N204026  002  Feb 08, 2013   Feb CTEC
     AB   +                          2MG                              N204026  002  Feb 08, 2013   Jan CTEC
>D>  AB   +                          3MG                              N204026  003  Feb 08, 2013   Nov CTEC
>A>       +                          3MG                              N204026  003  Feb 08, 2013   Nov CTEC
     AB   +                          3MG                              N204026  003  Feb 08, 2013   Apr CTEC
          +                          3MG                              N204026  003  Feb 08, 2013   Feb CTEC
     AB   +                          3MG                              N204026  003  Feb 08, 2013   Jan CTEC
>D>  AB   +!                         4MG                              N204026  004  Feb 08, 2013   Nov CTEC
>A>       +!                         4MG                              N204026  004  Feb 08, 2013   Nov CTEC
     AB   +!                         4MG                              N204026  004  Feb 08, 2013   Apr CTEC
          +!                         4MG                              N204026  004  Feb 08, 2013   Feb CTEC
     AB   +!                         4MG                              N204026  004  Feb 08, 2013   Jan CTEC

        PONESIMOD
          TABLET;ORAL
            PONVORY
          +!  JANSSEN PHARMS         2MG                              N213498  001  Mar 18, 2021   Aug CHRS
          +                          20MG                             N213498  010  Mar 18, 2021   Aug CHRS

        POSACONAZOLE
          FOR SUSPENSION, DELAYED RELEASE;ORAL
            NOXAFIL POWDERMIX KIT
          +!  MSD MERCK CO           300MG                            N214770  001  May 31, 2021   Oct CMFD
          + @                        300MG                            N214770  001  May 31, 2021   Jan DISC
          SOLUTION;INTRAVENOUS
            NOXAFIL
     AP   +!  MERCK SHARP DOHME      300MG/16.7ML (18MG/ML)           N205596  001  Mar 13, 2014   May CFTG
            POSACONAZOLE
     AP       PAR STERILE PRODUCTS   300MG/16.7ML (18MG/ML)           A208768  001  May 25, 2022   May NFTG
          TABLET, DELAYED RELEASE;ORAL
            POSACONAZOLE
>A>  AB       ACTAVIS LABS FL INC    100MG                            A207355  001  Nov 30, 2022   Nov NEWA
     AB       BIOCON PHARMA          100MG                            A214476  001  Feb 04, 2022   Jan NEWA
     AB       DR REDDYS              100MG                            A212500  001  Apr 07, 2022   Apr NEWA
     AB       SPECGX LLC             100MG                            A212226  001  May 10, 2022   Apr NEWA

        POTASSIUM ACETATE
          INJECTABLE;INJECTION
            POTASSIUM ACETATE
            @ EXELA PHARMA           2MEQ/ML                          A212692  001  Oct 20, 2021   Mar DISC

        POTASSIUM CHLORIDE
          CAPSULE, EXTENDED RELEASE;ORAL
            POTASSIUM CHLORIDE
            @ LANNETT CO INC         8MEQ                             A204210  001  Mar 28, 2016   Mar DISC
            @                        10MEQ                            A204210  002  Mar 28, 2016   Mar DISC
          FOR SOLUTION;ORAL
            POTASSIUM CHLORIDE
            @ GRANULES               20MEQ                            A213467  001  Jan 27, 2022   Jul DISC
     AA                              20MEQ                            A213467  001  Jan 27, 2022   Jan NEWA
     AA       RUBICON                20MEQ                            A214108  001  Mar 24, 2022   Mar NEWA
     AA       STRIDES PHARMA         20MEQ                            A211667  001  Mar 11, 2021   Oct CMFD
          INJECTABLE;INJECTION
            POTASSIUM CHLORIDE
     AP   +!  HOSPIRA                2MEQ/ML                          A080205  001                  Sep CRLD
            POTASSIUM CHLORIDE 10MEQ
     AP       FRESENIUS KABI USA     14.9MG/ML                        A211087  001  Sep 09, 2020   Mar CMFD
     AP                              746MG/100ML                      A211087  002  Sep 09, 2020   Mar CMFD
            POTASSIUM CHLORIDE 20MEQ
     AP       FRESENIUS KABI USA     29.8MG/ML                        A211087  003  Sep 09, 2020   Mar CMFD
     AP                              1.49GM/100ML                     A211087  005  May 07, 2021   Mar CMFD
            POTASSIUM CHLORIDE 40MEQ
     AP       FRESENIUS KABI USA     2.98GM/100ML                     A211087  004  Sep 09, 2020   Mar CMFD
```

SOLUTION;ORAL
POTASSIUM CHLORIDE

	AA	RUBICON	20MEQ/15ML	A214656	001	Jan 13, 2022	Jan NEWA
	AA		40MEQ/15ML	A214656	002	Jan 13, 2022	Jan NEWA
>A>	AA	STRIDES PHARMA	40MEQ/15ML	A211665	001	Nov 17, 2022	Nov NEWA
	@	TRIS PHARMA INC	20MEQ/15ML	A214076	001	Jan 26, 2022	Apr DISC
	AA		20MEQ/15ML	A214076	001	Jan 26, 2022	Jan NEWA
	@		40MEQ/15ML	A214076	002	Jan 26, 2022	Apr DISC
	AA		40MEQ/15ML	A214076	002	Jan 26, 2022	Jan NEWA
	AA	WES PHARMA INC	20MEQ/15ML	A213062	001	Jun 06, 2022	May NEWA
	AA		40MEQ/15ML	A213062	002	Jun 06, 2022	May NEWA

TABLET, EXTENDED RELEASE;ORAL
K-TAB

	+ @	ABBVIE	8MEQ	N018279	002	Aug 01, 1988	Mar DISC

POTASSIUM CHLORIDE

>D>	AB1	AMTA	10MEQ	A214395	001	Jan 28, 2021	Nov CAHN
	AB1		10MEQ	A214395	001	Jan 28, 2021	Jul CMFD
>D>	AB1		20MEQ	A214395	002	Jan 28, 2021	Nov CAHN
	AB1		20MEQ	A214395	002	Jan 28, 2021	Jul CMFD
>A>	AB1	GUANGZHOU NOVAKEN	10MEQ	A214395	001	Jan 28, 2021	Nov CAHN
>A>	AB1		20MEQ	A214395	002	Jan 28, 2021	Nov CAHN
	AB3	RUBICON	10MEQ	A215725	001	Jul 25, 2022	Jul NEWA
	AB3		20MEQ	A215725	002	Jul 25, 2022	Jul NEWA

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%

AP	+!	BAXTER HLTHCARE	150MG/100ML;450MG/100ML	N017648	005	Nov 26, 2002	Aug CTEC
AP		FRESENIUS KABI USA	150MG/100ML;450MG/100ML	A212347	001	Sep 17, 2020	Aug CMFD

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%

AP		FRESENIUS KABI USA	150MG/100ML;900MG/100ML	A212347	003	Jun 02, 2021	Aug CMFD

POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%

AP	+!	BAXTER HLTHCARE	300MG/100ML;900MG/100ML	N017648	002		Aug CTEC
AP		FRESENIUS KABI USA	300MG/100ML;900MG/100ML	A212347	002	Sep 17, 2020	Aug CMFD

PRALATREXATE

SOLUTION;INTRAVENOUS
FOLOTYN

	+	ACROTECH BIOPHARMA	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009	Oct CAHN
	+!		40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009	Oct CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL
MIRAPEX

	+ @	BOEHRINGER INGELHEIM	0.125MG	N020667	001	Jul 01, 1997	Mar DISC
	+ @		0.25MG	N020667	002	Jul 01, 1997	Mar DISC
	+ @		0.5MG	N020667	006	Feb 12, 1998	Mar DISC
	+ @		0.75MG	N020667	007	Jul 30, 2007	Mar DISC
	+ @		1MG	N020667	003	Jul 01, 1997	Mar DISC
	+ @		1.5MG	N020667	005	Jul 01, 1997	Mar DISC

PRAMIPEXOLE DIHYDROCHLORIDE

AB	!	GLENMARK GENERICS	0.25MG	A090781	002	Oct 08, 2010	Mar CHRS
AB		RISING	0.25MG	A211088	001	Oct 03, 2018	Sep CAHN
AB			0.5MG	A211088	002	Oct 03, 2018	Sep CAHN
AB			0.75MG	A211088	003	Oct 03, 2018	Sep CAHN
AB			1MG	A211088	004	Oct 03, 2018	Sep CAHN
AB			1.5MG	A211088	005	Oct 03, 2018	Sep CAHN
>A>	AB	ZYDUS PHARMS USA INC	0.75MG	A078920	006	Nov 23, 2022	Nov NEWA

TABLET, EXTENDED RELEASE;ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	0.375MG	A204518	001	Jan 02, 2019	Apr CMFD
AB			0.75MG	A204518	002	Jan 02, 2019	Apr CMFD
AB			1.5MG	A204518	003	Jan 02, 2019	Apr CMFD
AB			2.25MG	A204518	004	Jan 02, 2019	Apr CMFD
AB			3MG	A204518	005	Jan 02, 2019	Apr CMFD
AB			3.75MG	A204518	006	Jan 02, 2019	Apr CMFD
AB			4.5MG	A204518	007	Jan 02, 2019	Apr CMFD
	@	ANCHEN PHARMS	0.375MG	A202206	001	Feb 06, 2014	Oct DISC
	@		0.75MG	A202206	002	Feb 06, 2014	Oct DISC
	@		1.5MG	A202206	003	Feb 06, 2014	Oct DISC
	@		2.25MG	A202206	004	Feb 06, 2014	Oct DISC
	@		3MG	A202206	005	Feb 06, 2014	Oct DISC

TABLET, EXTENDED RELEASE;ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

	@	3.75MG	A202206	006	Feb 06, 2014	Oct DISC
	@	4.5MG	A202206	007	Feb 06, 2014	Oct DISC
AB	NOVAST LABS	0.375MG	A213444	001	Feb 03, 2022	Jan NEWA
AB		0.75MG	A213444	002	Feb 03, 2022	Jan NEWA
AB		1.5MG	A213444	003	Feb 03, 2022	Jan NEWA
AB		2.25MG	A213444	004	Feb 03, 2022	Jan NEWA
AB		3MG	A213444	005	Feb 03, 2022	Jan NEWA
AB		3.75MG	A213444	006	Feb 03, 2022	Jan NEWA
AB		4.5MG	A213444	007	Feb 03, 2022	Jan NEWA

PRASUGREL HYDROCHLORIDE

TABLET;ORAL
PRASUGREL

	@ CHARTWELL RX	EQ 5MG BASE	A205790	001	Oct 16, 2017	Aug CAHN
	@	EQ 10MG BASE	A205790	002	Oct 16, 2017	Aug CAHN
	@ USPHARMA WINDLAS	EQ 5MG BASE	A205790	001	Oct 16, 2017	Apr DISC
	@	EQ 10MG BASE	A205790	002	Oct 16, 2017	Apr DISC

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL
PRAZOSIN HYDROCHLORIDE

	@ ANI PHARMS	EQ 1MG BASE	A072577	002	May 16, 1989	Aug DISC
	@	EQ 2MG BASE	A072577	001	May 16, 1989	Aug DISC
	@	EQ 5MG BASE	A072577	003	May 16, 1989	Feb DISC
AB	APPCO	EQ 1MG BASE	A213406	001	Oct 21, 2022	Oct NEWA
AB		EQ 2MG BASE	A213406	002	Oct 21, 2022	Oct NEWA
AB		EQ 5MG BASE	A213406	003	Oct 21, 2022	Oct NEWA

PREDNISOLONE

TABLET;ORAL
PREDNISOLONE

+!	WATSON LABS	5MG	A080354	001		Mar CRLD

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT;OPHTHALMIC
BLEPHAMIDE S.O.P.

	@ ALLERGAN	0.2%;10%	A087748	001	Dec 03, 1986	Sep DISC

SUSPENSION;OPHTHALMIC
BLEPHAMIDE

+ @	ALLERGAN	0.2%;10%	N012813	002		Aug DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL
PREDNISOLONE SODIUM PHOSPHATE

AA	AMNEAL	EQ 15MG BASE/5ML	A216715	001	Oct 25, 2022	Oct NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
PREDNISOLONE SODIUM PHOSPHATE

	@ RISING	EQ 10MG BASE	A202179	001	Apr 10, 2013	Jul CAHN
	@	EQ 15MG BASE	A202179	002	Apr 10, 2013	Jul CAHN
	@	EQ 30MG BASE	A202179	003	Apr 10, 2013	Jul CAHN

PREDNISONE

SOLUTION;ORAL
PREDNISONE

+!	HIKMA	5MG/5ML	A088703	001	Nov 08, 1984	May CRLD

TABLET;ORAL
PREDNISONE

AB	AUROBINDO PHARMA LTD	2.5MG	A215672	001	Mar 28, 2022	Mar NEWA
AB		5MG	A215672	002	Mar 28, 2022	Mar NEWA
AB		10MG	A215672	003	Mar 28, 2022	Mar NEWA
AB		20MG	A215672	004	Mar 28, 2022	Mar NEWA
AB		50MG	A215672	005	Mar 28, 2022	Mar NEWA
>D>	@ ROXANE	25MG	A087833	001	May 04, 1982	Nov CRLD
>A>	+ @	25MG	A087833	001	May 04, 1982	Nov CRLD

TABLET, DELAYED RELEASE;ORAL
PREDNISONE

AB	ACTAVIS LABS FL INC	1MG	A204867	001	Apr 25, 2017	Oct CMFD
AB		2MG	A204867	002	Apr 25, 2017	Oct CMFD
AB		5MG	A204867	003	Apr 25, 2017	Oct CMFD

TABLET, DELAYED RELEASE;ORAL
RAYOS

AB	+	HORIZON	1MG	N202020	001	Jul 26, 2012	Oct CTEC
AB	+		2MG	N202020	002	Jul 26, 2012	Oct CTEC
AB	+!		5MG	N202020	003	Jul 26, 2012	Oct CTEC

PREGABALIN

CAPSULE;ORAL
PREGABALIN

AB		ALLIED	50MG	A210585	001	Dec 26, 2019	Feb CAHN
AB			75MG	A210585	002	Dec 26, 2019	Feb CAHN
AB			100MG	A210585	003	Dec 26, 2019	Feb CAHN
AB			150MG	A210585	004	Dec 26, 2019	Feb CAHN
AB			200MG	A210585	005	Dec 26, 2019	Feb CAHN
AB			300MG	A210585	006	Dec 26, 2019	Feb CAHN
AB		ESKAYEF	25MG	A212988	001	Mar 08, 2022	Feb NEWA
AB			50MG	A212988	002	Mar 08, 2022	Feb NEWA
AB			75MG	A212988	003	Mar 08, 2022	Feb NEWA
AB			100MG	A212988	004	Mar 08, 2022	Feb NEWA
AB			150MG	A212988	005	Mar 08, 2022	Feb NEWA
AB			200MG	A212988	006	Mar 08, 2022	Feb NEWA
AB			225MG	A212988	007	Mar 08, 2022	Feb NEWA
AB			300MG	A212988	008	Mar 08, 2022	Feb NEWA
	@	LUPIN LTD	25MG	A091040	001	May 03, 2022	Jul DISC
AB			25MG	A091040	001	May 03, 2022	Apr NEWA
	@		50MG	A091040	002	May 03, 2022	Jul DISC
AB			50MG	A091040	002	May 03, 2022	Apr NEWA
	@		75MG	A091040	003	May 03, 2022	Jul DISC
AB			75MG	A091040	003	May 03, 2022	Apr NEWA
	@		100MG	A091040	004	May 03, 2022	Jul DISC
AB			100MG	A091040	004	May 03, 2022	Apr NEWA
	@		150MG	A091040	005	May 03, 2022	Jul DISC
AB			150MG	A091040	005	May 03, 2022	Apr NEWA
	@		200MG	A091040	006	May 03, 2022	Jul DISC
AB			200MG	A091040	006	May 03, 2022	Apr NEWA
	@		225MG	A091040	007	May 03, 2022	Jul DISC
AB			225MG	A091040	007	May 03, 2022	Apr NEWA
	@		300MG	A091040	008	May 03, 2022	Jul DISC
AB			300MG	A091040	008	May 03, 2022	Apr NEWA
AB		MARKSANS PHARMA	25MG	A216197	001	Jul 18, 2022	Jul NEWA
AB			50MG	A216197	002	Jul 18, 2022	Jul NEWA
AB			75MG	A216197	003	Jul 18, 2022	Jul NEWA
AB			100MG	A216197	004	Jul 18, 2022	Jul NEWA
AB			150MG	A216197	005	Jul 18, 2022	Jul NEWA
AB			200MG	A216197	006	Jul 18, 2022	Jul NEWA
AB			225MG	A216197	007	Jul 18, 2022	Jul NEWA
AB			300MG	A216197	008	Jul 18, 2022	Jul NEWA
AB		PRINSTON INC	25MG	A207883	001	Sep 01, 2022	Aug NEWA
AB			50MG	A207883	002	Sep 01, 2022	Aug NEWA
AB			75MG	A207883	003	Sep 01, 2022	Aug NEWA
AB			100MG	A207883	004	Sep 01, 2022	Aug NEWA
AB			150MG	A207883	005	Sep 01, 2022	Aug NEWA
AB			200MG	A207883	006	Sep 01, 2022	Aug NEWA
AB			225MG	A207883	007	Sep 01, 2022	Aug NEWA
AB			300MG	A207883	008	Sep 01, 2022	Aug NEWA
AB		RENATA	50MG	A210585	001	Dec 26, 2019	Jul CAHN
AB			75MG	A210585	002	Dec 26, 2019	Jul CAHN
AB			100MG	A210585	003	Dec 26, 2019	Jul CAHN
AB			150MG	A210585	004	Dec 26, 2019	Jul CAHN
AB			200MG	A210585	005	Dec 26, 2019	Jul CAHN
AB			300MG	A210585	006	Dec 26, 2019	Jul CAHN

SOLUTION;ORAL
PREGABALIN

AA		INVATECH	20MG/ML	A212604	001	Feb 18, 2022	Feb NEWA

TABLET, EXTENDED RELEASE;ORAL
PREGABALIN

	@	MYLAN	82.5MG	A211948	001	Apr 13, 2021	Mar DISC
AB			82.5MG	A211948	001	Apr 13, 2021	Mar CAHN
	@		165MG	A211967	001	Nov 04, 2021	Mar DISC
AB		RUBICON	82.5MG	A215249	001	Mar 22, 2022	Mar NEWA
AB			165MG	A215249	002	Mar 22, 2022	Mar NEWA
AB			330MG	A215249	003	Mar 22, 2022	Mar NEWA
AB		SCIEGEN PHARMS INC	82.5MG	A215675	001	Sep 14, 2022	Sep NEWA

TABLET, EXTENDED RELEASE;ORAL
PREGABALIN

AB			165MG	A215675	002	Sep 14, 2022	Sep NEWA
AB			330MG	A215675	003	Sep 14, 2022	Sep NEWA
AB		ZYDUS PHARMS	82.5MG	A215577	001	Aug 26, 2022	Aug NEWA
AB			165MG	A215577	002	Aug 26, 2022	Aug NEWA
AB			330MG	A215577	003	Aug 26, 2022	Aug NEWA

PRIMIDONE

TABLET;ORAL
PRIMIDONE

AB		RUBICON	50MG	A214896	001	Jun 28, 2022	Jun NEWA
AB			250MG	A214896	002	Jun 28, 2022	Jun NEWA

PROBENECID

TABLET;ORAL
PROBENECID

		@ AUROBINDO PHARMA USA	500MG	A084211	002		Jul CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

>A>	AP	AMNEAL	EQ 5MG BASE/ML	A214192	001	Nov 28, 2022	Nov NEWA
	AP	EUGIA PHARMA	EQ 5MG BASE/ML	A213873	001	Jul 14, 2022	Jul NEWA
>A>	AP	HIKMA	EQ 5MG BASE/ML	A213630	001	Nov 22, 2022	Nov NEWA

PROCHLORPERAZINE MALEATE

TABLET;ORAL
PROCHLORPERAZINE MALEATE

>A>		@ CHARTWELL RX	EQ 5MG BASE	A040101	001	Jul 19, 1996	Nov CAHN
>A>		@	EQ 10MG BASE	A040101	002	Jul 19, 1996	Nov CAHN
>A>		@	EQ 25MG BASE	A040101	003	Jul 19, 1996	Nov CAHN
		@ MYLAN	EQ 5MG BASE	A040185	002	Oct 28, 1996	Sep DISC
		@	EQ 10MG BASE	A040185	001	Oct 28, 1996	Sep DISC
	AB	NOVITIUM PHARMA	EQ 5MG BASE	A216202	001	Jun 13, 2022	Jul CAHN
	AB		EQ 10MG BASE	A216202	002	Jun 13, 2022	Jul CAHN
>D>		@ SANDOZ	EQ 5MG BASE	A040101	001	Jul 19, 1996	Nov CAHN
>D>		@	EQ 10MG BASE	A040101	002	Jul 19, 1996	Nov CAHN
>D>		@	EQ 25MG BASE	A040101	003	Jul 19, 1996	Nov CAHN
	AB	ZENARA	EQ 5MG BASE	A216202	001	Jun 13, 2022	Jun NEWA
	AB		EQ 10MG BASE	A216202	002	Jun 13, 2022	Jun NEWA
	AB	ZYDUS	EQ 5MG BASE	A216495	001	Aug 08, 2022	Jul NEWA
	AB		EQ 10MG BASE	A216495	002	Aug 08, 2022	Jul NEWA

PROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
SPARINE

		@ HIKMA	25MG/ML	N010349	008		Jul CAHN
		@	50MG/ML	N010349	006		Jul CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
PROMETHAZINE HYDROCHLORIDE

AP	+!	WEST-WARD PHARMS INT	25MG/ML	A083312	001		Apr CRLD
AP	+!		50MG/ML	A083312	002		Apr CRLD

SUPPOSITORY;RECTAL
PROMETHAZINE HYDROCHLORIDE

AB		ANNORA PHARMA	12.5MG	A216446	001	Nov 02, 2022	Oct NEWA
AB			25MG	A216446	002	Nov 02, 2022	Oct NEWA

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
LARGON

		@ HIKMA	20MG/ML	N012382	002		Jul CAHN

PROPRANOLOL HYDROCHLORIDE

INJECTABLE;INJECTION
PROPRANOLOL HYDROCHLORIDE

		@ ATHENEX INC	1MG/ML	A075792	001	Aug 29, 2000	Feb DISC
		@ CHARTWELL INJECTABLE	1MG/ML	A075792	001	Aug 29, 2000	Mar CAHN
AP	!	HIKMA FARMACEUTICA	1MG/ML	A077760	001	Jan 31, 2008	Feb CTEC

```
          SOLUTION;ORAL
            PROPRANOLOL HYDROCHLORIDE
            @ PAI HOLDINGS PHARM     20MG/5ML                          A071984  001  Mar 03, 1989   Apr CAHN
            @                        40MG/5ML                          A071985  001  Mar 03, 1989   Apr CAHN
          TABLET;ORAL
            PROPRANOLOL HYDROCHLORIDE
            @ CHARTWELL RX           10MG                              A070663  001  Jun 13, 1986   Mar CAHN
            @                        20MG                              A070664  001  Jun 13, 1986   Mar CAHN
            @                        40MG                              A070665  001  Jun 13, 1986   Mar CAHN
            @                        60MG                              A070666  001  Oct 10, 1986   Mar CAHN
            @                        80MG                              A070667  001  Jun 13, 1986   Mar CAHN
>D>         @ IMPAX LABS INC         80MG                              A071976  001  Apr 06, 1988   Nov CMFD
>A> AB                               80MG                              A071976  001  Apr 06, 1988   Nov CMFD

        PROPYLTHIOURACIL
          TABLET;ORAL
            PROPYLTHIOURACIL
            @ CHARTWELL MOLECULAR    50MG                              A080016  001                  Aug CAHN

        PYRIDOSTIGMINE BROMIDE
          TABLET;ORAL
            PYRIDOSTIGMINE BROMIDE
    AB        EYWA                   30MG                              A211181  002  May 14, 2019   Jun CTEC
    AB        IMPAX LABS             30MG                              A040502  002  Jun 28, 2022   Jun NEWA

        PYRIMETHAMINE
          TABLET;ORAL
            PYRIMETHAMINE
    AB        AUROBINDO PHARMA LTD   25MG                              A216983  001  Oct 25, 2022   Oct NEWA

        QUETIAPINE FUMARATE
          TABLET;ORAL
            QUETIAPINE FUMARATE
    AB        HETERO LABS LTD V      EQ 25MG BASE                      A204316  001  Jun 16, 2022   Jun NEWA
    AB                               EQ 50MG BASE                      A204316  002  Jun 16, 2022   Jun NEWA
    AB                               EQ 100MG BASE                     A204316  003  Jun 16, 2022   Jun NEWA
    AB                               EQ 200MG BASE                     A204316  004  Jun 16, 2022   Jun NEWA
    AB                               EQ 300MG BASE                     A204316  005  Jun 16, 2022   Jun NEWA
    AB                               EQ 400MG BASE                     A204316  006  Jun 16, 2022   Jun NEWA
    AB        PRINSTON INC           EQ 25MG BASE                      A206954  001  Aug 24, 2022   Aug NEWA
    AB                               EQ 50MG BASE                      A206954  002  Aug 24, 2022   Aug NEWA
    AB                               EQ 100MG BASE                     A206954  003  Aug 24, 2022   Aug NEWA
    AB                               EQ 200MG BASE                     A206954  004  Aug 24, 2022   Aug NEWA
    AB                               EQ 300MG BASE                     A206954  005  Aug 24, 2022   Aug NEWA
    AB                               EQ 400MG BASE                     A206954  006  Aug 24, 2022   Aug NEWA
          TABLET, EXTENDED RELEASE;ORAL
            QUETIAPINE FUMARATE
    AB        PRINSTON INC           EQ 50MG BASE                      A208781  001  Apr 26, 2022   Apr NEWA
    AB                               EQ 150MG BASE                     A208781  002  Apr 26, 2022   Apr NEWA
    AB                               EQ 200MG BASE                     A208781  003  Apr 26, 2022   Apr NEWA
    AB                               EQ 300MG BASE                     A208781  004  Apr 26, 2022   Apr NEWA
>D> BX        SCIEGEN PHARMS INC     EQ 50MG BASE                      A209635  005  Nov 16, 2018   Nov CTEC
>A> AB                               EQ 50MG BASE                      A209635  005  Nov 16, 2018   Nov CTEC
>D> BX                               EQ 150MG BASE                     A209635  001  Nov 29, 2017   Nov CTEC
>A> AB                               EQ 150MG BASE                     A209635  001  Nov 29, 2017   Nov CTEC
>D> BX                               EQ 200MG BASE                     A209635  002  Nov 29, 2017   Nov CTEC
>A> AB                               EQ 200MG BASE                     A209635  002  Nov 29, 2017   Nov CTEC
>D> BX                               EQ 300MG BASE                     A209635  003  Nov 29, 2017   Nov CTEC
>A> AB                               EQ 300MG BASE                     A209635  003  Nov 29, 2017   Nov CTEC
>D> BX                               EQ 400MG BASE                     A209635  004  Nov 29, 2017   Nov CTEC
>A> AB                               EQ 400MG BASE                     A209635  004  Nov 29, 2017   Nov CTEC
    AB        UNICHEM                EQ 50MG BASE                      A215478  001  Aug 15, 2022   Aug NEWA
    AB                               EQ 150MG BASE                     A215478  002  Aug 15, 2022   Aug NEWA
    AB                               EQ 200MG BASE                     A215478  003  Aug 15, 2022   Aug NEWA
    AB                               EQ 300MG BASE                     A215478  004  Aug 15, 2022   Aug NEWA
    AB                               EQ 400MG BASE                     A215478  005  Aug 15, 2022   Aug NEWA
```

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

	@	CHARTWELL RX	EQ 5MG BASE	A076803	001	Mar 02, 2005	Mar CAHN
	@		EQ 10MG BASE	A076803	002	Mar 02, 2005	Mar CAHN
	@		EQ 20MG BASE	A076803	003	Mar 02, 2005	Mar CAHN
	@		EQ 40MG BASE	A076803	004	Mar 02, 2005	Mar CAHN

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

AB		EYWA	324MG	A212589	001	Sep 17, 2021	Aug CMFD
	@		324MG	A212589	001	Sep 17, 2021	Mar DISC
AB	!	SUN PHARM INDUSTRIES	324MG	A089338	001	Feb 11, 1987	Aug CTEC
	!		324MG	A089338	001	Feb 11, 1987	Mar CTEC

RALTEGRAVIR POTASSIUM

POWDER;ORAL

ISENTRESS

	+!	MSD SUB MERCK	EQ 100MG BASE/PACKET	N205786	001	Dec 20, 2013	Jun CAHN

TABLET;ORAL

ISENTRESS

	+!	MSD SUB MERCK	EQ 400MG BASE	N022145	001	Oct 12, 2007	Jun CAHN

ISENTRESS HD

	+!	MSD SUB MERCK	EQ 600MG BASE	N022145	002	May 26, 2017	Jun CAHN

TABLET, CHEWABLE;ORAL

ISENTRESS

	+	MSD SUB MERCK	EQ 25MG BASE	N203045	001	Dec 21, 2011	Jun CAHN
	+!		EQ 100MG BASE	N203045	002	Dec 21, 2011	Jun CAHN

RAMELTEON

TABLET;ORAL

RAMELTEON

AB		ENALTEC	8MG	A215435	001	Aug 24, 2022	Aug NEWA
AB		UPSHER SMITH LABS	8MG	A213815	001	Oct 26, 2020	Sep CAHN
>A> AB		XIROMED	8MG	A216209	001	Nov 25, 2022	Nov NEWA

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

	@	CHARTWELL RX	1.25MG	A077514	001	Jun 18, 2008	Mar CAHN
	@		2.5MG	A077514	002	Jun 18, 2008	Mar CAHN
	@		5MG	A077514	003	Jun 18, 2008	Mar CAHN
	@		10MG	A077514	004	Jun 18, 2008	Mar CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

	@	MYLAN LABS LTD	EQ 25MG BASE/ML	A079076	001	Jun 09, 2016	Jul DISC

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

	@	LANNETT CO INC	EQ 15MG BASE/ML	A078890	001	Jul 01, 2010	Jul DISC

RANOLAZINE

GRANULES, EXTENDED RELEASE;ORAL

ASPRUZYO SPRINKLE

	+	SPIL	500MG	N216018	001	Feb 28, 2022	Mar CAHN
	+!		1GM	N216018	002	Feb 28, 2022	Mar CAHN
	+	SUN PHARMA GLOBAL	500MG	N216018	001	Feb 28, 2022	Feb NEWA
	+!		1GM	N216018	002	Feb 28, 2022	Feb NEWA

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

AB		HETERO LABS LTD III	500MG	A212788	001	May 05, 2022	Apr NEWA
AB			1GM	A212788	002	May 05, 2022	Apr NEWA
AB		I3 PHARMS	500MG	A213517	001	Apr 27, 2022	Apr NEWA
AB			1GM	A213517	002	Apr 27, 2022	Apr NEWA
AB		VKT PHARMA	500MG	A214035	001	Jan 19, 2022	Jan NEWA
AB			1GM	A214035	002	Jan 19, 2022	Jan NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

>A>	AB	CHARTWELL RX	EQ 0.5MG BASE	A201892	001	Jul 27, 2018	Nov CAHN
>A>	AB		EQ 1MG BASE	A201892	002	Jul 27, 2018	Nov CAHN
		@ DR REDDYS	EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Jan DISC
		@	EQ 1MG BASE	A201942	002	Nov 18, 2021	Jan DISC
>D>	AB	SANDOZ INC	EQ 0.5MG BASE	A201892	001	Jul 27, 2018	Nov CAHN
>D>	AB		EQ 1MG BASE	A201892	002	Jul 27, 2018	Nov CAHN

REGADENOSON

SOLUTION;INTRAVENOUS

LEXISCAN

	AP	+! ASTELLAS	0.4MG/5ML (0.08MG/ML)	N022161	001	Apr 10, 2008	Apr CFTG

RAGADENOSON

	AP	IMS LTD	0.4MG/5ML (0.08MG/ML)	A214252	001	May 23, 2022	May NEWA

REGADENOSON

>D>		@ ACCORD HLTHCARE	0.4MG/5ML (0.08MG/ML)	A213236	001	Apr 11, 2022	Nov CMFD
>A>	AP		0.4MG/5ML (0.08MG/ML)	A213236	001	Apr 11, 2022	Nov CMFD
		@	0.4MG/5ML (0.08MG/ML)	A213236	001	Apr 11, 2022	Oct DISC
	AP		0.4MG/5ML (0.08MG/ML)	A213236	001	Apr 11, 2022	Apr NFTG
	AP	APOTEX	0.4MG/5ML (0.08MG/ML)	A207604	001	Apr 11, 2022	Apr NFTG
	AP	DR REDDYS	0.4MG/5ML (0.08MG/ML)	A213210	001	Apr 11, 2022	Apr NFTG
	AP	EUGIA PHARMA	0.4MG/5ML (0.08MG/ML)	A216437	001	Oct 26, 2022	Oct NEWA
	AP	GLAND PHARMA LTD	0.4MG/5ML (0.08MG/ML)	A207320	001	Jul 12, 2022	Jul NEWA
>D>	AP	HONG KONG	0.4MG/5ML (0.08MG/ML)	A212806	001	Apr 11, 2022	Nov CAHN
	AP		0.4MG/5ML (0.08MG/ML)	A212806	001	Apr 11, 2022	Apr NFTG
	AP	HOSPIRA	0.4MG/5ML (0.08MG/ML)	A214349	001	Aug 31, 2022	Aug NEWA
>D>	AP	IMS LTD	0.4MG/5ML (0.08MG/ML)	A214252	001	May 23, 2022	Nov DISC
>A>		@	0.4MG/5ML (0.08MG/ML)	A214252	001	May 23, 2022	Nov DISC
	AP		0.4MG/5ML (0.08MG/ML)	A214252	001	May 23, 2022	May CMS1
>A>	AP	MEITHEAL	0.4MG/5ML (0.08MG/ML)	A212806	001	Apr 11, 2022	Nov CAHN

REMIFENTANIL HYDROCHLORIDE

INJECTABLE;INJECTION

REMIFENTANIL HYDROCHLORIDE

	AP	HIKMA	EQ 1MG BASE/VIAL	A210594	001	Oct 13, 2020	Jul CAHN
	AP		EQ 2MG BASE/VIAL	A210594	002	Oct 13, 2020	Jul CAHN
	AP		EQ 5MG BASE/VIAL	A210594	003	Oct 13, 2020	Jul CAHN

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

		@ BOSCOGEN	0.5MG	A091517	001	Apr 24, 2015	Aug DISC
		@	1MG	A091517	002	Apr 24, 2015	Aug DISC
		@	2MG	A091517	003	Apr 24, 2015	Aug DISC

RIFAMPIN

CAPSULE;ORAL

RIFAMPIN

	AB	CHARTWELL MOLECULAR	150MG	A065390	001	Mar 28, 2008	Jun CAHN
	AB		300MG	A065390	002	Mar 28, 2008	Jun CAHN

RILUZOLE

FILM;ORAL

EXSERVAN

		+! AQUESTIVE	50MG	N212640	001	Nov 22, 2019	Aug CAHN

SUSPENSION;ORAL

TIGLUTIK KIT

		+! ITALFARMACO SA	50MG/10ML	N209080	001	Sep 05, 2018	Jun CAHN

RIOCIGUAT

TABLET;ORAL

ADEMPAS

	AB	+ BAYER HLTHCARE	0.5MG	N204819	001	Oct 08, 2013	Aug CFTG
	AB	+	1MG	N204819	002	Oct 08, 2013	Aug CFTG
	AB	+	1.5MG	N204819	003	Oct 08, 2013	Aug CFTG
	AB	+	2MG	N204819	004	Oct 08, 2013	Aug CFTG
	AB	+!	2.5MG	N204819	005	Oct 08, 2013	Aug CFTG

RIOCIGUAT

	AB	MSN	0.5MG	A211135	001	Sep 01, 2022	Aug NFTG

```
      TABLET;ORAL
        RIOCIGUAT
AB                            1MG                              A211135  002  Sep 01, 2022   Aug NFTG
AB                            1.5MG                            A211135  003  Sep 01, 2022   Aug NFTG
AB                            2MG                              A211135  004  Sep 01, 2022   Aug NFTG
AB                            2.5MG                            A211135  005  Sep 01, 2022   Aug NFTG

    RISEDRONATE SODIUM
      TABLET;ORAL
        ACTONEL
      + @ APIL                5MG                              N020835  002  Apr 14, 2000   Aug DISC
      + @                     30MG                             N020835  001  Mar 27, 1998   Aug DISC

    RISPERIDONE
      SOLUTION;ORAL
        RISPERIDONE
AA        CHARTWELL MOLECULAR 1MG/ML                           A202386  001  Jan 12, 2015   Aug CMFD
        @                     1MG/ML                           A202386  001  Jan 12, 2015   May CAHN
AA        LANNETT CO INC      1MG/ML                           A079158  001  Dec 03, 2010   May CAHN

    RITONAVIR
      TABLET;ORAL
        RITONAVIR
AB        CIPLA               100MG                            A202573  001  Jan 15, 2015   Mar CAHN
AB                            100MG                            A203759  001  May 10, 2022   Apr NEWA

    RIVASTIGMINE
      FILM, EXTENDED RELEASE;TRANSDERMAL
        RIVASTIGMINE
AB        ZYDUS PHARMS        4.6MG/24HR                       A206318  001  Mar 04, 2019   Aug CAHN
AB                            9.5MG/24HR                       A206318  002  Mar 04, 2019   Aug CAHN
AB                            13.3MG/24HR                      A206318  003  Mar 04, 2019   Aug CAHN

    RIZATRIPTAN BENZOATE
      TABLET;ORAL
        MAXALT
      + @ ORGANON LLC         EQ 5MG BASE                      N020864  001  Jun 29, 1998   Jul CAHN
AB    +!                      EQ 10MG BASE                     N020864  002  Jun 29, 1998   Jul CAHN
        RIZATRIPTAN BENZOATE
AB        CREEKWOOD PHARMS    EQ 5MG BASE                      A202047  001  Dec 31, 2012   May CAHN
AB                            EQ 10MG BASE                     A202047  002  Dec 31, 2012   May CAHN
        @ JUBILANT GENERICS   EQ 5MG BASE                      A203252  001  Dec 31, 2014   May DISC
        @                     EQ 10MG BASE                     A203252  002  Dec 31, 2014   May DISC
AB        PHARMGEN            EQ 5MG BASE                      A202047  001  Dec 31, 2012   Sep CAHN
AB                            EQ 10MG BASE                     A202047  002  Dec 31, 2012   Sep CAHN
        @ SANDOZ              EQ 5MG BASE                      A079230  001  Dec 31, 2012   Sep DISC
        @                     EQ 10MG BASE                     A079230  002  Dec 31, 2012   Sep DISC
      TABLET, ORALLY DISINTEGRATING;ORAL
        RIZATRIPTAN BENZOATE
        @ SANDOZ              EQ 5MG BASE                      A078739  001  Jul 01, 2013   Sep DISC
        @                     EQ 10MG BASE                     A078739  002  Jul 01, 2013   Sep DISC

    ROCURONIUM BROMIDE
      INJECTABLE;INJECTION
        ROCURONIUM BROMIDE
AP        PRINSTON INC        50MG/5ML (10MG/ML)               A212668  001  May 26, 2022   May NEWA
AP                            100MG/10ML (10MG/ML)             A212668  002  May 26, 2022   May NEWA

    ROFLUMILAST
      CREAM;TOPICAL
        ZORYVE
      +!  ARCUTIS             0.3%                             N215985  001  Jul 29, 2022   Jul NEWA
      TABLET;ORAL
        DALIRESP
AB    +   ASTRAZENECA         250MCG                           N022522  002  Jan 23, 2018   Aug CFTG
        ROFLUMILAST
AB        MICRO LABS          500MCG                           A208180  001  Mar 22, 2019   Aug CMFD
AB        MSN                 250MCG                           A208256  001  Sep 07, 2022   Aug NFTG
AB                            500MCG                           A208256  002  Sep 07, 2022   Aug NEWA
AB        MYLAN               500MCG                           A208257  001  Jul 13, 2018   Aug CMFD
AB        PRINSTON INC        500MCG                           A208299  001  May 10, 2022   Apr NEWA
AB        ZYDUS PHARMS        500MCG                           A208303  001  Feb 10, 2022   Sep CMFD
```

TABLET;ORAL
ROFLUMILAST

	@	500MCG	A208303	001	Feb 10, 2022	Jul DISC
AB		500MCG	A208303	001	Feb 10, 2022	Feb NEWA

ROMIDEPSIN

SOLUTION;INTRAVENOUS
ROMIDEPSIN

+	@ TEVA PHARMS USA INC	27.5MG/5.5ML (5MG/ML)	N208574	002	Mar 13, 2020	Jul DISC

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
ROPINIROLE HYDROCHLORIDE

AB	PRINSTON INC	EQ 2MG BASE	A204413	001	May 11, 2022	Apr NEWA
AB		EQ 4MG BASE	A204413	002	May 11, 2022	Apr NEWA
AB		EQ 6MG BASE	A204413	003	May 11, 2022	Apr NEWA
AB		EQ 8MG BASE	A204413	004	May 11, 2022	Apr NEWA
AB		EQ 12MG BASE	A204413	005	May 11, 2022	Apr NEWA

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION
ROPIVACAINE HYDROCHLORIDE

AP	GLAND PHARMA LTD	200MG/100ML (2MG/ML)	A210102	001	Aug 18, 2022	Aug NEWA
AP		400MG/200ML (2MG/ML)	A210102	002	Aug 18, 2022	Aug NEWA

ROSUVASTATIN CALCIUM

TABLET;ORAL
ROSUVASTATIN CALCIUM

AB	SCIEGEN PHARMS INC	EQ 5MG BASE	A206381	001	Apr 24, 2019	Oct CMFD
AB		EQ 10MG BASE	A206381	002	Apr 24, 2019	Oct CMFD
AB		EQ 20MG BASE	A206381	003	Apr 24, 2019	Oct CMFD
AB		EQ 40MG BASE	A206381	004	Apr 24, 2019	Oct CMFD
	@ STRIDES PHARMA	EQ 5MG BASE	A079161	001	Jul 19, 2016	Jan CAHN
	@	EQ 10MG BASE	A079161	002	Jul 19, 2016	Jan CAHN
	@	EQ 20MG BASE	A079161	003	Jul 19, 2016	Jan CAHN
	@	EQ 40MG BASE	A079161	004	Jul 19, 2016	Jan CAHN
	@ ZHEJIANG JINGXIN	EQ 5MG BASE	A206513	001	Mar 01, 2019	Mar CAHN
	@	EQ 10MG BASE	A206513	002	Mar 01, 2019	Mar CAHN
	@	EQ 20MG BASE	A206513	003	Mar 01, 2019	Mar CAHN
	@	EQ 40MG BASE	A206513	004	Mar 01, 2019	Mar CAHN

RUFINAMIDE

SUSPENSION;ORAL
RUFINAMIDE

AB	AUROBINDO PHARMA	40MG/ML	A216549	001	Oct 26, 2022	Oct NEWA
AB	GLASSHOUSE PHARMS	40MG/ML	A214009	001	Nov 07, 2022	Oct NEWA
	@ LUPIN LTD	40MG/ML	A213457	001	Dec 18, 2020	Apr DISC

TABLET;ORAL
RUFINAMIDE

	LUPIN LTD	100MG	A204964	001	Aug 17, 2022	Aug NFTG
AB		200MG	A204964	002	Aug 17, 2022	Aug NEWA
AB		400MG	A204964	003	Aug 17, 2022	Aug NEWA

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL
SAPROPTERIN DIHYDROCHLORIDE

AB	ANNORA PHARMA	100MG/PACKET	A215420	001	Aug 18, 2022	Aug NEWA
AB		500MG/PACKET	A215420	002	Aug 18, 2022	Aug NEWA
AB	DR REDDYS	500MG/PACKET	A215798	001	May 13, 2022	May NEWA

TABLET;ORAL
SAPROPTERIN DIHYDROCHLORIDE

AB	ANNORA PHARMA	100MG	A215534	001	Aug 23, 2022	Aug NEWA

SELEGILINE HYDROCHLORIDE

TABLET;ORAL
SELEGILINE HYDROCHLORIDE

	@ BOSCOGEN	5MG	A074912	001	Apr 30, 1998	Apr DISC

SELENIUM SULFIDE

LOTION/SHAMPOO;TOPICAL

SELENIUM SULFIDE

	!	PADAGIS US	2.5%	A089996	001	Jan 10, 1991	Jun CTEC
	@	WOCKHARDT BIO AG	2.5%	A088228	001	Sep 01, 1983	Jun DISC

SELINEXOR

TABLET;ORAL

XPOVIO

	+	KARYOPHARM THERAPS	20MG	N212306	001	Jul 03, 2019	Mar CHRS
	+!		60MG	N212306	004	Apr 15, 2021	Mar CHRS

SELPERCATINIB

CAPSULE;ORAL

RETEVMO

	+	LOXO ONCOL ELI LILLY	40MG	N213246	001	May 08, 2020	Sep CAHN
	+!		80MG	N213246	002	May 08, 2020	Sep CAHN

SEMAGLUTIDE

SOLUTION;SUBCUTANEOUS

OZEMPIC

	+!	NOVO	2MG/3ML (0.68MG/ML)	N209637	004	Oct 06, 2022	Oct NEWA
	+!		8MG/3ML (2.68MG/ML)	N209637	003	Mar 28, 2022	Apr NEWA

SERTRALINE HYDROCHLORIDE

CONCENTRATE;ORAL

ZOLOFT

AA	+!	VIATRIS	EQ 20MG BASE/ML	N020990	001	Dec 07, 1999	Jan CAHN

TABLET;ORAL

ZOLOFT

AB	+	VIATRIS	EQ 25MG BASE	N019839	005	Mar 06, 1996	Jan CAHN
AB	+		EQ 50MG BASE	N019839	001	Dec 30, 1991	Jan CAHN
AB	+!		EQ 100MG BASE	N019839	002	Dec 30, 1991	Jan CAHN
	+ @		EQ 150MG BASE	N019839	003	Dec 30, 1991	Jan CAHN
	+ @		EQ 200MG BASE	N019839	004	Dec 30, 1991	Jan CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

SEVELAMER CARBONATE

	@	LUPIN LTD	800MG/PACKET	A201513	001	Dec 23, 2021	Jul DISC
	@		2.4GM/PACKET	A201513	002	Dec 23, 2021	Jul DISC

TABLET;ORAL

SEVELAMER CARBONATE

AB		ARTHUR GRP	800MG	A200959	001	Mar 20, 2018	Sep CAHN
	@	LUPIN LTD	800MG	A204600	001	Jan 14, 2021	May DISC
AB		MICRO LABS	800MG	A215537	001	Feb 07, 2022	Jan NEWA
	@	STRIDES PHARMA	800MG	A201069	001	Aug 05, 2020	Jan CAHN

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

REVATIO

AB	+!	VIATRIS	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	Feb CAHN

SILDENAFIL CITRATE

AB		LUPIN LTD	EQ 10MG BASE/ML	A211638	001	Mar 23, 2022	Mar NEWA
AB		MSN	EQ 10MG BASE/ML	A214641	001	Feb 08, 2022	Jan NEWA
	@	TRIS PHARMA INC	EQ 10MG BASE/ML	A212312	001	Nov 17, 2021	Apr DISC
AB		ZYDUS	EQ 10MG BASE/ML	A215708	001	Sep 29, 2022	Sep NEWA

SOLUTION;INTRAVENOUS

REVATIO

AP	+!	VIATRIS	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Feb CAHN

TABLET;ORAL

REVATIO

AB	+!	VIATRIS	EQ 20MG BASE	N021845	001	Jun 03, 2005	Feb CAHN

VIAGRA

AB	+	VIATRIS	EQ 25MG BASE	N020895	001	Mar 27, 1998	Feb CAHN
AB	+		EQ 50MG BASE	N020895	002	Mar 27, 1998	Feb CAHN
AB	+!		EQ 100MG BASE	N020895	003	Mar 27, 1998	Feb CAHN

SILODOSIN

CAPSULE;ORAL

SILODOSIN

	@	UPSHER SMITH LABS	4MG	A213230	001	Jan 03, 2022	Feb DISC
	@		8MG	A213230	002	Jan 03, 2022	Feb DISC

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

	@	CHARTWELL RX	5MG	A077766	001	Dec 20, 2006	Mar CAHN
	@		10MG	A077766	002	Dec 20, 2006	Mar CAHN
	@		20MG	A077766	003	Dec 20, 2006	Mar CAHN
	@		40MG	A077766	004	Dec 20, 2006	Mar CAHN
	@		80MG	A077766	005	Dec 20, 2006	Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

SIMVASTATIN

>D>	@	SYNTHON PHARMS	10MG	N021961	001	Oct 09, 2007	Nov CRLD
>A>	+ @		10MG	N021961	001	Oct 09, 2007	Nov CRLD
>D>	@		20MG	N021961	002	Oct 09, 2007	Nov CRLD
>A>	+ @		20MG	N021961	002	Oct 09, 2007	Nov CRLD
>D>	@		40MG	N021961	003	Oct 09, 2007	Nov CRLD
>A>	+ @		40MG	N021961	003	Oct 09, 2007	Nov CRLD
>D>	@		80MG	N021961	004	Oct 09, 2007	Nov CRLD
>A>	+ @		80MG	N021961	004	Oct 09, 2007	Nov CRLD

SINCALIDE

POWDER;INTRAVENOUS

SINCALIDE

>A>	+!	MAIA PHARMS INC	0.005MG/VIAL	N210850	001	Nov 22, 2022	Nov NEWA

SIROLIMUS

GEL;TOPICAL

HYFTOR

	+!	NOBELPHARMA	0.2%	N213478	001	Mar 22, 2022	Mar NEWA

SOLUTION;ORAL

SIROLIMUS

	@	TORRENT	1MG/ML	A215016	001	Dec 27, 2021	Jun DISC

SODIUM BICARBONATE

INJECTABLE;INJECTION

SODIUM BICARBONATE

AP	!	HOSPIRA	0.5MEQ/ML	A202981	001	Mar 04, 2016	Apr CHRS

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.9%

>D>	+	B BRAUN	9MG/10ML	N019635	005	Aug 11, 2016	Nov CMS1
>A>	+		9MG/10ML	N019635	005	Aug 08, 2016	Nov CMS1

SOLUTION;INTRAVENOUS

SODIUM CHLORIDE 23.4%

AP		FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)	A212070	003	Feb 14, 2022	Feb NFTG
AP	+!	HOSPIRA	400MEQ/100ML (4MEQ/ML)	N018897	003	Jun 18, 2020	Feb CFTG

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F 18

	+ @	NIH NCI DCTD	10-200mCi/ML	N022494	001	Jan 26, 2011	Mar CRLD

SODIUM FLUORIDE F-18

>A> AP		BAMF	10-200mCi/ML	A216126	001	Dec 06, 2022	Nov NEWA

SODIUM IODIDE I-123

CAPSULE;ORAL

SODIUM IODIDE I 123

	@	GE HEALTHCARE	200uCi	N017630	003	Jan 08, 1993	Aug NEWA

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

SODIUM NITROPRUSSIDE

		@ AKORN	25MG/ML	A208635	001	May 04, 2017	Jun DISC
		@ ANDA REPOSITORY	25MG/ML	A209834	001	Jun 26, 2018	Sep CAHN
>D>	AP	AVET LIFESCIENCES	25MG/ML	A208923	001	Nov 08, 2022	Nov DISC
>A>		@	25MG/ML	A208923	001	Nov 08, 2022	Nov DISC
	AP		25MG/ML	A208923	001	Nov 08, 2022	Oct NEWA
	AP	BE PHARMS	25MG/ML	A214971	001	Jul 12, 2021	Apr CMFD
		@	25MG/ML	A214971	001	Jul 12, 2021	Jan DISC
	AP	CAPLIN	25MG/ML	A211016	001	Nov 29, 2019	Mar CAHN

SOLUTION;INTRAVENOUS

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

AP	+!	EXELA PHARMA	20MG/100ML (0.2MG/ML)	N209387	003	Jul 13, 2018	Aug CFTG
AP	+!		50MG/100ML (0.5MG/ML)	N209387	001	Mar 08, 2017	Aug CFTG

SODIUM NITROPRUSSIDE

		HAINAN POLY	10MG/50ML (0.2MG/ML)	A215846	001	Aug 26, 2022	Aug NFTG
AP			20MG/100ML (0.2MG/ML)	A215846	002	Aug 26, 2022	Aug NFTG
AP			50MG/100ML (0.5MG/ML)	A215846	003	Aug 26, 2022	Aug NFTG

SODIUM PHENYLBUTYRATE

PELLETS;ORAL

PHEBURANE

	+!	MEDUNIK	84GM/BOT	N216513	001	Jun 17, 2022	Jun NEWA

TABLET;ORAL

SODIUM PHENYLBUTYRATE

AB		GLENMARK PHARMS LTD	500MG	A216462	001	Nov 01, 2022	Oct NEWA

SODIUM PHENYLBUTYRATE; TAURURSODIOL

FOR SUSPENSION;ORAL

RELYVRIO

	+!	AMYLYX	3GM/PACKET; 1GM/PACKET	N216660	001	Sep 29, 2022	Sep NEWA

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL

VISICOL

		@ SALIX PHARMS	0.398GM;1.102GM	N021097	001	Sep 21, 2000	Aug CAIN

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE;INJECTION

SODIUM PHOSPHATES

AP		FRESENIUS KABI USA	142MG/ML;276MG/ML	A209997	001	Mar 30, 2022	Mar NFTG

SODIUM PHOSPHATES IN PLASTIC CONTAINER

AP	+!	HOSPIRA	142MG/ML;276MG/ML	N018892	001	May 10, 1983	Mar CFTG

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA		AIPING LIFE SCI	453.6GM/BOT	A090313	001	Dec 21, 2011	Oct CAHN
	+ @	PAI HOLDINGS PHARM	453.6GM/BOT	A088786	001	Sep 11, 1984	Apr CAHN

SUSPENSION;ORAL, RECTAL

KIONEX

AA		ANI PHARMS	15GM/60ML	A040028	001	Sep 17, 2007	Mar CMFD

SPS

AA	+!	CMP PHARMA INC	15GM/60ML	A087859	001	Dec 08, 1982	Mar CTEC

SODIUM TETRADECYL SULFATE

INJECTABLE;INJECTION

SODIUM TETRADECYL SULFATE

AP		HIKMA	60MG/2ML (30MG/ML)	A209937	001	Dec 09, 2019	Aug CAHN

SODIUM THIOSULFATE

SOLUTION;INTRAVENOUS

PEDMARK

	+!	FENNEC PHARMS INC	12.5GM/100ML (125MG/ML)	N212937	001	Sep 20, 2022	Sep NEWA

SOFOSBUVIR

TABLET;ORAL

SOFOSBUVIR

	@	TEVA PHARMS USA INC	400MG	A211353	001	Jan 27, 2022	Jul DISC
AB			400MG	A211353	001	Jan 27, 2022	Jan NFTG

SOVALDI

	+!	GILEAD SCIENCES INC	400MG	N204671	001	Dec 06, 2013	Jul CTEC
AB	+!		400MG	N204671	001	Dec 06, 2013	Jan CFTG

SOLIFENACIN SUCCINATE

TABLET;ORAL

SOLIFENACIN SUCCINATE

	@	ACCORD HLTHCARE	5MG	A207477	001	Jan 04, 2022	Jul DISC
	@		10MG	A207477	002	Jan 04, 2022	Jul DISC
	@	AMNEAL PHARMS CO	5MG	A209719	001	May 20, 2019	Jan DISC
	@		10MG	A209719	002	May 20, 2019	Jan DISC
AB		ANNORA PHARMA	5MG	A215761	001	Jun 15, 2022	Jun NEWA
AB			10MG	A215761	002	Jun 15, 2022	Jun NEWA

SOLRIAMFETOL HYDROCHLORIDE

TABLET;ORAL

SUNOSI

	+	AXSOME MALTA	EQ 75MG BASE	N211230	001	Jun 17, 2019	May CAHN
	+!		EQ 150MG BASE	N211230	002	Jun 17, 2019	May CAHN

SONIDEGIB PHOSPHATE

CAPSULE;ORAL

ODOMZO

	+!	SUN PHARM	EQ 200MG BASE	N205266	001	Jul 24, 2015	Feb CAHN

SORAFENIB TOSYLATE

TABLET;ORAL

NEXAVAR

AB	+!	BAYER HLTHCARE	EQ 200MG BASE	N021923	001	Dec 20, 2005	Apr CTEC

SORAFENIB TOSYLATE

AB		DR REDDYS	EQ 200MG BASE	A216073	001	Jun 07, 2022	May NEWA
AB		MYLAN	EQ 200MG BASE	A207012	001	Sep 10, 2020	Apr CMFD
AB		TEVA PHARMS USA INC	EQ 200MG BASE	A209567	001	Nov 12, 2020	Oct CMFD
>A> AB		YABAO PHARM	EQ 200MG BASE	A209050	001	Nov 09, 2022	Nov NEWA

SOTALOL HYDROCHLORIDE

SOLUTION;ORAL

SOTYLIZE

	+!	AZURITY	5MG/ML (5MG/ML)	N205108	001	Oct 22, 2014	Mar CAHN

TABLET;ORAL

BETAPACE

>D> AB	+	COVIS	80MG	N019865	001	Oct 30, 1992	Nov CAHN
>D> AB	+		120MG	N019865	005	Apr 20, 1994	Nov CAHN
>D> AB	+!		160MG	N019865	002	Oct 30, 1992	Nov CAHN
>D> AB	+		240MG	N019865	003	Oct 30, 1992	Nov CAHN
>D>	@		320MG	N019865	004	Oct 30, 1992	Nov CAHN
>A> AB	+	LEGACY PHARMA	80MG	N019865	001	Oct 30, 1992	Nov CAHN
>A> AB	+		120MG	N019865	005	Apr 20, 1994	Nov CAHN
>A> AB	+!		160MG	N019865	002	Oct 30, 1992	Nov CAHN
>A> AB	+		240MG	N019865	003	Oct 30, 1992	Nov CAHN
>A>	@		320MG	N019865	004	Oct 30, 1992	Nov CAHN

BETAPACE AF

>D>	@	COVIS	40MG	N021151	006	Apr 02, 2003	Nov CAHN
>D>	@		60MG	N021151	007	Apr 02, 2003	Nov CAHN
>D> AB	+		80MG	N021151	001	Feb 22, 2000	Nov CAHN
>D>	@		100MG	N021151	005	Mar 14, 2003	Nov CAHN
>D> AB	+		120MG	N021151	002	Feb 22, 2000	Nov CAHN
>D> AB	+!		160MG	N021151	003	Feb 22, 2000	Nov CAHN
>A>	@	LEGACY PHARMA	40MG	N021151	006	Apr 02, 2003	Nov CAHN
>A>	@		60MG	N021151	007	Apr 02, 2003	Nov CAHN
>A> AB	+		80MG	N021151	001	Feb 22, 2000	Nov CAHN
>A>	@		100MG	N021151	005	Mar 14, 2003	Nov CAHN
>A> AB	+		120MG	N021151	002	Feb 22, 2000	Nov CAHN
>A> AB	+!		160MG	N021151	003	Feb 22, 2000	Nov CAHN

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

AB		OXFORD PHARMS	25MG	A040750	001	Aug 29, 2006	Oct CMFD
AB			50MG	A040750	002	Aug 29, 2006	Oct CMFD
AB			100MG	A040750	003	Aug 29, 2006	Oct CMFD

STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

AP	!	MEDEFIL INC	100% (5ML)	A211188	004	Dec 02, 2019	Feb CTEC
AP		NEPHRON	100% (5ML)	A211222	001	Feb 10, 2021	Feb CMFD

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

SUCCINYLCHOLINE CHLORIDE

	@	BE PHARMS	20MG/ML	A216003	001	Feb 07, 2022	Aug DISC
AP			20MG/ML	A216003	001	Feb 07, 2022	Jan NEWA
AP		MEITHEAL	20MG/ML	A214514	001	Oct 19, 2021	Mar CAHN

SUCRALFATE

SUSPENSION;ORAL

SUCRALFATE

AB		MYLAN	1GM/10ML	A212913	001	Sep 12, 2022	Sep NEWA
AB		VISTAPHARM	1GM/10ML	A211884	001	Mar 15, 2022	Mar NEWA

TABLET;ORAL

SUCRALFATE

AB		AMNEAL PHARMS	1GM	A215576	001	Apr 15, 2022	Apr NEWA

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

	@	LUPIN LTD	200MG/5ML;40MG/5ML	A212699	001	Jan 05, 2021	May DISC
AB		NOVITIUM PHARMA	200MG/5ML;40MG/5ML	A214330	001	Feb 08, 2022	Jan NEWA

SULINDAC

TABLET;ORAL

SULINDAC

	@	RISING	150MG	A073039	002	Jun 22, 1993	Jul CAHN
	@		200MG	A073039	001	Jun 22, 1993	Jul CAHN

>A> SUMATRIPTAN

>A> SPRAY;NASAL

>A> SUMATRIPTAN

>A> AB		PADAGIS ISRAEL	5MG/SPRAY	A213465	002	Sep 21, 2020	Nov CAIN

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

	@	STERISCIENCE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	Feb CAHN
	@		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001	Jul 28, 2010	Feb CAHN

>D> SPRAY;NASAL

>D> SUMATRIPTAN

>D> AB		PADAGIS ISRAEL	5MG/SPRAY	A213465	002	Sep 21, 2020	Nov CAIN

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

AB		DR REDDYS	EQ 12.5MG BASE	A215843	001	Apr 11, 2022	Apr NEWA
AB			EQ 25MG BASE	A215843	002	Apr 11, 2022	Apr NEWA
AB			EQ 37.5MG BASE	A215843	003	Apr 11, 2022	Apr NEWA
AB			EQ 50MG BASE	A215843	004	Apr 11, 2022	Apr NEWA

TACROLIMUS

INJECTABLE;INJECTION

PROGRAF

>D> AP	+!	ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994	Nov CTEC
>A>	+!		EQ 5MG BASE/ML	N050709	001	Apr 08, 1994	Nov CTEC

```
          INJECTABLE;INJECTION
>D>         TACROLIMUS
>D> AP        HOSPIRA               EQ 5MG BASE/ML                    A203900  001  Aug 25, 2017   Nov DISC
>A>         @                       EQ 5MG BASE/ML                    A203900  001  Aug 25, 2017   Nov DISC

        TADALAFIL
          SUSPENSION;ORAL
            TADLIQ
          +!  CMP DEV LLC           20MG/5ML                          N214522  001  Jun 17, 2022   Jun NEWA
          TABLET;ORAL
            ALYQ
    AB2       TEVA PHARMS INC       20MG                              A216932  001  Oct 12, 2022   Sep NEWA
            TADALAFIL
    AB1       AUSTARPHARMA          2.5MG                             A208824  001  Oct 27, 2020   Mar CAHN
    AB1                             5MG                               A208824  002  Oct 27, 2020   Mar CAHN
    AB1                             10MG                              A208824  003  Oct 27, 2020   Mar CAHN
    AB1                             20MG                              A208824  004  Oct 27, 2020   Mar CAHN
            @ CHARTWELL RX          2.5MG                             A210716  001  Dec 29, 2020   May CAHN
            @                       5MG                               A210716  002  Dec 29, 2020   May CAHN
            @                       10MG                              A210716  003  Dec 29, 2020   May CAHN
            @                       20MG                              A210716  004  Dec 29, 2020   May CAHN
    AB1       PRINSTON INC          2.5MG                             A210609  001  Aug 11, 2022   Aug NEWA
    AB1                             5MG                               A210609  002  Aug 11, 2022   Aug NEWA
    AB1                             10MG                              A210609  003  Aug 11, 2022   Aug NEWA
    AB2                             20MG                              A210608  001  Aug 11, 2022   Aug NEWA
    AB1                             20MG                              A210609  004  Aug 11, 2022   Aug NEWA

        TAFENOQUINE SUCCINATE
          TABLET;ORAL
            ARAKODA
          +!  60 DEGREES PHARMS     EQ 100MG BASE                     N210607  001  Aug 08, 2018   Jul CAHN

        TAFLUPROST
          SOLUTION/DROPS;OPHTHALMIC
            TAFLUPROST
    AT        SANDOZ INC            0.0015%                           A209040  001  Jan 28, 2022   Jan NEWA
            ZIOPTAN
    AT    +!  THEA PHARMA           0.0015%                           N202514  001  Feb 10, 2012   Apr CAHN

        TAMSULOSIN HYDROCHLORIDE
          CAPSULE;ORAL
            TAMSULOSIN HYDROCHLORIDE
>D> AB        ACME LABS             0.4MG                             A214730  001  May 04, 2022   Nov DISC
>A>         @                       0.4MG                             A214730  001  May 04, 2022   Nov DISC
    AB                              0.4MG                             A214730  001  May 04, 2022   Apr NEWA

        TAPINAROF
          CREAM;TOPICAL
            VTAMA
          +!  DERMAVANT SCI         1%                                N215272  001  May 23, 2022   May NEWA

        TAVABOROLE
          SOLUTION;TOPICAL
            TAVABOROLE
    AB        CHARTWELL RX          5%                                A211963  001  Feb 03, 2021   Mar CAHN
    AB        IDENTIRX              5%                                A211963  001  Feb 03, 2021   Mar CMFD

        TAZAROTENE
          GEL;TOPICAL
            TAZAROTENE
    AB        COSETTE               0.05%                             A215433  001  Sep 13, 2022   Sep NFTG
    AB                              0.1%                              A214136  001  Sep 13, 2022   Sep NFTG
            TAZORAC
    AB    +!  ALLERGAN              0.05%                             N020600  001  Jun 13, 1997   Sep CFTG
    AB    +!                        0.1%                              N020600  002  Jun 13, 1997   Sep CFTG
          LOTION;TOPICAL
            ARAZLO
          +!  BAUSCH                0.045%                            N211882  001  Dec 18, 2019   May CAHN
```

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE;INJECTION

TECHNETIUM TC99M MERTIATIDE KIT

>A>	AP	MEDI-RADIOPHARMA	N/A	A206489	001	Feb 06, 2020	Nov CAHN
>D>	AP	SOMMER PHARMS II LLC	N/A	A206489	001	Feb 06, 2020	Nov CAHN

TECHNETIUM TC-99M SUCCIMER

POWDER;INTRAVENOUS

NEPHROSCAN

	+!	THERAGNOSTICS	N/A	N214993	001	Feb 18, 2022	Mar CAIN

TECHNETIUM TC-99M SUCCIMER KIT

POWDER;INTRAVENOUS

NEPHROSCAN

	+!	THERAGNOSTICS	N/A	N214993	001	Feb 18, 2022	Feb NEWA

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE;INJECTION

MYOVIEW

	+!	GE HEALTHCARE	N/A	N020372	001	Feb 09, 1996	Feb CMFD

TECOVIRIMAT

SOLUTION;INTRAVENOUS

TPOXX

	+!	SIGA TECHNOLOGIES	200MG/20ML (10MG/ML)	N214518	001	May 18, 2022	May NEWA

TEDUGLUTIDE RECOMBINANT

POWDER;SUBCUTANEOUS

GATTEX KIT

	+!	TAKEDA PHARMS USA	5MG/VIAL	N203441	001	Dec 21, 2012	Apr CAHN

TEGASEROD MALEATE

TABLET;ORAL

ZELNORM

	+ @	ALFASIGMA	EQ 6MG BASE	N021200	002	Jul 24, 2002	Jun DISC

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

	@	ANI PHARMS	5MG	A203490	001	Jul 13, 2016	Jun DISC
	@		20MG	A203490	002	Jul 13, 2016	Jun DISC
	@		100MG	A203490	003	Jul 13, 2016	Jun DISC
	@		140MG	A203490	004	Jul 13, 2016	Jun DISC
	@		180MG	A203490	005	Jul 13, 2016	Jun DISC
	@		250MG	A203490	006	Jul 13, 2016	Mar DISC
AB		HERITAGE	5MG	A078879	001	Mar 01, 2010	Jan CMFD
AB			20MG	A078879	002	Mar 01, 2010	Jan CMFD
AB			100MG	A078879	003	Mar 01, 2010	Jan CMFD
AB			140MG	A078879	005	Mar 01, 2010	Jan CMFD
AB			180MG	A078879	006	Mar 01, 2010	Jan CMFD
AB			250MG	A078879	004	Mar 01, 2010	Jan CMFD

TENAPANOR HYDROCHLORIDE

TABLET;ORAL

IBSRELA

	+!	ARDELYX INC	EQ 50MG BASE	N211801	001	Sep 12, 2019	Feb CMFD

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB		CHARTWELL	300MG	A206481	001	Jul 26, 2018	Jul CMFD

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

AB		CHARTWELL	EQ 250MG BASE	A078199	001	Jul 02, 2007	Mar CMFD
	@	HERITAGE PHARMA AVET	EQ 250MG BASE	A076377	001	Jul 02, 2007	Jul DISC

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

	@	AKORN	1MG/ML	A078151	001	Jan 07, 2008	Aug DISC
AP	!	CHARTWELL INJECTABLE	1MG/ML	A076770	001	Apr 23, 2004	Mar CAHN

TERLIPRESSIN ACETATE

POWDER;INTRAVENOUS

TERLIVAZ

+!	MALLINCKRODT IRELAND	EQ 0.85MG BASE/VIAL	N022231	001	Sep 14, 2022	Sep NEWA

TESTOSTERONE

GEL;TRANSDERMAL

ANDROGEL

+ @	ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309	002	Sep 07, 2012	Jan DISC
+ @		1.62% (40.5MG/2.5GM PACKET)	N022309	003	Sep 07, 2012	Jan DISC
+ @		25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan DISC
+ @		50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan DISC

TESTOSTERONE

AB1	!	ACTAVIS LABS UT INC	50MG/5GM PACKET	A076737	002	Jan 27, 2006	Jan CHRS
AB2	!	PADAGIS ISRAEL	1.62% (40.5MG/2.5GM PACKET)	A205781	002	Jul 12, 2017	Jan CHRS

TESTOSTERONE CYPIONATE

SOLUTION;INTRAMUSCULAR

TESTOSTERONE CYPIONATE

+ @	SLAYBACK PHARMA LLC	200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Sep DISC
+!		200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Jun NEWA

TESTOSTERONE UNDECANOATE

CAPSULE;ORAL

JATENZO

>D>	+	CLARUS	158MG	N206089	001	Mar 27, 2019	Nov CAHN
>D>	+		198MG	N206089	002	Mar 27, 2019	Nov CAHN
>D>	+!		237MG	N206089	003	Mar 27, 2019	Nov CAHN
>A>	+	TOLMAR	158MG	N206089	001	Mar 27, 2019	Nov CAHN
>A>	+		198MG	N206089	002	Mar 27, 2019	Nov CAHN
>A>	+!		237MG	N206089	003	Mar 27, 2019	Nov CAHN

KYZATREX

+	MARIUS PHARMS LLC	100MG	N213953	001	Jul 27, 2022	Jul NEWA
+		150MG	N213953	002	Jul 27, 2022	Jul NEWA
+!		200MG	N213953	003	Jul 27, 2022	Jul NEWA

TLANDO

+!	ANTARES PHARMA INC	112.5MG	N208088	001	Mar 28, 2022	Mar NEWA

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

@	HIKMA	12.5MG	A209739	001	Apr 08, 2019	Feb DISC
@		25MG	A209739	002	Apr 08, 2019	Feb DISC

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

AB		TEVA PHARMS INC	300MG	A216961	001	Oct 12, 2022	Sep NEWA
AB			450MG	A216961	002	Oct 12, 2022	Sep NEWA

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

THIAMINE HYDROCHLORIDE

AP		EUGIA PHARMA	100MG/ML	A208703	001	Apr 20, 2022	Apr NEWA

THIOGUANINE

TABLET;ORAL

THIOGUANINE

+!	WOODWARD SPECL	40MG	N012429	001			Apr CAHN

THIOTHIXENE

CAPSULE;ORAL

THIOTHIXENE

AB		AMNEAL	1MG	A215456	001	Feb 28, 2022	Feb NEWA
AB			2MG	A215456	002	Feb 28, 2022	Feb NEWA
AB			5MG	A215456	003	Feb 28, 2022	Feb NEWA
AB			10MG	A215456	004	Feb 28, 2022	Feb NEWA

TIAGABINE HYDROCHLORIDE

TABLET;ORAL

TIAGABINE HYDROCHLORIDE

	@	AMNEAL PHARMS CO	2MG	A208181	001	Dec 08, 2017	Jul DISC
	@		4MG	A208181	002	Dec 08, 2017	Jul DISC
	@		12MG	A208181	003	Dec 08, 2017	Jul DISC
	@		16MG	A208181	004	Dec 08, 2017	Jul DISC

TICAGRELOR

TABLET;ORAL

BRILINTA

	+	ASTRAZENECA	60MG	N022433	002	Sep 03, 2015	Feb CTEC

TICAGRELOR

	@	MYLAN	60MG	A208597	001	Jul 09, 2021	Feb DISC
	@		90MG	A208597	002	Jul 09, 2021	Feb DISC

TIGECYCLINE

POWDER;INTRAVENOUS

TIGECYCLINE

	@	XELLIA PHARMS APS	50MG/VIAL	A205722	001	Oct 18, 2019	Jun DISC

TIMOLOL

SOLUTION/DROPS;OPHTHALMIC

BETIMOL

AT	+!	THEA PHARMA	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Apr CAHN
AT	+!		EQ 0.5% BASE	N020439	002	Mar 31, 1995	Apr CAHN

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AB		DR REDDYS	EQ 0.25% BASE	A215733	001	Sep 22, 2022	Sep NEWA
AB			EQ 0.5% BASE	A215733	002	Sep 22, 2022	Sep NEWA
AB		GLAND PHARMA LTD	EQ 0.25% BASE	A214645	001	Jun 24, 2022	Jun NEWA

TIMOPTIC-XE

AB	+	BAUSCH	EQ 0.25% BASE	N020330	001	Nov 04, 1993	Apr CAHN
AB	+		EQ 0.5% BASE	N020330	002	Nov 04, 1993	Apr CAHN
AB	+	BAUSCH AND LOMB INC	EQ 0.25% BASE	N020330	001	Nov 04, 1993	Jul CAHN
AB	+		EQ 0.5% BASE	N020330	002	Nov 04, 1993	Jul CAHN

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

	@	AKORN	EQ 0.5% BASE	A074516	001	Mar 25, 1997	Jul DISC
	@		EQ 0.5% BASE	A075163	001	Sep 10, 2002	Sep DISC
AT3		INGENUS PHARMS LLC	EQ 0.25% BASE	A216533	001	Sep 13, 2022	Sep NEWA
AT3			EQ 0.5% BASE	A216533	002	Sep 13, 2022	Sep NEWA
AT3		MICRO LABS	EQ 0.5% BASE	A216596	001	Sep 07, 2022	Aug NEWA

TIMOPTIC

AT1	+	BAUSCH	EQ 0.25% BASE	N018086	001		Apr CAHN
AT1	+		EQ 0.5% BASE	N018086	002		Apr CAHN
AT1	+	BAUSCH AND LOMB INC	EQ 0.25% BASE	N018086	001		Jul CAHN
AT1	+		EQ 0.5% BASE	N018086	002		Jul CAHN

TIMOPTIC IN OCUDOSE

AT3	+!	BAUSCH AND LOMB INC	EQ 0.25% BASE	N019463	001	Nov 05, 1986	Feb CAHN
AT3	+!		EQ 0.5% BASE	N019463	002	Nov 05, 1986	Feb CAHN

TINIDAZOLE

TABLET;ORAL

TINIDAZOLE

	@	HIKMA	250MG	A201172	001	Apr 30, 2012	Sep DISC
	@		500MG	A201172	002	Apr 30, 2012	Sep DISC

TIOPRONIN

TABLET;ORAL

TIOPRONIN

AB		PAR PHARM INC	100MG	A216198	001	Jun 02, 2022	May NEWA

TIRZEPATIDE

SOLUTION;SUBCUTANEOUS

MOUNJARO

	+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	001	May 13, 2022	May NEWA
	+!		5MG/0.5ML (5MG/0.5ML)	N215866	002	May 13, 2022	May NEWA
	+!		7.5MG/0.5ML (7.5MG/0.5ML)	N215866	003	May 13, 2022	May NEWA
	+!		10MG/0.5ML (10MG/0.5ML)	N215866	004	May 13, 2022	May NEWA
	+!		12.5MG/0.5ML (12.5MG/0.5ML)	N215866	005	May 13, 2022	May NEWA
	+!		15MG/0.5ML (15MG/0.5ML)	N215866	006	May 13, 2022	May NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

ZANAFLEX

>D> AB	+	COVIS	EQ 2MG BASE	N021447	001	Aug 29, 2002	Nov CAHN
>D> AB	+		EQ 4MG BASE	N021447	002	Aug 29, 2002	Nov CAHN
>D> AB	+!		EQ 6MG BASE	N021447	003	Aug 29, 2002	Nov CAHN
>A> AB	+	LEGACY PHARMA	EQ 2MG BASE	N021447	001	Aug 29, 2002	Nov CAHN
>A> AB	+		EQ 4MG BASE	N021447	002	Aug 29, 2002	Nov CAHN
>A> AB	+!		EQ 6MG BASE	N021447	003	Aug 29, 2002	Nov CAHN

TABLET;ORAL

ZANAFLEX

>D>	+ @	COVIS	EQ 2MG BASE	N020397	002	Feb 04, 2000	Nov CAHN
>D> AB	+!		EQ 4MG BASE	N020397	001	Nov 27, 1996	Nov CAHN
>A>	+ @	LEGACY PHARMA	EQ 2MG BASE	N020397	002	Feb 04, 2000	Nov CAHN
>A> AB	+!		EQ 4MG BASE	N020397	001	Nov 27, 1996	Nov CAHN

TOBRAMYCIN

SOLUTION;INHALATION

TOBRAMYCIN

AN		MANKIND PHARMA	300MG/4ML	A216725	001	Sep 22, 2022	Sep NEWA

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

	@	AKORN	EQ 40MG BASE/ML	A205179	001	Sep 16, 2014	Aug DISC

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE;ORAL

TOFACITINIB

	@	ZYDUS PHARMS	EQ 11MG BASE	A214264	001	Aug 19, 2021	Jan DISC
	@		EQ 22MG BASE	A214264	002	Aug 19, 2021	Jan DISC

XELJANZ XR

	+	PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016	Jan CTEC
	+!		EQ 22MG BASE	N208246	002	Dec 12, 2019	Jan CTEC

TOLVAPTAN

TABLET;ORAL

SAMSCA

AB	+	OTSUKA	15MG	N022275	001	May 19, 2009	Feb CFTG

TOLVAPTAN

AB		ALKEM LABS LTD	15MG	A211891	003	Sep 06, 2022	Aug NEWA
AB		APOTEX	15MG	A207605	002	Sep 06, 2022	Aug NEWA
AB		HETERO LABS LTD V	15MG	A205646	002	Sep 06, 2022	Aug NEWA
AB		PAR PHARM INC	15MG	A206119	001	Feb 15, 2022	Feb NFTG
AB			30MG	A206119	002	Feb 15, 2022	Feb NEWA

TOPIRAMATE

CAPSULE;ORAL

TOPIRAMATE

>D>	@	MYLAN	15MG	A078418	001	Oct 14, 2009	Nov CAHN
>D>	@		25MG	A078418	002	Oct 14, 2009	Nov CAHN
>A>	@	STRIDES PHARMA	15MG	A078418	001	Oct 14, 2009	Nov CAHN
>A>	@		25MG	A078418	002	Oct 14, 2009	Nov CAHN

```
          CAPSULE, EXTENDED RELEASE;ORAL
            TOPIRAMATE
>A> AB2       ZYDUS PHARMS          25MG                            A208949  001  Nov 29, 2022   Nov NEWA
>A> AB2                             50MG                            A208949  002  Nov 29, 2022   Nov NEWA
>A> AB2                             100MG                           A208949  003  Nov 29, 2022   Nov NEWA
>A> AB2                             150MG                           A208949  004  Nov 29, 2022   Nov NEWA
>A> AB2                             200MG                           A208949  005  Nov 29, 2022   Nov NEWA
          TABLET;ORAL
            TOPIRAMATE
            @ UPSHER SMITH LABS     25MG                            A078499  001  Jan 07, 2010   Mar DISC
            @                       50MG                            A078499  002  Jan 07, 2010   Mar DISC
            @                       100MG                           A078499  003  Jan 07, 2010   Mar DISC
            @                       200MG                           A078499  004  Jan 07, 2010   Mar DISC

        TOPOTECAN HYDROCHLORIDE
          INJECTABLE;INJECTION
            TOPOTECAN HYDROCHLORIDE
    AP        TEYRO LABS            EQ 4MG BASE/VIAL                A091199  001  Dec 01, 2010   Apr CAHN
          SOLUTION;INTRAVENOUS
            TOPOTECAN HYDROCHLORIDE
            @ MYLAN LABS LTD        EQ 4MG BASE/4ML (EQ 1MG BASE/ML)  A206074  001  Nov 24, 2017   Mar DISC

        TRAMADOL HYDROCHLORIDE
          TABLET;ORAL
            TRAMADOL HYDROCHLORIDE
            @ MYLAN                 50MG                            A075986  001  Jun 21, 2002   Sep DISC
    AB    !   SUN PHARM INDS INC    50MG                            A075964  001  Jun 19, 2002   Sep CHRS
            ULTRAM
          + @ JANSSEN PHARMS        50MG                            N020281  002  Mar 03, 1995   Sep DISC
          + @                       100MG                           N020281  001  Mar 03, 1995   Aug CRLD
          TABLET, EXTENDED RELEASE;ORAL
            TRAMADOL HYDROCHLORIDE
            @ MYLAN                 100MG                           A205257  001  Dec 22, 2015   Sep DISC
            @                       200MG                           A205257  002  Dec 22, 2015   Jun DISC
            @                       300MG                           A205257  003  Dec 22, 2015   Jun DISC

        TRANDOLAPRIL
          TABLET;ORAL
            TRANDOLAPRIL
>A>         @ CHARTWELL MOLECULAR   1MG                             A077307  002  Jun 12, 2007   Nov CAHN
>A>         @                       2MG                             A077307  001  Jun 12, 2007   Nov CAHN
>A>         @                       4MG                             A077307  003  Jun 12, 2007   Nov CAHN
>D>         @ CIPLA                 1MG                             A077307  002  Jun 12, 2007   Nov CAHN
>D>         @                       2MG                             A077307  001  Jun 12, 2007   Nov CAHN
>D>         @                       4MG                             A077307  003  Jun 12, 2007   Nov CAHN

        TRANEXAMIC ACID
          INJECTABLE;INJECTION
            TRANEXAMIC ACID
            @ AKORN                 100MG/ML                        A206594  001  Sep 28, 2017   Jun DISC
            @                       100MG/ML                        A206634  001  Jun 09, 2016   Jun DISC
            @ ANDA REPOSITORY       100MG/ML                        A202755  001  Feb 25, 2016   Sep CAHN

        TRANYLCYPROMINE SULFATE
          TABLET;ORAL
            TRANYLCYPROMINE SULFATE
    AB        CROSSMEDIKA SA        EQ 10MG BASE                    A213503  001  Jun 27, 2022   Jun NEWA

        TREPROSTINIL
          POWDER;INHALATION
            TYVASO DPI
          +   UNITED THERAP         0.016MG/INH                     N214324  001  May 23, 2022   May NEWA
          +                         0.032MG/INH                     N214324  002  May 23, 2022   May NEWA
          +                         0.048MG/INH                     N214324  003  May 23, 2022   May NEWA
          +!                        0.064MG/INH                     N214324  004  May 23, 2022   May NEWA
```

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED;NASAL

NASACORT

	@	CHATTEM SANOFI	0.055MG/INH	N019798	001	Jul 11, 1991	Jan CAHN
	@		0.055MG/INH	N019798	001	Jul 11, 1991	Jan CAHN

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		ENCUBE	0.1%	A208848	001	Sep 18, 2017	Jul CAHN

FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR

ZILRETTA

	+!	PACIRA PHARMS INC	32MG/VIAL	N208845	001	Oct 06, 2017	Feb CAHN

INJECTABLE;INJECTION

TRIAMCINOLONE ACETONIDE

AB		CUSTOPHARM INC	40MG/ML	A213543	001	Jan 19, 2022	Jan NEWA
AB		EUGIA PHARMA	40MG/ML	A212400	001	Jul 05, 2022	Jun NEWA
AB		LONG GROVE PHARMS	40MG/ML	A213543	001	Jan 19, 2022	Jan CAHN
AB		MYLAN LABS LTD	40MG/ML	A212567	001	Nov 02, 2022	Oct NEWA

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		ENCUBE	0.1%	A205373	001	May 13, 2016	Jul CAHN

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

	@	PERRIGO PHARMA INTL	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jan CAHN

TRIAMCINOLONE HEXACETONIDE

INJECTABLE;INJECTION

ARISTOSPAN

+	@	SANDOZ INC	5MG/ML	N016466	001		Jul DISC
+	@		20MG/ML	N016466	002		Jul DISC

TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE

AB		EYWA	50MG	A214768	001	Jul 06, 2022	Jun NEWA
AB			100MG	A214768	002	Jul 06, 2022	Jun NEWA

TRIAZOLAM

TABLET;ORAL

TRIAZOLAM

AB		SANDOZ INC	0.125MG	A216890	001	Nov 08, 2022	Oct NEWA
AB			0.25MG	A216890	002	Nov 08, 2022	Oct NEWA

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

TRIENTINE HYDROCHLORIDE

	@	ACCORD HLTHCARE	250MG	A212929	001	Aug 30, 2021	Oct DISC
AB		ECI PHARMS LLC	250MG	A209945	001	Aug 13, 2021	Sep CAHN
AB		HETERO LABS LTD III	250MG	A216356	001	Jun 23, 2022	Jun NEWA
	@	LUPIN LTD	250MG	A211637	001	May 21, 2020	Apr DISC

TRIENTINE TETRAHYDROCHLORIDE

TABLET;ORAL

CUVRIOR

	+!	ORPHALAN	300MG	N215760	001	Apr 28, 2022	Apr NEWA

TRIFLURIDINE

SOLUTION/DROPS;OPHTHALMIC

TRIFLURIDINE

	@	AKORN	1%	A205438	001	Jul 28, 2017	Aug DISC

TRIMETHOPRIM

TABLET;ORAL

TRIMETHOPRIM

AB		NOVITIUM PHARMA	100MG	A216393	001	Oct 28, 2022	Oct NEWA

TRIPTORELIN PAMOATE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

TRIPTODUR KIT

	+!	AZURITY	EQ 22.5MG BASE/VIAL	N208956	001	Jun 29, 2017	Jun CAHN

TROSPIUM CHLORIDE

TABLET;ORAL

TROSPIUM CHLORIDE

AB		AMICI	20MG	A215781	001	Feb 16, 2022	Feb NEWA
AB		ENALTEC	20MG	A215781	001	Feb 16, 2022	May CAHN
AB		ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Jul CAHN

TRYPAN BLUE

SOLUTION;OPHTHALMIC

MEMBRANEBLUE

	+ @	DORC	0.15%	N022278	001	Feb 20, 2009	Jul DISC

UPADACITINIB

TABLET, EXTENDED RELEASE;ORAL

RINVOQ

	+	ABBVIE INC	15MG	N211675	001	Aug 16, 2019	Jan CHRS
	+		30MG	N211675	002	Jan 14, 2022	Apr CHRS
	+!		30MG	N211675	002	Jan 14, 2022	Jan NEWA
	+!		45MG	N211675	003	Mar 16, 2022	Mar NEWA

URSODIOL

CAPSULE;ORAL

ACTIGALL

	@	TEVA BRANDED PHARM	150MG	N019594	001	Dec 31, 1987	Apr CAHN
AB	+!		300MG	N019594	002	Dec 31, 1987	Apr CAHN

URSODIOL

>A> AB		AUROBINDO PHARMA LTD	300MG	A214849	001	Nov 28, 2022	Nov NEWA
	@	VGYAAN	300MG	A214329	001	Jul 28, 2021	Feb DISC

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

>D> AB		ATLANTIDE	EQ 500MG BASE	A090216	001	May 24, 2010	Nov CAHN
>D> AB			EQ 1GM BASE	A090216	002	May 24, 2010	Nov CAHN
>A> AB		WOCKHARDT BIO AG	EQ 500MG BASE	A090216	001	May 24, 2010	Nov CAHN
>A> AB			EQ 1GM BASE	A090216	002	May 24, 2010	Nov CAHN

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB		AIRIS PHARMA PVT LTD	50MG/ML	A210169	001	Feb 17, 2022	Feb NEWA
>A> AB		AUROBINDO PHARMA	50MG/ML	A215124	001	Nov 17, 2022	Nov NEWA
AB		HETERO LABS LTD V	50MG/ML	A211475	001	Oct 04, 2022	Sep NEWA
AB		MSN	50MG/ML	A210169	001	Feb 17, 2022	Aug CAHN

TABLET;ORAL

VALGANCICLOVIR HYDROCHLORIDE

	@	MYLAN	EQ 450MG BASE	A205151	001	Mar 03, 2021	Mar DISC
AB			EQ 450MG BASE	A205151	001	Mar 03, 2021	Mar CAHN

VALPROATE SODIUM

INJECTABLE;INJECTION

VALPROATE SODIUM

	@	MYLAN	EQ 100MG BASE/ML	A208120	001	Dec 22, 2021	May DISC

VALPROIC ACID

SYRUP;ORAL

VALPROIC ACID

AA		ECI PHARMS LLC	250MG/5ML	A090517	001	May 28, 2010	Sep CAHN
	@	WOCKHARDT BIO AG	250MG/5ML	A070868	001	Jul 01, 1986	Mar DISC

VALRUBICIN

SOLUTION;INTRAVESICAL

VALRUBICIN

AO		HIKMA	40MG/ML	A206430	001	Apr 19, 2019	Aug CAHN

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION;ORAL

FIRVANQ KIT

>D>	+!	AZURITY	EQ 25MG BASE/ML	N208910	001	Jan 26, 2018	Nov CFTG
>A> AB	+!		EQ 25MG BASE/ML	N208910	001	Jan 26, 2018	Nov CFTG
>D>	+!		EQ 50MG BASE/ML	N208910	002	Jan 26, 2018	Nov CFTG
>A> AB	+!		EQ 50MG BASE/ML	N208910	002	Jan 26, 2018	Nov CFTG
>A>		VANCOMYCIN HYDROCHLORIDE					
>A> AB		ALKEM LABS LTD	EQ 25MG BASE/ML	A214913	001	Nov 14, 2022	Nov NFTG
>A> AB			EQ 50MG BASE/ML	A214913	002	Nov 14, 2022	Nov NFTG

INJECTABLE;INJECTION

VANCOCIN HYDROCHLORIDE

	@	STERISCIENCE	EQ 500MG BASE/VIAL	A060180	001		Jan CAHN
	@		EQ 500MG BASE/VIAL	A062476	001	Mar 15, 1984	Jan CAHN
	@		EQ 500MG BASE/VIAL	A062716	001	Mar 13, 1987	Jan CAHN
	@		EQ 500MG BASE/VIAL	A062812	001	Nov 17, 1987	Jan CAHN
	@		EQ 1GM BASE/VIAL	A060180	002	Mar 21, 1986	Jan CAHN
	@		EQ 1GM BASE/VIAL	A062476	002	Mar 21, 1986	Jan CAHN
	@		EQ 1GM BASE/VIAL	A062716	002	Mar 13, 1987	Jan CAHN
	@		EQ 1GM BASE/VIAL	A062812	002	Nov 17, 1987	Jan CAHN
	@		EQ 10GM BASE/VIAL	A062812	003	Nov 17, 1987	Jan CAHN
		VANCOMYCIN HYDROCHLORIDE					
AP		ASPIRO	EQ 500MG BASE/VIAL	A216591	001	Jul 06, 2022	Jun NEWA
AP			EQ 1GM BASE/VIAL	A216591	002	Jul 06, 2022	Jun NEWA
AP		HOSPIRA	EQ 750MG BASE/VIAL	A062912	002	Jan 07, 2009	Sep CHRS
AP			EQ 750MG BASE/VIAL	A062933	002	May 27, 2009	Sep CHRS
	@	KNACK	EQ 500MG BASE/VIAL	A213059	001	Feb 15, 2022	Aug DISC
AP			EQ 500MG BASE/VIAL	A213059	001	Feb 15, 2022	Feb NEWA
	@		EQ 750MG BASE/VIAL	A213059	002	Feb 15, 2022	Aug DISC
AP			EQ 750MG BASE/VIAL	A213059	002	Feb 15, 2022	Feb NEWA
	@		EQ 1GM BASE/VIAL	A213059	003	Feb 15, 2022	Aug DISC
AP			EQ 1GM BASE/VIAL	A213059	003	Feb 15, 2022	Feb NEWA
AP		MEITHEAL	EQ 500MG BASE/VIAL	A215197	001	Jul 28, 2022	Oct CAHN
AP			EQ 750MG BASE/VIAL	A215195	001	Sep 15, 2022	Oct CAHN
AP			EQ 1GM BASE/VIAL	A215197	002	Jul 28, 2022	Oct CAHN
AP			EQ 5GM BASE/VIAL	A215196	001	Jul 27, 2022	Oct CAHN
AP			EQ 10GM BASE/VIAL	A215196	002	Jul 27, 2022	Oct CAHN
AP		NANJING KING-FRIEND	EQ 500MG BASE/VIAL	A215197	001	Jul 28, 2022	Jul NEWA
AP			EQ 750MG BASE/VIAL	A215195	001	Sep 15, 2022	Sep NEWA
AP			EQ 1GM BASE/VIAL	A215197	002	Jul 28, 2022	Jul NEWA
AP			EQ 5GM BASE/VIAL	A215196	001	Jul 27, 2022	Jul NEWA
AP			EQ 10GM BASE/VIAL	A215196	002	Jul 27, 2022	Jul NEWA
	@	SANDOZ	EQ 500MG BASE/VIAL	A090250	001	Apr 27, 2010	Oct DISC
	@		EQ 1GM BASE/VIAL	A090250	002	Apr 27, 2010	Oct DISC

POWDER;INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

	+ @	MYLAN LABS LTD	EQ 250MG BASE/VIAL	N209481	001	Jul 10, 2018	Feb DISC

VARDENAFIL HYDROCHLORIDE

TABLET;ORAL

LEVITRA

	+ @	BAYER HLTHCARE	EQ 20MG BASE	N021400	004	Aug 19, 2003	Feb DISC
		VARDENAFIL HYDROCHLORIDE					
AB	!	ZYDUS PHARMS	EQ 20MG BASE	A208960	004	Oct 31, 2018	Feb CHRS

TABLET, ORALLY DISINTEGRATING;ORAL

STAXYN

	+ @	BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	May DISC
		VARDENAFIL HYDROCHLORIDE					
AB	!	ALEMBIC PHARMS LTD	10MG	A208324	001	Nov 16, 2018	May CHRS

VARENICLINE TARTRATE

SPRAY;NASAL

TYRVAYA

	+!	OYSTER POINT PHARMA	EQ 0.03MG BASE/SPRAY	N213978	001	Oct 15, 2021	Aug CDFR

```
          TABLET;ORAL
            CHANTIX
          + @ PF PRISM CV          EQ 0.5MG BASE                    N021928  001  May 10, 2006   Apr DISC
          + @                      EQ 1MG BASE                      N021928  002  May 10, 2006   Apr DISC
    AB    +                        EQ 1MG BASE                      N021928  002  May 10, 2006   Feb CHRS
            VARENICLINE TARTRATE
              PAR PHARM INC        EQ 0.5MG BASE                    A201785  001  Aug 11, 2021   Apr CTEC
          !                        EQ 1MG BASE                      A201785  002  Aug 11, 2021   Apr CTEC
    AB    !                        EQ 1MG BASE                      A201785  002  Aug 11, 2021   Feb CHRS

        VASOPRESSIN
          SOLUTION;INTRAVENOUS
            VASOPRESSIN
    AP        AMNEAL               20UNITS/ML (20UNITS/ML)          A212944  001  Aug 05, 2022   Sep CPOT
    AP                             20UNTS/ML (20UNITS/ML)           A212944  001  Aug 05, 2022   Jul NEWA
    AP        AMPHASTAR PHARMS INC 20UNITS/ML (20UNITS/ML)          A211857  001  Jul 18, 2022   Jul NEWA
    AP        EUGIA PHARMA         20UNITS/ML (20UNITS/ML)          A214314  001  Aug 15, 2022   Aug NEWA

        VENLAFAXINE BESYLATE
          TABLET, EXTENDED RELEASE;ORAL
            VENLAFAXINE BESYLATE
          +!  ALMATICA             EQ 112.5MG BASE                  N215429  001  Jun 29, 2022   Jun NEWA

        VENLAFAXINE HYDROCHLORIDE
          CAPSULE, EXTENDED RELEASE;ORAL
            VENLAFAXINE HYDROCHLORIDE
>D> AB        ATLANTIDE            EQ 37.5MG BASE                   A078865  001  Apr 14, 2011   Nov CAHN
>D> AB                             EQ 75MG BASE                     A078865  002  Apr 14, 2011   Nov CAHN
>D> AB                             EQ 150MG BASE                    A078865  003  Apr 14, 2011   Nov CAHN
>A> AB        WOCKHARDT BIO AG     EQ 37.5MG BASE                   A078865  001  Apr 14, 2011   Nov CAHN
>A> AB                             EQ 75MG BASE                     A078865  002  Apr 14, 2011   Nov CAHN
>A> AB                             EQ 150MG BASE                    A078865  003  Apr 14, 2011   Nov CAHN
    AB        YICHANG HUMANWELL    EQ 37.5MG BASE                   A214654  001  Aug 06, 2021   Aug CMFD
            @                      EQ 37.5MG BASE                   A214654  001  Aug 06, 2021   Jan DISC
    AB                             EQ 75MG BASE                     A214654  002  Aug 06, 2021   Aug CMFD
            @                      EQ 75MG BASE                     A214654  002  Aug 06, 2021   Jan DISC
    AB                             EQ 150MG BASE                    A214654  003  Aug 06, 2021   Aug CMFD
            @                      EQ 150MG BASE                    A214654  003  Aug 06, 2021   Jan DISC
          TABLET, EXTENDED RELEASE;ORAL
            VENLAFAXINE HYDROCHLORIDE
>A> AB        JB CHEMS PHARMS      EQ 37.5MG BASE                   A216044  001  Nov 28, 2022   Nov NEWA
>A> AB                             EQ 75MG BASE                     A216044  002  Nov 28, 2022   Nov NEWA
>A> AB                             EQ 150MG BASE                    A216044  003  Nov 28, 2022   Nov NEWA
>A> AB                             EQ 225MG BASE                    A216044  004  Nov 28, 2022   Nov NEWA
            @ PHARMADAX INC        EQ 75MG BASE                     A214423  001  Jan 04, 2022   Jul DISC
            @                      EQ 150MG BASE                    A214423  002  Jan 04, 2022   Jul DISC
            @ SUNNY                EQ 75MG BASE                     A214423  001  Jan 04, 2022   Sep CAHN
            @                      EQ 150MG BASE                    A214423  002  Jan 04, 2022   Sep CAHN
    AB        ZYDUS PHARMS         EQ 37.5MG BASE                   A215622  001  Aug 30, 2022   Aug NEWA
    AB                             EQ 75MG BASE                     A215622  002  Aug 30, 2022   Aug NEWA
    AB                             EQ 150MG BASE                    A215622  003  Aug 30, 2022   Aug NEWA
    AB                             EQ 225MG BASE                    A215622  004  Aug 30, 2022   Aug NEWA

        VERAPAMIL HYDROCHLORIDE
          CAPSULE, EXTENDED RELEASE;ORAL
            VERAPAMIL HYDROCHLORIDE
            @ RISING               100MG                            A078306  001  Aug 09, 2007   Oct CAHN
            @                      200MG                            A078306  002  Aug 09, 2007   Oct CAHN
            @                      300MG                            A078306  003  Aug 09, 2007   Oct CAHN
            VERELAN
    AB    +   SOCIETAL CDMO        120MG                            N019614  001  May 29, 1990   Jun CAHN
    AB    +                        180MG                            N019614  003  Jan 09, 1992   Jun CAHN
    AB    +                        240MG                            N019614  002  May 29, 1990   Jun CAHN
          +!                       360MG                            N019614  004  May 10, 1996   Jun CAHN
            VERELAN PM
          +   SOCIETAL CDMO        100MG                            N020943  001  Nov 25, 1998   Jun CAHN
          +                        200MG                            N020943  002  Nov 25, 1998   Jun CAHN
          +!                       300MG                            N020943  003  Nov 25, 1998   Jun CAHN
          INJECTABLE;INJECTION
            VERAPAMIL HYDROCHLORIDE
    AP        ACIC PHARMS          2.5MG/ML                         A215829  001  Mar 17, 2022   Mar NEWA
    AP        MANKIND PHARMA       2.5MG/ML                         A214653  001  Jun 15, 2022   Jun NEWA
```

```
          TABLET;ORAL
            VERAPAMIL HYDROCHLORIDE
            @ CHARTWELL RX          40MG                          A073168  001  Jul 31, 1992   Mar CAHN
            @                       80MG                          A071423  001  May 24, 1988   Mar CAHN
            @                       120MG                         A071424  001  May 25, 1988   Mar CAHN

        VIGABATRIN
          FOR SOLUTION;ORAL
            VIGABATRIN
            @ GRANULES              500MG/PACKET                  A213469  001  Apr 24, 2020   Sep DISC
            @ LUPIN LTD             500MG/PACKET                  A211790  001  Mar 10, 2022   Jul DISC
     AA                             500MG/PACKET                  A211790  001  Mar 10, 2022   Mar NEWA
     AA       MSN                   500MG/PACKET                  A215363  001  Sep 07, 2022   Aug NEWA
          TABLET;ORAL
            VIGABATRIN
     AB       AMNEAL PHARMS         500MG                         A210042  001  Jun 22, 2022   Jun NEWA
     AB       AUROBINDO PHARMA LTD  500MG                         A215601  001  May 10, 2022   Apr NEWA
     AB       HIKMA                 500MG                         A213104  001  Aug 29, 2022   Aug NEWA
     AB       ZYDUS                 500MG                         A215707  001  Jan 19, 2022   Jan NEWA

        VILAZODONE HYDROCHLORIDE
          TABLET;ORAL
            VILAZODONE HYDROCHLORIDE
>A>  AB       INVAGEN PHARMS        20MG                          A208200  003  Dec 06, 2022   Nov NEWA
     AB       TEVA PHARMS USA       10MG                          A208212  001  Sep 30, 2019   May CMFD
     AB                             20MG                          A208212  002  Sep 30, 2019   May CMFD
     AB                             40MG                          A208212  003  Sep 30, 2019   May CMFD

        VINORELBINE TARTRATE
          INJECTABLE;INJECTION
            VINORELBINE TARTRATE
     AP   !   JIANGSU HANSOH PHARM  EQ 10MG BASE/ML               A091106  001  Sep 26, 2012   Apr CHRS

        VORICONAZOLE
          FOR SUSPENSION;ORAL
            VORICONAZOLE
            @ RISING                200MG/5ML                     A202361  001  May 28, 2013   Aug CAHN
          INJECTABLE;INTRAVENOUS
            VORICONAZOLE
     AP       HONG KONG             200MG/VIAL                    A214516  001  May 09, 2022   Apr NEWA
     AP       MEITHEAL              200MG/VIAL                    A214516  001  May 09, 2022   Jun CAHN
            @ MYLAN LABS LTD        200MG/VIAL                    A210849  001  Oct 11, 2022   Oct DISC
     AP                             200MG/VIAL                    A210849  001  Oct 11, 2022   Sep NEWA

        VORINOSTAT
          CAPSULE;ORAL
            ZOLINZA
          +!  MSD SUB MERCK         100MG                         N021991  001  Oct 06, 2006   Jun CAHN

        VORTIOXETINE HYDROBROMIDE
          TABLET;ORAL
            TRINTELLIX
          +   TAKEDA PHARMS USA     EQ 5MG BASE                   N204447  001  Sep 30, 2013   Mar CTEC
          +                         EQ 10MG BASE                  N204447  002  Sep 30, 2013   Mar CTEC
          +!                        EQ 20MG BASE                  N204447  004  Sep 30, 2013   Mar CTEC
            VORTIOXETINE HYDROBROMIDE
            @ ZYDUS PHARMS          EQ 5MG BASE                   A211146  001  Sep 17, 2021   Mar DISC
            @                       EQ 10MG BASE                  A211146  002  Sep 17, 2021   Mar DISC
            @                       EQ 20MG BASE                  A211146  003  Sep 17, 2021   Mar DISC

        VOXELOTOR
          TABLET;ORAL
            OXBRYTA
          +   GLOBAL BLOOD THERAPS  300MG                         N213137  002  Oct 14, 2022   Oct NEWA

        VUTRISIRAN
          SOLUTION;SUBCUTANEOUS
            AMVUTTRA
          +!  ALNYLAM PHARMS INC    25MG/0.5ML (25MG/0.5ML)       N215515  001  Jun 13, 2022   Jun NEWA
```

ZAFIRLUKAST

TABLET;ORAL

ZAFIRLUKAST

AB	RISING PHARMS	10MG	A204928	001	Aug 25, 2022	Aug NEWA
AB		20MG	A204928	002	Aug 25, 2022	Aug NEWA

ZALEPLON

CAPSULE;ORAL

ZALEPLON

AB	CHARTWELL MOLECULAR	5MG	A077505	001	Jun 20, 2008	Mar CAHN
AB		10MG	A077505	002	Jun 20, 2008	Mar CAHN

ZILEUTON

TABLET, EXTENDED RELEASE;ORAL

ZILEUTON

AB	ANNORA PHARMA	600MG	A215742	001	Oct 11, 2022	Sep NEWA
	@ TEVA PHARMS USA	600MG	A211043	001	May 03, 2022	Oct DISC

ZINC SULFATE

AB	TEVA PHARMS USA	600MG	A211043	001	May 03, 2022	Apr NEWA

ZINC CHLORIDE

INJECTABLE;INJECTION

ZINC CHLORIDE

	@ EXELA PHARMA	EQ 1MG ZINC/ML	A212007	001	May 21, 2021	Feb DISC

ZINC CHLORIDE IN PLASTIC CONTAINER

+!	HOSPIRA	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986	Feb CTEC

ZINC SULFATE

SOLUTION;INTRAVENOUS

ZINC SULFATE

AP	+! AM REGENT	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	N209377	002	Jul 18, 2019	Apr CFTG
AP	+!	EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	N209377	001	Jul 18, 2019	Apr CFTG
AP	GLAND PHARMA LTD	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A216249	001	May 03, 2022	Apr NFTG
AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A216249	002	May 03, 2022	Apr NFTG

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

GEODON

AB	+! VIATRIS	EQ 20MG BASE	N020825	001	Feb 05, 2001	Jan CAHN
AB	+	EQ 40MG BASE	N020825	002	Feb 05, 2001	Jan CAHN
AB	+	EQ 60MG BASE	N020825	003	Feb 05, 2001	Jan CAHN
AB	+	EQ 80MG BASE	N020825	004	Feb 05, 2001	Jan CAHN

ZIPRASIDONE MESYLATE

INJECTABLE;INTRAMUSCULAR

GEODON

AP	+! VIATRIS	EQ 20MG BASE/VIAL	N020919	001	Jun 21, 2002	Feb CPOT
AP	+!	EQ 20MG BASE/ML	N020919	001	Jun 21, 2002	Jan CAHN

ZIPRASIDONE MESYLATE

AP	GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A211908	001	Dec 26, 2019	Feb CPOT

POWDER;INTRAMUSCULAR

GEODON

AP	+! VIATRIS	EQ 20MG BASE/VIAL	N020919	001	Jun 21, 2002	Feb CDFR

ZIPRASIDONE MESYLATE

AP	GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A211908	001	Dec 26, 2019	Feb CDFR
AP	MSN	EQ 20MG BASE/VIAL	A216091	001	Sep 15, 2022	Sep NEWA

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS

ZOLEDRONIC ACID

AP	AMNEAL	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	May CAHN
	@ EUGIA PHARMA	EQ 4MG BASE/5ML	A207751	001	Sep 26, 2016	Jul DISC
	@	EQ 5MG BASE/100ML	A209125	001	Dec 08, 2017	Jul DISC

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

AB	CHARTWELL MOLECULAR	5MG	A077388	001	Jul 30, 2012	Mar CAHN
AB		10MG	A077388	002	Jul 30, 2012	Mar CAHN

ZONISAMIDE

SUSPENSION;ORAL

ZONISADE

+!	AZURITY	100MG/5ML	N214273	001	Jul 15, 2022	Jul NEWA

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL					
ACETAMINOPHEN, ASPIRIN AND CAFFEINE					
AUROBINDO PHARMA LTD	250MG;250MG;65MG	A211695	001	Feb 02, 2022	Jan NEWA

ADAPALENE

GEL;TOPICAL					
ADAPALENE					
TARO PHARMS	0.1%	A215940	001	Jan 14, 2022	Jan NEWA

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE;ORAL					
GAVISCON					
+ @ CHATTEM SANOFI	80MG;20MG	N018685	001	Dec 09, 1983	May DISC

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL					
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
BAJAJ	5MG/5ML	A091327	001	Oct 17, 2011	Jun CAHN
@ CHARTWELL RX	5MG/5ML	A090378	002	May 09, 2008	Mar CAHN
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
BAJAJ	5MG/5ML	A091327	002	Oct 17, 2011	Jun CAHN
@ CHARTWELL RX	5MG/5ML	A090378	001	May 09, 2008	Mar CAHN
TABLET;ORAL					
CETIRIZINE HYDROCHLORIDE ALLERGY					
GLENMARK PHARMS INC	5MG	A078427	003	Dec 28, 2007	May CAHN
	10MG	A078427	004	Dec 28, 2007	May CAHN
TABLET, CHEWABLE;ORAL					
CHILDREN'S ZYRTEC ALLERGY					
+ J AND J CONSUMER INC	2.5MG	N021621	007	Nov 30, 2020	Jun CMFD
+	10MG	N021621	004	Nov 16, 2007	Jun CMFD

CLEMASTINE FUMARATE

TABLET;ORAL					
CLEMASTINE FUMARATE					
@ L PERRIGO CO	1.34MG	A074512	001	Nov 22, 1995	Jul DISC

CROMOLYN SODIUM

SPRAY, METERED;NASAL					
CROMOLYN SODIUM					
@ PERRIGO	5.2MG/SPRAY	A075427	001	Dec 12, 2001	Sep DISC

DICLOFENAC SODIUM

GEL;TOPICAL					
DICLOFENAC SODIUM					
AKORN	1%	A209484	001	Nov 21, 2018	Mar CMKT

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL					
IBUPROFEN AND DIPHENHYDRAMINE CITRATE					
AUROBINDO PHARMA	38MG;200MG	A216204	001	May 31, 2022	May NEWA

DOCOSANOL

CREAM;TOPICAL					
DOCOSANOL					
@ ALEOR DERMACEUTICALS	10%	A215839	001	May 03, 2022	Oct DISC
	10%	A215839	001	May 03, 2022	Apr NEWA
ENCUBE	10%	A212385	001	Oct 07, 2022	Sep NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL					
ESOMEPRAZOLE MAGNESIUM					
GRAVITI PHARMS	EQ 20MG BASE	A216349	001	Jun 24, 2022	Jun NEWA
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL					
ESOMEPRAZOLE MAGNESIUM					
+ @ DEXCEL	EQ 20MG BASE	N214278	001	Oct 20, 2020	Jan DISC

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

	GLENMARK PHARMS INC	10MG	A077146	001	Mar 07, 2005	Jun CAHN
		20MG	A090837	001	Aug 04, 2010	May CAHN
	VKT PHARMA	10MG	A215822	001	Jan 28, 2022	Jan NEWA
		20MG	A215822	002	Jan 28, 2022	Jan NEWA

TABLET, CHEWABLE;ORAL

FAMOTIDINE

	@ PERRIGO	10MG	A075715	001	Aug 22, 2003	Oct DISC

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

ALLEGRA HIVES

+!	CHATTEM SANOFI	180MG	N020872	009	Jan 24, 2011	Oct CMFD

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	@ SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012	Jun DISC

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	@ SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012	Jun DISC

FEXOFENADINE HYDROCHLORIDE ALLERGY

	@ SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012	Jun DISC

FEXOFENADINE HYDROCHLORIDE HIVES

	@ SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012	Jun DISC

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+!	CHATTEM SANOFI	60MG;120MG	N020786	002	Jan 24, 2011	Jan CAHN
+!		60MG;120MG	N020786	002	Jan 24, 2011	Jan CAHN

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+!	CHATTEM SANOFI	180MG;240MG	N021704	002	Jan 24, 2011	Jan CAHN
+!		180MG;240MG	N021704	002	Jan 24, 2011	Jan CAHN

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	DR REDDYS	60MG;120MG	A215434	001	May 31, 2022	May NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

	DR REDDYS	600MG	A215932	001	Mar 15, 2022	Mar NEWA
		1.2GM	A215932	002	Mar 15, 2022	Mar NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

	GRANULES	600MG;60MG	A216082	001	Aug 22, 2022	Aug NEWA
		1.2GM;120MG	A216082	002	Aug 22, 2022	Aug NEWA
	L PERRIGO CO	600MG;60MG	A214407	001	Feb 01, 2022	Jan NEWA
		1.2GM;120MG	A214407	002	Feb 01, 2022	Jan NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

>D>	@ STRIDES PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A204469	001	Mar 28, 2018	Nov CMFD
>A>		EQ 200MG FREE ACID AND POTASSIUM SALT	A204469	001	Mar 28, 2018	Nov CMFD

SUSPENSION/DROPS;ORAL

IBUPROFEN

>D>	STRIDES PHARMA	50MG/1.25ML	A214071	001	Jun 09, 2022	Nov DISC
>A>	@	50MG/1.25ML	A214071	001	Jun 09, 2022	Nov DISC
		50MG/1.25ML	A214071	001	Jun 09, 2022	Jun NEWA

TABLET;ORAL

IBUPROFEN

	@ PERRIGO	200MG	A075995	001	Mar 14, 2002	Oct DISC
>D>	JUNIOR STRENGTH IBUPROFEN					
>D>	L PERRIGO CO	100MG	A075367	001	Apr 22, 1999	Nov DISC
>A>	@	100MG	A075367	001	Apr 22, 1999	Nov DISC
>D>	TAB-PROFEN					
>D>	PERRIGO	200MG	A072095	001	Dec 08, 1987	Nov DISC
>A>	@	200MG	A072095	001	Dec 08, 1987	Nov DISC

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
SUSPENSION;ORAL
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D>		PERRIGO	100MG/5ML;15MG/5ML	A076478	001	Nov 05, 2003	Nov DISC
>A>	@		100MG/5ML;15MG/5ML	A076478	001	Nov 05, 2003	Nov DISC

ISOPROPYL ALCOHOL
SOLUTION;TOPICAL
ZURAGARD

	+!	ZUREX PHARMA	70%	N210872	001	Apr 26, 2019	Jul CMFD

IVERMECTIN
LOTION;TOPICAL
IVERMECTIN

	@	TEVA PHARMS USA	0.5%	A212485	001	Mar 21, 2022	Sep DISC
			0.5%	A212485	001	Mar 21, 2022	Mar NEWA

KETOTIFEN FUMARATE
SOLUTION/DROPS;OPHTHALMIC
ALAWAY

		BAUSCH	EQ 0.025% BASE	A208158	001	Sep 24, 2020	Mar CPOT
		BAUSCH AND LOMB INC	EQ 0.025% BASE	A208158	001	Sep 24, 2020	Mar CAHN

CHILDREN'S ALAWAY

	+	BAUSCH AND LOMB	EQ 0.025% BASE	N021996	002	Feb 11, 2015	Mar CPOT
	+		EQ 0.035% BASE	N021996	002	Feb 11, 2015	Mar CTNA

LANSOPRAZOLE
CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

		GLENMARK PHARMS INC	15MG	A202727	001	May 18, 2012	May CAHN
>D>		LANNETT CO INC	15MG	A207157	001	Sep 29, 2017	Nov DISC
>A>	@		15MG	A207157	001	Sep 29, 2017	Nov DISC

LEVOCETIRIZINE DIHYDROCHLORIDE
SOLUTION;ORAL
XYZAL ALLERGY 24HR

	+!	CHATTEM SANOFI	2.5MG/5ML	N209090	001	Jan 31, 2017	Jan CAHN

TABLET;ORAL
XYZAL ALLERGY 24HR

	+!	CHATTEM SANOFI	5MG	N209089	001	Jan 31, 2017	Jan CAHN

LEVONORGESTREL
TABLET;ORAL
LEVONORGESTREL

	@	L PERRIGO CO	0.75MG	A090740	001	Dec 30, 2010	May DISC

LOPERAMIDE HYDROCHLORIDE
SOLUTION;ORAL
LOPERAMIDE HYDROCHLORIDE

	@	AKORN	1MG/5ML	A074352	001	Nov 17, 1995	Jun DISC

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE
TABLET;ORAL
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

		GRANULES	2MG;125MG	A215981	001	Aug 29, 2022	Aug NEWA

TABLET, CHEWABLE;ORAL
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

	@	PERRIGO	2MG;125MG	A076029	001	Aug 30, 2002	Oct DISC

LORATADINE
TABLET, CHEWABLE;ORAL
CHILDREN'S CLARITIN

	+	BAYER HEALTHCARE LLC	5MG	N021891	001	Aug 23, 2006	Apr CHRS

CLARITIN

	+!	BAYER HEALTHCARE LLC	10MG	N021891	002	Nov 21, 2018	Apr CHRS

MICONAZOLE NITRATE

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

>D>	!	PERRIGO	100MG	A074395	001	Mar 20, 1997	Nov DISC
>A>	@		100MG	A074395	001	Mar 20, 1997	Nov DISC

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL

		PERRIGO PHARMA INTL	5%	A091344	001	Apr 28, 2011	Jan CAHN

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

	@	AKORN	2%	A074731	001	Dec 24, 1996	Aug DISC

MINOXIDIL (FOR WOMEN)

	@	AKORN	2%	A074731	002	May 11, 2005	Aug DISC

MINOXIDIL EXTRA STRENGTH (FOR MEN)

>D>		PERRIGO NEW YORK	5%	A075737	001	Mar 15, 2002	Nov DISC
>A>	@		5%	A075737	001	Mar 15, 2002	Nov DISC

THEROXIDIL

		PURE SOURCE	2%	A078176	001	Nov 09, 2007	Jun CAHN
			5%	A076239	001	Aug 24, 2004	Jun CAHN

MOMETASONE FUROATE

SPRAY, METERED;NASAL

NASONEX 24HR ALLERGY

	+!	PERRIGO PHARMA INTL	0.05MG/SPRAY	N215712	001	Mar 17, 2022	Mar NEWA

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

		STRIDES PHARMA	EQ 200MG BASE	A215472	001	Aug 17, 2022	Aug NEWA

TABLET;ORAL

NAPROXEN SODIUM

		HETERO LABS LTD V	220MG	A211065	001	Oct 28, 2022	Oct NEWA
		YICHANG HUMANWELL	220MG	A212033	001	Aug 30, 2019	Jul CMFD

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS & COLD

	+ @	BAYER	220MG;120MG	N021076	001	Nov 29, 1999	Jan DISC

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D>		AUROBINDO PHARMA	220MG;120MG	A211360	001	Jun 01, 2022	Nov DISC
>A>	@		220MG;120MG	A211360	001	Jun 01, 2022	Nov DISC
			220MG;120MG	A211360	001	Jun 01, 2022	May NEWA
	!	PERRIGO	220MG;120MG	A076518	001	Mar 17, 2004	Jan CHRS

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

>D>		L PERRIGO CO	EQ 2MG BASE	A076776	001	Sep 16, 2004	Nov DISC
>A>	@		EQ 2MG BASE	A076776	001	Sep 16, 2004	Nov DISC
>D>			EQ 4MG BASE	A076778	001	Sep 16, 2004	Nov DISC
>A>	@		EQ 4MG BASE	A076778	001	Sep 16, 2004	Nov DISC
>D>		PERRIGO R AND D	EQ 2MG BASE	A078967	001	Apr 23, 2008	Nov DISC
>A>	@		EQ 2MG BASE	A078967	001	Apr 23, 2008	Nov DISC
>D>			EQ 4MG BASE	A078968	001	Apr 23, 2008	Nov DISC
>A>	@		EQ 4MG BASE	A078968	001	Apr 23, 2008	Nov DISC

TROCHE/LOZENGE;ORAL

NICOTINE POLACRILEX

		AUROBINDO PHARMA LTD	EQ 2MG BASE	A215357	001	May 13, 2022	May NEWA
			EQ 4MG BASE	A215357	002	May 13, 2022	May NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

	@	BAUSCH AND LOMB INC	EQ 0.1% BASE	A206046	001	Jul 26, 2017	Jun CAHN
	@	GLENMARK PHARMS INC	EQ 0.1% BASE	A200810	001	Jun 28, 2017	May CAHN
	@	MYLAN	EQ 0.2% BASE	A204620	001	Jun 16, 2020	May DISC
	@	RISING	EQ 0.1% BASE	A204392	001	Mar 21, 2018	Jul CAHN
	@		EQ 0.2% BASE	A204620	001	Jun 16, 2020	Jul CAHN

OMEPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

OMEPRAZOLE

+!	DEXCEL	20MG	N209400	001	Jul 05, 2017	Feb	CHRS

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

	L PERRIGO CO	EQ 20MG BASE	A216096	001	May 24, 2022	May	NEWA

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

>D>	PERRIGO R AND D	EQ 20MG BASE	A204152	001	Jul 30, 2015	Nov	DISC
>A>	@	EQ 20MG BASE	A204152	001	Jul 30, 2015	Nov	DISC

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

	@ CHARTWELL RX	20MG;1.1GM	A204137	001	Jul 15, 2016	Jul	CAHN

ZEGERID OTC

+!	RILEY CONSUMER	20MG;1.1GM	N022281	001	Dec 01, 2009	Mar	CAHN

FOR SUSPENSION;ORAL

ZEGERID OTC

+!	RILEY CONSUMER	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013	Mar	CAHN

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

+ @	ROXANE	1GM/ML	N018551	001	Feb 19, 1982	Jan	CRLD

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

!	L PERRIGO CO	120MG	A075153	001	Feb 26, 1999	Jun	CHRS

SUDAFED 12 HOUR

@	MCNEIL CONS	120MG	A073585	001	Oct 31, 1991	Jun	DISC

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@	PERRIGO	EQ 75MG BASE	A076195	001	Aug 30, 2002	Sep	DISC
@	PERRIGO R AND D	EQ 150MG BASE	A091429	001	May 11, 2011	Sep	DISC
@		EQ 150MG BASE	A091429	002	May 11, 2011	Sep	DISC
	THINQ PHARM-CRO PVT	EQ 75MG BASE	A210250	001	Aug 30, 2019	Jul	CAHN
		EQ 150MG BASE	A210228	001	Aug 30, 2019	Jul	CAHN

ZANTAC 150

+ @	CHATTEM SANOFI	EQ 150MG BASE	N021698	001	Aug 31, 2004	Jan	CAHN
+ @		EQ 150MG BASE	N021698	002	Mar 13, 2007	Jan	CAHN

ZANTAC 75

+ @	CHATTEM SANOFI	EQ 75MG BASE	N020520	001	Dec 19, 1995	Jan	CAHN

TABLET, EFFERVESCENT;ORAL

ZANTAC 75

+ @	CHATTEM SANOFI	EQ 75MG BASE	N020745	001	Feb 26, 1998	Jan	CAHN

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

NASACORT ALLERGY 24 HOUR

+!	CHATTEM SANOFI	0.055MG/SPRAY	N020468	002	Oct 11, 2013	Jan	CAHN
+!		0.055MG/SPRAY	N020468	002	Oct 11, 2013	Jan	CAHN

TRIAMCINOLONE ACETONIDE

	PERRIGO PHARMA INTL	0.055MG/SPRAY	A078104	002	Nov 14, 2014	Jan	CAHN

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 11 NOVEMBER 2022

NO NOVEMBER 2022 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO NOVEMBER 2022 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ PD						
N 215413 001	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
ABALOPARATIDE - TYMLOS						
N 208743 001	11255842	Jan 10, 2040	U-3322			
ABROCITINIB - CIBINQO						
N 213871 001	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034	U-3195			
ABROCITINIB - CIBINQO						
N 213871 002	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034	U-3195			
ABROCITINIB - CIBINQO						
N 213871 003	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034	U-3195			
ACALABRUTINIB MALEATE - CALQUENCE						
N 216387 001	10239883	Jul 11, 2032	U-2666		NCE	Oct 31, 2022
	10239883	Jul 11, 2032	U-2668			
	10272083	Jan 21, 2035	U-2519			
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	11059829	Jul 01, 2036	DS DP U-2145			
	11059829	Jul 01, 2036	DS DP U-2666			
	11059829	Jul 01, 2036	DS DP U-2667			
	11059829	Jul 01, 2036	DS DP U-2668			
	11059829	Jul 01, 2036	DS DP U-2669			
	11059829	Jul 01, 2036	DS DP U-2670			
	11059829	Jul 01, 2036	DS DP U-2671			
	7459554	Nov 24, 2026	DS			
	9290504	Jul 11, 2032	DS DP			
	9758524	Jul 11, 2032	U-2145			
AFATINIB DIMALEATE - GILOTRIF						
N 201292 001	10004743	Jul 05, 2030	DP		M-276	Apr 07, 2025
	10004743*PED	Jan 05, 2031			ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8426586*PED	Apr 10, 2030			PED	Oct 15, 2023
	8545884	Dec 19, 2029	DP		PED	Jul 12, 2025
	8545884*PED	Jun 19, 2030			PED	Oct 07, 2025
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
AFATINIB DIMALEATE - GILOTRIF						
N 201292 002	10004743	Jul 05, 2030	DP		M-276	Apr 07, 2025
	10004743*PED	Jan 05, 2031			ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8426586*PED	Apr 10, 2030			PED	Oct 15, 2023
	8545884	Dec 19, 2029	DP		PED	Jul 12, 2025
	8545884*PED	Jun 19, 2030			PED	Oct 07, 2025
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AFATINIB DIMALEATE - GILOTRIF						
N 201292 002	RE43431*PED	Jul 13, 2026				
AFATINIB DIMALEATE - GILOTRIF						
N 201292 003	10004743	Jul 05, 2030	DP		M-276	Apr 07, 2025
	10004743*PED	Jan 05, 2031			ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8426586*PED	Apr 10, 2030			PED	Oct 15, 2023
	8545884	Dec 19, 2029	DP		PED	Jul 12, 2025
	8545884*PED	Jun 19, 2030			PED	Oct 07, 2025
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
ALBUTEROL SULFATE - PROAIR HFA						
N 021457 001	11395889	May 18, 2031	DP			
ALBUTEROL SULFATE - PROAIR DIGIHALER						
N 205636 002	11266796	Feb 22, 2041	DP			
	11344685	Sep 26, 2039	DP			
	11351317	Feb 10, 2038	DP			
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	>A> 11464923	Jun 19, 2040	DP			
ALECTINIB HYDROCHLORIDE - ALECENSA						
N 208434 001	11433076	Apr 24, 2035	DP			
ALLOPURINOL; LESINURAD - DUZALLO						
N 209203 001	8357713	Dec 22, 2029	DP U-2104			
ALLOPURINOL; LESINURAD - DUZALLO						
N 209203 002	8357713	Dec 22, 2029	DP U-2104			
ALPELISIB - VIJOICE						
N 215039 001	8227462	Sep 28, 2030	DS DP		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
ALPELISIB - VIJOICE						
N 215039 002	8227462	Sep 28, 2030	DS DP		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
ALPELISIB - VIJOICE						
N 215039 003	8227462	Sep 28, 2030	DS DP		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
AMANTADINE HYDROCHLORIDE - GOCOVRI						
N 208944 001	11197835	Dec 02, 2030	U-2106			
AMANTADINE HYDROCHLORIDE - GOCOVRI						
N 208944 002	11197835	Dec 02, 2030	U-2106			
AMIFAMPRIDINE PHOSPHATE - FIRDAPSE						
N 208078 001	10626088	Feb 25, 2037	DP	>A>	NPP	Sep 29, 2025
	10793893	May 26, 2034	U-2956		ODE-223	Nov 28, 2025
	11268128	Jun 29, 2032	U-2956			
	11274331	Jun 29, 2032	U-2956			
	11274332	Jun 29, 2032	U-2956			
AMIKACIN SULFATE - ARIKAYCE KIT						
N 207356 001	11446318	May 15, 2035	U-2414			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ						
N 208081 001	11235169	Oct 15, 2040	U-3303			
AMISULPRIDE - BARHEMSYS						
N 209510 001	11357753	Feb 09, 2038	U-2754			
	9084765	Feb 26, 2034	U-1744			
	9084765	Feb 26, 2034	U-2754			
	9084765	Feb 26, 2034	U-3467			
AMISULPRIDE - BARHEMSYS						
N 209510 002	10525033	Mar 10, 2031	DP		NCE	Feb 26, 2025
	11357753	Feb 09, 2038	U-2754			
	9084765	Feb 26, 2034	U-1744			
	9084765	Feb 26, 2034	U-2754			
	9084765	Feb 26, 2034	U-3467			
	9545426	Mar 10, 2031	U-1744			
	9545426	Mar 10, 2031	U-2754			
	9889118	Mar 10, 2031	U-1744			
	9889118	Mar 10, 2031	U-2754			
AMLODIPINE BENZOATE - KATERZIA						
N 211340 001	11364230	Oct 06, 2037	DP			
	11471409	Oct 06, 2037	U-3447			
	11471409	Oct 06, 2037	U-3448			
	11484498	Oct 06, 2037	DP			
AMLODIPINE BESYLATE - NORLIQVA						
N 214439 001	11253474	Feb 24, 2041	DP U-3309			
	11253474	Feb 24, 2041	DP U-3310			
	11253474	Feb 24, 2041	DP U-3311			
	11458095	Feb 24, 2041	DP U-3309			
	11458095	Feb 24, 2041	DP U-3310			
	11458095	Feb 24, 2041	DP U-3311			
AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE - VOQUEZNA TRIPLE PAK						
N 215152 001	7977488	Aug 11, 2028	DS		NCE	May 03, 2027
	9186411	Aug 11, 2030	DP		GAIN	May 03, 2032
AMOXICILLIN; VONOPRAZAN FUMARATE - VOQUEZNA DUAL PAK						
N 215153 001	7977488	Aug 11, 2028	DS		NCE	May 03, 2027
	9186411	Aug 11, 2030	DP		GAIN	May 03, 2032
AMPHOTERICIN B - AMPHOTERICIN B						
A 212514 001					CGT	Aug 14, 2022
ANGIOTENSIN II ACETATE - GIAPREZA						
N 209360 003	10028995	Dec 18, 2034	U-2338			
	10335451	Dec 16, 2029	U-2581			
	10493124	Dec 18, 2034	U-2679			
	10500247	Dec 16, 2029	U-2680			
	10500247	Dec 16, 2029	U-2681			
	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
	9220745	Dec 18, 2034	U-2217			
	9220745	Dec 18, 2034	U-2218			
	9572856	Jul 18, 2031	U-2221			
	9867863	Dec 16, 2029	U-2231			
APOMORPHINE HYDROCHLORIDE - APOMORPHINE HYDROCHLORIDE						
A 212025 001					CGT	Aug 24, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 001	11419769	Dec 16, 2031	DP U-2825			
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 002	11419769	Dec 16, 2031	DP U-2825			
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 003	11419769	Dec 16, 2031	DP U-2825			
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 004	11419769	Dec 16, 2031	DP U-2825			
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 005	11419769	Dec 16, 2031	DP U-2825			
APREMILAST - OTEZLA						
N 205437 001	6962940	Mar 19, 2023	U-1504		I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
APREMILAST - OTEZLA						
N 205437 002	6962940	Mar 19, 2023	U-1504		I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
APREMILAST - OTEZLA						
N 205437 003	6962940	Mar 19, 2023	U-1504		I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APREMILAST - OTEZLA						
N 205437 003	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
APREPITANT - APONVIE						
N 216457 001	10500208	Sep 18, 2035	DP			
	10624850	Sep 18, 2035	U-3440			
	10953018	Sep 18, 2035	U-3440			
	11173118	Sep 18, 2035	DP			
	9561229	Sep 18, 2035	DP U-3440			
	9808465	Sep 18, 2035	U-3440			
	9974742	Sep 18, 2035	DP			
	9974793	Sep 18, 2035	DP			
	9974794	Sep 18, 2035	DP U-3440			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 001	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			
	11400087	Sep 24, 2033	U-814			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 002	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			
	11400087	Sep 24, 2033	U-814			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 003	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			
	11400087	Sep 24, 2033	U-814			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 004	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			
	11400087	Sep 24, 2033	U-814			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 001	11229378	Jul 11, 2031	DP			
>A>	11464423	Sep 15, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 001	>A> 11476952	Apr 28, 2026	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 002	11229378	Jul 11, 2031	DP			
	>A> 11464423	Sep 15, 2030	DP			
	>A> 11476952	Apr 28, 2026	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 003	11229378	Jul 11, 2031	DP			
	>A> 11464423	Sep 15, 2030	DP			
	>A> 11476952	Apr 28, 2026	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 004	11229378	Jul 11, 2031	DP			
	>A> 11464423	Sep 15, 2030	DP			
	>A> 11476952	Apr 28, 2026	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 005	11229378	Jul 11, 2031	DP			
	>A> 11464423	Sep 15, 2030	DP			
	>A> 11476952	Apr 28, 2026	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 006	11229378	Jul 11, 2031	DP			
	>A> 11464423	Sep 15, 2030	DP			
	>A> 11476952	Apr 28, 2026	DP			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 001	11273158	Apr 06, 2039	U-543			
	11406632	Mar 19, 2035	U-2402			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 002	11273158	Apr 06, 2039	U-543			
	11406632	Mar 19, 2035	U-2402			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 003	11273158	Apr 06, 2039	U-543			
	11406632	Mar 19, 2035	U-2402			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 004	11273158	Apr 06, 2039	U-543			
	11406632	Mar 19, 2035	U-2402			
ARIPIPRAZOLE LAUROXIL - ARISTADA INITIO KIT						
N 209830 001	11273158	Apr 06, 2039	U-543			
ASCIMINIB HYDROCHLORIDE - SCEMBLIX						
N 215358 001	11407735	May 14, 2040	DS		ODE-381	Oct 29, 2028
	8829195	May 13, 2033	DS U-1374		ODE-382	Oct 29, 2028
ASCIMINIB HYDROCHLORIDE - SCEMBLIX						
N 215358 002	11407735	May 14, 2040	DS		ODE-381	Oct 29, 2028
	8829195	May 13, 2033	DS U-1374		ODE-382	Oct 29, 2028
ATROPINE SULFATE - ATROPINE SULFATE						
A 216120 001					CGT	Jan 29, 2023
ATROPINE SULFATE - ATROPINE SULFATE						
A 216120 002					CGT	Jan 29, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AVACOPAN - TAVNEOS						
N 214487 001					ODE-377	Oct 07, 2028
AVANAFIL - STENDRA						
N 202276 001					>A> M-282	Oct 18, 2025
AVANAFIL - STENDRA						
N 202276 002					>A> M-282	Oct 18, 2025
AVANAFIL - STENDRA						
N 202276 003					>A> M-282	Oct 18, 2025
AXITINIB - INLYTA						
N 202324 001	10869924	Jan 12, 2037	U-3044			
AXITINIB - INLYTA						
N 202324 002	10869924	Jan 12, 2037	U-3044			
AZACITIDINE - VIDAZA						
N 050794 001					I-889	May 20, 2025
BACLOFEN - FLEQSUVY						
N 215602 001	11324696	Sep 29, 2037	DP			
	11446246	Sep 08, 2037	U-3433			
BALOXAVIR MARBOXIL - XOFLUZA						
N 210854 001	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
BALOXAVIR MARBOXIL - XOFLUZA						
N 210854 002	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
BALOXAVIR MARBOXIL - XOFLUZA						
N 210854 003	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
BALOXAVIR MARBOXIL - XOFLUZA						
N 214410 001	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
BARICITINIB - OLUMIANT						
N 207924 001	11045474	Nov 30, 2032	U-3372		I-890	Jun 13, 2025
	9089574	Nov 30, 2032	U-3372		I-891	May 10, 2025
BARICITINIB - OLUMIANT						
N 207924 002	11045474	Nov 30, 2032	U-3372		I-890	Jun 13, 2025
	9089574	Nov 30, 2032	U-3372		I-891	May 10, 2025
BARICITINIB - OLUMIANT						
N 207924 003	11045474	Nov 30, 2032	U-3372		I-890	Jun 13, 2025
	8158616	Jun 08, 2030	DS DP		I-891	May 10, 2025
	9089574	Nov 30, 2032	U-3372		NCE	May 31, 2023
BECLOMETHASONE DIPROPIONATE - QVAR 80						
N 020911 001	11395889	May 18, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BECLOMETHASONE DIPROPIONATE - QVAR 40						
N 020911 002	11395889	May 18, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER						
N 207921 001	11395888	Jan 26, 2038	DP			
	11395889	May 18, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER						
N 207921 002	11395888	Jan 26, 2038	DP			
	11395889	May 18, 2031	DP			
BELUMOSUDIL MESYLATE - REZUROCK						
N 214783 001	11311541	Apr 09, 2035	U-3369			
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 001					ODE*	Dec 07, 2022
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 002					ODE*	Dec 07, 2022
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 003					ODE*	Dec 07, 2022
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 004					ODE*	Dec 07, 2022
BENDAMUSTINE HYDROCHLORIDE - BELRAPZO						
N 205580 001					ODE*	Dec 07, 2022
BENZOYL PEROXIDE - EPSOLAY						
N 214510 001	10933046	Feb 19, 2040	DP U-3357		NP	Apr 22, 2025
	10945987	Feb 19, 2040	U-3356			
	11426378	Aug 18, 2040	U-3356			
	9687465	Nov 27, 2032	DP U-3356			
	9868103	Aug 08, 2028	DP U-3356			
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE						
A 212433 001					CGT	Mar 13, 2023
BEROTRALSTAT HYDROCHLORIDE - ORLADEYO						
N 214094 001	11230530	Mar 09, 2035	U-3300			
BEROTRALSTAT HYDROCHLORIDE - ORLADEYO						
N 214094 002	11230530	Mar 09, 2035	U-3300			
BETAINE - BETAINE						
A 214864 001					CGT	Aug 02, 2022
BEXAROTENE - BEXAROTENE						
A 215398 001					CGT	Nov 13, 2022
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY						
N 210251 002					NCE	Feb 07, 2023
					ODE-378	Oct 07, 2028
BREXANOLONE - ZULRESSO						
N 211371 001					NPP	Jun 16, 2025
BREXPIPRAZOLE - REXULTI						
N 205422 001	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BREXPIPRAZOLE - REXULTI						
N 205422 001	9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 002	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 003	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 004	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 005	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 006	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
BRIGATINIB - ALUNBRIG						
N 208772 001	9012462	Apr 28, 2031	DS			
BRIGATINIB - ALUNBRIG						
N 208772 002	9012462	Apr 28, 2031	DS			
BRIGATINIB - ALUNBRIG						
N 208772 003	9012462	Apr 28, 2031	DS			
BUDESONIDE - TARPEYO						
N 215935 001					NP	Dec 15, 2024
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT						
N 021929 001	11311558	Jan 29, 2023	DP			
	11311558*PED	Jul 29, 2023				
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT						
N 021929 002	11311558	Jan 29, 2023	DP			
	11311558*PED	Jul 29, 2023				
BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE						
N 212122 001	11331442	May 10, 2038	DP			
BUPIVACAINE - EXPAREL						
N 022496 001	11278494	Jan 22, 2041	DP U-3250			
	11304904	Jan 22, 2041	DP U-3346			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPIVACAINE - EXPAREL						
N 022496 001	11311486	Jan 22, 2041	DP U-3250			
	11357727	Jan 22, 2041	DP U-3380			
	11426348	Jan 22, 2041	DP U-3380			
	>A> 11452691	Jan 22, 2041	DP U-3439			
BUPIVACAINE - EXPAREL						
N 022496 002	11278494	Jan 22, 2041	DP U-3250			
	11304904	Jan 22, 2041	DP U-3346			
	11311486	Jan 22, 2041	DP U-3250			
	11357727	Jan 22, 2041	DP U-3380			
	11426348	Jan 22, 2041	DP U-3380			
	11452691	Jan 22, 2041	DP U-3439			
BUPIVACAINE - POSIMIR						
N 204803 001	11400019	Jan 12, 2041	DP			
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 001	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 002	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 003	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 004	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 001	11433066	Sep 18, 2032	U-3131			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 002	11433066	Sep 18, 2032	U-3131			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 003	11433066	Sep 18, 2032	U-3131			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 004	11433066	Sep 18, 2032	U-3131			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 005	11433066	Sep 18, 2032	U-3131			
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY						
N 215430 001	10058518	Nov 05, 2034	U-3419		NP	Aug 18, 2025
	10064857	Nov 05, 2034	U-3419			
	10080727	Nov 05, 2034	U-3419			
	10092560	Nov 05, 2034	U-3419			
	10092561	Nov 05, 2034	U-3419			
	10105327	Nov 05, 2034	U-3419			
	10105361	Nov 05, 2034	U-3419			
	10251879	Nov 05, 2034	U-3419			
	10463634	Nov 05, 2034	U-3419			
	10512643	Nov 05, 2034	U-3419			
	10548857	Nov 05, 2034	U-3419			
	10596167	Nov 05, 2034	U-3419			
	10772850	Nov 05, 2034	U-3419			
	10780064	Jan 07, 2040	U-3419			
	10780066	Nov 09, 2034	U-3419			
	10786469	Nov 05, 2034	U-3419			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY						
N 215430 001	10786496	Nov 05, 2034	U-3419			
	10799497	Nov 05, 2034	U-3419			
	10806710	Nov 05, 2034	U-3419			
	10864209	Nov 05, 2034	U-3419			
	10874663	Nov 05, 2034	U-3419			
	10874664	Nov 05, 2034	U-3419			
	10874665	Nov 05, 2034	U-3419			
	10881624	Nov 05, 2034	U-3419			
	10881657	Nov 05, 2034	U-3419			
	10894046	Nov 05, 2034	U-3419			
	10894047	Nov 05, 2034	U-3419			
	10898453	Nov 05, 2034	U-3419			
	10925842	Jan 07, 2040	U-3419			
	10933034	Nov 05, 2034	U-3419			
	10940124	Jan 07, 2040	U-3419			
	10945973	Nov 05, 2034	U-3419			
	10966941	Nov 05, 2034	U-3419			
	10966942	Jan 07, 2040	U-3419			
	10966974	Nov 05, 2034	U-3419			
	11020389	Nov 05, 2034	U-3419			
	11058648	Nov 05, 2034	U-3419			
	11090300	Nov 05, 2034	U-3419			
	11096937	Nov 05, 2034	U-3419			
	11123343	Nov 05, 2034	U-3419			
	11129826	Nov 05, 2034	U-3419			
	11141388	Nov 05, 2034	U-3419			
	11141416	Nov 05, 2034	U-3419			
	11147808	Nov 05, 2034	U-3419			
	11185515	Nov 05, 2034	U-3419			
	11191739	Nov 05, 2034	DP U-3419			
	11197839	Nov 05, 2034	DP U-3419			
	11207281	Nov 05, 2034	U-3419			
	11213521	Nov 05, 2034	U-3419			
	11229640	Nov 05, 2034	U-3419			
	11234946	Nov 05, 2034	U-3419			
	11253491	Nov 05, 2034	U-3419			
	11253492	Nov 05, 2034	U-3419			
	11273133	Nov 05, 2034	U-3419			
	11273134	Nov 05, 2034	U-3419			
	11285118	Nov 05, 2034	U-3419			
	11285146	Nov 05, 2034	U-3419			
	11291638	Nov 05, 2034	U-3419			
	11291665	Nov 05, 2034	U-3419			
	11298351	Nov 05, 2034	U-3419			
	11298352	Nov 05, 2034	U-3419			
	11311534	Nov 05, 2034	U-3419			
	11344544	Nov 05, 2034	U-3419			
	11357744	Nov 05, 2034	U-3419			
	11364233	Nov 05, 2034	U-3419			
	11382874	Nov 05, 2034	U-3419			
	11419867	Nov 05, 2034	U-3419			
	11426370	Nov 05, 2034	U-3419			
	11426401	Nov 05, 2034	U-3419			
	11433067	Nov 05, 2034	DP U-3419			
	11439636	Nov 05, 2034	U-3419			
	>A> 11478468	Nov 05, 2034	U-3419			
	>A> 11497721	Nov 05, 2034	U-3419			
	>A> 11510918	Nov 05, 2034	U-3419			
	8569328	Oct 29, 2033	DP U-3419			
	9168234	Nov 05, 2034	U-3419			
	9198905	Nov 05, 2034	U-3419			
	9205083	Nov 05, 2034	U-3419			
	9238032	Nov 05, 2034	U-3419			
	9278095	Nov 05, 2034	U-3419			
	9314462	Nov 05, 2034	U-3419			
	9370513	Nov 05, 2034	U-3419			
	9375429	Nov 05, 2034	U-3419			
	9408815	Nov 05, 2034	U-3419			
	9421176	Nov 05, 2034	U-3419			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY						
N 215430 001	9457023	Nov 05, 2034	U-3419			
	9457025	Nov 05, 2034	U-3419			
	9474731	Nov 05, 2034	U-3419			
	9486450	Nov 05, 2034	U-3419			
	9700528	Nov 05, 2034	U-3419			
	9700553	Nov 05, 2034	U-3419			
	9707191	Nov 05, 2034	U-3419			
	9763932	Nov 05, 2034	U-3419			
	9861595	Nov 05, 2034	U-3419			
	9867819	Nov 05, 2034	U-3419			
	9968568	Nov 05, 2034	U-3419			
BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE						
N 200063 001	11278544	Apr 21, 2024	U-1583			
	11324741	May 29, 2029	U-1583			
CABOTEGRAVIR - APRETUDE						
N 215499 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	11224597	Sep 15, 2031	DP			
	8410103	Apr 28, 2026	DS DP			
CABOTEGRAVIR SODIUM - VOCABRIA						
N 212887 001	8410103	Apr 28, 2026	DS DP U-3061		M-273	Jan 31, 2025
	8410103	Apr 28, 2026	DS DP U-3348		NPP	Mar 29, 2025
CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT						
N 212888 001	11224597	Sep 15, 2031	DP U-3348		D-184	Jan 31, 2025
	11389447	Jun 30, 2027	U-3405		NPP	Mar 29, 2025
	7125879	Apr 21, 2025	DS DP U-3348			
	8410103	Apr 28, 2026	DS DP U-3348			
CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT						
N 212888 002	11224597	Sep 15, 2031	DP U-3348		D-184	Jan 31, 2025
	11389447	Jun 30, 2027	U-3405		NPP	Mar 29, 2025
	7125879	Apr 21, 2025	DS DP U-3348			
	8410103	Apr 28, 2026	DS DP U-3348			
CABOZANTINIB S-MALATE - COMETRIQ						
N 203756 001	11298349	Feb 10, 2032	DP			
CABOZANTINIB S-MALATE - COMETRIQ						
N 203756 002	11298349	Feb 10, 2032	DP			
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 001	11298349	Feb 10, 2032	DP			
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 002	11298349	Feb 10, 2032	DP			
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 003	11298349	Feb 10, 2032	DP			
CALCIFEDIOL - RAYALDEE						
N 208010 001	11253528	Mar 14, 2034	DP			
CALCIUM GLUCONATE - CALCIUM GLUCONATE						
A 213071 001					CGT	May 05, 2023
CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV						
N 212690 001	10213400	Mar 15, 2033	U-2499			
	10213400*PED	Sep 15, 2033				
	10864181	Mar 15, 2033	U-3017			
	10864181*PED	Sep 15, 2033				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV						
N 212690 001	11253494	Mar 15, 2033	U-3323			
	11253494	Mar 15, 2033	U-3324			
	11253494*PED	Sep 15, 2033				
	11426373	Sep 19, 2037	U-3432			
	8731963	Dec 17, 2022	U-1110			
	8731963*PED	Jun 17, 2023				
	8772306	Mar 15, 2033	U-1532			
	8772306	Mar 15, 2033	U-3198			
	8772306*PED	Sep 15, 2033				
	9050302	Mar 15, 2033	U-1532			
	9050302*PED	Sep 15, 2033				
	9486426	Mar 15, 2033	U-1532			
	9486426*PED	Sep 15, 2033				
CANNABIDIOL - EPIDIOLEX						
N 210365 001	10918608	Oct 13, 2035	U-3071			
	10918608	Oct 13, 2035	U-3072			
	10918608	Oct 13, 2035	U-3073			
	11065209	Oct 13, 2035	U-3071			
	11096905	Oct 13, 2035	DS DP U-2780			
	11096905	Oct 13, 2035	DS DP U-2781			
	11154516	Jun 17, 2035	U-3235			
	11154516	Jun 17, 2035	U-3236			
	11207292	Apr 26, 2039	DS U-3235			
	11207292	Apr 26, 2039	DS U-3236			
	11207292	Apr 26, 2039	DS U-3277			
	11311498	Jun 17, 2035	U-3375			
	11311498	Jun 17, 2035	U-3376			
	11357741	Jun 17, 2035	U-2862			
	11400055	Oct 13, 2035	U-3071			
	11406623	Mar 01, 2041	U-3233			
	11446258	Jun 17, 2035	U-2780			
	11446258	Jun 17, 2035	U-2781			
	11446258	Jun 17, 2035	U-3071			
CARBIDOPA; LEVODOPA - DHIVY						
N 214869 001	11033521	Mar 28, 2039	DP U-219			
	11033521	Mar 28, 2039	DP U-3304			
	11033521	Mar 28, 2039	DP U-3305			
CARFILZOMIB - KYPROLIS						
N 202714 001	RE47954	Oct 21, 2029	U-3449			
CARFILZOMIB - KYPROLIS						
N 202714 002	RE47954	Oct 21, 2029	U-3449			
CARFILZOMIB - KYPROLIS						
N 202714 003	RE47954	Oct 21, 2029	U-3449			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 001	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 002	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 003	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 004	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
CASIMERSEN - AMONDYS 45						
N 213026 001	RE48960	Jun 28, 2025	DS DP U-3087			
	RE48960	Jun 28, 2025	DS DP U-3088			
CEFAZOLIN SODIUM - CEFAZOLIN AND DEXTROSE						
N 050779 001					NPP	Nov 23, 2023
CEFAZOLIN SODIUM - CEFAZOLIN AND DEXTROSE						
N 050779 002					NPP	Nov 23, 2023
CEFAZOLIN SODIUM - CEFAZOLIN AND DEXTROSE						
N 050779 003					NPP	Nov 23, 2023
CEFIDEROCOL SULFATE TOSYLATE - FETROJA						
N 209445 001	>A> 9238657	Nov 14, 2033	DS DP U-282			
	>A> 9238657	Nov 14, 2033	DS DP U-3470			
	>A> 9238657	Nov 14, 2033	DS DP U-3471			
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA						
N 206829 001	10420841	Mar 14, 2034	U-1672		NPP	Apr 21, 2025
	10420841	Mar 14, 2034	U-2631			
	10420841	Mar 14, 2034	U-3360			
	10420841	Mar 14, 2034	U-3361			
	11278622	Mar 14, 2034	U-3335			
	11278622	Mar 14, 2034	U-3336			
	7129232	May 15, 2028	DS DP U-1676			
	7129232	May 15, 2028	DS DP U-3360			
	7129232	May 15, 2028	DS DP U-3361			
	7129232	May 15, 2028	DS DP U-36			
	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
	8968753	Mar 14, 2034	U-3360			
	8968753	Mar 14, 2034	U-3361			
CELECOXIB; TRAMADOL HYDROCHLORIDE - SEGLENTIS						
N 213426 001	11478488	Apr 19, 2030	U-3244			
CETRORELIX ACETATE - CETRORELIX ACETATE						
A 215737 001					CGT	Apr 22, 2023
CHLOROPROCAINE HYDROCHLORIDE - IHEEZO						
N 216227 001	10792271	Sep 15, 2038	DP U-3457			
CIPROFLOXACIN - OTIPRIO						
N 207986 001	11246863	Nov 27, 2038	DP			
	11369566	Apr 21, 2029	DP			
CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI						
N 208352 001	11337989	Mar 15, 2033	U-1			
	11439610	Mar 15, 2033	DS DP			
	6706276	Mar 06, 2023	DP			
CLADRIBINE - MAVENCLAD						
N 022561 001	10849919	Nov 23, 2038	U-3411			
CLASCOTERONE - WINLEVI						
N 213433 001	11207332	Nov 20, 2028	DP U-3280			
	8865690	Jul 24, 2023	U-2942			
	9211295	Jul 24, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CLASCOTERONE - WINLEVI						
N 213433 001	9433628	Feb 28, 2029	DP			
CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE						
A 214668 001					CGT	Feb 01, 2023
CLINDAMYCIN PHOSPHATE - XACIATO						
N 215650 001	11129896	Sep 22, 2036	U-3293		NP	Dec 07, 2024
					GAIN	Dec 07, 2029
CLINDAMYCIN PHOSPHATE; TRETINOIN - CLINDAMYCIN PHOSPHATE AND TRETINOIN						
A 212845 001					CGT	Oct 09, 2022
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA						
N 207561 001	8633219	Apr 30, 2030	DP U-257			
	8633219*PED	Oct 30, 2030				
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD						
N 203100 001	8633219	Apr 30, 2030	DP U-257			
	8633219*PED	Oct 30, 2030				
COBIMETINIB FUMARATE - COTELLIC						
N 206192 001	10478400	Jun 29, 2036	DS DP U-1776		M-278	Jul 28, 2025
	10478400*PED	Dec 29, 2036			PED	Jan 28, 2026
	10590102	Jun 30, 2036	DS DP U-1776			
	10590102*PED	Dec 30, 2036				
	11087354	Jun 22, 2034	U-1776			
	11087354*PED	Dec 22, 2034				
	11254649	Jun 30, 2036	DS DP U-1776			
	11254649*PED	Dec 30, 2036				
	7803839	Nov 10, 2029	DS DP			
	7803839*PED	May 10, 2030				
	8362002	Oct 05, 2026	U-1776			
	8362002*PED	Apr 05, 2027				
CRIZOTINIB - XALKORI						
N 202570 001	7825137	May 12, 2027	U-3057		I-897	Jul 14, 2025
	7825137	May 12, 2027	U-3058			
	7825137	May 12, 2027	U-3403			
CRIZOTINIB - XALKORI						
N 202570 002	7825137	May 12, 2027	U-3057		I-897	Jul 14, 2025
	7825137	May 12, 2027	U-3058			
	7825137	May 12, 2027	U-3403			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 212501 003	10993952	Feb 15, 2036	DP			
CYSTEAMINE BITARTRATE - PROCYSBI						
N 203389 001	10143665	Aug 16, 2036	U-1399		ODE-162	Dec 22, 2024
	10143665*PED	Feb 16, 2037			PED	Jun 22, 2025
	10328037	Aug 16, 2036	U-1399			
	10328037*PED	Feb 16, 2037				
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	9925156	Jan 26, 2027	DS DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DS DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DS DP U-1399			
	9925158*PED	Jul 26, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CYSTEAMINE BITARTRATE - PROCYSBI						
N 203389 002	10143665	Aug 16, 2036	U-1399		ODE-162	Dec 22, 2024
	10143665*PED	Feb 16, 2037			PED	Jun 22, 2025
	10328037	Aug 16, 2036	U-1399			
	10328037*PED	Feb 16, 2037				
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	9925156	Jan 26, 2027	DS DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DS DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DS DP U-1399			
	9925158*PED	Jul 26, 2027				
CYSTEAMINE BITARTRATE - PROCYSBI						
N 213491 001	10143665	Aug 16, 2036	U-1399		ODE*	Dec 22, 2024
	10143665*PED	Feb 16, 2037			ODE*	Dec 22, 2024
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2025
	10328037*PED	Feb 16, 2037			PED	Jun 22, 2025
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	9925156	Jan 26, 2027	DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DP U-1399			
	9925158*PED	Jul 26, 2027				
CYSTEAMINE BITARTRATE - PROCYSBI						
N 213491 002	10143665	Aug 16, 2036	U-1399		ODE*	Dec 22, 2024
	10143665*PED	Feb 16, 2037			ODE*	Dec 22, 2024
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2025
	10328037*PED	Feb 16, 2037			PED	Jun 22, 2025
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	9925156	Jan 26, 2027	DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DP U-1399			
	9925158*PED	Jul 26, 2027				
CYSTEINE HYDROCHLORIDE - ELCYS						
N 210660 001	>A> 11510941	Jan 15, 2039	DP			
	>A> 11510942	Jan 15, 2039	DP U-2752			
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 001					I-894	Jun 22, 2025
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 002					I-894	Jun 22, 2025
DACOMITINIB - VIZIMPRO						
N 211288 001	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			
DACOMITINIB - VIZIMPRO						
N 211288 002	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DACOMITINIB - VIZIMPRO						
N 211288 003	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			
DANTROLENE SODIUM - RYANODEX						
N 205579 001	7758890	Jun 30, 2025	DP			
	8604072	Jul 20, 2022	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 001					M-238	Feb 22, 2022
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 002					M-238	Feb 22, 2022
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 003					M-238	Feb 22, 2022
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 004					M-238	Feb 22, 2022
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 005					M-238	Feb 22, 2022
DAPSONE - ACZONE						
N 207154 001	11273132	Nov 18, 2033	DP			
DAPTOMYCIN - DAPZURA RT						
N 213645 001	11173189	Mar 11, 2041	DP U-3294			
DARIDOREXANT HYDROCHLORIDE - QUVIVIQ						
N 214985 001	10023560	Dec 02, 2034	U-620		NCE	Apr 07, 2027
	9732075	Jun 12, 2033	DS DP U-620			
	9790208	Dec 02, 2034	DS DP			
DARIDOREXANT HYDROCHLORIDE - QUVIVIQ						
N 214985 002	10023560	Dec 02, 2034	U-620		NCE	Apr 07, 2027
	9732075	Jun 12, 2033	DS DP U-620			
	9790208	Dec 02, 2034	DS DP			
DAROLUTAMIDE - NUBEQA						
N 212099 001	11168058	Feb 27, 2038	DS DP		I-900	Aug 05, 2025
DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR - VIEKIRA PAK (COPACKAGED)						
N 206619 001	8501238	Dec 19, 2028	DS DP U-1636			
DEFERIPRONE - FERRIPROX						
N 212269 001	11357731	Oct 25, 2038	U-3083			
	11458103	Oct 25, 2038	DP			
DEFIBROTIDE SODIUM - DEFITELIO						
N 208114 001	11236328	Jun 22, 2032	U-3301			
DELAFLOXACIN MEGLUMINE - BAXDELA						
N 208610 001	7728143	Jun 19, 2031	DS			
DELAFLOXACIN MEGLUMINE - BAXDELA						
N 208611 001	7728143	Jun 19, 2031	DS			
DESMOPRESSIN ACETATE - NOCTIVA						
N 201656 001	11419914	Jun 15, 2030	U-3431			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DESMOPRESSIN ACETATE - NOCTIVA						
N 201656 002	11419914	Jun 15, 2030	U-3431			
DEUCRAVACITINIB - SOTYKTU						
N 214958 001	10000480	Nov 07, 2033	DS DP		NCE	Sep 09, 2027
	11021475	Nov 07, 2033	U-3434			
	RE47929	Nov 07, 2033	DS DP U-3434			
DEUTETRABENAZINE - AUSTEDO						
N 208082 001	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
DEUTETRABENAZINE - AUSTEDO						
N 208082 002	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
DEUTETRABENAZINE - AUSTEDO						
N 208082 003	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
DEXAMETHASONE - DEXAMETHASONE						
A 216295 001					CGT	Mar 08, 2023
DEXAMETHASONE - DEXTENZA						
N 208742 001	11458041	Nov 16, 2037	U-1680			
	11458041	Nov 16, 2037	U-3455			
DEXAMETHASONE - DEXYCU KIT						
N 208912 001	11097061	Jun 23, 2039	DP U-3418			
DEXAMETHASONE - HEMADY						
N 211379 001	11304961	Dec 18, 2037	DP U-3344			
DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI						
N 215390 001	10792246	Jun 26, 2039	DP U-3350		NP	Apr 05, 2025
>A>	11478422	Jun 26, 2039	DP			
>A>	11497711	Jun 26, 2039	DP			
>A>	11517524	Jun 26, 2039	DP			
DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI						
N 215390 002	10792246	Jun 26, 2039	DP U-3350		NP	Apr 05, 2025
>A>	11478422	Jun 26, 2039	DP			
>A>	11497711	Jun 26, 2039	DP			
>A>	11517524	Jun 26, 2039	DP			
DEXTROAMPHETAMINE - XELSTRYM						
N 215401 001	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXTROAMPHETAMINE - XELSTRYM						
N 215401 001	9474722	Oct 24, 2033	DP			
DEXTROAMPHETAMINE - XELSTRYM						
N 215401 002	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
DEXTROAMPHETAMINE - XELSTRYM						
N 215401 003	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
DEXTROAMPHETAMINE - XELSTRYM						
N 215401 004	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
DIAZEPAM - VALTOCO						
N 211635 001	11241414	Mar 27, 2029	DP			
DIAZEPAM - VALTOCO						
N 211635 002	11241414	Mar 27, 2029	DP			
DIAZEPAM - VALTOCO						
N 211635 003	11241414	Mar 27, 2029	DP			
DICLOFENAC EPOLAMINE - LICART						
N 206976 001	11344520	Feb 20, 2035	U-3393			
	11351133	Feb 20, 2035	U-3393			
DICLOXACILLIN SODIUM - DICLOXACILLIN SODIUM						
A 216845 001					CGT	Mar 29, 2023
DICLOXACILLIN SODIUM - DICLOXACILLIN SODIUM						
A 216845 002					CGT	Mar 29, 2023
DIGOXIN - DIGOXIN						
A 214982 001					CGT	Aug 16, 2022
DIHYDROERGOTAMINE MESYLATE - TRUDHESA						
N 213436 001	11266799	Nov 05, 2036	DP			
DIMETHYL FUMARATE - TECFIDERA						
N 204063 001	11246850	Nov 16, 2035	U-1384			
DIMETHYL FUMARATE - TECFIDERA						
N 204063 002	11246850	Nov 16, 2035	U-1384			
DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO						
N 211994 001	11234985	Jan 24, 2031	DP U-257			
DONEPEZIL HYDROCHLORIDE - ADLARITY						
N 212304 001	10016372	Jul 26, 2037	U-3334	>A>	NP	Mar 11, 2025
	10300025	Jul 26, 2037	DP			
	10307379	Jul 26, 2037	DP			
	10835499	May 20, 2038	DP U-3334			
	10966936	Aug 11, 2038	DP U-3334			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DONEPEZIL HYDROCHLORIDE - ADLARITY						
N 212304 001	11103463	Jul 26, 2037	U-3334			
	9993466	Jul 26, 2037	DP			
DONEPEZIL HYDROCHLORIDE - ADLARITY						
N 212304 002	10016372	Jul 26, 2037	U-3334	>A>	NP	Mar 11, 2025
	10300025	Jul 26, 2037	DP			
	10307379	Jul 26, 2037	DP			
	10835499	May 20, 2038	DP U-3334			
	10966936	Aug 11, 2038	DP U-3334			
	11103463	Jul 26, 2037	U-3334			
	9993466	Jul 26, 2037	DP			
DORAVIRINE - PIFELTRO						
N 210806 001	8486975	Oct 07, 2031	DS DP U-2394		NPP	Jan 27, 2025
	8486975	Oct 07, 2031	DS DP U-2630			
	8486975	Oct 07, 2031	DS DP U-3308			
DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO						
N 210807 001	8486975	Oct 07, 2031	DS DP U-2395		NPP	Jan 27, 2025
	8486975	Oct 07, 2031	DS DP U-2629			
	8486975	Oct 07, 2031	DS DP U-3307			
DOXEPIN HYDROCHLORIDE - DOXEPIN HYDROCHLORIDE						
A 213796 001					CGT	Oct 29, 2022
DOXEPIN HYDROCHLORIDE - SILENOR						
N 022036 001	11234954	Jan 18, 2028	U-620			
DOXEPIN HYDROCHLORIDE - SILENOR						
N 022036 002	11234954	Jan 18, 2028	U-620			
DRONABINOL - SYNDROS						
N 205525 001	11253472	Aug 06, 2028	DS DP			
DROSPIRENONE - SLYND						
N 211367 001	11291632	Jun 28, 2031	DP			
	11291633	Jun 28, 2031	DP			
	11351122	Jun 28, 2031	DP			
	11413249	Jun 28, 2031	U-2553			
	11439598	Jun 28, 2031	DP			
	11478487	Jun 28, 2031	DP			
DROSPIRENONE - DROSPIRENONE						
N 216285 001	10179140	Jun 28, 2031	U-2553		NP	Jun 29, 2025
	10603281	Jun 28, 2031	U-2553			
	10849857	Jun 28, 2031	DP U-2553			
	10987364	Jun 28, 2031	DP			
	11123299	Jun 28, 2031	DP			
	11291632	Jun 28, 2031	DP			
	11291633	Jun 28, 2031	DP			
	11351122	Jun 28, 2031	DP			
	11413249	Jun 28, 2031	U-2553			
	11439598	Jun 28, 2031	DP			
	11478487	Jun 28, 2031	DP			
	9603860	Jun 28, 2031	U-2553			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE						
N 212516 001	11202772	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE						
N 212516 002	11202772	Apr 13, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE							
N 212516 003		11202772	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE							
N 212516 004		11202772	Apr 13, 2037	DP			
DUVELISIB - COPIKTRA							
N 211155 001		11312718	Jan 10, 2032	DP			
DUVELISIB - COPIKTRA							
N 211155 002		11312718	Jan 10, 2032	DP			
EDARAVONE - RADICAVA ORS							
N 215446 001		10987341	Nov 01, 2039	DP		NP	May 12, 2025
		11241416	Nov 01, 2039	DP			
	>A>	11478450	Nov 01, 2039	U-3468			
EFINACONAZOLE - JUBLIA							
N 203567 001		11213519	Jan 03, 2028	U-2720			
ELAGOLIX SODIUM - ORILISSA							
N 210450 002		11344551	Mar 14, 2034	U-3388			
		11344551	Mar 14, 2034	U-3389			
ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)							
N 213388 001	>A>	11459305	Nov 07, 2028	DP U-2842			
ELBASVIR; GRAZOPREVIR - ZEPATIER							
N 208261 001						NPP	Dec 09, 2024
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)							
N 212273 001		11426407	Oct 06, 2035	DS DP U-3425			
		11453655	Dec 08, 2037	DS DP			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)							
N 212273 002		11426407	Oct 06, 2035	DS DP U-3425			
		11453655	Dec 08, 2037	DS DP			
ELIGLUSTAT TARTRATE - CERDELGA							
N 205494 001		11458119	Nov 24, 2030	DS DP			
ELTROMBOPAG OLAMINE - PROMACTA KIT							
N 207027 001		7795293	May 21, 2023	U-1306			
		7795293	May 21, 2023	U-1736			
		7795293*PED	Nov 21, 2023				
ELUXADOLINE - VIBERZI							
N 206940 001		11229627	Mar 14, 2033	DP			
		11311516	Mar 14, 2033	DP			
ELUXADOLINE - VIBERZI							
N 206940 002		11229627	Mar 14, 2033	DP			
		11311516	Mar 14, 2033	DP			
	>A>	11484527	Mar 14, 2033	U-3475			
EMPAGLIFLOZIN - JARDIANCE							
N 204629 001		9949997	May 17, 2034	U-2292		M-82	Feb 24, 2025
		9949997	May 17, 2034	U-3199			
		9949997	May 17, 2034	U-3325			
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY							
N 208215 002		7390791	Apr 17, 2025	DS DP			
		7390791*PED	Oct 17, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY							
N 208215 002		8754065	Aug 15, 2032	DS DP U-1663			
		8754065*PED	Feb 15, 2033				
		9296769	Aug 15, 2032	DS DP U-1663			
		9296769*PED	Feb 15, 2033				
ENALAPRIL MALEATE - EPANED							
N 208686 001		11173141	Mar 25, 2036	DP			
ENCORAFENIB - BRAFTOVI							
N 210496 002		9474754	Aug 05, 2033	U-2802			
ENTRECTINIB - ROZLYTREK							
N 212725 001		11253515	Jul 18, 2038	DP			
ENTRECTINIB - ROZLYTREK							
N 212725 002		11253515	Jul 18, 2038	DP			
EPHEDRINE SULFATE - EMERPHED							
N 213407 001		11241400	May 16, 2040	U-3183			
		11464752	May 16, 2040	DP			
	>A>	11478436	May 16, 2040	U-3183			
EPHEDRINE SULFATE - EPHEDRINE SULFATE							
N 213994 002		10869845	Jan 22, 2040	DP			
EPINEPHRINE - EPINEPHRINE							
N 205029 001	>A>	9283197	Aug 15, 2034	DP U-1828	Y		
	>A>	9283197	Aug 15, 2034	DP U-1829	Y		
	>A>	9283197	Aug 15, 2034	DP U-1830	Y		
EPINEPHRINE - SYMJEPI							
N 207534 001		11141540	Oct 20, 2036	DP U-3379			
EPINEPHRINE - SYMJEPI							
N 207534 002		11141540	Oct 20, 2036	DP U-3379			
ERAVACYCLINE DIHYDROCHLORIDE - XERAVA							
N 211109 001		10961190	Oct 19, 2037	DS			
ERAVACYCLINE DIHYDROCHLORIDE - XERAVA							
N 211109 002		10961190	Oct 19, 2037	DS			
ERIBULIN MESYLATE - HALAVEN							
N 201532 001		6214865	Jul 20, 2023	DS		M-280	Sep 13, 2025
		6214865*PED	Jan 20, 2024			PED	Mar 13, 2026
		RE46965	Jan 08, 2027	DP			
		RE46965*PED	Jul 08, 2027				
ERTUGLIFLOZIN - STEGLATRO							
N 209803 001						M-275	Sep 17, 2024
ERTUGLIFLOZIN - STEGLATRO							
N 209803 002						M-275	Sep 17, 2024
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET							
N 209806 001						M-275	Sep 17, 2024
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET							
N 209806 002						M-275	Sep 17, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 003					M-275	Sep 17, 2024
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 004					M-275	Sep 17, 2024
ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN						
N 209805 001					M-275	Sep 17, 2024
ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN						
N 209805 002					M-275	Sep 17, 2024
ESKETAMINE HYDROCHLORIDE - SPRAVATO						
N 211243 001	11311500	Sep 10, 2035	U-3034			
	11311500	Sep 10, 2035	U-3035			
	11311500	Sep 10, 2035	U-3036			
	11446260	Mar 14, 2034	U-3444			
	11446260	Mar 14, 2034	U-3445			
	11446260	Mar 14, 2034	U-3446			
	8785500	Mar 05, 2033	U-2502			
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 001	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 002	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 003	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 004	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			
ESTRADIOL - ESTRADIOL						
A 211783 001					CGT	Apr 08, 2023
ESTRADIOL - IMVEXXY						
N 208564 001	11241445	Nov 21, 2032	U-2316			
	11241445	Nov 21, 2032	U-2317			
	11246875	Nov 21, 2032	U-2316			
	11246875	Nov 21, 2032	U-2317			
	11266661	Feb 02, 2034	U-2316			
	11266661	Feb 02, 2034	U-2317			
	11304959	Nov 21, 2032	DP			
	11351182	Nov 21, 2032	U-2316			
	11351182	Nov 21, 2032	U-2317			
>A>	11497709	Nov 21, 2032	U-2316			
>A>	11497709	Nov 21, 2032	U-2317			
ESTRADIOL - IMVEXXY						
N 208564 002	11241445	Nov 21, 2032	U-2316			
	11241445	Nov 21, 2032	U-2317			
	11246875	Nov 21, 2032	U-2316			
	11246875	Nov 21, 2032	U-2317			
	11266661	Feb 02, 2034	U-2316			
	11266661	Feb 02, 2034	U-2317			
	11304959	Nov 21, 2032	DP			
	11351182	Nov 21, 2032	U-2316			
	11351182	Nov 21, 2032	U-2317			
>A>	11497709	Nov 21, 2032	U-2316			
>A>	11497709	Nov 21, 2032	U-2317			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESTRADIOL - IMVEXXY						
N 208564 002	11241445	Nov 21, 2032	U-2316			
	11241445	Nov 21, 2032	U-2317			
	11246875	Nov 21, 2032	U-2316			
	11246875	Nov 21, 2032	U-2317			
	11266661	Feb 02, 2034	U-2316			
	11266661	Feb 02, 2034	U-2317			
	11304959	Nov 21, 2032	DP			
	11351182	Nov 21, 2032	U-2316			
	11351182	Nov 21, 2032	U-2317			
	>A> 11497709	Nov 21, 2032	U-2316			
	>A> 11497709	Nov 21, 2032	U-2317			
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE						
N 214846 001	8058280	Jan 28, 2024	DS		I-898	Aug 05, 2025
ESTRADIOL; PROGESTERONE - BIJUVA						
N 210132 002	10052386	Nov 21, 2032	DP			
	10206932	Nov 21, 2032	U-2439			
	10675288	Nov 21, 2032	U-2439			
	11033626	Nov 21, 2032	DP U-2439			
	11166963	Nov 21, 2032	DP			
	8633178	Nov 21, 2032	DP			
	8846648	Nov 21, 2032	U-2439			
	8846649	Nov 21, 2032	DP U-2439			
	8933059	Nov 21, 2032	DP U-2439			
	8987237	Nov 21, 2032	DP			
	8993548	Nov 21, 2032	DP			
	8993549	Nov 21, 2032	DP			
	9114145	Nov 21, 2032	U-2439			
	9114146	Nov 21, 2032	DP U-2439			
	9301920	Nov 21, 2032	DP U-2439			
FEDRATINIB HYDROCHLORIDE - INREBIC						
N 212327 001	11400092	Sep 24, 2039	U-3409			
FENFLURAMINE HYDROCHLORIDE - FINTEPLA						
N 212102 001	10452815	Jun 29, 2038	U-2859		I-887	Mar 25, 2025
	10452815*PED	Dec 29, 2038			NP	Jun 25, 2023
	10478441	May 03, 2033	U-2860		ODE-312	Jun 25, 2027
	10478441*PED	Nov 03, 2033			PED	Dec 25, 2023
	10478442	May 03, 2033	U-2860		PED	Sep 25, 2025
	10478442*PED	Nov 03, 2033			PED	Dec 25, 2027
	10603290	Aug 02, 2037	U-2861			
	10603290	Aug 02, 2037	U-3347			
	10603290*PED	Feb 02, 2038				
	10947183	Dec 20, 2036	DS DP			
	10947183*PED	Jun 20, 2037				
	10950331	Sep 28, 2035	U-3098			
	10950331*PED	Mar 28, 2036				
	11040018	Aug 02, 2037	U-2861			
	11040018	Aug 02, 2037	U-3347			
	11040018*PED	Feb 02, 2038				
	11406606	Aug 02, 2037	U-3406			
	11406606	Aug 02, 2037	U-3407			
	11406606*PED	Feb 02, 2038				
	9549909	May 03, 2033	U-2858			
	9549909*PED	Nov 03, 2033				
	9603814	May 03, 2033	U-2858			
	9603814*PED	Nov 03, 2033				
	9603815	May 03, 2033	U-2858			
	9603815*PED	Nov 03, 2033				
	9610260	May 03, 2033	U-2858			
	9610260*PED	Nov 03, 2033				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENOPROFEN CALCIUM - FENOPROFEN CALCIUM						
A 214475 001					CGT	Feb 11, 2023
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 001	11123321	Oct 20, 2023	DS DP		U-2555	
	11123321	Oct 20, 2023	DS DP		U-2557	
	11123321	Oct 20, 2023	DS DP		U-3312	
	11123321	Oct 20, 2023	DS DP		U-3313	
	11291645	Oct 20, 2023	DS DP		U-3351	
	11291645	Oct 20, 2023	DS DP		U-3352	
	11433091	Jan 08, 2027			U-3435	
	11433091	Jan 08, 2027			U-3436	
	11433091	Jan 08, 2027			U-3437	
	11433091	Jan 08, 2027			U-3438	
>A>	11478502	Jan 08, 2027			U-3472	
>A>	11478502	Jan 08, 2027			U-3473	
>A>	11478502	Jan 08, 2027			U-3474	
	7754702	Feb 15, 2028			U-1432	
	7754702	Feb 15, 2028			U-2555	
	7754702	Feb 15, 2028			U-2556	
	7754702	Feb 15, 2028			U-2557	
	7754702	Feb 15, 2028			U-3312	
	7754702	Feb 15, 2028			U-3313	
	7754702	Feb 15, 2028			U-3314	
	8895612	Jan 08, 2027			U-1620	
	8895612	Jan 08, 2027			U-3050	
	8895612	Jan 08, 2027			U-3051	
	8895612	Jan 08, 2027			U-3115	
	8895612	Jan 08, 2027			U-3116	
	8895612	Jan 08, 2027			U-3315	
	8895612	Jan 08, 2027			U-3316	
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 002	11123321	Oct 20, 2023	DS DP		U-2555	
	11123321	Oct 20, 2023	DS DP		U-2557	
	11123321	Oct 20, 2023	DS DP		U-3312	
	11123321	Oct 20, 2023	DS DP		U-3313	
	11291645	Oct 20, 2023	DS DP		U-3351	
	11291645	Oct 20, 2023	DS DP		U-3352	
	11433091	Jan 08, 2027			U-3435	
	11433091	Jan 08, 2027			U-3436	
	11433091	Jan 08, 2027			U-3437	
	11433091	Jan 08, 2027			U-3438	
>A>	11478502	Jan 08, 2027			U-3472	
>A>	11478502	Jan 08, 2027			U-3473	
>A>	11478502	Jan 08, 2027			U-3474	
	7754702	Feb 15, 2028			U-2555	
	7754702	Feb 15, 2028			U-2556	
	7754702	Feb 15, 2028			U-2557	
	7754702	Feb 15, 2028			U-3312	
	7754702	Feb 15, 2028			U-3313	
	7754702	Feb 15, 2028			U-3314	
	8895612	Jan 08, 2027			U-1620	
	8895612	Jan 08, 2027			U-3050	
	8895612	Jan 08, 2027			U-3051	
	8895612	Jan 08, 2027			U-3115	
	8895612	Jan 08, 2027			U-3116	
	8895612	Jan 08, 2027			U-3315	
	8895612	Jan 08, 2027			U-3316	
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 003	11123321	Oct 20, 2023	DS DP		U-2555	
	11123321	Oct 20, 2023	DS DP		U-2557	
	11123321	Oct 20, 2023	DS DP		U-3312	
	11123321	Oct 20, 2023	DS DP		U-3313	
	11291645	Oct 20, 2023	DS DP		U-3351	
	11291645	Oct 20, 2023	DS DP		U-3352	
	11433091	Jan 08, 2027			U-3435	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 003	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	>A> 11478502	Jan 08, 2027	U-3472			
	>A> 11478502	Jan 08, 2027	U-3473			
	>A> 11478502	Jan 08, 2027	U-3474			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 004	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	>A> 11478502	Jan 08, 2027	U-3472			
	>A> 11478502	Jan 08, 2027	U-3473			
	>A> 11478502	Jan 08, 2027	U-3474			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	9376505	Oct 20, 2023	DS DP			
FERRIC OXYHYDROXIDE - VELPHORO						
N 205109 001	11234938	Nov 26, 2034	DP			
	11446252	Nov 26, 2034	DP			
FINAFLOXACIN - XTORO						
N 206307 001	9993483	Jul 02, 2030	DP			
FINERENONE - KERENDIA						
N 215341 001					M-279	Sep 01, 2025
FINERENONE - KERENDIA						
N 215341 002					M-279	Sep 01, 2025
FINGOLIMOD HYDROCHLORIDE - FINGOLIMOD HYDROCHLORIDE						
A 207971 001					PC	Mar 20, 2023
FINGOLIMOD HYDROCHLORIDE - FINGOLIMOD HYDROCHLORIDE						
A 207985 001					PC	Mar 20, 2023
FINGOLIMOD HYDROCHLORIDE - FINGOLIMOD HYDROCHLORIDE						
A 207991 001					PC	Mar 20, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FINGOLIMOD HYDROCHLORIDE - FINGOLIMOD HYDROCHLORIDE						
A 208008 001					PC	Mar 20, 2023
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%						
N 207648 001					NPP	Mar 22, 2025
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%						
N 207648 002					NPP	Mar 22, 2025
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%						
N 207648 003					NPP	Mar 22, 2025
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%						
N 207648 004					NPP	Mar 22, 2025
FLIBANSERIN - ADDYI						
N 022526 001	7151103	May 09, 2028	U-1734			
FLORTAUCIPIR F-18 - TAUVID						
N 212123 003	8932557	May 19, 2029	DS			
FLORTAUCIPIR F-18 - TAUVID						
N 212123 004	8932557	May 19, 2029	DS			
FLUOCINOLONE ACETONIDE - YUTIQ						
N 210331 001	7998108	Jan 12, 2028	DP U-3410			
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 004	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
>A>	11464923	Jun 19, 2040	DP			
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 005	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
>A>	11464923	Jun 19, 2040	DP			
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 006	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
>A>	11464923	Jun 19, 2040	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 006	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	>A> 11464923	Jun 19, 2040	DP			
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 008	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	>A> 11464923	Jun 19, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Nov 08, 2030	DP			
	8714149*PED	May 08, 2031				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 004	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 004	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	>A> 11464923	Jun 19, 2040	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 005	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	>A> 11464923	Jun 19, 2040	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 006	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	>A> 11464923	Jun 19, 2040	DP			
FOSAPREPITANT DIMEGLUMINE - EMEND						
N 022023 001					D-186	May 02, 2025
FOSAPREPITANT DIMEGLUMINE - EMEND						
N 022023 002					D-186	May 02, 2025
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO						
N 210493 001	11312698	May 23, 2032	DS DP			
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO						
N 210493 002	11312698	May 23, 2032	DS DP			
FOSTAMATINIB DISODIUM - TAVALISSE						
N 209299 001	RE48898	Jan 19, 2026	DP			
FOSTAMATINIB DISODIUM - TAVALISSE						
N 209299 002	RE48898	Jan 19, 2026	DP			
FUROSEMIDE - FUROSCIX						
N 209988 001	10272064	Apr 03, 2034	DP			
	11433044	Apr 03, 2034	U-3462			
	9884039	Apr 03, 2034	U-3462			
FUTIBATINIB - LYTGOBI						
N 214801 001	10434103	Mar 31, 2036	DS DP		NCE	Sep 30, 2027
	9108973	Feb 23, 2033	DS DP U-3456			
GADOPICLENOL - ELUCIREM						
N 216986 001	>A> 10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	>A> 8114863	Sep 19, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GADOPICLENOL - ELUCIREM							
N 216986 002	>A>	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	>A>	8114863	Sep 19, 2028	DS			
GADOPICLENOL - ELUCIREM							
N 216986 003	>A>	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	>A>	8114863	Sep 19, 2028	DS			
GADOPICLENOL - ELUCIREM							
N 216986 004	>A>	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	>A>	8114863	Sep 19, 2028	DS			
GADOPICLENOL - ELUCIREM							
N 216986 005	>A>	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	>A>	8114863	Sep 19, 2028	DS			
GADOPICLENOL - ELUCIREM							
N 216986 006	>A>	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	>A>	8114863	Sep 19, 2028	DS			
GADOPICLENOL - ELUCIREM							
N 216986 007	>A>	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	>A>	8114863	Sep 19, 2028	DS			
GALLIUM GA-68 DOTATOC - GALLIUM GA 68 DOTATOC							
N 210828 001						ODE-383	Aug 21, 2026
						W	Aug 21, 2026
GALLIUM GA-68 GOZETOTIDE - ILLUCCIX							
N 214032 001		11027031	Jul 28, 2035	U-3317			
GALLIUM GA-68 GOZETOTIDE - LOCAMETZ							
N 215841 001		11369590	Aug 15, 2028	DS DP U-3400		NP	Mar 23, 2025
GANAXOLONE - ZTALMY							
N 215904 001		10603308	Aug 10, 2037	U-3374		NCE	Jun 01, 2027
		7858609	Nov 28, 2026	DP			
		8022054	Nov 28, 2026	DP			
		8318714	Nov 28, 2026	DP			
		8367651	Nov 28, 2026	DP			
		8618087	Nov 28, 2026	U-3374			
		9029355	Nov 28, 2026	DP			
		9056116	Nov 28, 2026	U-3374			
GIVOSIRAN SODIUM - GIVLAARI							
N 212194 001		11028392	Oct 03, 2034	DS DP U-2672			
GLECAPREVIR; PIBRENTASVIR - MAVYRET							
N 209394 001		11246866	Jun 24, 2036	DP			
		11246866*PED	Dec 24, 2036				
	>A>	11484534	Mar 14, 2034	U-3237			
	>A>	11484534*PED	Sep 14, 2034				
		RE48923	May 08, 2035	DS			
		RE48923*PED	Nov 08, 2035				
GLECAPREVIR; PIBRENTASVIR - MAVYRET							
N 215110 001		RE48923	May 08, 2035	DS			
		RE48923*PED	Nov 08, 2035				
GLYCOPYRROLATE - LONHALA MAGNAIR KIT							
N 208437 001		11278683	Aug 16, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HALOBETASOL PROPIONATE - LEXETTE						
N 210566 001					NPP	Aug 18, 2024
HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT						
N 022555 001	11235168	Jan 04, 2038	U-2250			
	11311620	Dec 19, 2036	U-2250			
HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE						
A 215586 001					CGT	Oct 09, 2022
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 001	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 002	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 003	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 004	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 005	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 006	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 007	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)						
N 021945 004	11304962	May 02, 2036	U-2236			
	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
IBRUTINIB - IMBRUVICA						
N 205552 001	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10294231	Jun 03, 2033	DP			
	10294231*PED	Dec 03, 2033				
	10294232	Jun 03, 2033	DP			
	10294232*PED	Dec 03, 2033				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 001	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10752634	Jun 03, 2033	DP			
	10752634*PED	Dec 03, 2033				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1683			
	8999999	Jun 03, 2031	U-1684			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1745			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS DP			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS DP			
	9296753*PED	Apr 30, 2034				
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 001	9540382*PED	Feb 18, 2034				
	9713617	Jun 03, 2033	DP			
	9713617*PED	Dec 03, 2033				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2150			
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 205552 002	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10294231	Jun 03, 2033	DP			
	10294231*PED	Dec 03, 2033				
	10294232	Jun 03, 2033	DP			
	10294232*PED	Dec 03, 2033				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 002	8497277	Dec 28, 2026	U-1947			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2228			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9540382*PED	Feb 18, 2034				
	9713617	Jun 03, 2033	DP			
	9713617*PED	Dec 03, 2033				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 210563 001	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 001	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034			U-2654	
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031			U-1456	
	10478439	Jun 03, 2031			U-1650	
	10478439	Jun 03, 2031			U-1684	
	10478439	Jun 03, 2031			U-1946	
	10478439	Jun 03, 2031			U-1947	
	10478439	Jun 03, 2031			U-2241	
	10478439	Jun 03, 2031			U-2242	
	10478439	Jun 03, 2031			U-2665	
	10478439	Jun 03, 2031			U-3422	
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031			U-1456	
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034			U-2846	
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031			U-1491	
	10751342	Jun 03, 2031			U-1946	
	10751342	Jun 03, 2031			U-2943	
	10751342	Jun 03, 2031			U-2944	
	10751342*PED	Dec 03, 2031				
	10752634	Jun 03, 2033	DP			
	10752634*PED	Dec 03, 2033				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026			U-1456	
	8476284	Dec 28, 2026			U-1650	
	8476284	Dec 28, 2026			U-1946	
	8476284	Dec 28, 2026			U-1947	
	8476284	Dec 28, 2026			U-2241	
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026			U-1456	
	8497277	Dec 28, 2026			U-1491	
	8497277	Dec 28, 2026			U-1650	
	8497277	Dec 28, 2026			U-1946	
	8497277	Dec 28, 2026			U-1947	
	8497277	Dec 28, 2026			U-2241	
	8497277	Dec 28, 2026			U-2242	
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027			U-1491	
	8563563	Apr 26, 2027			U-1650	
	8563563	Apr 26, 2027			U-1946	
	8563563	Apr 26, 2027			U-2241	
	8563563	Apr 26, 2027			U-2242	
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026			U-1491	
	8703780	Dec 28, 2026			U-2242	
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031			U-1456	
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026			U-1456	
	8952015	Dec 28, 2026			U-1491	
	8952015	Dec 28, 2026			U-1650	
	8952015	Dec 28, 2026			U-1946	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 001	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 210563 002	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 002	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 002	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 210563 003	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277*PED	Jun 28, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 003	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 210563 004	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 004	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034			U-2654	
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031			U-1456	
	10478439	Jun 03, 2031			U-1650	
	10478439	Jun 03, 2031			U-1684	
	10478439	Jun 03, 2031			U-1946	
	10478439	Jun 03, 2031			U-1947	
	10478439	Jun 03, 2031			U-2241	
	10478439	Jun 03, 2031			U-2242	
	10478439	Jun 03, 2031			U-2665	
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031			U-1456	
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034			U-2846	
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031			U-1491	
	10751342	Jun 03, 2031			U-1946	
	10751342	Jun 03, 2031			U-2943	
	10751342	Jun 03, 2031			U-2944	
	10751342*PED	Dec 03, 2031				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026			U-1456	
	8476284	Dec 28, 2026			U-1650	
	8476284	Dec 28, 2026			U-1946	
	8476284	Dec 28, 2026			U-1947	
	8476284	Dec 28, 2026			U-2241	
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026			U-1456	
	8497277	Dec 28, 2026			U-1491	
	8497277	Dec 28, 2026			U-1650	
	8497277	Dec 28, 2026			U-1946	
	8497277	Dec 28, 2026			U-1947	
	8497277	Dec 28, 2026			U-2241	
	8497277	Dec 28, 2026			U-2242	
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027			U-1491	
	8563563	Apr 26, 2027			U-1650	
	8563563	Apr 26, 2027			U-1946	
	8563563	Apr 26, 2027			U-2241	
	8563563	Apr 26, 2027			U-2242	
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026			U-1491	
	8703780	Dec 28, 2026			U-2242	
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031			U-1456	
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026			U-1456	
	8952015	Dec 28, 2026			U-1491	
	8952015	Dec 28, 2026			U-1650	
	8952015	Dec 28, 2026			U-1946	
	8952015	Dec 28, 2026			U-1947	
	8952015	Dec 28, 2026			U-2241	
	8952015	Dec 28, 2026			U-2242	
	8952015*PED	Jun 28, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 004	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 217003 001	10106548	Jun 03, 2033	DS DP		NP	Aug 24, 2025
	10125140	Jun 03, 2033	DS DP		PED	Feb 24, 2026
	10478439	Jun 03, 2031	U-3422			
	10961251	Jun 03, 2033	DP			
	7514444	Dec 28, 2026	DS DP			
	8008309	Nov 13, 2027	DS DP			
	8497277	Dec 28, 2026	U-3422			
	8697711	Dec 28, 2026	DS DP			
	8735403	Dec 28, 2026	DS DP			
	8754091	Dec 28, 2026	DP			
	8957079	Dec 28, 2026	DS DP			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-3422			
ICOSAPENT ETHYL - ICOSAPENT ETHYL						
A 209525 001					PC	Mar 08, 2023
ICOSAPENT ETHYL - VASCEPA						
N 202057 001	11213504	Apr 29, 2030	U-3292			
	11298333	Jun 28, 2033	U-3358			
	11369582	Jun 28, 2033	U-2841			
ICOSAPENT ETHYL - VASCEPA						
N 202057 002	11213504	Apr 29, 2030	U-3292			
	11298333	Jun 28, 2033	U-3358			
	11369582	Jun 28, 2033	U-2841			
IMIQUIMOD - ZYCLARA						
N 022483 001	11202752	Apr 30, 2030	U-1455			
	11202752	Apr 30, 2030	U-172			
IMIQUIMOD - ZYCLARA						
N 022483 002	11318130	Dec 11, 2029	U-68			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INCLISIRAN SODIUM - LEQVIO						
N 214012 001	10125369	Aug 18, 2034	DS DP U-3272		NCE	Dec 22, 2026
	10131907	Aug 24, 2028	DS DP U-3272			
	10266825	Nov 04, 2023	U-3272			
	10273477	Mar 08, 2024	DS			
	10590418	Jul 19, 2022	U-3272			
	10669544	Mar 08, 2024	DS			
	10806791	Dec 04, 2028	DS			
	10851377	Aug 25, 2036	U-3272			
	11078485	Nov 04, 2023	DS U-3272			
	8106022	Dec 12, 2029	DS DP U-3272			
	8222222	Dec 29, 2027	U-3272			
	8232383	Feb 20, 2023	DS DP			
	8546143	Apr 23, 2022	DS U-3272			
	8809292	May 10, 2027	DS DP U-3272			
	8828956	Dec 04, 2028	DS DP U-3272			
	9074213	Mar 09, 2022	DS U-3272			
	9370582	Dec 04, 2028	DS DP U-3272			
	9708610	Jan 01, 2024	DS DP U-3272			
	9708615	Mar 08, 2024	DS			
INDIGOTINDISULFONATE SODIUM - BLUDIGO						
N 216264 001	10927258	Dec 23, 2037	DS		NCE	Jul 08, 2027
>A>	11499050	Dec 23, 2037	DS			
IODIXANOL - IODIXANOL						
A 214271 001					CGT	Jan 09, 2023
IODIXANOL - IODIXANOL						
A 214271 002					CGT	Jan 09, 2023
IRINOTECAN HYDROCHLORIDE - ONIVYDE						
N 207793 001	11369597	Jun 12, 2033	U-1848			
ISOSORBIDE DINITRATE - ISOSORBIDE DINITRATE						
A 211290 001					CGT	Jun 20, 2022
IVACAFTOR - KALYDECO						
N 207925 001	11147770	Feb 27, 2033	DP U-3339			
IVACAFTOR - KALYDECO						
N 207925 002	11147770	Feb 27, 2033	DP U-3339			
IVACAFTOR - KALYDECO						
N 207925 003	11147770	Feb 27, 2033	DP U-3339			
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 206038 001	8846718	Jul 02, 2029	U-1717			
	8846718	Jul 02, 2029	U-1908			
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 206038 002	8846718	Jul 02, 2029	U-1908			
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 001	8846718	Jul 02, 2029	U-2375		NPP	Sep 02, 2025
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 002	8846718	Jul 02, 2029	U-2375		NPP	Sep 02, 2025
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 003	10597384	Dec 04, 2028	DS DP U-3430		NS	Sep 02, 2025
	10646481	Aug 13, 2029	DP			
	7495103	May 20, 2027	DS DP			
	7973038	Nov 08, 2026	U-3424			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 003	8324242	Aug 05, 2027	U-3424			
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-3426			
	8741933	Nov 08, 2026	U-3424			
	8754224	Dec 28, 2026	DS DP			
	8846718	Jul 02, 2029	U-3427			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-3427			
	9192606	Sep 29, 2029	DP U-3428			
	9216969	Nov 08, 2026	DP			
	9670163	Dec 28, 2026	DP U-3429			
	9931334	Dec 28, 2026	DP U-3429			
IVOSIDENIB - TIBSOVO						
N 211192 001	10610125	Jun 21, 2030	U-2784		I-893	May 25, 2025
	10610125	Jun 21, 2030	U-2785			
	10610125	Jun 21, 2030	U-3385			
	10653710	Oct 18, 2036	U-3387			
	10799490	Mar 13, 2035	DP U-2981			
	10799490	Mar 13, 2035	DP U-2982			
	10799490	Mar 13, 2035	DP U-3384			
	10980788	Jun 07, 2039	U-3112			
	10980788	Jun 07, 2039	U-3113			
	10980788	Jun 07, 2039	U-3214			
	10980788	Jun 07, 2039	U-3383			
	9474779	Aug 19, 2033	DS DP U-2350			
	9474779	Aug 19, 2033	DS DP U-2533			
	9474779	Aug 19, 2033	DS DP U-2534			
	9474779	Aug 19, 2033	DS DP U-3213			
	9474779	Aug 19, 2033	DS DP U-3386			
	9850277	Jan 18, 2033	DS DP U-2350			
	9850277	Jan 18, 2033	DS DP U-2533			
	9850277	Jan 18, 2033	DS DP U-2534			
	9850277	Jan 18, 2033	DS DP U-3213			
	9850277	Jan 18, 2033	DS DP U-3386			
	9968595	Mar 13, 2035	DP U-2351			
	9968595	Mar 13, 2035	DP U-2533			
	9968595	Mar 13, 2035	DP U-2534			
	9968595	Mar 13, 2035	DP U-3384			
KETOTIFEN FUMARATE - ACUVUE THERAVISION WITH KETOTIFEN						
N 022388 001	9474746	Mar 27, 2028	DP		NP	Feb 25, 2025
	9962376	Jun 27, 2030	DP			
LACOSAMIDE - VIMPAT						
N 022253 001					NPP	Oct 14, 2024
LACOSAMIDE - VIMPAT						
N 022253 002					NPP	Oct 14, 2024
LACOSAMIDE - VIMPAT						
N 022253 003					NPP	Oct 14, 2024
LACOSAMIDE - VIMPAT						
N 022253 004					NPP	Oct 14, 2024
LACOSAMIDE - VIMPAT						
N 022254 001					NPP	Oct 14, 2024
LACOSAMIDE - VIMPAT						
N 022255 001					NPP	Oct 14, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - LENALIDOMIDE						
A 201452 001					PC	Aug 30, 2022
LENALIDOMIDE - LENALIDOMIDE						
A 201452 002					PC	Aug 30, 2022
LENALIDOMIDE - LENALIDOMIDE						
A 201452 003					PC	Aug 30, 2022
LENALIDOMIDE - LENALIDOMIDE						
A 201452 004					PC	Aug 30, 2022
LENALIDOMIDE - LENALIDOMIDE						
A 209348 001					PC	Mar 06, 2023
LENALIDOMIDE - LENALIDOMIDE						
A 209348 002					PC	Mar 06, 2023
LENVATINIB MESYLATE - LENVIMA						
N 206947 001					M-272	Dec 19, 2024
LENVATINIB MESYLATE - LENVIMA						
N 206947 002					M-272	Dec 19, 2024
LESINURAD - ZURAMPIC						
N 207988 001	8357713	Dec 22, 2029	DP U-1801			
	8357713	Dec 22, 2029	DP U-1802			
	8357713	Dec 22, 2029	DP U-1803			
LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)						
N 209935 001	8415355	Mar 13, 2031	DS DP		NPP	Dec 10, 2024
LEVOKETOCONAZOLE - RECORLEV						
N 214133 001	10098877	Jan 10, 2026	U-3283			
	10517868	Jan 10, 2026	U-3283			
	10835530	Jan 10, 2026	U-3283			
	11020393	Mar 02, 2040	U-3282			
	11278547	Mar 02, 2040	U-3282			
	11478471	Jan 10, 2026	U-3283			
	9918984	Jan 10, 2026	U-3283			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 013	10537538	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 014	10537538	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 015	10537538	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - ERMEZA						
N 215809 001	9345772	Feb 27, 2035	DP			
LIDOCAINE - ZTLIDO						
N 207962 001	11278623	May 10, 2031	DP			
LIRAGLUTIDE RECOMBINANT - SAXENDA						
N 206321 001	11311679	Jan 20, 2026	DP			
	11446443	Oct 20, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LORAZEPAM - LOREEV XR						
N 214826 004	8999393	Jan 08, 2034	DP U-3210			
LORLATINIB - LORBRENA						
N 210868 001	11299500	Oct 04, 2038	DS			
LORLATINIB - LORBRENA						
N 210868 002	11299500	Oct 04, 2038	DS			
LOTEPREDNOL ETABONATE - INVELTYS						
N 210565 001	11219597	May 03, 2033	U-3278			
	11219597	May 03, 2033	U-3279			
LOTEPREDNOL ETABONATE - EYSUVIS						
N 210933 001	11219596	May 03, 2033	U-2985			
LUMASIRAN SODIUM - OXLUMO						
N 214103 001	11261447	Nov 20, 2038	DS DP U-2995		>A> I-901	Oct 06, 2025
	11401517	Aug 14, 2035	DS DP U-2995			
	11446380	Oct 09, 2035	DS DP			
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 001	10117867	May 27, 2029	U-3271		I-882	Dec 17, 2024
	11026951	Dec 03, 2034	U-3274			
	RE48839	Dec 28, 2029	U-3271			
	RE48839	Dec 28, 2029	U-814			
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 002	10117867	May 27, 2029	U-3271		NCE	Dec 20, 2024
	10464938	Mar 12, 2028	DP			
	10695345	Aug 30, 2039	DP U-814			
	11026951	Dec 03, 2034	U-3364			
	11052084	Aug 30, 2039	DP U-3362			
	11052084	Aug 30, 2039	DP U-3363			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE48825	Feb 12, 2029	DS			
	RE48839	Dec 28, 2029	U-3271			
	RE48839	Dec 28, 2029	U-814			
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 003	10117867	May 27, 2029	U-3271		NCE	Dec 20, 2024
	10464938	Mar 12, 2028	DP			
	10695345	Aug 30, 2039	DP U-814			
	11026951	Dec 03, 2034	U-3364			
	11052084	Aug 30, 2039	DP U-3362			
	11052084	Aug 30, 2039	DP U-3363			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE48825	Feb 12, 2029	DS			
	RE48839	Dec 28, 2029	U-3271			
	RE48839	Dec 28, 2029	U-814			
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN - PLUVICTO						
N 215833 001	10398791	Oct 17, 2034	DS DP		NCE	Mar 23, 2027
	10406240	Aug 15, 2028	DS DP U-3345			
	11318121	Aug 15, 2028	DS DP U-3345			
MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB						
N 213135 001	11382864	Aug 04, 2037	U-3164			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE - SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE						
A 202511 001					PC	Mar 06, 2023
MARALIXIBAT CHLORIDE - LIVMARLI						
N 214662 001	11229647	Feb 12, 2040	U-3290		ODE-379	Sep 29, 2028
	11260053	May 26, 2031	U-3290			
	11376251	Oct 26, 2032	U-3290			
	>A> 11497745	Feb 12, 2040	U-3290			
MARAVIROC - MARAVIROC						
A 203347 001					PC	Aug 06, 2022
MARAVIROC - MARAVIROC						
A 203347 002					PC	Aug 06, 2022
MARIBAVIR - LIVTENCITY						
N 215596 001					NCE	Nov 23, 2026
MAVACAMTEN - CAMZYOS						
N 214998 001	9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
	9585883	Jun 19, 2034	U-3373			
MAVACAMTEN - CAMZYOS						
N 214998 002	9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
	9585883	Jun 19, 2034	U-3373			
MAVACAMTEN - CAMZYOS						
N 214998 003	9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
	9585883	Jun 19, 2034	U-3373			
MAVACAMTEN - CAMZYOS						
N 214998 004	9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
	9585883	Jun 19, 2034	U-3373			
MELOXICAM - ANJESO						
N 210583 001	11253478	May 26, 2030	DP U-3318			
	11458145	Mar 08, 2039	U-3318			
MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO						
N 214383 001	11344622	Apr 25, 2032	U-3093			
	6992207	Jun 25, 2023	DS DP U-3093			
MEROPENEM; VABORBACTAM - VABOMERE						
N 209776 001	11376237	Apr 06, 2039	U-3421			
MESALAMINE - MESALAMINE						
A 214585 001					CGT	Nov 14, 2022
METHOTREXATE - OTREXUP						
N 204824 001	11446441	Jan 24, 2026	DP			
METHOTREXATE - OTREXUP						
N 204824 002	11446441	Jan 24, 2026	DP			
METHOTREXATE - OTREXUP						
N 204824 003	11446441	Jan 24, 2026	DP			
METHOTREXATE - OTREXUP						
N 204824 004	11446441	Jan 24, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHOTREXATE - OTREXUP						
N 204824 005	11446441	Jan 24, 2026	DP			
METHOTREXATE - OTREXUP						
N 204824 006	11446441	Jan 24, 2026	DP			
METHOTREXATE - OTREXUP						
N 204824 007	11446441	Jan 24, 2026	DP			
METHOTREXATE - OTREXUP						
N 204824 008	11446441	Jan 24, 2026	DP			
METHYLPHENIDATE - COTEMPLA XR-ODT						
N 205489 001	11166947	Jan 25, 2038	U-3299			
METHYLPHENIDATE - COTEMPLA XR-ODT						
N 205489 002	11166947	Jan 25, 2038	U-3299			
METHYLPHENIDATE - COTEMPLA XR-ODT						
N 205489 003	11166947	Jan 25, 2038	U-3299			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 001	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 002	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 003	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 004	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 005	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI						
N 209388 001					NP	Jun 19, 2023
MIDOSTAURIN - RYDAPT						
N 207997 001	7973031	Oct 09, 2028	U-2007			
MIGALASTAT HYDROCHLORIDE - GALAFOLD						
N 208623 001	11234972	Mar 15, 2037	U-2371			
	11241422	May 16, 2027	U-2371			
	11278536	May 30, 2038	U-2371			
	11278537	May 30, 2038	U-2371			
	11278538	May 30, 2038	U-2371			
	11278539	May 30, 2038	U-2371			
	11278540	May 30, 2038	U-2371			
	11304940	May 30, 2038	DS			
	11357761	May 30, 2038	U-2371			
	11357762	May 30, 2038	U-2371			
	11357763	May 30, 2038	U-2371			
	11357764	May 30, 2038	DS			
	11357765	May 30, 2038	DS			
	11357784	Feb 06, 2039	U-2371			
	11376244	May 30, 2038	DS			
	11389436	May 30, 2038	U-2371			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MIGALASTAT HYDROCHLORIDE - GALAFOLD						
N 208623 001	11389437	May 30, 2038	U-2371			
	11426396	May 30, 2038	DS			
	11458128	May 30, 2038	U-2371			
	8592362	Feb 12, 2029	U-2371	Y		
MITAPIVAT SULFATE - PYRUKYND						
N 216196 001	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
MITAPIVAT SULFATE - PYRUKYND						
N 216196 002	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
MITAPIVAT SULFATE - PYRUKYND						
N 216196 003	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS						
N 211746 001	10016443	Sep 04, 2034	U-3297		NP	Jan 13, 2025
	10376526	Sep 04, 2034	DP			
	10517880	Sep 04, 2034	DP U-3297			
	10548907	Sep 04, 2034	U-3297			
	10561672	Sep 04, 2034	DP			
	10646500	Sep 04, 2034	U-3297			
	10758550	Sep 04, 2034	U-3296			
	10765686	Sep 04, 2034	U-3295			
	11400101	Sep 04, 2034	U-3297			
	9078923	Sep 04, 2034	DP U-3297			
	9370483	Sep 04, 2034	DP			
	9750754	Sep 04, 2034	DP U-3297			
	9937189	Sep 04, 2034	DP			
NALOXONE HYDROCHLORIDE - KLOXXADO						
N 212045 001	11135155	Aug 26, 2034	DP			
NALOXONE HYDROCHLORIDE - ZIMHI						
N 212854 001	11027072	May 24, 2039	DP			
NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)						
N 215457 001	10143792	May 24, 2031	U-2476			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			
	10737028	Nov 23, 2024	DP			
	7731690	Jan 15, 2025	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)						
N 215457 001	8608698	Nov 23, 2024	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9474869	Feb 28, 2031	DP U-1907			
	9737669	Nov 23, 2024	DP			
	9814838	Feb 28, 2031	DP			
NAPROXEN SODIUM - NAPROXEN SODIUM						
N 021920 001	11090280	Mar 03, 2026	DP U-1731			
	11090280	Mar 03, 2026	DP U-1732			
NEOSTIGMINE METHYLSULFATE - NEOSTIGMINE METHYLSULFATE						
A 216291 001					CGT	Jan 21, 2023
NILOTINIB HYDROCHLORIDE - TASIGNA						
N 022068 001					ODE-380	Sep 23, 2028
					PED	Mar 23, 2029
NILOTINIB HYDROCHLORIDE - TASIGNA						
N 022068 002					ODE-380	Sep 23, 2028
					PED	Mar 23, 2029
NILOTINIB HYDROCHLORIDE - TASIGNA						
N 022068 003					ODE-380	Sep 23, 2028
					PED	Mar 23, 2029
NIMODIPINE - NYMALIZE						
N 203340 002	11207306	Apr 16, 2038	U-2804			
	11413277	Apr 16, 2038	DP U-2804			
>A>	11517563	Apr 16, 2038	DP			
NITRIC OXIDE - GENOSYL						
N 202860 001	11291793	Aug 18, 2025	DP			
	11383059	Aug 18, 2025	U-3037			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE						
N 214628 001	10159657	Jan 30, 2038	DP			
	10226436	Jan 30, 2038	DP U-3461			
	10420735	Jan 30, 2038	DP U-3461			
	10568850	Jan 30, 2038	DP			
	11413259	Jan 30, 2038	DP U-3461			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE						
N 214628 002	10159657	Jan 30, 2038	DP			
	10226436	Jan 30, 2038	DP U-3461			
	10420735	Jan 30, 2038	DP U-3461			
	10568850	Jan 30, 2038	DP			
	11413259	Jan 30, 2038	DP U-3461			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE						
N 214628 003	10159657	Jan 30, 2038	DP			
	10226436	Jan 30, 2038	DP U-3461			
	10420735	Jan 30, 2038	DP U-3461			
	10568850	Jan 30, 2038	DP			
	11413259	Jan 30, 2038	DP U-3461			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE						
N 215700 001	10888534	Apr 26, 2039	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE						
N 215700 002	10888534	Apr 26, 2039	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE						
N 215700 003	10888534	Apr 26, 2039	DP			
OBETICHOLIC ACID - OCALIVA						
N 207999 001	RE48286	Feb 21, 2027	DS DP			
OBETICHOLIC ACID - OCALIVA						
N 207999 002	RE48286	Feb 21, 2027	DS DP			
OCTREOTIDE ACETATE - MYCAPSSA						
N 208232 001	11338011	Feb 03, 2036	U-2857			
ODEVIXIBAT - BYLVAY						
N 215498 001	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
ODEVIXIBAT - BYLVAY						
N 215498 002	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
ODEVIXIBAT - BYLVAY						
N 215498 003	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
ODEVIXIBAT - BYLVAY						
N 215498 004	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 001	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 002	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 003	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 004	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			
OLAPARIB - LYNPARZA						
N 208558 001	8071579	Aug 12, 2027	U-2101		I-885	Mar 11, 2025
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8071579	Aug 12, 2027	U-3333			
	8143241	Aug 12, 2027	U-2101			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLAPARIB - LYNPARZA						
N 208558 001	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8859562	Aug 04, 2031	U-3333			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	8912187	Mar 12, 2024	U-3333			
OLAPARIB - LYNPARZA						
N 208558 002	8071579	Aug 12, 2027	U-2101		I-885	Mar 11, 2025
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8071579	Aug 12, 2027	U-3333			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLAPARIB - LYNPARZA						
N 208558 002	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8859562	Aug 04, 2031	U-3333			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	8912187	Mar 12, 2024	U-3333			
OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEP						
N 213593 001	10751333	Jul 16, 2039	DP			
	11103492	Jul 16, 2039	DP			
OMIDENEPAG ISOPROPYL - OMLONTI						
N 215092 001	10179127	Jan 08, 2035	DP U-3454		NCE	Sep 22, 2027
	10702511	Jan 08, 2035	DP U-3454			
	10765750	Jan 08, 2035	DP			
	10774072	Jun 10, 2035	DS			
	11197849	Jan 08, 2035	DP U-3454			
	8648097	Oct 13, 2029	DS DP			
	8685986	Oct 13, 2029	DP			
	9415038	Jan 08, 2035	DP U-3454			
	RE48183	Jan 08, 2035	DP U-3454			
OTESECONAZOLE - VIVJOA						
N 215888 001	10414751	Mar 17, 2036	DS DP		NCE	Apr 26, 2027
	11247981	May 09, 2033	U-3366		GAIN	Apr 26, 2032
	8236962	Apr 22, 2031	DS DP			
	8754227	Apr 22, 2031	U-3366			
	9840492	Mar 17, 2036	DS DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 001	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 002	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 003	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 004	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 005	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 006	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 007	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ						
N 212520 001	11311515	Dec 16, 2039	DP			
	11324722	Dec 16, 2039	U-2849			
PACRITINIB CITRATE - VONJO						
N 208712 001	8153632	Jan 17, 2029	DS DP U-3331		NCE	Feb 28, 2027
	8153632	Jan 17, 2029	DS DP U-3332			
	8980873	Mar 25, 2030	DS DP U-3331			
	8980873	Mar 25, 2030	DS DP U-3332			
	9573964	May 05, 2028	U-3331			
	9573964	May 05, 2028	U-3332			
PAFOLACIANINE SODIUM - CYTALUX						
N 214907 001	10881747	Aug 26, 2033	DS DP U-3291			
	9061057	Aug 26, 2033	DS DP U-3291			
	9254341	Oct 04, 2033	DS DP			
	9333270	Aug 26, 2033	DS DP U-3291			
	9341629	Aug 26, 2033	DS DP			
	9789208	Aug 26, 2033	DS DP U-3291			
PALIPERIDONE PALMITATE - INVEGA HAFYERA						
N 207946 005	11304951	May 07, 2041	U-3349			
	11324751	May 07, 2041	U-3359			
PALIPERIDONE PALMITATE - INVEGA HAFYERA						
N 207946 006	11304951	May 07, 2041	U-3349			
	11324751	May 07, 2041	U-3359			
PEGCETACOPLAN - EMPAVELI						
N 215014 001	11292815	Nov 15, 2033	DS DP U-3124			
	11292815	Nov 15, 2033	DS DP U-3354			
PEMIGATINIB - PEMAZYRE						
N 213736 001	11466004	May 03, 2039	U-3464		I-899	Aug 26, 2025
	11466004	May 03, 2039	U-3465			
	11466004	May 03, 2039	U-3466			
PEMIGATINIB - PEMAZYRE						
N 213736 002	11466004	May 03, 2039	U-3464		I-899	Aug 26, 2025
	11466004	May 03, 2039	U-3465			
	11466004	May 03, 2039	U-3466			
PEMIGATINIB - PEMAZYRE						
N 213736 003	11466004	May 03, 2039	U-3464		I-899	Aug 26, 2025
	11466004	May 03, 2039	U-3465			
	11466004	May 03, 2039	U-3466			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PERAMPANEL - FYCOMPA						
N 202834 001	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
PERAMPANEL - FYCOMPA						
N 202834 002	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
PERAMPANEL - FYCOMPA						
N 202834 003	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
PERAMPANEL - FYCOMPA						
N 202834 004	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
PERAMPANEL - FYCOMPA						
N 202834 005	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
PERAMPANEL - FYCOMPA						
N 202834 006	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
PERAMPANEL - FYCOMPA						
N 208277 001	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
PERFLUTREN - DEFINITY						
N 021064 001	11266750	Mar 16, 2037	U-665			
PERFLUTREN - DEFINITY RT						
N 021064 002	11266750	Mar 16, 2037	U-665			
	11395856	Dec 28, 2035	DS DP U-665			
PEXIDARTINIB HYDROCHLORIDE - TURALIO						
N 211810 001	7893075	May 04, 2033	DS			
PEXIDARTINIB HYDROCHLORIDE - TURALIO						
N 211810 002	>A> 10189833	May 05, 2036	U-2606		>A> NCE	Aug 02, 2024
	>A> 10435404	Jul 24, 2038	DP		>A> ODE*	Aug 02, 2026
	>A> 10730876	May 05, 2036	DS			
	>A> 10941142	Jul 24, 2038	DP			
	>A> 10961240	Jul 24, 2038	U-2606			
	>A> 7893075	May 04, 2033	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEXIDARTINIB HYDROCHLORIDE - TURALIO							
N 211810 002	>A>	8404700	Nov 21, 2027	DS			
	>A>	8461169	Apr 19, 2028	U-2606			
	>A>	8722702	Nov 21, 2027	DS			
	>A>	9169250	Nov 21, 2027	DS			
	>A>	9358235	Jun 08, 2033	U-2606			
	>A>	9802932	May 05, 2036	DS			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA							
N 022580 001		8580299	Jun 14, 2029	U-3399		NPP	Jun 24, 2025
		8895057	Jun 09, 2028	U-3398			
		9011906	Jun 09, 2028	U-3398			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA							
N 022580 002		8580299	Jun 14, 2029	U-3399		NPP	Jun 24, 2025
		8895057	Jun 09, 2028	U-3398			
		9011906	Jun 09, 2028	U-3398			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA							
N 022580 003		8580299	Jun 14, 2029	U-3399		NPP	Jun 24, 2025
		8895057	Jun 09, 2028	U-3398			
		9011906	Jun 09, 2028	U-3398			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA							
N 022580 004		8580299	Jun 14, 2029	U-3399		NPP	Jun 24, 2025
		8895057	Jun 09, 2028	U-3398			
		9011906	Jun 09, 2028	U-3398			
PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE							
A 216859 001						CGT	Apr 05, 2023
PHYTONADIONE - PHYTONADIONE							
A 214596 001						CGT	Oct 30, 2022
PHYTONADIONE - PHYTONADIONE							
A 214596 002						CGT	Oct 30, 2022
PILOCARPINE HYDROCHLORIDE - VUITY							
N 214028 001		11285134	Apr 24, 2039	U-3252			
PIMAVANSERIN TARTRATE - NUPLAZID							
N 210793 001		11452721	Aug 27, 2038	DP			
PIRFENIDONE - ESBRIET							
N 022535 001		8383150	May 10, 2028	DP U-2361			
PIRFENIDONE - ESBRIET							
N 208780 001		8383150	May 10, 2028	DP U-2361			
PIRFENIDONE - ESBRIET							
N 208780 002		8383150	May 10, 2028	DP U-2361			
PIRFENIDONE - ESBRIET							
N 208780 003		8383150	May 10, 2028	DP U-2361			
PITOLISANT HYDROCHLORIDE - WAKIX							
N 211150 001		8207197	Mar 07, 2030	DS DP			
PITOLISANT HYDROCHLORIDE - WAKIX							
N 211150 002		8207197	Mar 07, 2030	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PLECANATIDE - TRULANCE						
N 208745 001	11319346	Mar 01, 2032	DP			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 001	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 002	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 003	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 004	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
POSACONAZOLE - NOXAFIL						
N 205053 001					I-881	Jun 17, 2024
POSACONAZOLE - NOXAFIL						
N 205596 001					I-881	Jun 17, 2024
PRALSETINIB - GAVRETO						
N 213721 001	11273160	Apr 03, 2039	U-2952			
PRASTERONE - INTRAROSA						
N 208470 001	8957054	Jan 08, 2030	U-1922			
RANOLAZINE - ASPRUZYO SPRINKLE						
N 216018 001	>A> 11510878	Jan 24, 2038	DP			
RANOLAZINE - ASPRUZYO SPRINKLE						
N 216018 002	10898444	Jan 24, 2038	DP			
	>A> 11510878	Jan 24, 2038	DP			
REMDESIVIR - VEKLURY						
N 214787 001	10695361	Sep 16, 2036	U-2984		D-183	Jan 21, 2025
	10695361	Sep 16, 2036	U-3249		NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-3367			
	10695361	Sep 16, 2036	U-3368			
	11007208	Sep 16, 2036	U-2984			
	11007208	Sep 16, 2036	U-3249			
	11007208	Sep 16, 2036	U-3367			
	11007208	Sep 16, 2036	U-3368			
	11266681	Jul 10, 2038	U-2984			
	11266681	Jul 10, 2038	U-3249			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
REMDESIVIR - VEKLURY						
N 214787 001	11266681	Jul 10, 2038	U-3367			
	11266681	Jul 10, 2038	U-3368			
	11382926	Sep 16, 2036	U-3367			
	11382926	Sep 16, 2036	U-3368			
	>A> 11491169	May 28, 2041	U-3484			
	>A> 11491169	May 28, 2041	U-3485			
	>A> 11492353	Dec 08, 2031	DS			
REMDESIVIR - VEKLURY						
N 214787 002	10695361	Sep 16, 2036	U-2984		D-183	Jan 21, 2025
	10695361	Sep 16, 2036	U-3249		NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-3367			
	10695361	Sep 16, 2036	U-3368			
	11007208	Sep 16, 2036	U-2984			
	11007208	Sep 16, 2036	U-3249			
	11007208	Sep 16, 2036	U-3367			
	11007208	Sep 16, 2036	U-3368			
	11266681	Jul 10, 2038	U-2984			
	11266681	Jul 10, 2038	U-3249			
	11266681	Jul 10, 2038	U-3367			
	11266681	Jul 10, 2038	U-3368			
	11382926	Sep 16, 2036	U-3367			
	11382926	Sep 16, 2036	U-3368			
	>A> 11491169	May 28, 2041	U-3484			
	>A> 11491169	May 28, 2041	U-3485			
	>A> 11492353	Dec 08, 2031	DS			
REMIMAZOLAM BESYLATE - BYFAVO						
N 212295 001	10961250	Jul 10, 2027	DP U-2968			
REVEFENACIN - YUPELRI						
N 210598 001	11247969	Mar 10, 2025	DP			
	11484531	Oct 23, 2039	U-2440			
RIBOCICLIB SUCCINATE - KISQALI						
N 209092 001	8415355	Mar 13, 2031	DS DP		NPP	Dec 10, 2024
RIFAMYCIN SODIUM - AEMCOLO						
N 210910 001					NCE	Nov 16, 2023
					GAIN	Nov 16, 2028
RILPIVIRINE HYDROCHLORIDE - EDURANT						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3353			
RIOCIGUAT - ADEMPAS						
N 204819 001	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
RIOCIGUAT - ADEMPAS						
N 204819 002	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
RIOCIGUAT - ADEMPAS						
N 204819 003	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
RIOCIGUAT - ADEMPAS						
N 204819 004	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIOCIGUAT - ADEMPAS						
N 204819 005	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
RIPRETINIB - QINLOCK						
N 213973 001	11266635	Aug 12, 2040	U-3330			
	11344536	Aug 12, 2040	U-3381			
	11395818	Dec 30, 2040	DP			
	11426390	Aug 12, 2040	U-3416			
	11433056	Aug 12, 2040	U-3423			
RISDIPLAM - EVRYSDI						
N 213535 001					NPP	May 27, 2025
RIVAROXABAN - XARELTO						
N 022406 001	9415053	Nov 13, 2024	DP U-1167		>A> M-284	Mar 10, 2023
	9415053	Nov 13, 2024	DP U-2142			
	9415053	Nov 13, 2024	DP U-2640			
	9415053	Nov 13, 2024	DP U-3284			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
	9539218	Feb 17, 2034	U-3288			
	9539218*PED	Aug 17, 2034				
RIVAROXABAN - XARELTO						
N 022406 002	9415053	Nov 13, 2024	DP U-1200		>A> M-284	Mar 10, 2023
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-3286			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-3289			
	9539218*PED	Aug 17, 2034				
RIVAROXABAN - XARELTO						
N 022406 003	9415053	Nov 13, 2024	DP U-1200		>A> M-284	Mar 10, 2023
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-3287			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-3285			
	9539218*PED	Aug 17, 2034				
RIVAROXABAN - XARELTO						
N 022406 004					>A> M-284	Mar 10, 2023
RIVAROXABAN - XARELTO						
N 215859 001	7157456	Aug 28, 2024	DS DP		NP	Dec 20, 2024
					PED	Jun 20, 2025
ROFLUMILAST - ROFLUMILAST						
A 208213 001					>A> PC	Apr 17, 2023
ROFLUMILAST - ROFLUMILAST						
A 208247 001					>A> PC	Apr 17, 2023
ROFLUMILAST - ROFLUMILAST						
A 208256 001					PC	Apr 18, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROFLUMILAST - ROFLUMILAST						
A 208257 001					>A> PC	Apr 17, 2023
ROFLUMILAST - ZORYVE						
N 215985 001	10940142	Jun 07, 2037	DP		NP	Jul 29, 2025
	11129818	Aug 25, 2037	DP U-3408			
	9884050	Jun 07, 2037	DP			
	9907788	Jun 07, 2037	DP U-3408			
RUXOLITINIB PHOSPHATE - OPZELURA						
N 215309 001	10610530	Jun 12, 2028	U-3229		I-896	Jul 18, 2025
	10610530	Jun 12, 2028	U-3404			
	10869870	May 20, 2031	U-3229			
	10869870	May 20, 2031	U-3404			
	11219624	May 20, 2031	DP U-3229			
	8822481	Jun 12, 2028	U-3229			
	8822481	Jun 12, 2028	U-3404			
	9079912	Dec 12, 2026	U-3229			
	9079912	Dec 12, 2026	U-3404			
	9974790	Dec 12, 2026	U-3229			
	9974790	Dec 12, 2026	U-3404			
SECNIDAZOLE - SOLOSEC						
N 209363 001	10335390	Sep 04, 2035	DP U-2583		NPP	Jan 26, 2025
	10335390	Sep 04, 2035	DP U-3270			
	10682338	Sep 04, 2035	DP U-2583			
	10682338	Sep 04, 2035	DP U-3270			
	10849884	Sep 04, 2035	DP U-2583			
	10849884	Sep 04, 2035	DP U-3169			
	10849884	Sep 04, 2035	DP U-3270			
	10849884	Sep 04, 2035	DP U-3302			
	10857133	Sep 04, 2035	DP U-2583			
	10857133	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-2583			
	11000507	Sep 04, 2035	DP U-3169			
	11000507	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-3302			
	11000508	Sep 04, 2035	DP U-2583			
	11000508	Sep 04, 2035	DP U-3169			
	11000508	Sep 04, 2035	DP U-3270			
	11000508	Sep 04, 2035	DP U-3302			
	11020377	Sep 04, 2035	DP U-2583			
	11020377	Sep 04, 2035	DP U-3169			
	11020377	Sep 04, 2035	DP U-3270			
	11020377	Sep 04, 2035	DP U-3302			
	11324721	Sep 04, 2035	DP U-2583			
	11324721	Sep 04, 2035	DP U-3169			
	11324721	Sep 04, 2035	DP U-3270			
	11324721	Sep 04, 2035	DP U-3302			
SELPERCATINIB - RETEVMO						
N 213246 001	10137124	Oct 10, 2037	U-2826			
	10137124	Oct 10, 2037	U-2827			
	10137124	Oct 10, 2037	U-2828			
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3451			
	10137124	Oct 10, 2037	U-3452			
	10137124	Oct 10, 2037	U-3453			
	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3451			
	10172851	Oct 10, 2037	U-3452			
	10172851	Oct 10, 2037	U-3453			
	10584124	Oct 10, 2038	DS U-2826			
	10584124	Oct 10, 2038	DS U-2827			
	10584124	Oct 10, 2038	DS U-2828			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELPERCATINIB - RETEVMO						
N 213246 001	10584124	Oct 10, 2038	DS U-3450			
	10584124	Oct 10, 2038	DS U-3451			
	10584124	Oct 10, 2038	DS U-3452			
	10584124	Oct 10, 2038	DS U-3453			
	10786489	Oct 10, 2038	DP U-2971			
	10786489	Oct 10, 2038	DP U-2972			
	10786489	Oct 10, 2038	DP U-2973			
	10786489	Oct 10, 2038	DP U-2974			
	10786489	Oct 10, 2038	DP U-2975			
	10786489	Oct 10, 2038	DP U-2976			
	10786489	Oct 10, 2038	DP U-2977			
	10786489	Oct 10, 2038	DP U-3450			
	10786489	Oct 10, 2038	DP U-3451			
	10786489	Oct 10, 2038	DP U-3452			
	10786489	Oct 10, 2038	DP U-3453			
SELPERCATINIB - RETEVMO						
N 213246 002	10137124	Oct 10, 2037	U-2826			
	10137124	Oct 10, 2037	U-2827			
	10137124	Oct 10, 2037	U-2828			
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3451			
	10137124	Oct 10, 2037	U-3452			
	10137124	Oct 10, 2037	U-3453			
	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10584124	Oct 10, 2038	DS U-2826			
	10584124	Oct 10, 2038	DS U-2827			
	10584124	Oct 10, 2038	DS U-2828			
	10584124	Oct 10, 2038	DS U-3450			
	10584124	Oct 10, 2038	DS U-3451			
	10584124	Oct 10, 2038	DS U-3452			
	10584124	Oct 10, 2038	DS U-3453			
	10786489	Oct 10, 2038	DP U-2971			
	10786489	Oct 10, 2038	DP U-2972			
	10786489	Oct 10, 2038	DP U-2973			
	10786489	Oct 10, 2038	DP U-2974			
	10786489	Oct 10, 2038	DP U-2975			
	10786489	Oct 10, 2038	DP U-2976			
	10786489	Oct 10, 2038	DP U-2977			
	10786489	Oct 10, 2038	DP U-3450			
	10786489	Oct 10, 2038	DP U-3451			
	10786489	Oct 10, 2038	DP U-3452			
	10786489	Oct 10, 2038	DP U-3453			
SEMAGLUTIDE - OZEMPIC						
N 209637 001	11311679	Jan 20, 2026	DP			
	11446443	Oct 20, 2025	DP			
SEMAGLUTIDE - OZEMPIC						
N 209637 002	11311679	Jan 20, 2026	DP			
	11446443	Oct 20, 2025	DP			
SEMAGLUTIDE - OZEMPIC						
N 209637 003	10220155	Jul 17, 2026	DP		D-185	Mar 28, 2025
	10357616	Jan 20, 2026	DP		NCE	Dec 05, 2022
	10376652	Jan 20, 2026	DP			
	11097063	Jul 17, 2026	DP			
	11311679	Jan 20, 2026	DP			
	11446443	Oct 20, 2025	DP			
	7762994	May 23, 2024	DP			
	8114833	Aug 13, 2025	DP			
	8129343	Dec 05, 2031	DS DP U-3355			
	8536122	Mar 20, 2026	DS DP U-3355			
	8579869	Jun 30, 2023	DP			
	8684969	Oct 20, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEMAGLUTIDE - OZEMPIC						
N 209637 003	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 29, 2027	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
SEMAGLUTIDE - OZEMPIC						
N 209637 004	>A> 10220155	Jul 17, 2026	DP			
	>A> 10335462	Jun 21, 2033	DP U-2580			
	>A> 10357616	Jan 20, 2026	DP			
	>A> 10376652	Jan 20, 2026	DP			
	>A> 11097063	Jul 17, 2026	DP			
	>A> 11311679	Jan 20, 2026	DP			
	>A> 11446443	Oct 20, 2025	DP			
	>A> 7762994	May 23, 2024	DP			
	>A> 8114833	Aug 13, 2025	DP			
	>A> 8129343	Dec 05, 2031	DS DP U-3469			
	>A> 8536122	Mar 20, 2026	DS DP U-3469			
	>A> 8579869	Jun 30, 2023	DP			
	>A> 8684969	Oct 20, 2025	DP			
	>A> 8920383	Jul 17, 2026	DP			
	>A> 9108002	Jan 20, 2026	DP			
	>A> 9132239	Feb 01, 2032	DP			
	>A> 9457154	Sep 29, 2027	DP			
	>A> 9616180	Jan 20, 2026	DP			
	>A> 9687611	Feb 27, 2027	DP			
	>A> 9775953	Jul 17, 2026	DP			
	>A> 9861757	Jan 20, 2026	DP			
	>A> RE46363	Aug 03, 2026	DP			
SEMAGLUTIDE - RYBELSUS						
N 213051 001	11382957	Dec 16, 2031	DP			
SEMAGLUTIDE - RYBELSUS						
N 213051 002	11382957	Dec 16, 2031	DP			
SEMAGLUTIDE - RYBELSUS						
N 213051 003	11382957	Dec 16, 2031	DP			
SEMAGLUTIDE - WEGOVY						
N 215256 001	11318191	Feb 17, 2041	DP U-3162			
SEMAGLUTIDE - WEGOVY						
N 215256 002	11318191	Feb 17, 2041	DP U-3162			
SEMAGLUTIDE - WEGOVY						
N 215256 003	11318191	Feb 17, 2041	DP U-3162			
SEMAGLUTIDE - WEGOVY						
N 215256 004	11318191	Feb 17, 2041	DP U-3162			
SEMAGLUTIDE - WEGOVY						
N 215256 005	11318191	Feb 17, 2041	DP U-3162			
SETMELANOTIDE ACETATE - IMCIVREE						
N 213793 001					I-892	Jun 16, 2025
SINCALIDE - SINCALIDE						
N 210850 001	>A> 11110063	Apr 20, 2038	DP U-3481			
	>A> 11110063	Apr 20, 2038	DP U-3482			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SINCALIDE - SINCALIDE							
N 210850 001	>A>	11110063	Apr 20, 2038	DP U-3483			
	>A>	11318100	Apr 20, 2038	DP U-3477			
	>A>	11318100	Apr 20, 2038	DP U-3478			
	>A>	11318100	Apr 20, 2038	DP U-3479			
	>A>	11318100	Apr 20, 2038	DP U-3480			
SIPONIMOD FUMARIC ACID - MAYZENT							
N 209884 001		7939519	Aug 27, 2028	DS DP		M-274	Mar 01, 2025
SIPONIMOD FUMARIC ACID - MAYZENT							
N 209884 002		7939519	Aug 27, 2028	DS DP		M-274	Mar 01, 2025
SIPONIMOD FUMARIC ACID - MAYZENT							
N 209884 003		7939519	Aug 27, 2028	DS DP		M-274	Mar 01, 2025
SIROLIMUS - FYARRO							
N 213312 001	>A>	11497737	Oct 28, 2040	DP			
SIROLIMUS - HYFTOR							
N 213478 001						NP	Mar 22, 2025
SODIUM NITRITE - SODIUM NITRITE							
N 203922 001		9687506	Feb 10, 2030	DP U-3394			
		9687506	Feb 10, 2030	DP U-3395			
SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE							
N 201444 001		10479686	Jul 07, 2030	DP U-3390			
		9345724	Jul 07, 2030	DS DP U-2015			
		9585912	Jul 07, 2030	DS DP			
		9687506	Feb 10, 2030	DP U-3394			
		9687506	Feb 10, 2030	DP U-3395			
SODIUM OXYBATE - XYREM							
N 021196 001		10213400	Mar 15, 2033	U-2499			
		10213400*PED	Sep 15, 2033				
		10864181	Mar 15, 2033	U-1532			
		10864181*PED	Sep 15, 2033				
		11253494	Mar 15, 2033	U-3323			
		11253494	Mar 15, 2033	U-3324			
		11253494*PED	Sep 15, 2033				
SODIUM PHENYLBUTYRATE; TAURURSODIOL - RELYVRIO							
N 216660 001		10251896	Dec 24, 2033	U-3460		NCE	Sep 29, 2027
		10857162	Dec 24, 2033	U-3460			
		11071742	Dec 24, 2033	DP			
		9872865	Dec 24, 2033	U-3460			
SODIUM THIOSULFATE - SODIUM THIOSULFATE							
N 203923 001		10479686	Jul 07, 2030	DP U-3390			
		9345724	Jul 07, 2030	DS DP U-2015			
		9585912	Jul 07, 2030	DS DP			
SODIUM THIOSULFATE - PEDMARK							
N 212937 001		10596190	Jan 05, 2038	U-3443	>A>	NP	Sep 20, 2025
		11291728	Jul 01, 2039	DP			
SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA							
N 207078 001		11406662	Feb 10, 2032	DS			
SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA							
N 207078 002		11406662	Feb 10, 2032	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR - SOVALDI						
N 212480 001					ODE*	Apr 07, 2024
					PED	Oct 07, 2024
SOFOSBUVIR - SOVALDI						
N 212480 002					ODE*	Apr 07, 2024
					PED	Oct 07, 2024
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 208341 001					M-277	Apr 27, 2025
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 208341 002					M-277	Apr 27, 2025
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 214187 001					M-277	Apr 27, 2025
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 214187 002					M-277	Apr 27, 2025
SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI						
N 209195 001	11338007	Jun 01, 2037	DP U-2039			
	11338007	Jun 01, 2037	DP U-2040			
	11338007*PED	Dec 01, 2037				
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI						
N 211230 001	11439597	Nov 05, 2034	DP			
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI						
N 211230 002	11439597	Nov 05, 2034	DP			
SONIDEGIB PHOSPHATE - ODOMZO						
N 205266 001	10266523	Mar 30, 2036	DS DP			
SOTORASIB - LUMAKRAS						
N 214665 001	10519146	May 21, 2038	DS DP			
	11236091	May 20, 2040	DS DP U-3306			
	11426404	Aug 11, 2040	U-3306			
SPINOSAD - NATROBA						
N 022408 001	9895388	Nov 25, 2033	U-3365			
SPIRONOLACTONE - CAROSPIR						
N 209478 001	11389461	Oct 28, 2036	DP			
	11395828	Oct 28, 2036	U-2109			
	11395828	Oct 28, 2036	U-3401			
	11395828	Oct 28, 2036	U-3402			
	>A> 11491166	Oct 28, 2036	DP			
STIRIPENTOL - DIACOMIT						
N 206709 001					>A> M-281	Jul 14, 2025
STIRIPENTOL - DIACOMIT						
N 206709 002					>A> M-281	Jul 14, 2025
STIRIPENTOL - DIACOMIT						
N 207223 001					>A> NPP	Jul 14, 2025
STIRIPENTOL - DIACOMIT						
N 207223 002					>A> NPP	Jul 14, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SUCRALFATE - SUCRALFATE						
A 211884 001					CGT	Sep 11, 2022
SUMATRIPTAN - TOSYMRA						
N 210884 001	11337962	Jun 16, 2030	DP U-1719			
SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH						
N 208223 001	11364224	Jan 29, 2036	U-72			
TACROLIMUS - ENVARSUS XR						
N 206406 001	11077096	Aug 30, 2024	DP			
	11419823	May 30, 2028	DP			
TACROLIMUS - ENVARSUS XR						
N 206406 002	11077096	Aug 30, 2024	DP			
	11419823	May 30, 2028	DP			
TACROLIMUS - ENVARSUS XR						
N 206406 003	11077096	Aug 30, 2024	DP			
	11419823	May 30, 2028	DP			
TADALAFIL - TADLIQ						
N 214522 001	11382917	Dec 24, 2038	DP U-3397			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 001	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 002	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 003	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 004	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 005	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
TAPINAROF - VTAMA						
N 215272 001	10195160	May 19, 2036	DP		NCE	May 23, 2027
	10426743	May 19, 2036	U-2625			
	10647649	Nov 13, 2038	DS			
	11458108	May 19, 2036	DP			
TASIMELTEON - HETLIOZ						
N 205677 001	11266622	Aug 29, 2035	U-3003			
	11285129	Jan 25, 2033	U-3342			
	11285129	Jan 25, 2033	U-3343			
TASIMELTEON - HETLIOZ LQ						
N 214517 001	11266622	Aug 29, 2035	U-3003			
	11285129	Jan 25, 2033	U-3342			
TAZAROTENE - TAZAROTENE						
A 214136 001					CGT	Mar 13, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TAZAROTENE - ARAZLO						
N 211882 001	11311482	May 11, 2038	U-2368			
TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT						
N 202207 001	9439985	Jan 30, 2029	DP			
TECOVIRIMAT - TPOXX						
N 208627 001	7737168	Sep 04, 2031	U-2346			
TECOVIRIMAT - TPOXX						
N 214518 001	10576165	Aug 02, 2031	DP		NCE	Jul 13, 2023
	7737168	Sep 04, 2031	U-3377			
	8039504	Jul 23, 2027	DP			
	8124643	Jun 18, 2024	DS DP			
	8530509	Jun 18, 2024	DP			
	8802714	Jun 18, 2024	U-3377			
	9233097	Aug 02, 2031	DP			
	9907859	Aug 02, 2031	U-3377			
TEDUGLUTIDE RECOMBINANT - GATTEX KIT						
N 203441 001	7847061	Nov 01, 2025	U-1320	Y		
	7847061*PED	May 01, 2026				
	9060992	Nov 01, 2025	U-1320	Y		
	9060992*PED	May 01, 2026				
TELOTRISTAT ETIPRATE - XERMELO						
N 208794 001	7709493	Feb 28, 2031	DS U-1979			
TENAPANOR HYDROCHLORIDE - IBSRELA						
N 211801 001	8541448	Aug 01, 2033	DS DP			
TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY						
N 208464 001	>A> 8754065	Aug 15, 2032	DS DP U-1275		NPP	Oct 17, 2025
	>A> 8754065	Aug 15, 2032	DS DP U-999			
	>A> 8754065*PED	Feb 15, 2033				
	>A> 9296769	Aug 15, 2032	DS DP U-1275			
	>A> 9296769	Aug 15, 2032	DS DP U-999			
	>A> 9296769*PED	Feb 15, 2033				
TERLIPRESSIN ACETATE - TERLIVAZ						
N 022231 001					NCE	Sep 14, 2027
TESTOSTERONE CYPIONATE - TESTOSTERONE CYPIONATE						
N 216318 001	11311554	Mar 25, 2039	DP			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)						
N 209863 001	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)						
N 209863 002	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)						
N 209863 003	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
TESTOSTERONE UNDECANOATE - JATENZO						
N 206089 001	11331325	Jan 06, 2027	U-2506			
	11426416	Apr 12, 2030	U-3420			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE UNDECANOATE - JATENZO						
N 206089 002	11331325	Jan 06, 2027	U-2506			
	11426416	Apr 12, 2030	U-3420			
TESTOSTERONE UNDECANOATE - JATENZO						
N 206089 003	11331325	Jan 06, 2027	U-2506			
	11426416	Apr 12, 2030	U-3420			
TESTOSTERONE UNDECANOATE - TLANDO						
N 208088 001	10226473	Nov 30, 2030	U-1500		NP	Mar 28, 2025
	10716794	Nov 30, 2030	U-1500			
	11304960	Jan 08, 2029	DP U-1500			
	11311555	Nov 30, 2030	U-1500			
	11364249	Nov 30, 2030	U-1500			
	11433083	Nov 30, 2030	U-1500			
	>A> 11464735	Apr 28, 2041	DP U-1500			
	8778922	Jan 08, 2029	DP U-1500			
	8865695	Jan 08, 2029	U-1500			
	9943527	Nov 30, 2030	U-1500			
	9949985	Nov 30, 2030	U-1500			
TESTOSTERONE UNDECANOATE - KYZATREX						
N 213953 001	10576089	Dec 31, 2030	DP U-2506		NP	Jul 27, 2025
	10576090	Dec 31, 2030	DP			
TESTOSTERONE UNDECANOATE - KYZATREX						
N 213953 002	10576089	Dec 31, 2030	DP U-2506		NP	Jul 27, 2025
	10576090	Dec 31, 2030	DP			
TESTOSTERONE UNDECANOATE - KYZATREX						
N 213953 003	10576089	Dec 31, 2030	DP U-2506		NP	Jul 27, 2025
	10576090	Dec 31, 2030	DP			
TICAGRELOR - BRILINTA						
N 022433 001	10300065	Jan 27, 2036	U-2541		I-848	Nov 05, 2023
	10300065	Jan 27, 2036	U-2542		I-851	May 28, 2023
	10300065*PED	Jul 27, 2036			>A> M-283	May 09, 2025
	8425934	Apr 17, 2030	DP		PED	Nov 28, 2023
	8425934*PED	Oct 17, 2030			PED	May 05, 2024
	RE46276	Oct 30, 2024	DS DP U-1935		>A> PED	Nov 09, 2025
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
	RE46276	Oct 30, 2024	DS DP U-2988			
	RE46276*PED	Apr 30, 2025				
TICAGRELOR - BRILINTA						
N 022433 002	10300065	Jan 27, 2036	U-2541		I-848	Nov 05, 2023
	10300065	Jan 27, 2036	U-2542		I-851	May 28, 2023
	10300065*PED	Jul 27, 2036			>A> M-283	May 09, 2025
	8425934	Apr 17, 2030	DP		PED	Nov 28, 2023
	8425934*PED	Oct 17, 2030			PED	May 05, 2024
	RE46276	Oct 30, 2024	DS DP U-1935		>A> PED	Nov 09, 2025
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
	RE46276	Oct 30, 2024	DS DP U-2988			
	RE46276*PED	Apr 30, 2025				
TIMOLOL MALEATE - TIMOLOL MALEATE						
A 212592 001					CGT	Aug 25, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIMOLOL MALEATE - TIMOLOL MALEATE						
A 212592 002					CGT	Aug 25, 2022
TIOPRONIN - THIOLA EC						
N 211843 001	11458104	Nov 14, 2038	U-3441		ODE*	Jun 28, 2026
TIOPRONIN - THIOLA EC						
N 211843 002	11458104	Nov 14, 2038	U-3441		ODE*	Jun 28, 2026
TIRZEPATIDE - MOUNJARO						
N 215866 001	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO						
N 215866 002	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO						
N 215866 003	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO						
N 215866 004	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO						
N 215866 005	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO						
N 215866 006	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIVOZANIB HYDROCHLORIDE - FOTIVDA						
N 212904 001 >A>	11504365	Nov 05, 2039	U-3476			
	6821987	Apr 26, 2023	DS DP U-3100			
TIVOZANIB HYDROCHLORIDE - FOTIVDA						
N 212904 002 >A>	11504365	Nov 05, 2039	U-3476			
	6821987	Apr 26, 2023	DS DP U-3100			
TOBRAMYCIN - TOBI PODHALER						
N 201688 001 >A>	11484671	Nov 07, 2024	DP U-909			
TOFACITINIB CITRATE - XELJANZ						
N 203214 001					I-879	Dec 14, 2024
TOFACITINIB CITRATE - XELJANZ						
N 203214 002					I-879	Dec 14, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOFACITINIB CITRATE - XELJANZ XR						
N 208246 001	11253523	Mar 14, 2034	U-3326		I-879	Dec 14, 2024
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
TOFACITINIB CITRATE - XELJANZ XR						
N 208246 002	11253523	Mar 14, 2034	U-3326			
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
TOLVAPTAN - TOLVAPTAN						
A 206119 001					PC	Sep 06, 2022
TOPIRAMATE - EPRONTIA						
N 214679 001	11433046	Aug 21, 2040	U-3413			
	11433046	Aug 21, 2040	U-3414			
	11433046	Aug 21, 2040	U-3415			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 001					I-895	Jun 22, 2025
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 002					I-895	Jun 22, 2025
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 003					I-895	Jun 22, 2025
TREPROSTINIL - TYVASO DPI						
N 214324 001	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL - TYVASO DPI						
N 214324 002	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL - TYVASO DPI						
N 214324 003	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL - TYVASO DPI						
N 214324 004	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TRETINOIN - ALTRENO						
N 209353 001	11324710	Aug 22, 2038	U-2368			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR						
N 215760 001	10988436	May 03, 2039	DS		NP	Apr 28, 2025
	11072577	May 03, 2039	U-3370			
TUCATINIB - TUKYSA						
N 213411 001 >A>	11504370	Mar 25, 2033	U-2788			
TUCATINIB - TUKYSA						
N 213411 002 >A>	11504370	Mar 25, 2033	U-2788			
ULIPRISTAL ACETATE - ELLA						
N 022474 001					M-271	Jun 24, 2024
UMBRALISIB TOSYLATE - UKONIQ						
N 213176 001	10981919	Jul 02, 2033	U-3063			
	10981919	Jul 02, 2033	U-3064			
UPADACITINIB - RINVOQ						
N 211675 001	10995095	Oct 17, 2036	U-3298		I-880	Dec 14, 2024
	11365198	Oct 17, 2036	U-3275		I-883	Jan 14, 2025
	8962629	Jan 15, 2031	DS U-3255		I-886	Mar 16, 2025
	8962629	Jan 15, 2031	DS U-3275		I-888	Apr 29, 2025
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3371			
UPADACITINIB - RINVOQ						
N 211675 002	10344036	Oct 17, 2036	DP		I-883	Jan 14, 2025
	10550126	Oct 17, 2036	U-3298		I-886	Mar 16, 2025
	10730883	Oct 17, 2036	DP		NCE	Aug 16, 2024
	10981923	Oct 17, 2036	DS			
	10981924	Oct 17, 2036	DP			
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS U-3341			
	9951080	Oct 17, 2036	DS DP			
	RE47221	Dec 01, 2030	DS			
UPADACITINIB - RINVOQ						
N 211675 003	10202393	Oct 17, 2036	DP		I-886	Mar 16, 2025
	10981923	Oct 17, 2036	DS		NCE	Aug 16, 2024
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS U-3341			
	9951080	Oct 17, 2036	DS DP			
	RE47221	Dec 01, 2030	DS			
VALBENAZINE TOSYLATE - INGREZZA						
N 209241 001	11311532	Sep 18, 2038	DP U-1995			
	8039627	Apr 11, 2031	DS DP			
VALBENAZINE TOSYLATE - INGREZZA						
N 209241 002	11311532	Sep 18, 2038	DP U-1995			
	8039627	Apr 11, 2031	DS DP			
VALBENAZINE TOSYLATE - INGREZZA						
N 209241 003	11311532	Sep 18, 2038	DP U-1995			
	8039627	Apr 11, 2031	DS DP			
VARENICLINE TARTRATE - TYRVAYA						
N 213978 001	11224598	Oct 19, 2035	U-1900			
VASOPRESSIN - VASOPRESSIN						
A 211538 001					PC	Jul 17, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VASOPRESSIN - VASOSTRICT						
N 204485 005	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
VENETOCLAX - VENCLEXTA						
N 208573 001	11369599	May 23, 2032	DP			
	11413282	Sep 06, 2033	U-3412			
VENETOCLAX - VENCLEXTA						
N 208573 002	11369599	May 23, 2032	DP			
	11413282	Sep 06, 2033	U-3412			
VENETOCLAX - VENCLEXTA						
N 208573 003	11369599	May 23, 2032	DP			
	11413282	Sep 06, 2033	U-3412			
VENLAFAXINE BESYLATE - VENLAFAXINE BESYLATE						
N 215429 001	6717015	Mar 27, 2023	DS DP U-451			
	7776358	May 16, 2028	DP			
VERICIGUAT - VERQUVO						
N 214377 001	11439642	May 19, 2031	U-3062			
VERICIGUAT - VERQUVO						
N 214377 002	11439642	May 19, 2031	U-3062			
VERICIGUAT - VERQUVO						
N 214377 003	11439642	May 19, 2031	U-3062			
VILOXAZINE HYDROCHLORIDE - QELBREE						
N 211964 001	11324753	Sep 04, 2029	U-727		NPP	Apr 29, 2025
	11458143	Sep 04, 2029	U-3442			
VILOXAZINE HYDROCHLORIDE - QELBREE						
N 211964 002	11324753	Sep 04, 2029	U-727		NPP	Apr 29, 2025
	11458143	Sep 04, 2029	U-3442			
VILOXAZINE HYDROCHLORIDE - QELBREE						
N 211964 003	11324753	Sep 04, 2029	U-727		NPP	Apr 29, 2025
	11458143	Sep 04, 2029	U-3442			
VOCLOSPORIN - LUPKYNIS						
N 213716 001	7332472	Oct 17, 2023	DS DP U-3056			
VORAPAXAR SULFATE - ZONTIVITY						
N 204886 001	7304078	Dec 23, 2027	DS DP U-1512			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 001	11458134	Jun 15, 2027	DP U-3463			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 002	11458134	Jun 15, 2027	DP U-3463			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 003	11458134	Jun 15, 2027	DP U-3463			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 004	11458134	Jun 15, 2027	DP U-3463			
VOXELOTOR - OXBRYTA						
N 213137 001	11452720	Feb 06, 2035	U-3459			
	>A> 9018210	Nov 25, 2033	DS DP			
VOXELOTOR - OXBRYTA						
N 213137 002	>A> 10017491	Dec 28, 2032	DP			
	>A> 10034879	Dec 28, 2032	DS DP			
	>A> 10493035	Oct 12, 2037	DP			
	>A> 10722502	Feb 06, 2035	DP			
	>A> 10806733	Dec 28, 2032	DS			
	>A> 11020382	Dec 02, 2036	U-3133			
	>A> 11020382	Dec 02, 2036	U-3134			
	11452720	Feb 06, 2035	U-3459			
	>A> 9018210	Nov 25, 2033	DS DP			
	>A> 9248199	Jan 29, 2034	U-2676			
	>A> 9248199	Jan 29, 2034	U-2715			
	>A> 9447071	Feb 06, 2035	DS DP			
VOXELOTOR - OXBRYTA						
N 216157 001	10017491	Dec 28, 2032	DP			
	10034879	Dec 28, 2032	DS DP			
	10722502	Feb 06, 2035	DP			
	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036	U-3133			
	11020382	Dec 02, 2036	U-3134			
	11452720	Feb 06, 2035	U-3459			
	>A> 9018210	Nov 25, 2033	DS DP			
	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			
VUTRISIRAN - AMVUTTRA						
N 215515 001	10131907	Aug 24, 2028	DS DP U-3396		NCE	Jun 13, 2027
	10208307	Jul 28, 2036	DS DP U-3396			
	10570391	Nov 16, 2032	DS DP U-3396			
	10612024	Aug 14, 2035	DS DP U-3396			
	10683501	Jul 28, 2036	DS DP U-3396			
	10806791	Dec 04, 2028	DS			
	11286486	Jul 28, 2036	DS DP U-3396			
	11401517	Aug 14, 2035	DS DP U-3396			
	8106022	Dec 12, 2029	DS DP U-3396			
	8828956	Dec 04, 2028	DS DP U-3396			
	9370581	Dec 04, 2028	DS DP U-3396			
	9399775	Nov 16, 2032	DS DP U-3396			
ZANUBRUTINIB - BRUKINSA						
N 213217 001	>A> 10570139	Apr 22, 2034	U-1745			
	>A> 10570139	Apr 22, 2034	U-2145			
	>A> 10570139	Apr 22, 2034	U-3063			
	>A> 11142528	Apr 22, 2034	DP U-1745			
	>A> 11142528	Apr 22, 2034	DP U-2145			
	>A> 11142528	Apr 22, 2034	DP U-3063			
ZINC SULFATE - ZINC SULFATE						
A 216249 001					CGT	Dec 24, 2022
ZINC SULFATE - ZINC SULFATE						
A 216249 002					CGT	Dec 24, 2022
ZIPRASIDONE HYDROCHLORIDE - GEODON						
N 020825 001					M-232	Jan 28, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZIPRASIDONE HYDROCHLORIDE - GEODON						
N 020825 002					M-232	Jan 28, 2025
ZIPRASIDONE HYDROCHLORIDE - GEODON						
N 020825 003					M-232	Jan 28, 2025
ZIPRASIDONE HYDROCHLORIDE - GEODON						
N 020825 004					M-232	Jan 28, 2025
ZONISAMIDE - ZONISADE						
N 214273 001	11478456	Aug 18, 2038	U-3458			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 42ND Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm